{"PMC7172120": [["The Structures of Alphaviruses and FlavivirusesUnlike many enveloped viruses, both alphaviruses Strauss et al. 1995, Mancini et al. 2000 and flaviviruses (Ferlenghi et al., 2001) have a defined structure that makes them amenable to precise structural studies using the approach of cryoelectron microscopy (Baker et al., 1999).", [["Alphaviruses", "TREATMENT", 18, 30], ["Flaviviruses", "TREATMENT", 35, 47], ["cryoelectron microscopy", "TEST", 281, 304], ["Alphaviruses", "OBSERVATION", 18, 30], ["enveloped", "OBSERVATION_MODIFIER", 59, 68], ["viruses", "OBSERVATION", 69, 76]]], ["The alphavirus structure is illustrated in Figure 2.", [["The alphavirus structure", "PROBLEM", 0, 24], ["alphavirus structure", "OBSERVATION", 4, 24]]], ["The nucleocapsid of the virus is composed of 240 molecules of capsid protein (shown in yellow-orange colors) arranged in a regular T=4 icosahedral lattice.", [["240 molecules", "PROTEIN", 45, 58], ["capsid protein", "PROTEIN", 62, 76], ["the virus", "PROBLEM", 20, 29], ["capsid protein", "PROBLEM", 62, 76], ["a regular T=4 icosahedral lattice", "TREATMENT", 121, 154], ["virus", "OBSERVATION", 24, 29], ["capsid protein", "OBSERVATION", 62, 76]]], ["The nucleocapsid is surrounded by a lipid envelope (green) derived from the host, in which are anchored two virus glycoproteins called E1 and E2 (blue).", [["lipid envelope", "CELLULAR_COMPONENT", 36, 50], ["E1", "GENE_OR_GENE_PRODUCT", 135, 137], ["E2", "GENE_OR_GENE_PRODUCT", 142, 144], ["virus glycoproteins", "PROTEIN", 108, 127], ["E1", "PROTEIN", 135, 137], ["a lipid envelope", "PROBLEM", 34, 50], ["E1 and E2 (blue", "TREATMENT", 135, 150], ["nucleocapsid", "OBSERVATION", 4, 16]]], ["The glycoproteins penetrate the lipid bilayer and E2 makes contact with the capsid protein.", [["lipid bilayer", "ANATOMY", 32, 45], ["E2", "CHEMICAL", 50, 52], ["lipid bilayer", "CELLULAR_COMPONENT", 32, 45], ["E2", "SIMPLE_CHEMICAL", 50, 52], ["capsid protein", "PROTEIN", 76, 90], ["The glycoproteins", "TREATMENT", 0, 17]]], ["E1 and a precursor to E2, variously called PE2 or p62, form a heterodimer that is essential for virus assembly.", [["E2", "CHEMICAL", 22, 24], ["E1", "GENE_OR_GENE_PRODUCT", 0, 2], ["E2", "GENE_OR_GENE_PRODUCT", 22, 24], ["PE2", "GENE_OR_GENE_PRODUCT", 43, 46], ["p62", "GENE_OR_GENE_PRODUCT", 50, 53], ["E1", "PROTEIN", 0, 2], ["E2", "PROTEIN", 22, 24], ["PE2", "PROTEIN", 43, 46], ["p62", "PROTEIN", 50, 53], ["heterodimer", "PROTEIN", 62, 73], ["a heterodimer", "TREATMENT", 60, 73], ["virus", "PROBLEM", 96, 101]]], ["The E1-PE2 heterodimer is cleaved by furin to form an E1-E2 heterodimer during transport of the glycoproteins to the cell surface or during virus assembly.", [["cell surface", "ANATOMY", 117, 129], ["E2", "CHEMICAL", 57, 59], ["E1", "GENE_OR_GENE_PRODUCT", 4, 6], ["PE2", "GENE_OR_GENE_PRODUCT", 7, 10], ["furin", "GENE_OR_GENE_PRODUCT", 37, 42], ["cell surface", "CELLULAR_COMPONENT", 117, 129], ["E1", "PROTEIN", 4, 6], ["PE2 heterodimer", "PROTEIN", 7, 22], ["furin", "PROTEIN", 37, 42], ["E1", "PROTEIN", 54, 56], ["E2 heterodimer", "PROTEIN", 57, 71], ["glycoproteins", "PROTEIN", 96, 109], ["The E1-PE2 heterodimer", "TREATMENT", 0, 22], ["an E1-E2 heterodimer", "TREATMENT", 51, 71], ["the glycoproteins", "TREATMENT", 92, 109]]], ["In the assembled virion, the E1-E2 heterodimers are arranged in a regular T=4 icosahedral lattice in which sets of three heterodimers form trimeric assemblies called spikes that project from the surface of the virion.", [["surface", "ANATOMY", 195, 202], ["virion", "ANATOMY", 210, 216], ["E2", "CHEMICAL", 32, 34], ["virion", "CELLULAR_COMPONENT", 17, 23], ["surface", "CELLULAR_COMPONENT", 195, 202], ["virion", "CELLULAR_COMPONENT", 210, 216], ["E1", "PROTEIN", 29, 31], ["E2 heterodimers", "PROTEIN", 32, 47], ["heterodimers", "PROTEIN", 121, 133], ["trimeric assemblies", "PROTEIN", 139, 158], ["the E1-E2 heterodimers", "TREATMENT", 25, 47], ["a regular T=4 icosahedral lattice", "TREATMENT", 64, 97], ["spikes", "PROBLEM", 166, 172], ["virion", "ANATOMY", 17, 23], ["virion", "ANATOMY", 210, 216]]], ["Thus, alphaviruses are icosahedral structures that contain a lipid bilayer sandwiched between two protein shells, each of which possesses T=4 icosahedral symmetry.The Structures of Alphaviruses and FlavivirusesThe structure of flaviviruses is less well understood.", [["lipid bilayer", "ANATOMY", 61, 74], ["flaviviruses", "DISEASE", 227, 239], ["alphaviruses", "PROBLEM", 6, 18], ["a lipid bilayer sandwiched between two protein shells", "TREATMENT", 59, 112], ["Alphaviruses", "TREATMENT", 181, 193], ["Flaviviruses", "TREATMENT", 198, 210], ["flaviviruses", "PROBLEM", 227, 239], ["alphaviruses", "OBSERVATION", 6, 18], ["Alphaviruses", "OBSERVATION", 181, 193], ["flaviviruses", "OBSERVATION", 227, 239]]], ["However, it is known that the assembly process resembles that of alphaviruses.", [["alphaviruses", "DISEASE", 65, 77], ["alphaviruses", "PROBLEM", 65, 77]]], ["A glycoprotein heterodimer consisting of virus glycoproteins called prM (for precursor to M) and E is first formed.", [["prM (for precursor to M)", "GENE_OR_GENE_PRODUCT", 68, 92], ["glycoprotein heterodimer", "PROTEIN", 2, 26], ["virus glycoproteins", "PROTEIN", 41, 60], ["prM", "PROTEIN", 68, 71], ["E", "PROTEIN", 97, 98], ["A glycoprotein heterodimer", "TREATMENT", 0, 26], ["virus glycoproteins", "TREATMENT", 41, 60]]], ["Both glycoproteins penetrate the bilayer, and cleavage of prM to M by furin occurs during assembly.", [["prM to M", "GENE_OR_GENE_PRODUCT", 58, 66], ["furin", "GENE_OR_GENE_PRODUCT", 70, 75], ["prM", "PROTEIN", 58, 61], ["furin", "PROTEIN", 70, 75], ["glycoproteins", "OBSERVATION_MODIFIER", 5, 18], ["penetrate", "OBSERVATION_MODIFIER", 19, 28], ["bilayer", "OBSERVATION_MODIFIER", 33, 40]]], ["Flaviviruses appear to utilize T=3 symmetry, however, and there are no projecting spikes on the surface of the virion.", [["surface", "ANATOMY", 96, 103], ["virion", "ANATOMY", 111, 117], ["T=3", "GENE_OR_GENE_PRODUCT", 31, 34], ["surface", "CELLULAR_COMPONENT", 96, 103], ["virion", "CELLULAR_COMPONENT", 111, 117], ["Flaviviruses", "PROBLEM", 0, 12], ["projecting spikes", "PROBLEM", 71, 88], ["no", "UNCERTAINTY", 68, 70], ["projecting", "OBSERVATION_MODIFIER", 71, 81], ["spikes", "OBSERVATION", 82, 88], ["virion", "ANATOMY", 111, 117]]], ["Instead the glycoproteins, or at least glycoprotein E, lies flat on the surface of the virion to form a fairly smooth layer that coats the surface of the lipid bilayer Kuhn and Rossmann 1995, Rey et al. 1995.The Structures of Alphaviruses and FlavivirusesIn alphaviruses, it was widely assumed that E1 and E2, which form an easily demonstrable heterodimer in the virion, both contribute to the projecting spikes.", [["surface", "ANATOMY", 72, 79], ["virion", "ANATOMY", 87, 93], ["surface", "ANATOMY", 139, 146], ["E2", "CHEMICAL", 306, 308], ["glycoprotein E", "GENE_OR_GENE_PRODUCT", 39, 53], ["surface", "CELLULAR_COMPONENT", 72, 79], ["virion", "CELLULAR_COMPONENT", 87, 93], ["surface", "CELLULAR_COMPONENT", 139, 146], ["Alphaviruses", "GENE_OR_GENE_PRODUCT", 226, 238], ["E1", "GENE_OR_GENE_PRODUCT", 299, 301], ["E2", "GENE_OR_GENE_PRODUCT", 306, 308], ["glycoproteins", "PROTEIN", 12, 25], ["glycoprotein E", "PROTEIN", 39, 53], ["E1", "PROTEIN", 299, 301], ["E2", "PROTEIN", 306, 308], ["heterodimer", "PROTEIN", 344, 355], ["Alphaviruses", "PROBLEM", 226, 238], ["FlavivirusesIn alphaviruses", "PROBLEM", 243, 270], ["E1 and E2", "TREATMENT", 299, 308], ["the projecting spikes", "PROBLEM", 390, 411], ["smooth", "OBSERVATION_MODIFIER", 111, 117], ["layer", "OBSERVATION_MODIFIER", 118, 123], ["surface", "OBSERVATION_MODIFIER", 139, 146], ["Alphaviruses", "OBSERVATION", 226, 238], ["Flaviviruses", "OBSERVATION", 243, 255], ["heterodimer", "OBSERVATION", 344, 355], ["virion", "ANATOMY", 363, 369], ["projecting spikes", "OBSERVATION", 394, 411]]], ["Thus, the absence of spikes in flaviviruses, together with the difference in triangulation numbers, suggested that the structures of alphaviruses and flaviviruses were unrelated.", [["alphaviruses", "DISEASE", 133, 145], ["flaviviruses", "DISEASE", 150, 162], ["alphaviruses", "ORGANISM", 133, 145], ["spikes in flaviviruses", "PROBLEM", 21, 43], ["triangulation numbers", "TEST", 77, 98], ["the structures of alphaviruses", "PROBLEM", 115, 145], ["flaviviruses", "PROBLEM", 150, 162], ["alphaviruses", "OBSERVATION", 133, 145]]], ["However, the paper by Lescar et al. (2001) shows that the fold of alphavirus E1 is related to that for flavivirus E, suggesting that the two proteins have a common ancestral source.", [["alphavirus E1", "ORGANISM", 66, 79], ["flavivirus E", "ORGANISM", 103, 115], ["alphavirus E1", "PROTEIN", 66, 79], ["flavivirus E", "SPECIES", 103, 115], ["the fold of alphavirus E1", "PROBLEM", 54, 79], ["flavivirus E", "PROBLEM", 103, 115], ["alphavirus", "OBSERVATION", 66, 76]]], ["They propose a fit of E1 into the cryo-EM density of Semliki Forest virus determined to 9 \u00c5 resolution (Mancini et al., 2000).", [["Semliki Forest virus", "ORGANISM", 53, 73], ["E1", "PROTEIN", 22, 24], ["Semliki Forest virus", "SPECIES", 53, 73], ["Semliki Forest virus", "TREATMENT", 53, 73], ["Semliki Forest virus", "OBSERVATION", 53, 73]]], ["The paper by Pletnev et al. (2001) shows that the bulk of E1 does not contribute to the outer portions of the spike but, instead, forms a layer closely apposed to the lipid bilayer, analogous to the position of E in the flavivirion.", [["lipid bilayer", "ANATOMY", 167, 180], ["lipid bilayer", "CELLULAR_COMPONENT", 167, 180], ["E1", "PROTEIN", 58, 60], ["the spike", "PROBLEM", 106, 115], ["spike", "OBSERVATION", 110, 115]]], ["They also show that E2 projects upward to the full-length of the spike.", [["E2", "CHEMICAL", 20, 22], ["E2", "GENE_OR_GENE_PRODUCT", 20, 22], ["the spike", "PROBLEM", 61, 70], ["spike", "OBSERVATION_MODIFIER", 65, 70]]], ["Thus, E1 forms what has been called the skirt that surrounds the lipid bilayer and part of the lower domains of the spikes, whereas E2 forms the projecting part of the spike.", [["lipid bilayer", "ANATOMY", 65, 78], ["E2", "CHEMICAL", 132, 134], ["E1", "GENE_OR_GENE_PRODUCT", 6, 8], ["lipid bilayer", "CELLULAR_COMPONENT", 65, 78], ["E2", "GENE_OR_GENE_PRODUCT", 132, 134], ["E1", "PROTEIN", 6, 8], ["E2", "PROTEIN", 132, 134], ["the spike", "PROBLEM", 164, 173], ["spikes", "OBSERVATION", 116, 122], ["spike", "OBSERVATION_MODIFIER", 168, 173]]], ["The absence of spikes in flaviviruses could then be due to a difference between the cleaved E2 and M. E2 is \u223c420 amino acids in size, of which about 360 residues form the ectodomain, whereas M is only about 75 residues long, of which about 38 residues are present in the ectodomain.", [["E2", "CHEMICAL", 92, 94], ["E2", "CHEMICAL", 102, 104], ["amino acids", "CHEMICAL", 113, 124], ["amino acids", "CHEMICAL", 113, 124], ["E2", "GENE_OR_GENE_PRODUCT", 92, 94], ["M. E2", "GENE_OR_GENE_PRODUCT", 99, 104], ["amino acids", "AMINO_ACID", 113, 124], ["ectodomain", "PROTEIN", 171, 181], ["ectodomain", "PROTEIN", 271, 281], ["spikes", "PROBLEM", 15, 21], ["flaviviruses", "PROBLEM", 25, 37], ["amino acids", "TEST", 113, 124], ["spikes", "OBSERVATION_MODIFIER", 15, 21], ["size", "OBSERVATION_MODIFIER", 128, 132], ["ectodomain", "ANATOMY", 271, 281]]], ["Thus, one can imagine that an immature flavivirion containing prM (about 170 residues) rather than M might more resemble the alphavirus structure, with short projecting spikes, but cleavage to M removes the spikes.The Evolution of Enveloped VirusesThe parallels between the assembly of alphaviruses and flaviviruses and the similarities in structure revealed by the present studies suggest that an enveloped virus with an icosahedral structure arose long ago and has diverged into these two familes.", [["flavivirion", "GENE_OR_GENE_PRODUCT", 39, 50], ["prM", "GENE_OR_GENE_PRODUCT", 62, 65], ["Viruses", "ORGANISM", 241, 248], ["prM", "PROTEIN", 62, 65], ["an immature flavivirion", "PROBLEM", 27, 50], ["the alphavirus structure", "PROBLEM", 121, 145], ["short projecting spikes", "PROBLEM", 152, 175], ["the spikes", "PROBLEM", 203, 213], ["Enveloped Viruses", "PROBLEM", 231, 248], ["alphaviruses", "PROBLEM", 286, 298], ["flaviviruses", "PROBLEM", 303, 315], ["an enveloped virus", "PROBLEM", 395, 413], ["an icosahedral structure", "PROBLEM", 419, 443], ["immature", "OBSERVATION_MODIFIER", 30, 38], ["flavivirion", "OBSERVATION", 39, 50], ["alphavirus", "OBSERVATION", 125, 135], ["Enveloped", "OBSERVATION_MODIFIER", 231, 240], ["Viruses", "OBSERVATION", 241, 248], ["alphaviruses", "OBSERVATION", 286, 298], ["enveloped", "OBSERVATION_MODIFIER", 398, 407], ["virus", "OBSERVATION", 408, 413], ["icosahedral structure", "OBSERVATION", 422, 443]]], ["Many other enveloped viruses whose structures are more or less known use quite different assembly mechanisms (van Regenmortel et al., 2000).", [["enveloped", "OBSERVATION_MODIFIER", 11, 20], ["viruses", "OBSERVATION", 21, 28]]], ["Influenza virus (family Myxoviridae) or respiratory syncytial virus (family Paramyxoviridae), for example, have helical nucleocapsids.", [["Influenza virus", "DISEASE", 0, 15], ["respiratory syncytial virus", "DISEASE", 40, 67], ["Influenza virus", "ORGANISM", 0, 15], ["family Myxoviridae", "ORGANISM", 17, 35], ["respiratory syncytial virus", "ORGANISM", 40, 67], ["Influenza virus", "SPECIES", 0, 15], ["respiratory syncytial virus", "SPECIES", 40, 67], ["Influenza virus", "SPECIES", 0, 15], ["respiratory syncytial virus", "SPECIES", 40, 67], ["Influenza virus (family Myxoviridae)", "TREATMENT", 0, 36], ["respiratory syncytial virus", "PROBLEM", 40, 67], ["helical nucleocapsids", "PROBLEM", 112, 133]]], ["Although each virus has two glycoproteins in the envelope, one of which is cleaved by furin during transport or assembly, these two glycoproteins do not interact during assembly.", [["furin", "GENE_OR_GENE_PRODUCT", 86, 91], ["furin", "PROTEIN", 86, 91], ["glycoproteins", "PROTEIN", 132, 145], ["each virus", "PROBLEM", 9, 19], ["virus", "OBSERVATION", 14, 19], ["two", "OBSERVATION_MODIFIER", 24, 27], ["glycoproteins", "OBSERVATION_MODIFIER", 28, 41]]], ["Instead, each glycoprotein forms spikes that consist of homomultimers.", [["homomultimers", "GENE_OR_GENE_PRODUCT", 56, 69], ["glycoprotein", "PROTEIN", 14, 26], ["homomultimers", "PROTEIN", 56, 69], ["each glycoprotein forms spikes", "PROBLEM", 9, 39]]], ["The assembled virions are not uniform in composition or structure.", [["virions", "ANATOMY", 14, 21], ["The assembled virions", "PROBLEM", 0, 21], ["virions", "OBSERVATION", 14, 21], ["not", "UNCERTAINTY", 26, 29], ["uniform", "OBSERVATION_MODIFIER", 30, 37]]], ["Rather than forming regular structures in which the envelope proteins are present in quasi-equivalent positions, virions are pleomorphic and do not have a fixed composition.", [["virions", "ANATOMY", 113, 120], ["virions", "CELLULAR_COMPONENT", 113, 120], ["envelope proteins", "PROTEIN", 52, 69], ["the envelope proteins", "PROBLEM", 48, 69], ["a fixed composition", "PROBLEM", 153, 172], ["envelope", "OBSERVATION_MODIFIER", 52, 60], ["proteins", "OBSERVATION", 61, 69], ["fixed", "OBSERVATION_MODIFIER", 155, 160], ["composition", "OBSERVATION_MODIFIER", 161, 172]]], ["Retroviruses, such as HIV, use yet another assembly mechanism.", [["Retroviruses", "ORGANISM", 0, 12], ["HIV", "ORGANISM", 22, 25], ["HIV", "SPECIES", 22, 25], ["HIV", "SPECIES", 22, 25], ["Retroviruses", "TREATMENT", 0, 12], ["HIV", "PROBLEM", 22, 25]]], ["The immature nucleocapsids are assembled using radial symmetry and are not icosahedral in structure (Wilk et al., 2001).", [["nucleocapsids", "ANATOMY", 13, 26], ["nucleocapsids", "CELLULAR_COMPONENT", 13, 26], ["The immature nucleocapsids", "PROBLEM", 0, 26], ["immature", "OBSERVATION_MODIFIER", 4, 12], ["nucleocapsids", "OBSERVATION", 13, 26], ["radial symmetry", "OBSERVATION", 47, 62], ["not", "UNCERTAINTY", 71, 74], ["icosahedral", "OBSERVATION_MODIFIER", 75, 86]]], ["The glycoproteins do not form a regular icosahedral lattice and the final composition of the virion is not rigorously constrained.", [["virion", "CELLULAR_COMPONENT", 93, 99], ["glycoproteins", "PROTEIN", 4, 17], ["The glycoproteins", "TREATMENT", 0, 17], ["a regular icosahedral lattice", "TREATMENT", 30, 59]]], ["In fact, nucleocapsids will bud in the absence of glycoproteins.", [["nucleocapsids", "ANATOMY", 9, 22], ["bud", "ANATOMY", 28, 31], ["nucleocapsids", "CELLULAR_COMPONENT", 9, 22], ["glycoproteins", "PROTEIN", 50, 63], ["nucleocapsids", "OBSERVATION", 9, 22]]], ["Thus, it is possible that the ability to form a regular icosahedral, enveloped virus may have arisen only once.", [["a regular icosahedral, enveloped virus", "PROBLEM", 46, 84]]], ["It is interesting to note that hepatitis C virus (genus Hepacivirus, family Flaviviridae), which is only distantly related to the members of the genus Flavivirus, is also thought to possess a glycoprotein with the same fold as the flavivirus E protein (Yagnik et al., 2000).", [["hepatitis C", "DISEASE", 31, 42], ["hepatitis C virus", "ORGANISM", 31, 48], ["genus Hepacivirus", "ORGANISM", 50, 67], ["family Flaviviridae", "ORGANISM", 69, 88], ["glycoprotein", "PROTEIN", 192, 204], ["flavivirus E protein", "PROTEIN", 231, 251], ["hepatitis C virus", "SPECIES", 31, 48], ["hepatitis C virus", "SPECIES", 31, 48], ["hepatitis C virus", "PROBLEM", 31, 48], ["the genus Flavivirus", "PROBLEM", 141, 161], ["a glycoprotein", "PROBLEM", 190, 204], ["the flavivirus E protein", "TEST", 227, 251], ["genus Flavivirus", "ANATOMY", 145, 161]]], ["Although the structure of hepaciviruses is unknown, it may be similar to that of flaviviruses.", [["hepaciviruses", "DISEASE", 26, 39], ["flaviviruses", "DISEASE", 81, 93], ["hepaciviruses", "GENE_OR_GENE_PRODUCT", 26, 39], ["flaviviruses", "PROBLEM", 81, 93], ["flaviviruses", "OBSERVATION", 81, 93]]], ["Further afield, it would be of interest to determine the structure of arteriviruses (family Arteriviridae), which are enveloped viruses whose genome organization and mechanism of RNA synthesis are related to those of coronaviruses (family Coronaviridae), but whose nucleocapsid is icosahedral rather than helical like coronaviruses (Snijder and Meulenberg, 1998).Are Alphaviruses and Flaviviruses Related by Linear Descent from a Common Ancestor?The results of Lescar et al. (2001) and of Pletnev et al. (2001) make it likely that the glycoproteins that form the surface of the virions of alphaviruses and flaviviruses derived from a common ancestor that arose long ago.", [["surface", "ANATOMY", 563, 570], ["Flaviviruses", "DISEASE", 384, 396], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 70, 83], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 92, 105], ["coronaviruses", "ORGANISM", 217, 230], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 239, 252], ["surface", "CELLULAR_COMPONENT", 563, 570], ["glycoproteins", "PROTEIN", 535, 548], ["RNA synthesis", "PROBLEM", 179, 192], ["coronaviruses", "PROBLEM", 217, 230], ["Alphaviruses", "PROBLEM", 367, 379], ["Flaviviruses", "PROBLEM", 384, 396], ["the glycoproteins", "PROBLEM", 531, 548], ["alphaviruses", "PROBLEM", 589, 601], ["flaviviruses", "PROBLEM", 606, 618], ["RNA synthesis", "OBSERVATION", 179, 192], ["Alphaviruses", "OBSERVATION", 367, 379], ["Flaviviruses", "OBSERVATION", 384, 396], ["Linear", "OBSERVATION_MODIFIER", 408, 414]]], ["The genome organizations of the two families of viruses, illustrated in Figure 1, make clear that recombination was at least partially responsible for the current genomes.", [["viruses", "PROBLEM", 48, 55], ["viruses", "OBSERVATION", 48, 55]]], ["It seems likely that during evolution the module that encodes the structural genes became associated with different modules encoding genes for RNA replication.", [["structural genes", "DNA", 66, 82], ["RNA replication", "TREATMENT", 143, 158], ["seems likely", "UNCERTAINTY", 3, 15]]], ["This hypothesis is supported by comparisons of alphaviruses with a number of plant viruses.", [["alphaviruses", "PROBLEM", 47, 59], ["plant viruses", "PROBLEM", 77, 90], ["plant viruses", "OBSERVATION", 77, 90]]], ["Plant viruses belonging to at least four different families have been found to possess RNA replication genes that are homologous to genes found in alpha-viruses.", [["Plant viruses", "ORGANISM", 0, 13], ["alpha-viruses", "CANCER", 147, 160], ["RNA replication genes", "DNA", 87, 108], ["Plant viruses", "PROBLEM", 0, 13], ["RNA replication genes", "PROBLEM", 87, 108], ["viruses", "OBSERVATION", 6, 13]]], ["However, the viruses have clearly undergone multiple recombination events in which new proteins have been introduced from other viruses or from the host during the evolution of this diverse group of viruses (Strauss et al., 1996).", [["the viruses", "PROBLEM", 9, 20], ["multiple recombination events", "PROBLEM", 44, 73], ["new proteins", "PROBLEM", 83, 95], ["other viruses", "PROBLEM", 122, 135], ["viruses", "OBSERVATION", 13, 20], ["multiple", "OBSERVATION_MODIFIER", 44, 52], ["recombination events", "OBSERVATION", 53, 73]]], ["A comparison of tobacco mosaic virus (TMV) and Sindbis virus is shown in Figure 3.", [["tobacco mosaic virus (TMV) and Sindbis virus", "DISEASE", 16, 60], ["tobacco mosaic virus", "ORGANISM", 16, 36], ["TMV", "ORGANISM", 38, 41], ["Sindbis virus", "ORGANISM", 47, 60], ["tobacco mosaic virus", "SPECIES", 16, 36], ["Sindbis virus", "SPECIES", 47, 60], ["tobacco mosaic virus", "SPECIES", 16, 36], ["TMV", "SPECIES", 38, 41], ["Sindbis virus", "SPECIES", 47, 60], ["tobacco mosaic virus (TMV) and Sindbis virus", "PROBLEM", 16, 60], ["tobacco mosaic virus", "OBSERVATION", 16, 36]]], ["Although several of the RNA replication proteins of Sindbis virus and TMV are homologous (shaded areas in the nonstructural proteins), and the mechanisms of RNA synthesis are related, the structural genes of these two viruses are unrelated and the structures of the resulting virions are entirely different.", [["virions", "ANATOMY", 276, 283], ["Sindbis virus", "ORGANISM", 52, 65], ["TMV", "ORGANISM", 70, 73], ["RNA replication proteins", "PROTEIN", 24, 48], ["nonstructural proteins", "PROTEIN", 110, 132], ["Sindbis virus", "SPECIES", 52, 65], ["Sindbis virus", "SPECIES", 52, 65], ["TMV", "SPECIES", 70, 73], ["Sindbis virus", "PROBLEM", 52, 65], ["TMV", "PROBLEM", 70, 73], ["homologous (shaded areas in the nonstructural proteins", "PROBLEM", 78, 132], ["RNA synthesis", "PROBLEM", 157, 170], ["these two viruses", "PROBLEM", 208, 225], ["Sindbis virus", "OBSERVATION", 52, 65], ["nonstructural proteins", "OBSERVATION_MODIFIER", 110, 132], ["RNA synthesis", "OBSERVATION", 157, 170], ["viruses", "OBSERVATION", 218, 225], ["virions", "OBSERVATION", 276, 283], ["different", "OBSERVATION_MODIFIER", 297, 306]]], ["TMV is not enveloped and the virion, which contains a single species of capsid protein, is a helical structure with the appearance of a rigid rod (Figure 4).", [["TMV", "ORGANISM", 0, 3], ["virion", "CELLULAR_COMPONENT", 29, 35], ["capsid protein", "PROTEIN", 72, 86], ["helical structure", "PROTEIN", 93, 110], ["TMV", "SPECIES", 0, 3], ["TMV", "PROBLEM", 0, 3], ["a single species of capsid protein", "PROBLEM", 52, 86], ["a rigid rod", "TREATMENT", 134, 145], ["not", "UNCERTAINTY", 7, 10], ["enveloped", "OBSERVATION_MODIFIER", 11, 20], ["virion", "OBSERVATION_MODIFIER", 29, 35], ["capsid protein", "OBSERVATION", 72, 86], ["helical structure", "OBSERVATION_MODIFIER", 93, 110], ["rigid rod", "OBSERVATION", 136, 145]]], ["Thus, it is not uncommon for structural modules to evolve independently of RNA replication modules, with mixing to form new combinations effected by recombination.The Ecology of Alphaviruses and FlavivirusesThere are currently recognized about 75 flaviviruses and 25 alphaviruses.", [["alphaviruses", "DISEASE", 267, 279], ["RNA replication modules", "DNA", 75, 98], ["structural modules", "PROBLEM", 29, 47], ["RNA replication modules", "PROBLEM", 75, 98], ["Alphaviruses", "TREATMENT", 178, 190], ["Flaviviruses", "PROBLEM", 195, 207], ["RNA replication", "OBSERVATION", 75, 90], ["Alphaviruses", "OBSERVATION", 178, 190]]], ["Many of these viruses, but especially many of the flaviviruses, cause enormous numbers of cases of human illness each year.", [["flaviviruses", "DISEASE", 50, 62], ["human illness", "DISEASE", 99, 112], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["these viruses", "PROBLEM", 8, 21], ["the flaviviruses", "PROBLEM", 46, 62], ["viruses", "OBSERVATION", 14, 21], ["flaviviruses", "OBSERVATION", 50, 62]]], ["To cite a few flavivirus examples, the dengue viruses, of which there are four serotypes, cause an estimated 100 million cases of dengue fever each year; yellow fever virus is still widespread in Africa and Latin America; Japanese encephalitis virus is widespread in Asia; and West Nile virus has recently appeared in the Americas (the New York City area) for the first time.", [["dengue", "DISEASE", 39, 45], ["dengue fever", "DISEASE", 130, 142], ["yellow fever", "DISEASE", 154, 166], ["Japanese encephalitis", "DISEASE", 222, 243], ["dengue viruses", "ORGANISM", 39, 53], ["yellow fever virus", "ORGANISM", 154, 172], ["Japanese encephalitis virus", "ORGANISM", 222, 249], ["West Nile virus", "ORGANISM", 277, 292], ["yellow fever virus", "SPECIES", 154, 172], ["Japanese encephalitis virus", "SPECIES", 222, 249], ["Nile virus", "SPECIES", 282, 292], ["dengue viruses", "SPECIES", 39, 53], ["yellow fever virus", "SPECIES", 154, 172], ["Japanese encephalitis virus", "SPECIES", 222, 249], ["West Nile virus", "SPECIES", 277, 292], ["the dengue viruses", "PROBLEM", 35, 53], ["dengue fever", "PROBLEM", 130, 142], ["yellow fever virus", "PROBLEM", 154, 172], ["Japanese encephalitis virus", "PROBLEM", 222, 249], ["West Nile virus", "PROBLEM", 277, 292], ["encephalitis", "OBSERVATION", 231, 243]]], ["A hallmark of both alphaviruses and flaviviruses is that most of the viruses are transmitted by blood-sucking arthropods, that is, the viruses alternate between infection of an arthropod host and a vertebrate host.", [["blood", "ANATOMY", 96, 101], ["alphaviruses and flaviviruses", "DISEASE", 19, 48], ["infection", "DISEASE", 161, 170], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["A hallmark of both alphaviruses", "PROBLEM", 0, 31], ["flaviviruses", "PROBLEM", 36, 48], ["the viruses", "PROBLEM", 65, 76], ["the viruses", "PROBLEM", 131, 142], ["infection", "PROBLEM", 161, 170], ["hallmark", "OBSERVATION_MODIFIER", 2, 10], ["both", "OBSERVATION_MODIFIER", 14, 18], ["alphaviruses", "OBSERVATION", 19, 31], ["flaviviruses", "OBSERVATION", 36, 48], ["viruses", "OBSERVATION", 69, 76], ["infection", "OBSERVATION", 161, 170]]], ["Although a number of viruses belonging to other families of RNA viruses are known to be arboviruses (so called because they are arthropod-borne), only certain genera in the family Bunyaviridae rival the alphaviruses and flaviviruses in the number of and geographic range occupied by arboviruses (van Regenmortel et al., 2000).", [["arboviruses", "DISEASE", 88, 99], ["Bunyaviridae", "DISEASE", 180, 192], ["alphaviruses", "DISEASE", 203, 215], ["flaviviruses", "DISEASE", 220, 232], ["arboviruses", "DISEASE", 283, 294], ["Bunyaviridae", "ORGANISM", 180, 192], ["viruses", "PROBLEM", 21, 28], ["RNA viruses", "PROBLEM", 60, 71], ["arboviruses", "PROBLEM", 88, 99], ["flaviviruses", "PROBLEM", 220, 232], ["viruses", "OBSERVATION", 21, 28], ["RNA viruses", "OBSERVATION", 60, 71], ["alphaviruses", "OBSERVATION", 203, 215], ["flaviviruses", "OBSERVATION", 220, 232]]], ["Perhaps the (related) structures of alphaviruses and flaviviruses have been important in allowing them to occupy and largely dominate the ecological niche represented by arboviruses.", [["alphaviruses", "DISEASE", 36, 48], ["arboviruses", "DISEASE", 170, 181], ["the (related) structures of alphaviruses", "PROBLEM", 8, 48], ["flaviviruses", "PROBLEM", 53, 65], ["arboviruses", "PROBLEM", 170, 181], ["alphaviruses", "OBSERVATION", 36, 48], ["ecological niche", "OBSERVATION", 138, 154], ["arboviruses", "OBSERVATION", 170, 181]]]], "983ad6288fa838c9038e4367fa155d701aa7fb8b": [["ing exceptional X-ray, infrared and radio luminosity for a CWB.", [["exceptional X-ray", "TEST", 4, 21]]], ["The system was identified via infrared imaging to be likely a hierarchical triple, with a massive central CWB that dominates the high-energy, non-thermal, and infrared emission, and a third massive northern companion 0 \u2032\u2032 .7 away.", [["infrared imaging", "TEST", 30, 46], ["a massive central CWB", "PROBLEM", 88, 109], ["infrared emission", "TEST", 159, 176], ["hierarchical", "OBSERVATION_MODIFIER", 62, 74], ["triple", "OBSERVATION", 75, 81], ["massive", "OBSERVATION_MODIFIER", 90, 97], ["central CWB", "OBSERVATION", 98, 109], ["high", "OBSERVATION_MODIFIER", 129, 133], ["massive", "OBSERVATION_MODIFIER", 190, 197], ["northern", "OBSERVATION_MODIFIER", 198, 206]]], ["The defining feature of Apep is a spectacular 12 \u2032\u2032 mid-infrared dust plume centred on the central binary.", [["a spectacular 12 \u2032\u2032 mid-infrared dust plume", "PROBLEM", 32, 75], ["spectacular", "OBSERVATION_MODIFIER", 34, 45], ["dust plume", "OBSERVATION", 65, 75], ["central", "ANATOMY_MODIFIER", 91, 98], ["binary", "ANATOMY_MODIFIER", 99, 105]]], ["While the dust plume strongly resembles the pinwheel nebulae, additional intricate structures suggest that there are unknown processes sculpting the outflow from Apep.", [["pinwheel nebulae", "ANATOMY", 44, 60], ["the dust plume", "PROBLEM", 6, 20], ["the pinwheel nebulae", "PROBLEM", 40, 60], ["dust plume", "OBSERVATION", 10, 20], ["pinwheel nebulae", "OBSERVATION", 44, 60], ["outflow", "ANATOMY_MODIFIER", 149, 156]]], ["In particular, Callingham et al. (2019) found that the velocity of the gas in the central binary is a factor of six higher than the velocity derived from the observed proper motion of the dust pattern.", [["velocity", "OBSERVATION_MODIFIER", 55, 63], ["gas", "OBSERVATION", 71, 74], ["central", "ANATOMY_MODIFIER", 82, 89], ["proper motion", "OBSERVATION", 167, 180], ["dust pattern", "OBSERVATION", 188, 200]]], ["As the dust and gas are expected to be coextensive, such a discrepancy between the speed derived from spectra and dust are inconsistent with the existing models of the dynamics of such colliding-wind systems.", [["dust", "ORGANISM_SUBSTANCE", 7, 11], ["the dust and gas", "TEST", 3, 19], ["a discrepancy", "PROBLEM", 57, 70], ["gas", "OBSERVATION", 16, 19]]], ["In standard CWB dust-producing models with isotropic stellar winds, newly formed dust assumes the velocity of the shock compressed stellar wind (Cant\u00f3 et al. 1996) , generally \u224880 percent of the fastest wind in the system (e.g. Marchenko et al. 2003) .", [["shock", "DISEASE", 114, 119], ["stellar winds", "OBSERVATION", 53, 66], ["dust", "OBSERVATION", 81, 85], ["velocity", "OBSERVATION_MODIFIER", 98, 106], ["shock", "OBSERVATION", 114, 119], ["stellar wind", "OBSERVATION", 131, 143]]], ["The newly formed dust grains are then quickly accelerated to velocities closer to that of the stellar winds in a fraction of an orbital period (Pittard 2009; Williams et al. 2009a ).", [["dust grains", "MULTI-TISSUE_STRUCTURE", 17, 28], ["The newly formed dust grains", "PROBLEM", 0, 28], ["velocities", "TEST", 61, 71], ["newly", "OBSERVATION_MODIFIER", 4, 9], ["formed", "OBSERVATION_MODIFIER", 10, 16], ["dust grains", "OBSERVATION", 17, 28], ["velocities", "OBSERVATION_MODIFIER", 61, 71], ["stellar winds", "OBSERVATION", 94, 107], ["fraction", "OBSERVATION_MODIFIER", 113, 121], ["orbital", "ANATOMY", 128, 135]]], ["All other known Pinwheel nebulae display congruous spectroscopic and dust expansion speeds.", [["Pinwheel nebulae", "SPECIES", 16, 32], ["congruous spectroscopic and dust expansion speeds", "PROBLEM", 41, 90], ["Pinwheel nebulae", "OBSERVATION", 16, 32], ["dust expansion", "OBSERVATION", 69, 83], ["speeds", "OBSERVATION_MODIFIER", 84, 90]]], ["Callingham et al. (2019) proposed that the contradiction between the measured dust and gas speeds in Apep can be resolved if the system is capable of launching extremely anisotropic winds, for example due to rapid rotation of the WR star in the central binary.", [["Apep", "SIMPLE_CHEMICAL", 101, 105], ["gas speeds", "OBSERVATION", 87, 97], ["central", "ANATOMY_MODIFIER", 245, 252]]], ["This would imply that Apep is the first known Galactic analogue to long-duration gamma-ray burst progenitors, and a unique laboratory for astrophysics occurring otherwise only at cosmological distances.", [["progenitors", "CELL", 97, 108], ["gamma-ray burst progenitors", "CELL_TYPE", 81, 108], ["astrophysics", "PROBLEM", 138, 150]]], ["However, such a conclusion presents its own difficulties as there has not been any definitive observations of critically-rotating WR stars, despite such systems being favoured to exist by longduration gamma-ray burst models (Woosley & Heger 2006) .", [["critically-rotating WR stars", "PROBLEM", 110, 138], ["such systems", "PROBLEM", 148, 160]]]], "04c7cc7215fe4e62c7a9c32e9b47eeb026defb14": [["AbstractWe report a case of a kidney transplant recipient who presented with acute kidney injury and nephrotic-range proteinuria in a context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.", [["kidney", "ANATOMY", 30, 36], ["kidney", "ANATOMY", 83, 89], ["acute kidney injury", "DISEASE", 77, 96], ["nephrotic", "DISEASE", 101, 110], ["proteinuria", "DISEASE", 117, 128], ["acute respiratory syndrome coronavirus", "DISEASE", 152, 190], ["infection", "DISEASE", 206, 215], ["kidney", "ORGAN", 30, 36], ["kidney", "ORGAN", 83, 89], ["SARS-CoV-2", "ORGANISM", 194, 204], ["severe acute respiratory syndrome coronavirus", "SPECIES", 145, 190], ["SARS-CoV-2", "SPECIES", 194, 204], ["a kidney transplant recipient", "TREATMENT", 28, 57], ["acute kidney injury", "PROBLEM", 77, 96], ["nephrotic-range proteinuria", "PROBLEM", 101, 128], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 145, 190], ["SARS", "PROBLEM", 194, 198], ["infection", "PROBLEM", 206, 215], ["kidney", "ANATOMY", 30, 36], ["transplant", "OBSERVATION", 37, 47], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["kidney", "ANATOMY", 83, 89], ["injury", "OBSERVATION", 90, 96], ["nephrotic", "OBSERVATION", 101, 110], ["range proteinuria", "OBSERVATION", 111, 128], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["respiratory syndrome coronavirus", "OBSERVATION", 158, 190], ["infection", "OBSERVATION", 206, 215]]], ["Kidney biopsy revealed collapsing glomerulopathy.", [["Kidney", "ANATOMY", 0, 6], ["glomerulopathy", "DISEASE", 34, 48], ["Kidney biopsy", "MULTI-TISSUE_STRUCTURE", 0, 13], ["Kidney biopsy", "TEST", 0, 13], ["collapsing glomerulopathy", "PROBLEM", 23, 48], ["biopsy", "OBSERVATION", 7, 13], ["collapsing", "OBSERVATION_MODIFIER", 23, 33], ["glomerulopathy", "OBSERVATION", 34, 48]]], ["Droplet-based digital PCR did not detect the presence of SARS-CoV-2 RNA in the biopsy fragment, and the virus was barely detectable in the plasma at the time of the biopsy.", [["biopsy fragment", "ANATOMY", 79, 94], ["plasma", "ANATOMY", 139, 145], ["SARS", "DISEASE", 57, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["biopsy fragment", "MULTI-TISSUE_STRUCTURE", 79, 94], ["plasma", "ORGANISM_SUBSTANCE", 139, 145], ["SARS-CoV-2 RNA", "RNA", 57, 71], ["SARS-CoV", "SPECIES", 57, 65], ["Droplet", "TEST", 0, 7], ["digital PCR", "TEST", 14, 25], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["the biopsy fragment", "TEST", 75, 94], ["the virus", "PROBLEM", 100, 109], ["the biopsy", "TEST", 161, 171], ["SARS", "OBSERVATION", 57, 61], ["CoV", "OBSERVATION_MODIFIER", 62, 65], ["biopsy fragment", "OBSERVATION", 79, 94], ["virus", "OBSERVATION", 104, 109], ["biopsy", "OBSERVATION", 165, 171]]], ["SARS-CoV-2 RNAemia peaked several days later, followed by a seroconversion despite the absence of circulating CD19-positive lymphocytes at admission due to rituximab-based treatment of antibodymediated rejection 3 months earlier.", [["CD19-positive lymphocytes", "ANATOMY", 110, 135], ["SARS", "DISEASE", 0, 4], ["rituximab", "CHEMICAL", 156, 165], ["SARS-CoV-2", "ORGANISM", 0, 10], ["CD19", "GENE_OR_GENE_PRODUCT", 110, 114], ["rituximab", "SIMPLE_CHEMICAL", 156, 165], ["CD19", "PROTEIN", 110, 114], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["RNAemia", "PROBLEM", 11, 18], ["a seroconversion", "PROBLEM", 58, 74], ["circulating CD19", "TEST", 98, 114], ["positive lymphocytes", "PROBLEM", 115, 135], ["rituximab", "TREATMENT", 156, 165], ["antibodymediated rejection", "PROBLEM", 185, 211], ["positive lymphocytes", "OBSERVATION", 115, 135], ["rejection", "OBSERVATION", 202, 211]]], ["Genotyping for the two risk alleles of the apolipoprotein L1 (APOL1) gene revealed that the donor carried the low-risk G0/G2 genotype.", [["apolipoprotein L1", "GENE_OR_GENE_PRODUCT", 43, 60], ["APOL1", "GENE_OR_GENE_PRODUCT", 62, 67], ["apolipoprotein L1 (APOL1) gene", "DNA", 43, 73]]], ["This case illustrates that COVID-19 may promote a collapsing glomerulopathy in kidney allografts with a low-risk APOL1 genotype, in the absence of detectable SARS-CoV2 RNA in the kidney, and that podocyte injury may precede SARS-CoV2 RNAemia.IntroductionKidney injury is frequent in patients with novel coronavirus disease 2019 (COVID-19) 1 .", [["kidney allografts", "ANATOMY", 79, 96], ["kidney", "ANATOMY", 179, 185], ["podocyte", "ANATOMY", 196, 204], ["COVID-19", "CHEMICAL", 27, 35], ["glomerulopathy", "DISEASE", 61, 75], ["SARS", "DISEASE", 224, 228], ["IntroductionKidney injury", "DISEASE", 242, 267], ["coronavirus disease", "DISEASE", 303, 322], ["COVID-19", "CHEMICAL", 27, 35], ["COVID-19", "GENE_OR_GENE_PRODUCT", 27, 35], ["kidney", "ORGAN", 79, 85], ["allografts", "TISSUE", 86, 96], ["APOL1", "GENE_OR_GENE_PRODUCT", 113, 118], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 158, 167], ["kidney", "ORGAN", 179, 185], ["podocyte", "CELL", 196, 204], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 224, 233], ["patients", "ORGANISM", 283, 291], ["SARS-CoV2 RNA", "RNA", 158, 171], ["patients", "SPECIES", 283, 291], ["COVID", "TEST", 27, 32], ["a collapsing glomerulopathy", "PROBLEM", 48, 75], ["kidney allografts", "TREATMENT", 79, 96], ["a low-risk APOL1 genotype", "PROBLEM", 102, 127], ["detectable SARS", "PROBLEM", 147, 162], ["CoV2 RNA in the kidney", "PROBLEM", 163, 185], ["podocyte injury", "PROBLEM", 196, 211], ["SARS", "PROBLEM", 224, 228], ["CoV2 RNAemia", "PROBLEM", 229, 241], ["IntroductionKidney injury", "PROBLEM", 242, 267], ["novel coronavirus disease", "PROBLEM", 297, 322], ["COVID", "TEST", 329, 334], ["collapsing", "OBSERVATION_MODIFIER", 50, 60], ["glomerulopathy", "OBSERVATION", 61, 75], ["kidney", "ANATOMY", 79, 85], ["allografts", "OBSERVATION", 86, 96], ["detectable", "OBSERVATION_MODIFIER", 147, 157], ["SARS", "OBSERVATION", 158, 162], ["kidney", "ANATOMY", 179, 185], ["podocyte", "ANATOMY", 196, 204], ["injury", "OBSERVATION", 205, 211], ["injury", "OBSERVATION", 261, 267]]], ["It is proposed that kidney cells are targeted by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thereby causing kidney lesions, viral RNA has been detected in various kidney compartments of patients who died from COVID-19, including glomeruli 2, 3 .IntroductionCritically, podocytes express membrane proteins such as angiotensin-converting enzyme 2 (ACE2) that are considered to facilitate SARS-CoV-2 entry within the cell 4 .", [["kidney cells", "ANATOMY", 20, 32], ["kidney lesions", "ANATOMY", 127, 141], ["kidney compartments", "ANATOMY", 182, 201], ["glomeruli", "ANATOMY", 248, 257], ["podocytes", "ANATOMY", 288, 297], ["membrane", "ANATOMY", 306, 314], ["cell", "ANATOMY", 433, 437], ["acute respiratory syndrome coronavirus", "DISEASE", 56, 94], ["kidney lesions", "DISEASE", 127, 141], ["angiotensin", "CHEMICAL", 332, 343], ["kidney cells", "CELL", 20, 32], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 49, 96], ["SARS-CoV-2", "ORGANISM", 98, 108], ["kidney lesions", "PATHOLOGICAL_FORMATION", 127, 141], ["kidney compartments", "MULTI-TISSUE_STRUCTURE", 182, 201], ["patients", "ORGANISM", 205, 213], ["podocytes", "CELL", 288, 297], ["membrane", "CELLULAR_COMPONENT", 306, 314], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 332, 363], ["ACE2", "GENE_OR_GENE_PRODUCT", 365, 369], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 405, 415], ["cell 4", "CELL", 433, 439], ["kidney cells", "CELL_TYPE", 20, 32], ["viral RNA", "RNA", 143, 152], ["podocytes", "CELL_TYPE", 288, 297], ["membrane proteins", "PROTEIN", 306, 323], ["angiotensin-converting enzyme 2", "PROTEIN", 332, 363], ["ACE2", "PROTEIN", 365, 369], ["patients", "SPECIES", 205, 213], ["severe acute respiratory syndrome coronavirus", "SPECIES", 49, 94], ["SARS-CoV-2", "SPECIES", 98, 108], ["kidney cells", "PROBLEM", 20, 32], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 49, 94], ["SARS", "TEST", 98, 102], ["CoV", "TEST", 103, 106], ["kidney lesions", "PROBLEM", 127, 141], ["viral RNA", "PROBLEM", 143, 152], ["COVID", "TEST", 228, 233], ["membrane proteins", "PROBLEM", 306, 323], ["angiotensin", "TEST", 332, 343], ["SARS", "TEST", 405, 409], ["CoV", "TEST", 410, 413], ["kidney", "ANATOMY", 20, 26], ["cells", "OBSERVATION", 27, 32], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["respiratory syndrome", "OBSERVATION", 62, 82], ["kidney", "ANATOMY", 127, 133], ["lesions", "OBSERVATION", 134, 141], ["viral RNA", "OBSERVATION", 143, 152], ["kidney", "ANATOMY", 182, 188], ["glomeruli", "ANATOMY", 248, 257]]], ["Consequently, SARS-CoV-2 could have a preferential tropism for glomerular cells, and podocyte injury occurring upon SARS-CoV-2 infection may result in collapsing glomerulopathy in native kidneys.", [["glomerular cells", "ANATOMY", 63, 79], ["podocyte", "ANATOMY", 85, 93], ["kidneys", "ANATOMY", 187, 194], ["infection", "DISEASE", 127, 136], ["glomerulopathy", "DISEASE", 162, 176], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["glomerular cells", "CELL", 63, 79], ["podocyte", "CELL", 85, 93], ["SARS-CoV-2", "ORGANISM", 116, 126], ["kidneys", "ORGAN", 187, 194], ["glomerular cells", "CELL_TYPE", 63, 79], ["SARS-CoV", "SPECIES", 14, 22], ["SARS-CoV", "SPECIES", 116, 124], ["SARS", "PROBLEM", 14, 18], ["glomerular cells", "PROBLEM", 63, 79], ["podocyte injury", "PROBLEM", 85, 100], ["SARS", "PROBLEM", 116, 120], ["CoV-2 infection", "PROBLEM", 121, 136], ["collapsing glomerulopathy in native kidneys", "PROBLEM", 151, 194], ["glomerular cells", "OBSERVATION", 63, 79], ["podocyte", "ANATOMY", 85, 93], ["injury", "OBSERVATION", 94, 100], ["collapsing", "OBSERVATION_MODIFIER", 151, 161], ["glomerulopathy", "OBSERVATION", 162, 176], ["native", "ANATOMY_MODIFIER", 180, 186], ["kidneys", "ANATOMY", 187, 194]]], ["However, the presence of the virus in glomerular cells has never been formally demonstrated in living patients [5] [6] [7] .", [["glomerular cells", "ANATOMY", 38, 54], ["glomerular cells", "CELL", 38, 54], ["patients", "ORGANISM", 102, 110], ["glomerular cells", "CELL_TYPE", 38, 54], ["patients", "SPECIES", 102, 110], ["the virus in glomerular cells", "PROBLEM", 25, 54], ["virus", "OBSERVATION", 29, 34], ["glomerular cells", "OBSERVATION", 38, 54]]], ["Thus, the mechanism by which SARS-CoV-2 infection promotes glomerular injury is an unresolved issue.IntroductionAccording to the \"second-hit hypothesis\" 8 , these forms of acute glomerulopathy may be predisposed to occur with a genetic background of high-risk apolipoprotein L1 (APOL1) allelic variants.", [["glomerular", "ANATOMY", 59, 69], ["SARS", "DISEASE", 29, 33], ["infection", "DISEASE", 40, 49], ["glomerular injury", "DISEASE", 59, 76], ["glomerulopathy", "DISEASE", 178, 192], ["SARS-CoV-2", "ORGANISM", 29, 39], ["glomerular", "TISSUE", 59, 69], ["high-risk apolipoprotein L1", "GENE_OR_GENE_PRODUCT", 250, 277], ["APOL1", "GENE_OR_GENE_PRODUCT", 279, 284], ["apolipoprotein L1 (APOL1) allelic variants", "DNA", 260, 302], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37], ["2 infection", "PROBLEM", 38, 49], ["glomerular injury", "PROBLEM", 59, 76], ["acute glomerulopathy", "PROBLEM", 172, 192], ["high-risk apolipoprotein L1 (APOL1) allelic variants", "PROBLEM", 250, 302], ["glomerular", "ANATOMY", 59, 69], ["injury", "OBSERVATION", 70, 76], ["unresolved", "OBSERVATION_MODIFIER", 83, 93], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["glomerulopathy", "OBSERVATION", 178, 192], ["L1", "ANATOMY", 275, 277]]], ["Indeed, two cases of COVID-19-associated collapsing glomerulonephritis were tested and found to carry two high-risk APOL1 genetic variants (G1 or G2) 6, 7 , suggesting that SARS-CoV-2 infection may act as a trigger promoting collapsing glomerulopathy lesions in at-risk patients with COVID-19.", [["glomerulopathy lesions", "ANATOMY", 236, 258], ["COVID-19", "CHEMICAL", 21, 29], ["glomerulonephritis", "DISEASE", 52, 70], ["SARS", "DISEASE", 173, 177], ["infection", "DISEASE", 184, 193], ["glomerulopathy", "DISEASE", 236, 250], ["SARS-CoV-2", "ORGANISM", 173, 183], ["glomerulopathy lesions", "PATHOLOGICAL_FORMATION", 236, 258], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 270, 278], ["COVID", "TEST", 21, 26], ["collapsing glomerulonephritis", "PROBLEM", 41, 70], ["SARS", "PROBLEM", 173, 177], ["CoV-2 infection", "PROBLEM", 178, 193], ["collapsing glomerulopathy lesions", "PROBLEM", 225, 258], ["COVID", "TEST", 284, 289], ["collapsing", "OBSERVATION_MODIFIER", 41, 51], ["glomerulonephritis", "OBSERVATION", 52, 70], ["SARS", "OBSERVATION", 173, 177], ["collapsing", "OBSERVATION_MODIFIER", 225, 235], ["glomerulopathy", "OBSERVATION", 236, 250]]], ["9 We herein describe a kidney transplant recipient (KTR) who, 3 months after an episode of acute antibody-mediated rejection (ABMR), was diagnosed with COVID-19 at which time he was found to have collapsing glomerulopathy in the absence of detectable SARS-CoV2 RNA in the kidney.", [["kidney", "ANATOMY", 23, 29], ["kidney", "ANATOMY", 272, 278], ["glomerulopathy", "DISEASE", 207, 221], ["kidney", "ORGAN", 23, 29], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 251, 260], ["kidney", "ORGAN", 272, 278], ["SARS-CoV2 RNA", "RNA", 251, 264], ["a kidney transplant recipient", "TREATMENT", 21, 50], ["acute antibody-mediated rejection", "PROBLEM", 91, 124], ["ABMR", "PROBLEM", 126, 130], ["COVID", "TEST", 152, 157], ["collapsing glomerulopathy", "PROBLEM", 196, 221], ["detectable SARS", "PROBLEM", 240, 255], ["CoV2 RNA in the kidney", "PROBLEM", 256, 278], ["kidney", "ANATOMY", 23, 29], ["transplant", "OBSERVATION", 30, 40], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["antibody", "OBSERVATION", 97, 105], ["rejection", "OBSERVATION", 115, 124], ["collapsing", "OBSERVATION_MODIFIER", 196, 206], ["glomerulopathy", "OBSERVATION", 207, 221], ["detectable", "OBSERVATION_MODIFIER", 240, 250], ["SARS", "OBSERVATION", 251, 255], ["CoV2 RNA", "OBSERVATION", 256, 264], ["kidney", "ANATOMY", 272, 278]]], ["In addition, the donor APOL1 genotype was \"low risk\" (G0/G2).", [["APOL1", "GENE_OR_GENE_PRODUCT", 23, 28], ["APOL1", "PROTEIN", 23, 28], ["the donor APOL1 genotype", "TEST", 13, 37]]], ["The onset of glomerular injury was dissociated from SARS-CoV-2 viremia as it preceded it.", [["glomerular", "ANATOMY", 13, 23], ["glomerular injury", "DISEASE", 13, 30], ["SARS", "DISEASE", 52, 56], ["viremia", "DISEASE", 63, 70], ["glomerular", "TISSUE", 13, 23], ["glomerular injury", "PROBLEM", 13, 30], ["SARS", "PROBLEM", 52, 56], ["CoV", "PROBLEM", 57, 60], ["viremia", "PROBLEM", 63, 70], ["glomerular", "ANATOMY", 13, 23], ["injury", "OBSERVATION", 24, 30], ["viremia", "OBSERVATION", 63, 70]]], ["Viremia occurred secondarily, and resolved with seroconversion, despite the absence of circulating CD19-positive lymphocytes at admission.Case reportA 29-year-old-man of sub-Saharan origin who had kidney failure due to urinary schistosomiasis received a kidney transplant from a deceased donor in 2015 (the ethnicity of the donor is unknown).", [["lymphocytes", "ANATOMY", 113, 124], ["kidney", "ANATOMY", 197, 203], ["urinary", "ANATOMY", 219, 226], ["kidney", "ANATOMY", 254, 260], ["Viremia", "DISEASE", 0, 7], ["kidney failure", "DISEASE", 197, 211], ["urinary schistosomiasis", "DISEASE", 219, 242], ["CD19", "GENE_OR_GENE_PRODUCT", 99, 103], ["man", "ORGANISM", 163, 166], ["kidney", "ORGAN", 197, 203], ["kidney", "ORGAN", 254, 260], ["CD19", "PROTEIN", 99, 103], ["man", "SPECIES", 163, 166], ["Viremia", "PROBLEM", 0, 7], ["seroconversion", "PROBLEM", 48, 62], ["circulating CD19", "TEST", 87, 103], ["positive lymphocytes", "PROBLEM", 104, 124], ["kidney failure", "PROBLEM", 197, 211], ["urinary schistosomiasis", "PROBLEM", 219, 242], ["a kidney transplant", "TREATMENT", 252, 271], ["positive lymphocytes", "OBSERVATION", 104, 124], ["kidney", "ANATOMY", 197, 203], ["failure", "OBSERVATION", 204, 211], ["urinary", "ANATOMY", 219, 226], ["schistosomiasis", "OBSERVATION", 227, 242], ["kidney", "ANATOMY", 254, 260], ["transplant", "OBSERVATION", 261, 271]]], ["The immunosuppression regimen was prednisone, tacrolimus, and mycophenolate mofetil.", [["prednisone", "CHEMICAL", 34, 44], ["tacrolimus", "CHEMICAL", 46, 56], ["mycophenolate mofetil", "CHEMICAL", 62, 83], ["prednisone", "CHEMICAL", 34, 44], ["tacrolimus", "CHEMICAL", 46, 56], ["mycophenolate mofetil", "CHEMICAL", 62, 83], ["prednisone", "SIMPLE_CHEMICAL", 34, 44], ["tacrolimus", "SIMPLE_CHEMICAL", 46, 56], ["mycophenolate mofetil", "SIMPLE_CHEMICAL", 62, 83], ["The immunosuppression regimen", "TREATMENT", 0, 29], ["prednisone", "TREATMENT", 34, 44], ["tacrolimus", "TREATMENT", 46, 56], ["mycophenolate mofetil", "TREATMENT", 62, 83], ["immunosuppression", "OBSERVATION", 4, 21], ["mycophenolate mofetil", "OBSERVATION", 62, 83]]], ["His baseline serum creatinine was 135 \u00b5mol/L. A biopsy-proven ABMR episode was diagnosed in January 2020 ( Figure 1A , B and C).", [["serum", "ANATOMY", 13, 18], ["creatinine", "CHEMICAL", 19, 29], ["creatinine", "CHEMICAL", 19, 29], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["creatinine", "SIMPLE_CHEMICAL", 19, 29], ["His baseline serum creatinine", "TEST", 0, 29], ["A biopsy", "TEST", 46, 54], ["ABMR episode", "PROBLEM", 62, 74], ["ABMR", "OBSERVATION", 62, 66]]], ["At the time of ABMR diagnosis, serum creatinine was 289 \u00b5mol/L (estimated glomerular filtration rate was 28 ml/min/1.73 m 2 and urinary albumin-creatinine ratio [UACR] was 3.7 mg/mmol).", [["serum", "ANATOMY", 31, 36], ["glomerular", "ANATOMY", 74, 84], ["urinary", "ANATOMY", 128, 135], ["creatinine", "CHEMICAL", 37, 47], ["creatinine", "CHEMICAL", 144, 154], ["creatinine", "CHEMICAL", 37, 47], ["creatinine", "CHEMICAL", 144, 154], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["creatinine", "SIMPLE_CHEMICAL", 37, 47], ["glomerular", "TISSUE", 74, 84], ["urinary", "ORGANISM_SUBDIVISION", 128, 135], ["albumin", "GENE_OR_GENE_PRODUCT", 136, 143], ["creatinine", "SIMPLE_CHEMICAL", 144, 154], ["ABMR diagnosis", "TEST", 15, 29], ["serum creatinine", "TEST", 31, 47], ["glomerular filtration rate", "TEST", 74, 100], ["urinary albumin", "TEST", 128, 143], ["creatinine ratio", "TEST", 144, 160], ["UACR", "TEST", 162, 166], ["ABMR", "OBSERVATION", 15, 19]]], ["The patient had the following donor-specific antibodies : anti-DQ5 (MFI : 23412), anti-DQ8 (MFI : 8299), and anti DP*03 (MFI : 4975).", [["patient", "ORGANISM", 4, 11], ["anti-DQ5", "GENE_OR_GENE_PRODUCT", 58, 66], ["donor-specific antibodies", "PROTEIN", 30, 55], ["anti-DQ5", "PROTEIN", 58, 66], ["anti-DQ8", "PROTEIN", 82, 90], ["patient", "SPECIES", 4, 11], ["anti DP", "TEST", 109, 116]]], ["Treatment consisted of high-dose of corticosteroids (methylprednisolone 500 mg /day for 3 days), rituximab, (375 mg/m 2 ), 5 plasma exchanges, and a high dose of IV immunoglobulins (2 g/kg).", [["plasma", "ANATOMY", 125, 131], ["methylprednisolone", "CHEMICAL", 53, 71], ["rituximab", "CHEMICAL", 97, 106], ["corticosteroids", "CHEMICAL", 36, 51], ["methylprednisolone", "CHEMICAL", 53, 71], ["methylprednisolone", "SIMPLE_CHEMICAL", 53, 71], ["rituximab", "SIMPLE_CHEMICAL", 97, 106], ["plasma", "ORGANISM_SUBSTANCE", 125, 131], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 165, 180], ["IV immunoglobulins", "PROTEIN", 162, 180], ["Treatment", "TREATMENT", 0, 9], ["high-dose of corticosteroids", "TREATMENT", 23, 51], ["methylprednisolone", "TREATMENT", 53, 71], ["rituximab", "TREATMENT", 97, 106], ["a high dose of IV immunoglobulins", "TREATMENT", 147, 180]]], ["Maintenance immunosuppression consisted of prednisone 10 mg/day, tacrolimus 6 mg/day, and mycophenolate mofetil 500mg twice a day.", [["prednisone", "CHEMICAL", 43, 53], ["tacrolimus", "CHEMICAL", 65, 75], ["mycophenolate mofetil", "CHEMICAL", 90, 111], ["prednisone", "CHEMICAL", 43, 53], ["tacrolimus", "CHEMICAL", 65, 75], ["mycophenolate mofetil", "CHEMICAL", 90, 111], ["prednisone", "SIMPLE_CHEMICAL", 43, 53], ["tacrolimus", "SIMPLE_CHEMICAL", 65, 75], ["mycophenolate mofetil", "SIMPLE_CHEMICAL", 90, 111], ["Maintenance immunosuppression", "TREATMENT", 0, 29], ["prednisone", "TREATMENT", 43, 53], ["tacrolimus", "TREATMENT", 65, 75], ["mycophenolate mofetil", "TREATMENT", 90, 111]]], ["Kidney function did not fully recover (Figure 2 ).Case reportIn the second week of May 2020, he was admitted to the hospital because of fever, cough, and vomiting, which had started five days earlier.", [["Kidney", "ANATOMY", 0, 6], ["fever", "DISEASE", 136, 141], ["cough", "DISEASE", 143, 148], ["vomiting", "DISEASE", 154, 162], ["Kidney", "ORGAN", 0, 6], ["Kidney function", "TEST", 0, 15], ["fever", "PROBLEM", 136, 141], ["cough", "PROBLEM", 143, 148], ["vomiting", "PROBLEM", 154, 162], ["fever", "OBSERVATION", 136, 141], ["cough", "OBSERVATION", 143, 148]]], ["A reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 on a naso-pharyngeal swab sample was positive at admission.", [["pharyngeal swab sample", "ANATOMY", 89, 111], ["SARS-CoV-2", "ORGANISM", 68, 78], ["pharyngeal swab", "MULTI-TISSUE_STRUCTURE", 89, 104], ["reverse transcriptase", "PROTEIN", 2, 23], ["SARS-CoV", "SPECIES", 68, 76], ["A reverse transcriptase-polymerase chain reaction", "PROBLEM", 0, 49], ["RT-PCR) test", "TEST", 51, 63], ["SARS", "PROBLEM", 68, 72], ["CoV", "TEST", 73, 76], ["a naso-pharyngeal swab sample", "TEST", 82, 111], ["pharyngeal", "ANATOMY", 89, 99]]], ["CRP level was increased at 92 mg/L (normal < 5 mg/L), as well as fibrinogen 5.7 g/L (normal range 1.5-3.5 g/L), D-dimers 1050 ng/mL (normal < 500 ng/mL), ferritin 2672 \u00b5g/L (normal range 24-336 \u00b5g/L), and LDH 477 UI/L (normal < 240 UI/L), reflecting systemic inflammation ( Figure S1 ).Case reportAcute kidney injury was present at admission with a serum creatinine of 534 \u00b5mol/L and a nephrotic range proteinuria (urinary protein-creatinine ratio, 0.8 g/mmol; UACR, 490 mg/mmol; serum albumin, 2.8 g/dL) (Figure 2 and Figure S2 ).", [["kidney", "ANATOMY", 303, 309], ["serum", "ANATOMY", 349, 354], ["urinary", "ANATOMY", 415, 422], ["serum", "ANATOMY", 480, 485], ["inflammation", "DISEASE", 259, 271], ["reportAcute kidney injury", "DISEASE", 291, 316], ["creatinine", "CHEMICAL", 355, 365], ["nephrotic", "DISEASE", 386, 395], ["proteinuria", "DISEASE", 402, 413], ["creatinine", "CHEMICAL", 431, 441], ["creatinine", "CHEMICAL", 355, 365], ["creatinine", "CHEMICAL", 431, 441], ["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 65, 75], ["D-dimers", "GENE_OR_GENE_PRODUCT", 112, 120], ["ferritin", "GENE_OR_GENE_PRODUCT", 154, 162], ["kidney", "ORGAN", 303, 309], ["serum", "ORGANISM_SUBSTANCE", 349, 354], ["creatinine", "SIMPLE_CHEMICAL", 355, 365], ["urinary", "ORGANISM_SUBSTANCE", 415, 422], ["creatinine", "SIMPLE_CHEMICAL", 431, 441], ["serum", "ORGANISM_SUBSTANCE", 480, 485], ["albumin", "GENE_OR_GENE_PRODUCT", 486, 493], ["CRP", "PROTEIN", 0, 3], ["fibrinogen", "PROTEIN", 65, 75], ["ferritin", "PROTEIN", 154, 162], ["CRP level", "TEST", 0, 9], ["fibrinogen", "TEST", 65, 75], ["D-dimers", "TEST", 112, 120], ["ferritin", "TEST", 154, 162], ["\u00b5g", "TEST", 194, 196], ["LDH", "TEST", 205, 208], ["UI", "TEST", 213, 215], ["UI", "TEST", 232, 234], ["systemic inflammation", "PROBLEM", 250, 271], ["Case reportAcute kidney injury", "PROBLEM", 286, 316], ["a serum creatinine", "TEST", 347, 365], ["a nephrotic range proteinuria", "PROBLEM", 384, 413], ["urinary protein", "TEST", 415, 430], ["creatinine ratio", "TEST", 431, 447], ["UACR", "TEST", 461, 465], ["serum albumin", "TEST", 480, 493], ["Figure", "TEST", 506, 512], ["systemic", "OBSERVATION_MODIFIER", 250, 258], ["inflammation", "OBSERVATION", 259, 271], ["kidney", "ANATOMY", 303, 309], ["injury", "OBSERVATION", 310, 316], ["nephrotic", "OBSERVATION", 386, 395], ["proteinuria", "OBSERVATION", 402, 413], ["urinary", "ANATOMY", 415, 422]]], ["Urinary concentrations of the low molecular weight proteins retinol binding protein and \u03b22-microglobulin were 100 to 1000 times the normal value, indicating that the tubular compartment was injured.Case reportA kidney biopsy performed 2 days after admission revealed a collapsing glomerulopathy with pronounced podocyte hyperplasia and hypertrophy in absence of evidence of ABMR (Figure 1 D and E) .", [["Urinary", "ANATOMY", 0, 7], ["tubular compartment", "ANATOMY", 166, 185], ["kidney", "ANATOMY", 211, 217], ["podocyte", "ANATOMY", 311, 319], ["retinol", "CHEMICAL", 60, 67], ["glomerulopathy", "DISEASE", 280, 294], ["hyperplasia", "DISEASE", 320, 331], ["hypertrophy", "DISEASE", 336, 347], ["retinol", "CHEMICAL", 60, 67], ["Urinary", "ORGANISM_SUBSTANCE", 0, 7], ["retinol binding protein", "GENE_OR_GENE_PRODUCT", 60, 83], ["\u03b22-microglobulin", "GENE_OR_GENE_PRODUCT", 88, 104], ["tubular compartment", "MULTI-TISSUE_STRUCTURE", 166, 185], ["kidney", "ORGAN", 211, 217], ["podocyte", "PATHOLOGICAL_FORMATION", 311, 319], ["low molecular weight proteins", "PROTEIN", 30, 59], ["retinol binding protein", "PROTEIN", 60, 83], ["\u03b22", "PROTEIN", 88, 90], ["Urinary concentrations", "TEST", 0, 22], ["retinol binding protein", "TEST", 60, 83], ["\u03b22-microglobulin", "TEST", 88, 104], ["Case reportA kidney biopsy", "TEST", 198, 224], ["a collapsing glomerulopathy", "PROBLEM", 267, 294], ["pronounced podocyte hyperplasia", "PROBLEM", 300, 331], ["hypertrophy", "PROBLEM", 336, 347], ["ABMR", "PROBLEM", 374, 378], ["concentrations", "OBSERVATION_MODIFIER", 8, 22], ["tubular compartment", "ANATOMY", 166, 185], ["kidney", "ANATOMY", 211, 217], ["biopsy", "OBSERVATION", 218, 224], ["collapsing", "OBSERVATION_MODIFIER", 269, 279], ["glomerulopathy", "OBSERVATION", 280, 294], ["pronounced", "OBSERVATION_MODIFIER", 300, 310], ["podocyte", "ANATOMY", 311, 319], ["hyperplasia", "OBSERVATION", 320, 331], ["hypertrophy", "OBSERVATION", 336, 347], ["ABMR", "OBSERVATION", 374, 378]]], ["Acute proximal tubular injury was severe with tubular dilatations, flattening of the tubular epithelium, loss of the brush border and detached tubular epithelial cells in the lumen (Figure 1 F) .", [["tubular", "ANATOMY", 15, 22], ["tubular", "ANATOMY", 46, 53], ["tubular epithelium", "ANATOMY", 85, 103], ["brush border", "ANATOMY", 117, 129], ["tubular epithelial cells", "ANATOMY", 143, 167], ["lumen", "ANATOMY", 175, 180], ["tubular", "MULTI-TISSUE_STRUCTURE", 15, 22], ["tubular", "TISSUE", 46, 53], ["tubular epithelium", "TISSUE", 85, 103], ["brush border", "CELLULAR_COMPONENT", 117, 129], ["tubular epithelial cells", "CELL", 143, 167], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 175, 180], ["detached tubular epithelial cells", "CELL_TYPE", 134, 167], ["Acute proximal tubular injury", "PROBLEM", 0, 29], ["tubular dilatations", "PROBLEM", 46, 65], ["flattening of the tubular epithelium", "PROBLEM", 67, 103], ["loss of the brush border", "PROBLEM", 105, 129], ["detached tubular epithelial cells", "PROBLEM", 134, 167], ["proximal", "ANATOMY_MODIFIER", 6, 14], ["tubular", "ANATOMY_MODIFIER", 15, 22], ["injury", "OBSERVATION", 23, 29], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["tubular", "ANATOMY_MODIFIER", 46, 53], ["dilatations", "OBSERVATION", 54, 65], ["flattening", "OBSERVATION_MODIFIER", 67, 77], ["tubular", "ANATOMY_MODIFIER", 85, 92], ["epithelium", "ANATOMY_MODIFIER", 93, 103], ["loss", "OBSERVATION_MODIFIER", 105, 109], ["brush", "ANATOMY_MODIFIER", 117, 122], ["border", "ANATOMY_MODIFIER", 123, 129], ["detached", "OBSERVATION_MODIFIER", 134, 142], ["tubular epithelial cells", "OBSERVATION", 143, 167], ["lumen", "ANATOMY_MODIFIER", 175, 180]]], ["C4D staining of peritubular capillaries was negative (Figure 1 G) .", [["peritubular capillaries", "ANATOMY", 16, 39], ["C4D", "GENE_OR_GENE_PRODUCT", 0, 3], ["peritubular capillaries", "TISSUE", 16, 39], ["C4D staining", "TEST", 0, 12], ["peritubular capillaries", "TEST", 16, 39], ["staining", "OBSERVATION", 4, 12], ["peritubular", "ANATOMY_MODIFIER", 16, 27], ["capillaries", "ANATOMY", 28, 39], ["negative", "OBSERVATION", 44, 52]]], ["There was no evidence of thrombotic microangiopathy.", [["thrombotic microangiopathy", "DISEASE", 25, 51], ["thrombotic microangiopathy", "PROBLEM", 25, 51], ["no evidence of", "UNCERTAINTY", 10, 24], ["thrombotic", "OBSERVATION_MODIFIER", 25, 35], ["microangiopathy", "OBSERVATION", 36, 51]]], ["Immunofluorescence assays on glomeruli were negative for IgG, IgM, IgA, C3, C1q, \u03ba and \u03bb light chains.", [["glomeruli", "ANATOMY", 29, 38], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 29, 38], ["IgG", "GENE_OR_GENE_PRODUCT", 57, 60], ["IgM", "GENE_OR_GENE_PRODUCT", 62, 65], ["IgA", "GENE_OR_GENE_PRODUCT", 67, 70], ["C3", "GENE_OR_GENE_PRODUCT", 72, 74], ["C1q", "GENE_OR_GENE_PRODUCT", 76, 79], ["\u03ba", "GENE_OR_GENE_PRODUCT", 81, 82], ["\u03bb light chains", "GENE_OR_GENE_PRODUCT", 87, 101], ["IgG", "PROTEIN", 57, 60], ["IgM", "PROTEIN", 62, 65], ["IgA", "PROTEIN", 67, 70], ["C3", "PROTEIN", 72, 74], ["C1q", "PROTEIN", 76, 79], ["\u03ba", "PROTEIN", 81, 82], ["\u03bb light chains", "PROTEIN", 87, 101], ["Immunofluorescence assays", "TEST", 0, 25], ["glomeruli", "TEST", 29, 38], ["IgG", "TEST", 57, 60], ["IgM", "TEST", 62, 65], ["IgA", "TEST", 67, 70], ["C3", "TEST", 72, 74], ["C1q", "TEST", 76, 79], ["glomeruli", "ANATOMY", 29, 38]]], ["Electron microscopy of the biopsy specimen was not performed.Case reportSerological tests for human immunodeficiency virus, hepatitis B and C viruses were negative.", [["biopsy specimen", "ANATOMY", 27, 42], ["human immunodeficiency virus, hepatitis B", "DISEASE", 94, 135], ["biopsy specimen", "CANCER", 27, 42], ["human immunodeficiency virus", "ORGANISM", 94, 122], ["hepatitis B and C viruses", "ORGANISM", 124, 149], ["human", "SPECIES", 94, 99], ["immunodeficiency virus", "SPECIES", 100, 122], ["human immunodeficiency virus", "SPECIES", 94, 122], ["Electron microscopy", "TEST", 0, 19], ["the biopsy specimen", "TEST", 23, 42], ["Case reportSerological tests", "TEST", 61, 89], ["human immunodeficiency virus", "PROBLEM", 94, 122], ["hepatitis B and C viruses", "TEST", 124, 149]]], ["PCR testing of blood samples for cytomegalovirus, Epstein Barr virus, parvovirus B19 and BK polyomavirus all gave negative results.", [["blood samples", "ANATOMY", 15, 28], ["parvovirus B19", "DISEASE", 70, 84], ["blood samples", "ORGANISM_SUBSTANCE", 15, 28], ["cytomegalovirus", "ORGANISM", 33, 48], ["Epstein Barr virus", "ORGANISM", 50, 68], ["parvovirus B19", "ORGANISM", 70, 84], ["BK polyomavirus", "ORGANISM", 89, 104], ["parvovirus B19", "SPECIES", 70, 84], ["Epstein Barr virus", "SPECIES", 50, 68], ["parvovirus B19", "SPECIES", 70, 84], ["BK polyomavirus", "SPECIES", 89, 104], ["PCR testing", "TEST", 0, 11], ["blood samples", "TEST", 15, 28], ["cytomegalovirus", "PROBLEM", 33, 48], ["Epstein Barr virus", "TEST", 50, 68], ["parvovirus B19", "TEST", 70, 84], ["BK polyomavirus", "TEST", 89, 104]]], ["Recurrent schistosomiasis was ruled out by the absence of schistosome eggs in urine.Case reportDroplet-based digital PCR (ddPCR)-based was used to detect the presence of SARS-CoV-2 nucleic acids in fluids and tissue (Item S1). ddPCR is an ultrasensitive technology with a higher efficiency compared to classical qPCR for the detection of rare events 10, 11 .", [["eggs", "ANATOMY", 70, 74], ["urine", "ANATOMY", 78, 83], ["fluids", "ANATOMY", 198, 204], ["tissue", "ANATOMY", 209, 215], ["schistosomiasis", "DISEASE", 10, 25], ["SARS", "DISEASE", 170, 174], ["nucleic acids", "CHEMICAL", 181, 194], ["schistosome", "ORGANISM", 58, 69], ["eggs", "ORGANISM_SUBSTANCE", 70, 74], ["urine", "ORGANISM_SUBSTANCE", 78, 83], ["fluids", "TISSUE", 198, 204], ["tissue", "TISSUE", 209, 215], ["SARS-CoV", "SPECIES", 170, 178], ["Recurrent schistosomiasis", "PROBLEM", 0, 25], ["schistosome eggs in urine", "PROBLEM", 58, 83], ["digital PCR", "TEST", 109, 120], ["SARS", "PROBLEM", 170, 174], ["CoV", "TEST", 175, 178], ["nucleic acids", "TEST", 181, 194], ["ddPCR", "TEST", 227, 232], ["a higher efficiency", "PROBLEM", 270, 289], ["classical qPCR", "TEST", 302, 316], ["the detection", "TEST", 321, 334], ["rare events", "PROBLEM", 338, 349], ["schistosomiasis", "OBSERVATION", 10, 25], ["schistosome eggs", "OBSERVATION", 58, 74]]], ["SARS-CoV-2 RNA detected by this method was barely detectable in the plasma at the time of the biopsy (17 copies/ml), peaked thereafter at high concentrations (up to 1000 copies/ml), and rapidly decreased (Figure 2) .", [["plasma", "ANATOMY", 68, 74], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["plasma", "ORGANISM_SUBSTANCE", 68, 74], ["SARS-CoV-2 RNA", "RNA", 0, 14], ["SARS", "TEST", 0, 4], ["this method", "TEST", 27, 38], ["the biopsy", "TEST", 90, 100], ["high concentrations", "PROBLEM", 138, 157], ["rapidly", "OBSERVATION_MODIFIER", 186, 193], ["decreased", "OBSERVATION_MODIFIER", 194, 203]]], ["The clearance of the virus was concomitant with seroconversion.", [["the virus", "PROBLEM", 17, 26], ["seroconversion", "PROBLEM", 48, 62], ["virus", "OBSERVATION", 21, 26]]], ["Indeed, IgG antibodies against SARS-CoV-2 nucleocapsid (assayed with the ARCHITECT i2000 immunoassay analyzer [Abbott]) were absent at admission and were detected 14 days after (Titration: 2.7 IU/l:, cutoff: 1.4 UI/l) despite the absence of circulating CD19-positive cells at admission, and 3 per microliter 15 days later (Figure 2) .", [["CD19-positive cells", "ANATOMY", 253, 272], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 8, 22], ["SARS-CoV-2 nucleocapsid", "ORGANISM", 31, 54], ["CD19", "GENE_OR_GENE_PRODUCT", 253, 257], ["IgG antibodies", "PROTEIN", 8, 22], ["SARS-CoV-2 nucleocapsid", "PROTEIN", 31, 54], ["CD19", "PROTEIN", 253, 257], ["positive cells", "CELL_TYPE", 258, 272], ["CoV-2", "SPECIES", 36, 41], ["SARS-CoV", "SPECIES", 31, 39], ["IgG antibodies", "TEST", 8, 22], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["nucleocapsid", "PROBLEM", 42, 54], ["the ARCHITECT i2000 immunoassay analyzer", "TEST", 69, 109], ["Titration", "TEST", 178, 187], ["cutoff", "TEST", 200, 206], ["UI", "TEST", 212, 214], ["circulating CD19", "TEST", 241, 257], ["positive cells", "PROBLEM", 258, 272], ["positive cells", "OBSERVATION", 258, 272]]], ["Critically, SARS-CoV-2 RNA was not found in the kidney biopsy fragment or in urine (which was also collected before the peak of viremia).Case reportThe donor was found to have a APOL1 G0/G2 genotype, which is considered low risk 8 ; the genotype of the recipient was G0/G0.", [["kidney biopsy fragment", "ANATOMY", 48, 70], ["urine", "ANATOMY", 77, 82], ["viremia", "DISEASE", 128, 135], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 12, 22], ["kidney", "ORGAN", 48, 54], ["biopsy fragment", "ORGANISM_SUBSTANCE", 55, 70], ["urine", "ORGANISM_SUBSTANCE", 77, 82], ["APOL1", "GENE_OR_GENE_PRODUCT", 178, 183], ["SARS-CoV-2 RNA", "RNA", 12, 26], ["kidney biopsy fragment", "DNA", 48, 70], ["SARS-CoV", "SPECIES", 12, 20], ["Critically, SARS", "PROBLEM", 0, 16], ["CoV", "TEST", 17, 20], ["the kidney biopsy fragment", "PROBLEM", 44, 70], ["viremia", "PROBLEM", 128, 135], ["low risk", "PROBLEM", 220, 228], ["SARS", "OBSERVATION", 12, 16], ["kidney", "ANATOMY", 48, 54], ["biopsy", "OBSERVATION", 55, 61], ["viremia", "OBSERVATION", 128, 135], ["APOL1", "OBSERVATION", 178, 183]]], ["The donor was a carrier of the high risk HLA DR4 genotype, and the recipient carried the high risk HLA B44 genotype 12 .", [["HLA DR4", "GENE_OR_GENE_PRODUCT", 41, 48], ["HLA DR4", "PROTEIN", 41, 48], ["the high risk HLA DR4 genotype", "PROBLEM", 27, 57], ["the recipient", "TREATMENT", 63, 76]]], ["Systematic screen for other genes that are associated with collapsing glomerulopathy was not performed.Case reportMycophenolate mofetil was discontinued temporarily.", [["glomerulopathy", "DISEASE", 70, 84], ["reportMycophenolate mofetil", "CHEMICAL", 108, 135], ["reportMycophenolate mofetil", "CHEMICAL", 108, 135], ["reportMycophenolate mofetil", "SIMPLE_CHEMICAL", 108, 135], ["Systematic screen", "TEST", 0, 17], ["collapsing glomerulopathy", "PROBLEM", 59, 84], ["Case reportMycophenolate mofetil", "TREATMENT", 103, 135], ["glomerulopathy", "OBSERVATION", 70, 84]]], ["The patient did not require intensive care support but fever and inflammation resolved at the same time viremia cleared (Figure 2 and Figure S1 ).", [["fever", "DISEASE", 55, 60], ["inflammation", "DISEASE", 65, 77], ["viremia", "DISEASE", 104, 111], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["intensive care support", "TREATMENT", 28, 50], ["fever", "PROBLEM", 55, 60], ["inflammation", "PROBLEM", 65, 77], ["viremia", "PROBLEM", 104, 111], ["inflammation", "OBSERVATION", 65, 77]]], ["Four weeks after the diagnosis of collapsing glomerulopathy, kidney function only partially recovered with a serum creatinine of 325 \u00b5mol/L, severely increased UACR (171 mg/mmol), and a normalized serum albumin (3.7 g/dl) (Figure 2) .", [["kidney", "ANATOMY", 61, 67], ["serum", "ANATOMY", 109, 114], ["serum", "ANATOMY", 197, 202], ["glomerulopathy", "DISEASE", 45, 59], ["creatinine", "CHEMICAL", 115, 125], ["creatinine", "CHEMICAL", 115, 125], ["kidney", "ORGAN", 61, 67], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["creatinine", "SIMPLE_CHEMICAL", 115, 125], ["serum", "ORGANISM_SUBSTANCE", 197, 202], ["albumin", "GENE_OR_GENE_PRODUCT", 203, 210], ["collapsing glomerulopathy", "PROBLEM", 34, 59], ["kidney function", "TEST", 61, 76], ["a serum creatinine", "TEST", 107, 125], ["severely increased UACR", "PROBLEM", 141, 164], ["a normalized serum albumin", "TEST", 184, 210], ["collapsing", "OBSERVATION_MODIFIER", 34, 44], ["glomerulopathy", "OBSERVATION", 45, 59], ["kidney", "ANATOMY", 61, 67], ["increased", "OBSERVATION_MODIFIER", 150, 159], ["UACR", "OBSERVATION", 160, 164]]], ["SARS-CoV-2 was no longer detected on a naso-pharyngeal swab sample.", [["pharyngeal swab sample", "ANATOMY", 44, 66], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "TEST", 0, 8], ["a naso-pharyngeal swab sample", "TEST", 37, 66], ["no longer", "UNCERTAINTY", 15, 24], ["pharyngeal", "ANATOMY", 44, 54]]], ["The immunosuppression regimen at the end of the follow-up was prednisone 10 mg/day, tacrolimus 6 mg/day (T0 5.8 ng/mL) and mycophenolate mofetil was resumed at 500 mg twice a day.DiscussionWe describe biopsy-proven collapsing glomerulopathy occurring in a KRT with 14 .", [["prednisone", "CHEMICAL", 62, 72], ["tacrolimus", "CHEMICAL", 84, 94], ["mycophenolate mofetil", "CHEMICAL", 123, 144], ["glomerulopathy", "DISEASE", 226, 240], ["prednisone", "CHEMICAL", 62, 72], ["tacrolimus", "CHEMICAL", 84, 94], ["mycophenolate mofetil", "CHEMICAL", 123, 144], ["prednisone", "SIMPLE_CHEMICAL", 62, 72], ["tacrolimus", "SIMPLE_CHEMICAL", 84, 94], ["mycophenolate mofetil", "SIMPLE_CHEMICAL", 123, 144], ["The immunosuppression regimen", "TREATMENT", 0, 29], ["prednisone", "TREATMENT", 62, 72], ["tacrolimus", "TREATMENT", 84, 94], ["mycophenolate mofetil", "TREATMENT", 123, 144], ["biopsy", "TEST", 201, 207], ["collapsing glomerulopathy", "PROBLEM", 215, 240], ["a KRT", "TREATMENT", 254, 259], ["collapsing", "OBSERVATION_MODIFIER", 215, 225], ["glomerulopathy", "OBSERVATION", 226, 240]]], ["However, the detection of virus in kidney tissue may be challenging in terms of sensitivity and specificity [15] [16] [17] .", [["kidney tissue", "ANATOMY", 35, 48], ["kidney tissue", "TISSUE", 35, 48], ["virus in kidney tissue", "PROBLEM", 26, 48], ["sensitivity", "TEST", 80, 91], ["specificity", "TEST", 96, 107], ["virus", "OBSERVATION", 26, 31], ["kidney", "ANATOMY", 35, 41]]], ["Thus, highly sensitive and specific methods are required to detect the presence of the virus in the setting of COVID-19-related kidney diseases.", [["kidney", "ANATOMY", 128, 134], ["COVID-19", "CHEMICAL", 111, 119], ["kidney diseases", "DISEASE", 128, 143], ["COVID-19", "GENE_OR_GENE_PRODUCT", 111, 119], ["kidney", "ORGAN", 128, 134], ["the virus", "PROBLEM", 83, 92], ["COVID", "TEST", 111, 116], ["kidney diseases", "PROBLEM", 128, 143], ["virus", "OBSERVATION", 87, 92], ["kidney", "ANATOMY", 128, 134], ["diseases", "OBSERVATION", 135, 143]]], ["Despite the use of ddPCR-an ultrasensitive method to detect nucleic acids-we did not found SARS-CoV-2 RNA in the kidney biopsy fragment.", [["kidney biopsy fragment", "ANATOMY", 113, 135], ["nucleic acids", "CHEMICAL", 60, 73], ["ddPCR", "SIMPLE_CHEMICAL", 19, 24], ["nucleic acids", "SIMPLE_CHEMICAL", 60, 73], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 91, 101], ["kidney biopsy", "MULTI-TISSUE_STRUCTURE", 113, 126], ["SARS-CoV-2 RNA", "RNA", 91, 105], ["kidney biopsy fragment", "DNA", 113, 135], ["ddPCR", "TEST", 19, 24], ["an ultrasensitive method", "TEST", 25, 49], ["nucleic acids", "TEST", 60, 73], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99], ["2 RNA in the kidney biopsy fragment", "PROBLEM", 100, 135], ["kidney", "ANATOMY", 113, 119], ["biopsy fragment", "OBSERVATION", 120, 135]]], ["A false-negative finding is unlikely because the endogenous control (RNase P) was correctly amplified.", [["RNase", "GENE_OR_GENE_PRODUCT", 69, 74], ["RNase P", "PROTEIN", 69, 76], ["false", "OBSERVATION", 2, 7], ["negative", "OBSERVATION", 8, 16]]], ["Thus, the temporal sequence of occurrence of a collapsing glomerulopathy negative for SARS-CoV-2 RNA followed by SARS-CoV-2 RNAemia is a strong, but not definitive, argument for the role of a circulating factor produced upon SARS-CoV-2 infection, rather than a direct cytopathic effect of the virus 18 .DiscussionThis collapsing glomerulopathy in the setting of SARS-CoV-2 infection occurred in a low-risk APOL1 (G0/G2) donor background 8 .", [["glomerulopathy", "DISEASE", 58, 72], ["SARS", "DISEASE", 86, 90], ["infection", "DISEASE", 236, 245], ["glomerulopathy", "DISEASE", 329, 343], ["SARS", "DISEASE", 362, 366], ["infection", "DISEASE", 373, 382], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 86, 96], ["SARS-CoV-2", "ORGANISM", 113, 123], ["SARS-CoV-2", "ORGANISM", 225, 235], ["SARS-CoV-2", "ORGANISM", 362, 372], ["SARS-CoV-2 RNA", "RNA", 86, 100], ["circulating factor", "PROTEIN", 192, 210], ["SARS-CoV", "SPECIES", 86, 94], ["SARS-CoV", "SPECIES", 113, 121], ["SARS-CoV", "SPECIES", 225, 233], ["SARS-CoV", "SPECIES", 362, 370], ["a collapsing glomerulopathy", "PROBLEM", 45, 72], ["SARS", "PROBLEM", 86, 90], ["CoV", "TEST", 91, 94], ["SARS", "TEST", 113, 117], ["CoV", "TEST", 118, 121], ["a circulating factor", "PROBLEM", 190, 210], ["SARS", "PROBLEM", 225, 229], ["CoV-2 infection", "PROBLEM", 230, 245], ["a direct cytopathic effect of the virus", "PROBLEM", 259, 298], ["This collapsing glomerulopathy", "PROBLEM", 313, 343], ["SARS", "PROBLEM", 362, 366], ["CoV", "PROBLEM", 367, 370], ["2 infection", "PROBLEM", 371, 382], ["collapsing", "OBSERVATION_MODIFIER", 47, 57], ["glomerulopathy", "OBSERVATION", 58, 72], ["infection", "OBSERVATION", 236, 245], ["collapsing", "OBSERVATION_MODIFIER", 318, 328], ["glomerulopathy", "OBSERVATION", 329, 343], ["SARS", "OBSERVATION", 362, 366], ["infection", "OBSERVATION", 373, 382]]], ["APOL1 risk alleles are associated with a higher rate of occurrence for de novo collapsing glomerulopathy 12 and there is growing experimental evidence to suggest that kidney-specific expression of the APOL1 G1 and G2 risk variants may interfere with normal podocyte homeostasis 8 .", [["kidney", "ANATOMY", 167, 173], ["podocyte", "ANATOMY", 257, 265], ["glomerulopathy", "DISEASE", 90, 104], ["APOL1", "GENE_OR_GENE_PRODUCT", 0, 5], ["kidney", "ORGAN", 167, 173], ["APOL1", "GENE_OR_GENE_PRODUCT", 201, 206], ["podocyte", "CELL", 257, 265], ["APOL1 risk alleles", "DNA", 0, 18], ["APOL1 G1 and G2 risk variants", "DNA", 201, 230], ["APOL1 risk alleles", "PROBLEM", 0, 18], ["de novo collapsing glomerulopathy", "PROBLEM", 71, 104], ["the APOL1 G1", "PROBLEM", 197, 209], ["G2 risk variants", "PROBLEM", 214, 230], ["collapsing", "OBSERVATION_MODIFIER", 79, 89], ["glomerulopathy", "OBSERVATION", 90, 104], ["kidney", "ANATOMY", 167, 173], ["podocyte homeostasis", "OBSERVATION", 257, 277]]], ["APOL1 expression is enhanced in inflammatory settings, including interferons, lipopolysaccharids, Toll-like receptor agonists, tumor necrosis factor, and other cytokines with robust upregulation 8 , and type I interferons stimulate APOL1 expression in vitro, causing severe podocyte injury 18 .", [["podocyte", "ANATOMY", 274, 282], ["tumor", "DISEASE", 127, 132], ["necrosis", "DISEASE", 133, 141], ["APOL1", "GENE_OR_GENE_PRODUCT", 0, 5], ["interferons", "GENE_OR_GENE_PRODUCT", 65, 76], ["lipopolysaccharids", "SIMPLE_CHEMICAL", 78, 96], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 98, 116], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 127, 148], ["type I interferons", "GENE_OR_GENE_PRODUCT", 203, 221], ["APOL1", "GENE_OR_GENE_PRODUCT", 232, 237], ["APOL1", "PROTEIN", 0, 5], ["interferons", "PROTEIN", 65, 76], ["lipopolysaccharids", "PROTEIN", 78, 96], ["tumor necrosis factor", "PROTEIN", 127, 148], ["cytokines", "PROTEIN", 160, 169], ["type I interferons", "PROTEIN", 203, 221], ["APOL1", "PROTEIN", 232, 237], ["interferons", "TREATMENT", 65, 76], ["lipopolysaccharids", "TREATMENT", 78, 96], ["receptor agonists", "TREATMENT", 108, 125], ["tumor necrosis factor", "PROBLEM", 127, 148], ["robust upregulation", "TREATMENT", 175, 194], ["type I interferons", "TREATMENT", 203, 221], ["severe podocyte injury", "PROBLEM", 267, 289], ["enhanced", "OBSERVATION_MODIFIER", 20, 28], ["inflammatory", "OBSERVATION_MODIFIER", 32, 44], ["tumor", "OBSERVATION_MODIFIER", 127, 132], ["necrosis", "OBSERVATION", 133, 141], ["severe", "OBSERVATION_MODIFIER", 267, 273], ["podocyte", "ANATOMY", 274, 282], ["injury", "OBSERVATION", 283, 289]]], ["Inheritance of risk of kidney disease conferred by the G1 and G2 APOL1 variants follows a largely recessive pattern, even if a much smaller effect is often observed in G1 heterozygotes that has not been seen in G2 heterozygotes 8 .", [["kidney", "ANATOMY", 23, 29], ["kidney disease", "DISEASE", 23, 37], ["kidney", "ORGAN", 23, 29], ["APOL1", "GENE_OR_GENE_PRODUCT", 65, 70], ["G1 and G2 APOL1 variants", "DNA", 55, 79], ["kidney disease", "PROBLEM", 23, 37], ["a largely recessive pattern", "PROBLEM", 88, 115], ["G1 heterozygotes", "PROBLEM", 168, 184], ["kidney", "ANATOMY", 23, 29], ["disease", "OBSERVATION", 30, 37]]], ["However, one cannot exclude that, in the specific context of infection due SARS-CoV-2, and in a highly systemic inflammatory burden with activation of type I interferon-mediated signaling pathways, inheriting one copy of the G2 allele may sensitize podocytes to injury.", [["podocytes", "ANATOMY", 249, 258], ["infection", "DISEASE", 61, 70], ["SARS", "DISEASE", 75, 79], ["CoV-2", "GENE_OR_GENE_PRODUCT", 80, 85], ["type I interferon", "GENE_OR_GENE_PRODUCT", 151, 168], ["podocytes", "CELL", 249, 258], ["type I interferon", "PROTEIN", 151, 168], ["G2 allele", "DNA", 225, 234], ["podocytes", "CELL_TYPE", 249, 258], ["SARS-CoV", "SPECIES", 75, 83], ["infection", "PROBLEM", 61, 70], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83], ["a highly systemic inflammatory burden", "PROBLEM", 94, 131], ["type I interferon", "TREATMENT", 151, 168], ["injury", "PROBLEM", 262, 268], ["infection", "OBSERVATION", 61, 70], ["highly", "OBSERVATION_MODIFIER", 96, 102], ["systemic", "OBSERVATION_MODIFIER", 103, 111], ["inflammatory", "OBSERVATION", 112, 124], ["injury", "OBSERVATION", 262, 268]]], ["IgG production in the context of circulating B cells depletion remain to be established.DiscussionIn conclusion, this case illustrates that a high-risk APOL1 donor background is not a prerequisite for severe podocyte injury to occur in kidney allografts in a context of COVID-19.DiscussionOur findings suggest that a direct cytopathogenic effect of SARS-CoV2 may not be instrumental for the development of collapsing glomerulopathy.", [["B cells", "ANATOMY", 45, 52], ["podocyte", "ANATOMY", 208, 216], ["kidney allografts", "ANATOMY", 236, 253], ["SARS", "DISEASE", 349, 353], ["glomerulopathy", "DISEASE", 417, 431], ["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["B cells", "CELL", 45, 52], ["APOL1", "GENE_OR_GENE_PRODUCT", 152, 157], ["podocyte", "CELL", 208, 216], ["kidney allografts", "MULTI-TISSUE_STRUCTURE", 236, 253], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 349, 358], ["IgG", "PROTEIN", 0, 3], ["circulating B cells", "CELL_TYPE", 33, 52], ["IgG production", "PROBLEM", 0, 14], ["circulating B cells depletion", "TREATMENT", 33, 62], ["a high-risk APOL1 donor background", "PROBLEM", 140, 174], ["severe podocyte injury", "PROBLEM", 201, 223], ["kidney allografts", "TREATMENT", 236, 253], ["COVID", "TEST", 270, 275], ["a direct cytopathogenic effect of SARS-CoV2", "PROBLEM", 315, 358], ["collapsing glomerulopathy", "PROBLEM", 406, 431], ["cells depletion", "OBSERVATION", 47, 62], ["podocyte", "ANATOMY", 208, 216], ["injury", "OBSERVATION", 217, 223], ["kidney", "ANATOMY", 236, 242], ["allografts", "OBSERVATION", 243, 253], ["collapsing", "OBSERVATION_MODIFIER", 406, 416], ["glomerulopathy", "OBSERVATION", 417, 431]]], ["Figure S1 : Evolution of inflammatory markers during follow-up.", [["inflammatory markers", "PROTEIN", 25, 45], ["inflammatory markers", "PROBLEM", 25, 45], ["inflammatory", "OBSERVATION", 25, 37]]]], "PMC7538843": [["BackgroundExercise adherence is the extent to which a person\u2019s behavior corresponds with agreed recommendations from health care providers [1].", [["person", "SPECIES", 54, 60]]], ["The benefits of exercise can only be obtained when a person is adhering to the prescribed exercises.", [["person", "SPECIES", 53, 59]]], ["Multiple factors are associated with exercise adherence such as sociocultural factors, knowledge towards exercise, self-efficacy, ethnicity, and economic status of an individual [2].", [["Multiple factors", "PROBLEM", 0, 16]]], ["There is no gold standard outcome tool to measure the exercise adherence rate in the Nepalese cultural context and background.", [["no", "UNCERTAINTY", 9, 11], ["gold", "OBSERVATION_MODIFIER", 12, 16]]], ["People commonly use self-reported diaries to reflect exercise adherence; however, they lack standardization, accuracy, and possess self-presentation bias that limits their validity [4].", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["The Exercise Adherence Rating Scale (EARS) is one of the commonly used outcome tools, which helps to identify the adherence rate of exercises and reasons for adherence and non-adherence [5].BackgroundThe original English version of the EARS is a 16-item, self-reported questionnaire, which assesses the adherence of prescribed exercises [6].", [["EARS", "ANATOMY", 236, 240]]], ["The EARS consist of 3 sections.", [["sections", "ANATOMY", 22, 30], ["EARS", "DNA", 4, 8], ["EARS", "ANATOMY", 4, 8]]], ["This section consists of 5 items, which are related to the way of doing activities and exercise that people often do to improve their physical quality of life.", [["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107]]], ["A possible summed score of section \u2018B\u2019 and \u2018C\u2019 range from 0 to 64.", [["section", "TEST", 27, 34]]], ["A higher overall score indicates better exercise adherence [5].BackgroundThe internal consistency (0.81), test\u2013retest reliability (0.94), constructs validity (70%) and face validity of the original version of the EARS have been established [5, 6].", [["A higher overall score", "PROBLEM", 0, 22], ["test\u2013retest reliability", "TEST", 106, 129], ["constructs validity", "TEST", 138, 157], ["face validity", "TEST", 168, 181], ["internal", "ANATOMY_MODIFIER", 77, 85], ["EARS", "ANATOMY", 213, 217]]], ["Acknowledged with good validity and reliability, the EARS scale has been established as an appropriate and feasible tool to assess exercise adherence.BackgroundThe \u201ccross-cultural adaptation\u201d is a process that looks at both language (translation) and cultural adaptation issues for a questionnaire to use in another setting [7].", [["the EARS scale", "TEST", 49, 63]]], ["Cross-cultural adaptation is important when an instrument has to be used in a different language, setting and time because of the diversified context of geography, ethnicity, economic status, culture, and diseases [2, 8].", [["culture", "TEST", 192, 199], ["diseases", "PROBLEM", 205, 213]]], ["When there is no tool available to assess exercise adherence in Nepal, a tool that is valid and reliable in measuring exercise adherence of Nepali-speaking individuals was required.", [["individuals", "ORGANISM", 156, 167], ["no", "UNCERTAINTY", 14, 16]]], ["Following cross-cultural adaptation, it is mandatory to establish psychometric properties such as validity, reliability, sensitivity and specificity of the adopted tool to use it in the clinical practice and research.", [["cross-cultural adaptation", "TREATMENT", 10, 35]]], ["Therefore, this study aimed to conduct the cross-cultural adaptation of the EARS to the Nepali language and investigate its reliability and validity.Cross-cultural adaptation ::: Methods and materialsBeaton Guidelines is one of the commonly used guidelines for the translation and cross-cultural adaptation of measurement tools [7].", [["this study", "TEST", 11, 21], ["Methods and materialsBeaton Guidelines", "TREATMENT", 179, 217], ["the translation", "TREATMENT", 261, 276], ["measurement tools", "TEST", 310, 327]]], ["As per the suggestion from the developer of the tool, Dr. Emma L Godfrey, we considered (a) Beaton guidelines and (b) evidence of cross-cultural adaptation process followed in a study by Takasaki et al., in 2017 [7, 9] to cross-culturally adapt the EARS into Nepali language.", [["cross-cultural adaptation process", "PROBLEM", 130, 163], ["a study", "TEST", 176, 183]]], ["The five steps of cross-cultural adaptation were; forward translation, synthesis, back translation, expert committee review, and pre-testing, which are described in Fig. 1.Cross-cultural adaptation ::: Methods and materialsTwo independent non-medical translators, who were bilingual in English and Nepali language, translated the original English EARS into the Nepali language and developed two forward translated versions (FT1 and FT2).", [["FT1", "DNA", 424, 427], ["cross-cultural adaptation", "TREATMENT", 18, 43]]], ["A meeting was held among two translators and investigators of the present study to reach a consensus objectively.", [["the present study", "TEST", 62, 79]]], ["All minor issues encountered were addressed and resolved, as there were no major issues.", [["All minor issues", "PROBLEM", 0, 16], ["major issues", "PROBLEM", 75, 87], ["minor", "OBSERVATION_MODIFIER", 4, 9], ["issues", "OBSERVATION", 10, 16], ["no", "UNCERTAINTY", 72, 74], ["major", "OBSERVATION_MODIFIER", 75, 80]]], ["Through consensus, a common forward translation (FT12) was synthesized.", [["FT12", "DNA", 49, 53]]], ["Two Physiotherapists who were bilingual in English and Nepali language then back-translated the FT12 version into English.", [["FT12", "DNA", 96, 100]]], ["The purpose of the back translation was for validity checking to make sure that the adapted version was reflecting the same item content as the original version [10].", [["the back translation", "TREATMENT", 15, 35], ["validity checking", "TEST", 44, 61]]], ["The back-translated versions were reviewed, and a consensus version was developed [7, 9].Cross-cultural adaptation ::: Methods and materialsPretesting was done on 10 individuals with pre-diabetic conditions (who were not included in the reliability and validity testing) to explore clarity, understandability, comprehensibility, and feasibility of the adapted version of the EARS using a visual analog scale; ranging from 0 (not clear at all and difficult to understand) to 10 (clear and easy to understand).", [["a consensus version", "TEST", 48, 67], ["validity testing", "TEST", 253, 269], ["a visual analog scale", "TEST", 386, 407], ["back", "ANATOMY", 4, 8]]], ["The average score of 8.1 indicated that the adapted version was clear, comprehensible, and understandable.", [["The average score", "TEST", 0, 17]]], ["No ambiguity of meaning on any item was reported.", [["ambiguity", "PROBLEM", 3, 12], ["ambiguity", "OBSERVATION", 3, 12]]], ["Thus, the pre-testing version was considered as a final version without any modification in the original English version.", [["the pre-testing version", "TEST", 6, 29]]], ["Thus, a Nepali version of EARS (N-EARS) was cross-culturally adapted (see Additional file 1).", [["a Nepali version of EARS (N-EARS)", "TREATMENT", 6, 39], ["EARS", "ANATOMY", 26, 30]]], ["The Nepali version of the EARS was submitted to the developer of the tool and an appreciation email response was received.Validation of N-EARS ::: Methods and materialsIndividuals at the pre-diabetic stage (who were not included during the pre-testing phase of cross-cultural adaptation) as well as patients with various conditions were screened.", [["patients", "ORGANISM", 299, 307], ["N-EARS", "PROTEIN", 136, 142], ["patients", "SPECIES", 299, 307], ["EARS", "ANATOMY", 26, 30]]], ["Patients were eligible if they satisfied the following inclusion criteria: (1) individuals with pre-diabetes (HbA1c level from 5.7 to 6.4%) [12] or any patients with a confirmed diagnosis of any disease who were prescribed with home exercises by the physiotherapists, and (2) aged 18 years or older and (3) those who were called for follow-up at the clinic after two weeks of the exercise prescription.", [["pre-diabetes", "DISEASE", 96, 108], ["Patients", "ORGANISM", 0, 8], ["individuals", "ORGANISM", 79, 90], ["patients", "ORGANISM", 152, 160], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 152, 160], ["pre-diabetes", "PROBLEM", 96, 108], ["HbA1c level", "TEST", 110, 121], ["any disease", "PROBLEM", 191, 202], ["the exercise prescription", "TREATMENT", 376, 401], ["disease", "OBSERVATION", 195, 202]]], ["Any disease or conditions like recent surgery that limited participants from doing exercises were excluded from the study.Procedure ::: Methods and materialsIndividuals were screened at a clinic of the Dhulikhel Hospital, Nepal from November 2019 to February 2020.", [["participants", "SPECIES", 59, 71], ["Any disease or conditions", "PROBLEM", 0, 25], ["recent surgery", "TREATMENT", 31, 45], ["the study", "TEST", 112, 121], ["disease", "OBSERVATION", 4, 11], ["surgery", "OBSERVATION", 38, 45]]], ["During the follow-up visit after two weeks, participants\u2019 consent was obtained, demographic information was taken, and they were asked to fill the adapted version of the EARS at the same clinic.", [["participants", "SPECIES", 44, 56]]], ["The assessor instructed the participants who rated their level of exercise adherence and reasons for adherence/non-adherence by re-calling their exercise performance level in the previous two weeks.", [["participants", "SPECIES", 28, 40]]], ["Pre-diabetic participants were purposively included in this study because all the participants were staff of the hospital and educated, which is required for any self-administered tool.", [["participants", "ORGANISM", 13, 25], ["participants", "SPECIES", 13, 25], ["participants", "SPECIES", 82, 94], ["this study", "TEST", 55, 65]]], ["Besides, we recruited participants with various conditions from the outpatient department of the hospital intending to increase the generalizability of the outcome.", [["participants", "SPECIES", 22, 34]]], ["However, the number of participants with various conditions was small due to the literacy factor.Statistical analysis ::: Methods and materialsThe mean with standard deviation and number with percentage were described during demographic and clinical data analysis.", [["participants", "SPECIES", 23, 35], ["various conditions", "PROBLEM", 41, 59], ["clinical data analysis", "TEST", 241, 263], ["mean", "OBSERVATION_MODIFIER", 147, 151], ["standard deviation", "OBSERVATION", 157, 175]]], ["Cronbach\u2019s alpha (\u03b1) was calculated to determine internal consistency.", [["Cronbach\u2019s alpha", "GENE_OR_GENE_PRODUCT", 0, 16], ["Cronbach\u2019s alpha", "TEST", 0, 16]]], ["Exploratory Factor Analysis (EFA) was performed in the study by Newman-Beinart et al., to determine factors in the original English tool [5].", [["Exploratory Factor Analysis", "TEST", 0, 27], ["EFA", "TEST", 29, 32]]], ["To compare the findings with the study, we performed EFA to explore construct validity.", [["the study", "TEST", 29, 38], ["EFA", "TEST", 53, 56]]], ["Kaiser\u2013Meyer\u2013Olkin (KMO) test and Bartlett\u2019s test were used to check for sampling adequacy and sphericity, respectively.", [["Bartlett\u2019s test", "TEST", 34, 49], ["sampling adequacy", "TEST", 73, 90], ["sphericity", "TEST", 95, 105]]], ["The minimum recommended value of 0.60 was considered for sampling adequacy [13].", [["sampling adequacy", "TEST", 57, 74]]], ["The Varimax rotation was used during the analysis.", [["The Varimax rotation", "TREATMENT", 0, 20], ["the analysis", "TEST", 37, 49]]], ["Eigenvalues were calculated to select the number of components in EFA [5].", [["EFA", "CHEMICAL", 66, 69], ["Eigenvalues", "TEST", 0, 11]]], ["Receiver Operating Characteristic (ROC) curve was analyzed to identify cutoff score, sensitivity and specificity of N-EARS.", [["cutoff score", "TEST", 71, 83], ["sensitivity", "TEST", 85, 96]]], ["Data were analyzed using SPSS (version 21.00).", [["SPSS (version", "TEST", 25, 38]]], ["The significant level was considered at p < 0.05.Test of reliability ::: ResultsAs shown in Table 2, the Cronbach\u2019s alpha was 0.94 for adherence behavior.", [["Cronbach\u2019s alpha", "GENE_OR_GENE_PRODUCT", 105, 121], ["ResultsAs", "TEST", 73, 82], ["the Cronbach\u2019s alpha", "TEST", 101, 121], ["adherence behavior", "PROBLEM", 135, 153], ["significant", "OBSERVATION_MODIFIER", 4, 15]]], ["The Cronbach\u2019s alpha if item deleted ranged from 0.91 to 0.93 for 6-item adherence behavior.", [["Cronbach\u2019s alpha", "GENE_OR_GENE_PRODUCT", 4, 20], ["The Cronbach\u2019s alpha", "TEST", 0, 20]]], ["Removal of any item would result in lower Cronbach\u2019s alpha, and therefore each item has to be retained.Test of validity ::: ResultsConstruct validity of 6-items of Section \u2018B\u201d was explored using an EFA.", [["Cronbach\u2019s alpha", "GENE_OR_GENE_PRODUCT", 42, 58], ["Removal", "TREATMENT", 0, 7], ["any item", "PROBLEM", 11, 19], ["ResultsConstruct validity", "TEST", 124, 149], ["EFA", "OBSERVATION", 198, 201]]], ["The KMO value for 6-items adherence behavior was 0.7, exceeding the recommended minimum value of 0.60 which verified sampling adequacy for the analysis.", [["The KMO value", "TEST", 0, 13], ["the analysis", "TEST", 139, 151]]], ["Bartlett\u2019s test for sphericity indicated that correlations between items were sufficiently large (Chi-square: 110.2, p < 0.001) for factor analysis.", [["Bartlett\u2019s test", "TEST", 0, 15], ["sphericity", "TEST", 20, 30], ["Chi-square", "TEST", 98, 108], ["factor analysis", "TEST", 132, 147], ["large", "OBSERVATION_MODIFIER", 91, 96]]], ["Thus, the criteria for sampling adequacy and sphericity for the 6-items adherence behavior scale was achieved.", [["sampling adequacy", "TEST", 23, 40], ["sphericity", "TEST", 45, 55]]], ["As depicted in Table 3, the EFA of 6-items adherence behavior revealed the presence of one factor with an Eigen value exceeding one.", [["EFA", "CHEMICAL", 28, 31], ["the EFA", "TEST", 24, 31]]], ["The scree-plot suggested for extraction of only one factor with strong loading (75.8%).Test of validity ::: ResultsThe ROC curve for the 6-items adherence behavior scale, as shown in Fig. 2, demonstrated that Area Under the Curve (AUC) was 0.9 with a 95% confidence interval 0.8\u20131.00 at p = 0.004.", [["The scree-plot", "TEST", 0, 14], ["extraction", "TREATMENT", 29, 39], ["The ROC curve", "TEST", 115, 128], ["behavior scale", "TEST", 155, 169]]], ["The cutoff score was found 17.5 with 89% sensitivity and 78% specificity.Correlation ::: ResultsAs a means of validating 6-item adherence behavior, the correlation analysis was done between 6-item adherence behavior with 10-item reasons for adherence/non-adherence scale, which demonstrated significant correlation (Pearson\u2019s Coefficient, PC: 0.8, p < 0.001).", [["The cutoff score", "TEST", 0, 16], ["the correlation analysis", "TEST", 148, 172], ["adherence/non-adherence scale", "TEST", 241, 270], ["PC", "TEST", 339, 341]]], ["The 6-items adherence scale demonstrated significant correlation with item 1 (PC = 0.7, p = 0.002), item 2 (PC = 0.6, p = 0.02), item 4 (PC = 0.8, p < 0.001), item 6 (PC = 0.8, p < 0.001), item 7 (PC = 0.7, p = 0.001) and with item 10 (PC = 0.8, p < 0.001), but there was no significant correlation with items 3, 5, 8 and 9 (p > 0.05) of 10-item reasons for adherence/non-adherence.Cross-cultural adaptation ::: DiscussionThe EARS was cross-culturally adapted to the Nepali language based on Beaton guidelines [7].", [["EARS", "DNA", 426, 430], ["item", "TEST", 70, 74], ["PC", "TEST", 78, 80], ["p", "TEST", 88, 89], ["item", "TEST", 100, 104], ["PC", "TEST", 108, 110], ["p", "TEST", 118, 119], ["item", "TEST", 129, 133], ["PC", "TEST", 137, 139], ["p", "TEST", 147, 148], ["item", "TEST", 159, 163], ["PC", "TEST", 167, 169], ["p", "TEST", 177, 178], ["item", "TEST", 189, 193], ["PC", "TEST", 197, 199], ["p", "TEST", 207, 208], ["item", "TEST", 227, 231], ["PC", "TEST", 236, 238], ["non-adherence", "PROBLEM", 368, 381]]], ["The forward and back translation as well as adaptation procedure revealed no content or language-related issues.", [["The forward and back translation", "TREATMENT", 0, 32], ["adaptation procedure", "TREATMENT", 44, 64], ["language-related issues", "PROBLEM", 88, 111], ["back", "ANATOMY", 16, 20]]], ["Through pre-testing, good clarity and understandability of the N-EARS were demonstrated.", [["EARS", "DNA", 65, 69], ["good", "OBSERVATION_MODIFIER", 21, 25], ["clarity", "OBSERVATION", 26, 33]]], ["In contrast to the findings of a study by Meade et al., where re-framing for some items was required [6], there was no need of refining or redefining any item or words while adapting to the Nepali language.", [["a study", "TEST", 31, 38]]], ["The N-EARS was formatted in such a way so that it is concise, short, easy to administer, and looks attractive.", [["N-EARS", "PROTEIN", 4, 10]]], ["In section \u2018A\u2019 of the tool, participants did not have any issues in understanding the questions.", [["participants", "SPECIES", 28, 40]]], ["However, in agreement with the findings from the study by Meade et al., they had difficulty in completing the answers of the questions when exercises were not prescribed in appropriate dosage or, when prescribed dosage was not understood [6].Reliability of N-EARS ::: DiscussionThe internal consistency was assessed to evaluate the degree of the interrelatedness among the items [14].", [["the study", "TEST", 45, 54]]], ["The internal consistency of N-EARS was excellent (\u03b1 = 0.94) for 6-item adherence behavior [14, 15].", [["N-EARS", "TEST", 28, 34], ["internal", "ANATOMY_MODIFIER", 4, 12]]], ["The internal consistency of the original English versions was 0.8 and that of the Brazilian version was 0.88 for 6-item adherence behavior [5, 11].", [["internal", "OBSERVATION_MODIFIER", 4, 12], ["consistency", "OBSERVATION_MODIFIER", 13, 24]]], ["The present study demonstrated higher internal consistency (\u03b1 = 0.94) of N-EARS than both English and Brazilian versions.", [["The present study", "TEST", 0, 17], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["internal", "OBSERVATION_MODIFIER", 38, 46], ["consistency", "OBSERVATION_MODIFIER", 47, 58]]], ["An \u03b1 value of 0.70\u20130.95 were considered acceptable values [16].", [["An \u03b1 value", "TEST", 0, 10]]], ["Therefore, the internal consistency of N-EARS of 6-item adherence behavior was comparable with the values of English as well as Brazilian versions and it was within acceptable range.Reliability of N-EARS ::: DiscussionSince the recommendation was against adding up of items to calculate a final score in 10-items for reasons of adherence/non-adherence, we did not determine the internal consistency of the 10-items [5].", [["N-EARS", "PROTEIN", 197, 203]]], ["This was not established even in the original English version by Naomi et al. [5] and the Brazilian version by De Lira et al. [11].Validity of N-EARS ::: DiscussionThe EFA demonstrated adequate construct validity of the 6-item adherence behavior scale of N-EARS.", [["The EFA", "TEST", 164, 171]]], ["The factor loading was higher than that of the original version which demonstrated 71% factor loading [5] and other self-reported outcome measures [17].", [["The factor loading", "TEST", 0, 18]]], ["We could not perform EFA on 10-item reasons for adherence/non-adherence as it could not fulfill the criteria of sampling adequacy (KMO < 0.60) [13], which was in contrast with the Brazilian version (KMO = 0.64) [11].Validity of N-EARS ::: DiscussionThe ROC curve was used to analyze the predictive effect of the 6-item adherence scale [18].", [["EFA", "CHEMICAL", 21, 24], ["EFA", "TEST", 21, 24], ["adherence/non-adherence", "PROBLEM", 48, 71], ["sampling adequacy", "TEST", 112, 129], ["KMO", "TEST", 131, 134], ["The ROC curve", "TEST", 249, 262]]], ["The AUC of the total score of the 6-item adherence behavior scale was 0.91 which was statistically significant and suggested a predictive validity which is in line with literature evidence [18, 19].", [["The AUC", "TEST", 0, 7], ["behavior scale", "TEST", 51, 65], ["a predictive validity", "PROBLEM", 125, 146]]], ["The cutoff score of the tool was 17.5 with a sensitivity of 89% and specificity of 78% that discriminates adherent and non-adherent participants with respect to exercises.", [["participants", "SPECIES", 132, 144], ["The cutoff score", "TEST", 0, 16], ["the tool", "TEST", 20, 28], ["a sensitivity", "TEST", 43, 56], ["specificity", "TEST", 68, 79], ["adherent", "OBSERVATION_MODIFIER", 106, 114]]], ["A study by De Lira et al., in the Brazilian version demonstrated a cutoff score of 17 with sensitivity and specificity higher than 80% [11]; findings that are comparable to the present study.", [["A study", "TEST", 0, 7], ["a cutoff score", "TEST", 65, 79], ["sensitivity", "TEST", 91, 102], ["specificity", "TEST", 107, 118], ["the present study", "TEST", 173, 190]]], ["We also compared our findings with a study by Wang et al., in which a similar scale for exercise adherence was used.", [["a study", "TEST", 35, 42], ["exercise adherence", "TREATMENT", 88, 106]]], ["The sensitivity of 87.2% and specificity of 76.3% reported in the study was similar to the findings of our study [18].Validity of N-EARS ::: DiscussionThe cutoff score of 17.5 indicated that any individual obtaining score > 17.5 out of 24 on the 6-item adherence scale is said to be adherent to the prescribed exercises.", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 29, 40], ["the study", "TEST", 62, 71], ["our study", "TEST", 103, 112], ["The cutoff score", "TEST", 151, 167], ["any individual obtaining score", "TEST", 191, 221]]], ["However, the cutoff score has to be cautiously used during interpretation because without knowing the level of exercise that is necessary for treatment to be effective, a cutoff score in assessing exercise adherence may not be useful [5, 19].", [["the cutoff score", "TEST", 9, 25], ["treatment", "TREATMENT", 142, 151], ["a cutoff score", "TEST", 169, 183]]], ["The cutoff score, sensitivity, and specificity reflected a preliminary predictive validity, which was not established even in the original version of the EARS and was a limitation [5].", [["The cutoff score", "TEST", 0, 16], ["sensitivity", "TEST", 18, 29]]], ["On the other hand, completely relying on the established guidelines with the back translation reflecting the same item content as the original version supported good face validity of the N-EARS [7, 10, 20].Validity of N-EARS ::: DiscussionThe correlation between the total score of 6-item adherence behavior and 10-item reasons for adherence/non-adherence demonstrated the validity of the N-EARS.", [["N-EARS", "CHEMICAL", 187, 193], ["N-EARS", "PROTEIN", 389, 395], ["the back translation", "PROBLEM", 73, 93], ["the total score", "TEST", 263, 278], ["adherence/non-adherence", "PROBLEM", 332, 355]]], ["The strength of correlation has been used in describing validity in patient-reported outcome measures [6, 21].", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75]]], ["The 6-item adherence scale demonstrated a strong correlation (0.6\u20130.8) with items 1, 2, 4, 6, 7, and 10 of 10-item reasons for adherence/non-adherence in the present study.", [["items", "TEST", 76, 81], ["adherence/non-adherence", "PROBLEM", 127, 150], ["the present study", "TEST", 154, 171], ["non-adherence", "OBSERVATION_MODIFIER", 137, 150]]], ["The reasons for adherence/non-adherence in the participants of a study by Newan-Beinart et al. were item numbers 1, 2, 3, 4, 7, and 9 [5].", [["participants", "SPECIES", 47, 59], ["a study", "TEST", 63, 70], ["item numbers", "TEST", 100, 112]]], ["Thus, the 10-items adherence/non-adherence gives clear information on reasons for adherence/non-adherence to exercise on one-to-one analysis, which may vary from one participant to another.Strengths and limitations ::: DiscussionThe strengths of this study include: (1) the method of cross-cultural adaptation that followed the established guidelines giving a methodological strength; (2) the reliability and validity were established on pre-diabetic who were healthy during the recruitment and on patients with various other health conditions as well.", [["patients", "ORGANISM", 498, 506], ["patients", "SPECIES", 498, 506], ["this study", "TEST", 246, 256], ["cross-cultural adaptation", "TREATMENT", 284, 309]]], ["We could evaluate the feasibility of the N-EARS on healthy individuals who were recommended for exercises to prevent disease or remain fit and on patients who were prescribed exercises to treat their impairments or, activity limitations.", [["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["exercises", "TREATMENT", 96, 105], ["disease", "PROBLEM", 117, 124], ["exercises", "TREATMENT", 175, 184], ["their impairments", "PROBLEM", 194, 211]]], ["Therefore, the reliability and validity were demonstrated in the heterogeneous group of participants; and (3) the N-EARS yielded identical psychometric properties as original EARS.Strengths and limitations ::: DiscussionOur study also has some limitations.", [["participants", "SPECIES", 88, 100], ["DiscussionOur study", "TEST", 210, 229], ["heterogeneous", "OBSERVATION_MODIFIER", 65, 78]]], ["First, the study had a small sample size.", [["the study", "TEST", 7, 16], ["a small sample size", "PROBLEM", 21, 40], ["small", "OBSERVATION_MODIFIER", 23, 28], ["sample", "OBSERVATION_MODIFIER", 29, 35], ["size", "OBSERVATION_MODIFIER", 36, 40]]], ["Due to the COVID-19 pandemic, the data collection was stopped, and a preliminary analysis was done with the sample that we had collected before the study was halted in March 2020.", [["the COVID", "TEST", 7, 16], ["pandemic", "PROBLEM", 20, 28], ["the data collection", "TEST", 30, 49], ["a preliminary analysis", "TEST", 67, 89], ["the study", "TEST", 144, 153]]], ["Since preliminary analysis met the criteria for sample adequacy, the final analysis was performed with the current sample.", [["preliminary analysis", "TEST", 6, 26], ["the final analysis", "TEST", 65, 83], ["the current sample", "TEST", 103, 121]]], ["Second, participants had to recall how much they adhered to the prescribed exercises during the last two weeks while scoring exercise adherence level.", [["participants", "SPECIES", 8, 20]]], ["Hence, there might be a possibility of recall bias during scoring.", [["might be a possibility", "UNCERTAINTY", 13, 35]]], ["Finally, participants had to be literate in order to respond to the EARS.", [["participants", "SPECIES", 9, 21], ["EARS", "ANATOMY", 68, 72]]], ["An oral response version of the scale would probably be of interest for future research.ConclusionsThe EARS has been cross-culturally adapted to the Nepali language.", [["oral", "ANATOMY", 3, 7], ["oral", "ORGANISM_SUBDIVISION", 3, 7], ["EARS", "DNA", 103, 107], ["the scale", "TREATMENT", 28, 37], ["EARS", "ANATOMY", 103, 107]]], ["This study provided excellent internal consistency and adequate face, construct as well as predictive validity of the N-EARS.", [["N-EARS", "PROTEIN", 118, 124], ["This study", "TEST", 0, 10]]], ["The N-EARS yielded identical psychometric properties as the original EARS.", [["N-EARS", "PROTEIN", 4, 10], ["The N-EARS", "TEST", 0, 10], ["EARS", "ANATOMY", 69, 73]]], ["A cutoff score of 17.5 was found with good sensitivity and specificity.", [["A cutoff score", "TEST", 0, 14]]], ["The findings of the present study provided evidence to use N-EARS in research and clinical practice that might facilitate the evaluation of exercise-related interventions.", [["the present study", "TEST", 16, 33], ["the evaluation", "TEST", 122, 136], ["exercise-related interventions", "TREATMENT", 140, 170]]], ["Further studies are recommended to investigate other psychometric properties of the N-EARS with a larger sample including various diseases.", [["Further studies", "TEST", 0, 15], ["a larger sample", "PROBLEM", 96, 111], ["various diseases", "PROBLEM", 122, 138], ["diseases", "OBSERVATION", 130, 138]]]], "ea800dcdcf09ab648a3229d2f1e02159877a4f53": [["IntroductionFeline oral squamous cell carcinoma (FOSCC) is the 4 th most common feline neoplasm and there is no effective treatment for this disease.", [["oral squamous cell carcinoma", "ANATOMY", 19, 47], ["FOSCC", "ANATOMY", 49, 54], ["neoplasm", "ANATOMY", 87, 95], ["squamous cell carcinoma", "DISEASE", 24, 47], ["FOSCC", "DISEASE", 49, 54], ["feline neoplasm", "DISEASE", 80, 95], ["oral squamous cell carcinoma", "CANCER", 19, 47], ["FOSCC", "CANCER", 49, 54], ["feline", "ORGANISM", 80, 86], ["neoplasm", "CANCER", 87, 95], ["IntroductionFeline oral squamous cell carcinoma", "PROBLEM", 0, 47], ["the 4 th most common feline neoplasm", "PROBLEM", 59, 95], ["effective treatment", "TREATMENT", 112, 131], ["this disease", "PROBLEM", 136, 148], ["squamous cell carcinoma", "OBSERVATION", 24, 47], ["4 th most", "OBSERVATION_MODIFIER", 63, 72], ["common feline", "OBSERVATION_MODIFIER", 73, 86], ["neoplasm", "OBSERVATION", 87, 95], ["no", "UNCERTAINTY", 109, 111], ["effective", "OBSERVATION_MODIFIER", 112, 121]]], ["FOSCC has commonly been proposed as the best model for human head and neck squamous cell carcinomas (HNSCC).", [["head and neck squamous cell carcinomas", "ANATOMY", 61, 99], ["HNSCC", "ANATOMY", 101, 106], ["FOSCC", "CHEMICAL", 0, 5], ["head and neck squamous cell carcinomas", "DISEASE", 61, 99], ["HNSCC", "DISEASE", 101, 106], ["FOSCC", "CANCER", 0, 5], ["human", "ORGANISM", 55, 60], ["head and neck squamous cell carcinomas", "CANCER", 61, 99], ["HNSCC", "CANCER", 101, 106], ["FOSCC", "PROTEIN", 0, 5], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["human head and neck squamous cell carcinomas", "PROBLEM", 55, 99], ["head", "ANATOMY", 61, 65], ["neck", "ANATOMY", 70, 74], ["squamous cell carcinomas", "OBSERVATION", 75, 99]]], ["HNSCC can be divided into human papillomavirus (HPV) positive and HPV-negative cancers.", [["HNSCC", "ANATOMY", 0, 5], ["cancers", "ANATOMY", 79, 86], ["HNSCC", "DISEASE", 0, 5], ["human papillomavirus (HPV) positive and HPV-negative cancers", "DISEASE", 26, 86], ["HNSCC", "CANCER", 0, 5], ["human", "ORGANISM", 26, 31], ["papillomavirus", "ORGANISM", 32, 46], ["HPV", "ORGANISM", 48, 51], ["HPV", "ORGANISM", 66, 69], ["cancers", "CANCER", 79, 86], ["human", "SPECIES", 26, 31], ["human papillomavirus", "SPECIES", 26, 46], ["HPV", "SPECIES", 48, 51], ["HPV", "SPECIES", 66, 69], ["human papillomavirus", "TEST", 26, 46], ["HPV", "PROBLEM", 66, 69], ["cancers", "PROBLEM", 79, 86], ["negative", "OBSERVATION_MODIFIER", 70, 78], ["cancers", "OBSERVATION", 79, 86]]], ["The largest papillomavirus (PV) genera is the alpha-PVs, which includes subtypes HPV-16 and 18 that have the highest malignant transformation potential.", [["papillomavirus", "ORGANISM", 12, 26], ["alpha-PVs", "GENE_OR_GENE_PRODUCT", 46, 55], ["HPV-16", "ORGANISM", 81, 87], ["alpha-PVs", "PROTEIN", 46, 55], ["PV", "SPECIES", 28, 30], ["The largest papillomavirus", "TEST", 0, 26], ["the alpha-PVs", "TEST", 42, 55], ["subtypes HPV", "TEST", 72, 84], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["papillomavirus", "OBSERVATION", 12, 26], ["alpha-PVs", "OBSERVATION", 46, 55], ["subtypes", "OBSERVATION_MODIFIER", 72, 80], ["HPV", "OBSERVATION", 81, 84], ["highest", "OBSERVATION_MODIFIER", 109, 116], ["malignant transformation", "OBSERVATION", 117, 141]]], ["PVs are non-enveloped circular doublestranded DNA (dsDNA) viruses with 5 or 6 early (E1, E2, E4, +/-E5, E6, E7) genes and two late genes (L1 and L2).", [["PVs", "MULTI-TISSUE_STRUCTURE", 0, 3], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["dsDNA", "CELLULAR_COMPONENT", 51, 56], ["E2", "GENE_OR_GENE_PRODUCT", 89, 91], ["E4", "GENE_OR_GENE_PRODUCT", 93, 95], ["E6", "GENE_OR_GENE_PRODUCT", 104, 106], ["E7", "GENE_OR_GENE_PRODUCT", 108, 110], ["non-enveloped circular doublestranded DNA (dsDNA) viruses", "DNA", 8, 65], ["5 or 6 early (E1, E2, E4, +/-E5, E6, E7) genes", "DNA", 71, 117], ["L1", "DNA", 138, 140], ["L2", "DNA", 145, 147], ["PVs", "PROBLEM", 0, 3], ["non-enveloped circular doublestranded DNA (dsDNA) viruses", "PROBLEM", 8, 65], ["E1", "TEST", 85, 87], ["E2", "TEST", 89, 91], ["E4", "TEST", 93, 95], ["E6", "TEST", 104, 106], ["non-enveloped", "OBSERVATION_MODIFIER", 8, 21], ["circular", "OBSERVATION_MODIFIER", 22, 30], ["L1", "ANATOMY_MODIFIER", 138, 140], ["L2", "ANATOMY_MODIFIER", 145, 147]]], ["All PVs contain a highly conserved L1 gene and thus family-specific consensus PCR primers can be used to amplify a region in this gene.", [["PVs", "ANATOMY", 4, 7], ["PVs", "MULTI-TISSUE_STRUCTURE", 4, 7], ["L1 gene", "DNA", 35, 42], ["consensus PCR primers", "DNA", 68, 89], ["PCR primers", "TREATMENT", 78, 89]]], ["There are currently only 5 Felis catus PV (FcaPV) species known to infect domestic cats.", [["Felis catus PV", "ORGANISM", 27, 41], ["FcaPV", "GENE_OR_GENE_PRODUCT", 43, 48], ["cats", "ORGANISM", 83, 87], ["cats", "SPECIES", 83, 87], ["Felis catus PV", "SPECIES", 27, 41]]], ["FcaPV DNA, especially FcaPV-2, and induced changes in cell regulation (increased p16 identified by IHC staining) have been detected in the majority of BISCs, Supplementary Table 1 (Lange et al., 2009; Munday, 2014; Munday et al., 2007) .", [["cell", "ANATOMY", 54, 58], ["BISCs", "ANATOMY", 151, 156], ["FcaPV", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["FcaPV-2", "GENE_OR_GENE_PRODUCT", 22, 29], ["cell", "CELL", 54, 58], ["p16", "GENE_OR_GENE_PRODUCT", 81, 84], ["FcaPV DNA", "DNA", 0, 9], ["FcaPV-2", "DNA", 22, 29], ["p16", "PROTEIN", 81, 84], ["FcaPV", "SPECIES", 0, 5], ["FcaPV DNA", "TEST", 0, 9], ["FcaPV", "TEST", 22, 27], ["induced changes in cell regulation", "PROBLEM", 35, 69], ["increased p16", "PROBLEM", 71, 84], ["IHC staining", "TEST", 99, 111], ["cell regulation", "OBSERVATION", 54, 69], ["increased", "OBSERVATION_MODIFIER", 71, 80]]], ["PV DNA and increased p16 have also been detected in 75% of UV-protected cutaneous SCC, and thus PV is likely a causative agent in feline BISCs and UV-protected cutaneous SCC, Supplementary Table 1 (Munday, 2014; Munday et al., 2011a) .", [["cutaneous SCC", "ANATOMY", 72, 85], ["BISCs", "ANATOMY", 137, 142], ["cutaneous SCC", "ANATOMY", 160, 173], ["UV", "CHEMICAL", 59, 61], ["cutaneous SCC", "DISEASE", 72, 85], ["cutaneous SCC", "DISEASE", 160, 173], ["PV", "CELLULAR_COMPONENT", 0, 2], ["DNA", "CELLULAR_COMPONENT", 3, 6], ["p16", "GENE_OR_GENE_PRODUCT", 21, 24], ["cutaneous SCC", "CANCER", 72, 85], ["feline", "ORGANISM", 130, 136], ["BISCs", "CANCER", 137, 142], ["cutaneous SCC", "CANCER", 160, 173], ["PV DNA", "DNA", 0, 6], ["p16", "PROTEIN", 21, 24], ["feline", "SPECIES", 130, 136], ["PV", "SPECIES", 0, 2], ["PV", "SPECIES", 96, 98], ["PV DNA", "PROBLEM", 0, 6], ["increased p16", "PROBLEM", 11, 24], ["protected cutaneous SCC", "PROBLEM", 62, 85], ["increased", "OBSERVATION_MODIFIER", 11, 20], ["p16", "OBSERVATION", 21, 24], ["cutaneous", "ANATOMY", 72, 81], ["SCC", "OBSERVATION", 82, 85]]], ["Previous studies have used either PV consensus PCR primers or PV type specific PCR primers and have not found strong evidence to support a viral etiology, Supplementary Table 2.", [["PV consensus PCR primers", "DNA", 34, 58], ["PCR primers", "DNA", 79, 90], ["PV", "SPECIES", 34, 36], ["PV", "SPECIES", 62, 64], ["Previous studies", "TEST", 0, 16], ["PV consensus PCR primers", "TEST", 34, 58], ["PV type specific PCR primers", "PROBLEM", 62, 90]]], ["In summary, to date PV has only been found in 6 of 177 FOSCC samples in peer-reviewed journals and the association between PV and FOSCC thus remains weak.", [["FOSCC samples", "ANATOMY", 55, 68], ["FOSCC", "DISEASE", 130, 135], ["FOSCC samples", "CANCER", 55, 68], ["PV", "MULTI-TISSUE_STRUCTURE", 123, 125], ["FOSCC", "CANCER", 130, 135], ["PV", "SPECIES", 20, 22], ["PV", "TEST", 20, 22], ["weak", "PROBLEM", 149, 153], ["PV", "ANATOMY", 123, 125], ["weak", "OBSERVATION", 149, 153]]], ["Contrary to these previous studies, an abstract presented at the 2015 Veterinary Cancer Society (VCS) conference detected PV with consensus PCR primers in all of the 12 FOSCC samples that were evaluated (Skor, 2015) .IntroductionNext generation sequencing (NGS) can substantially increase the sensitivity and specificity of virus detection as it is not limited by primer specificity.", [["FOSCC samples", "ANATOMY", 169, 182], ["Cancer", "DISEASE", 81, 87], ["FOSCC samples", "CANCER", 169, 182], ["consensus PCR primers", "DNA", 130, 151], ["PV", "SPECIES", 122, 124], ["these previous studies", "TEST", 12, 34], ["consensus PCR primers", "PROBLEM", 130, 151], ["Next generation sequencing (NGS", "TREATMENT", 229, 260], ["the sensitivity", "TEST", 289, 304], ["virus detection", "TEST", 324, 339], ["Cancer", "OBSERVATION", 81, 87]]], ["Amplicon-based survey sequencing approaches, such as 16S rRNA gene sequencing, have been utilized to study bacterial diversity, but a similar method cannot be used for viruses due to the lack of universally conserved genes.", [["16S rRNA gene", "DNA", 53, 66], ["universally conserved genes", "DNA", 195, 222], ["Amplicon", "TREATMENT", 0, 8], ["16S rRNA gene sequencing", "TEST", 53, 77], ["bacterial diversity", "PROBLEM", 107, 126], ["a similar method", "TREATMENT", 132, 148], ["viruses", "PROBLEM", 168, 175]]], ["ViroCap, a hybridization-based capture and NGS approach, has the ability to enrich nucleic acids from all currently known DNA and RNA viruses from vertebrate hosts (excluding endogenous retroviruses) for which probes are included (Wylie et al., 2015) .", [["ViroCap", "CHEMICAL", 0, 7], ["nucleic acids", "CHEMICAL", 83, 96], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["retroviruses", "ORGANISM", 186, 198], ["ViroCap", "PROTEIN", 0, 7], ["ViroCap", "TREATMENT", 0, 7], ["a hybridization", "TREATMENT", 9, 24], ["NGS approach", "TREATMENT", 43, 55], ["nucleic acids", "TREATMENT", 83, 96], ["known DNA", "PROBLEM", 116, 125], ["RNA viruses from vertebrate hosts", "PROBLEM", 130, 163], ["endogenous retroviruses", "PROBLEM", 175, 198], ["RNA viruses", "OBSERVATION", 130, 141]]], ["Compared to PCR, ViroCap can detect viruses that are divergent from reference genome sequences (e.g. anellovirus family), and it has the ability to generate complete or nearly complete genome sequences because probes are tiled across the full length of the genomes.", [["ViroCap", "GENE_OR_GENE_PRODUCT", 17, 24], ["ViroCap", "DNA", 17, 24], ["reference genome sequences", "DNA", 68, 94], ["genome sequences", "DNA", 185, 201], ["PCR", "TEST", 12, 15], ["ViroCap", "TREATMENT", 17, 24], ["viruses", "PROBLEM", 36, 43], ["reference genome sequences", "TEST", 68, 94], ["viruses", "OBSERVATION", 36, 43], ["full length", "OBSERVATION_MODIFIER", 238, 249], ["genomes", "OBSERVATION", 257, 264]]], ["ViroCap has been utilized on human vaginal swabs (Wylie et al., 2018b) , whole blood, plasma, cerebrospinal fluid, nasopharyngeal swabs, tracheal aspirates, skin swabs, and stool (Wylie et al., 2018a (Wylie et al., , 2015 and in a Coronavirus outbreak in Canada Geese (Papineau et al., 2019) .", [["vaginal swabs", "ANATOMY", 35, 48], ["whole blood", "ANATOMY", 73, 84], ["plasma", "ANATOMY", 86, 92], ["cerebrospinal fluid", "ANATOMY", 94, 113], ["nasopharyngeal swabs", "ANATOMY", 115, 135], ["tracheal aspirates", "ANATOMY", 137, 155], ["skin swabs", "ANATOMY", 157, 167], ["ViroCap", "CHEMICAL", 0, 7], ["ViroCap", "GENE_OR_GENE_PRODUCT", 0, 7], ["human", "ORGANISM", 29, 34], ["vaginal swabs", "ORGANISM_SUBSTANCE", 35, 48], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["plasma", "ORGANISM_SUBSTANCE", 86, 92], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 94, 113], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 115, 135], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 137, 155], ["skin swabs", "MULTI-TISSUE_STRUCTURE", 157, 167], ["stool", "ORGANISM_SUBSTANCE", 173, 178], ["ViroCap", "PROTEIN", 0, 7], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["ViroCap", "TREATMENT", 0, 7], ["human vaginal swabs", "TREATMENT", 29, 48], ["whole blood", "TEST", 73, 84], ["plasma", "TEST", 86, 92], ["cerebrospinal fluid", "TEST", 94, 113], ["nasopharyngeal swabs", "TEST", 115, 135], ["tracheal aspirates", "TEST", 137, 155], ["skin swabs", "TEST", 157, 167], ["cerebrospinal", "ANATOMY", 94, 107], ["fluid", "OBSERVATION", 108, 113], ["nasopharyngeal", "ANATOMY", 115, 129], ["tracheal", "ANATOMY", 137, 145], ["aspirates", "OBSERVATION", 146, 155], ["skin", "ANATOMY", 157, 161], ["stool", "ANATOMY", 173, 178]]], ["To the author's knowledge, the current study would be the first companion animal study to utilize a targeted capture and NGS strategy to study the virome.", [["the current study", "TEST", 27, 44], ["animal study", "TEST", 74, 86], ["a targeted capture", "TREATMENT", 98, 116], ["NGS strategy", "TREATMENT", 121, 133]]], ["ViroCap is the most definitive method used to date to characterize the virome of the oral mucosa of cats and to find a viral cause of FOSCC.PatientsFormalin-fixed, paraffin embedded (FFPE) samples from 20 cats diagnosed with FOSCC in 2012-2013 were obtained from the University of Missouri Veterinary Medical Diagnostic Laboratory (MU VMDL), Table 1 .", [["oral mucosa", "ANATOMY", 85, 96], ["FOSCC", "ANATOMY", 134, 139], ["FFPE", "ANATOMY", 183, 187], ["samples", "ANATOMY", 189, 196], ["FOSCC", "DISEASE", 134, 139], ["FOSCC", "DISEASE", 225, 230], ["ViroCap", "GENE_OR_GENE_PRODUCT", 0, 7], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 85, 96], ["cats", "ORGANISM", 100, 104], ["FOSCC", "CANCER", 134, 139], ["Patients", "ORGANISM", 140, 148], ["cats", "ORGANISM", 205, 209], ["cats", "SPECIES", 100, 104], ["Patients", "SPECIES", 140, 148], ["cats", "SPECIES", 205, 209], ["ViroCap", "TREATMENT", 0, 7], ["a viral cause of FOSCC", "PROBLEM", 117, 139], ["PatientsFormalin-fixed, paraffin embedded (FFPE", "TREATMENT", 140, 187], ["FOSCC", "TEST", 225, 230], ["oral mucosa", "ANATOMY", 85, 96]]], ["Banked FFPE samples from 8 presumed PV-positive control tumors were also obtained from the MU VMDL.", [["FFPE samples", "ANATOMY", 7, 19], ["tumors", "ANATOMY", 56, 62], ["VMDL", "ANATOMY", 94, 98], ["tumors", "DISEASE", 56, 62], ["FFPE samples", "CANCER", 7, 19], ["PV", "GENE_OR_GENE_PRODUCT", 36, 38], ["tumors", "CANCER", 56, 62], ["PV", "SPECIES", 36, 38], ["Banked FFPE samples", "TEST", 0, 19], ["PV", "TEST", 36, 38], ["positive control tumors", "PROBLEM", 39, 62], ["PV", "ANATOMY", 36, 38], ["tumors", "OBSERVATION", 56, 62]]], ["Presumed PVnegative controls consisted of 9 fresh frozen (FF) tumor negative oral mucosal biopsy samples (combined tongue and gingival mucosa) from adult cats obtained from the University of Missouri Veterinary Health Center and Central Missouri Humane Society.", [["tumor", "ANATOMY", 62, 67], ["oral mucosal biopsy samples", "ANATOMY", 77, 104], ["tongue", "ANATOMY", 115, 121], ["gingival mucosa", "ANATOMY", 126, 141], ["tumor", "DISEASE", 62, 67], ["tumor", "CANCER", 62, 67], ["oral mucosal biopsy samples", "TISSUE", 77, 104], ["tongue", "ORGAN", 115, 121], ["gingival mucosa", "MULTI-TISSUE_STRUCTURE", 126, 141], ["cats", "ORGANISM", 154, 158], ["cats", "SPECIES", 154, 158], ["PVnegative controls", "PROBLEM", 9, 28], ["9 fresh frozen (FF)", "TREATMENT", 42, 61], ["oral mucosal biopsy samples", "TEST", 77, 104], ["combined tongue and gingival mucosa", "PROBLEM", 106, 141], ["mucosal", "ANATOMY", 82, 89], ["biopsy", "OBSERVATION", 90, 96], ["tongue", "ANATOMY", 115, 121], ["gingival mucosa", "ANATOMY", 126, 141], ["Central", "ANATOMY_MODIFIER", 229, 236]]], ["None of the samples in this study have been used in any previous study.DNA extraction, library preparation and captureDual indexed libraries from the fresh frozen and FFPE samples were pooled separately and hybridized to the ViroCap probe set as 2 separate reactions.", [["samples", "ANATOMY", 12, 19], ["FFPE samples", "ANATOMY", 167, 179], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["FFPE samples", "CANCER", 167, 179], ["captureDual indexed libraries", "DNA", 111, 140], ["ViroCap probe", "DNA", 225, 238], ["the samples", "TEST", 8, 19], ["this study", "TEST", 23, 33], ["any previous study", "TEST", 52, 70], ["DNA extraction", "TREATMENT", 71, 85], ["library preparation", "TREATMENT", 87, 106], ["captureDual indexed libraries", "TREATMENT", 111, 140], ["the fresh frozen", "TREATMENT", 146, 162], ["FFPE samples", "TEST", 167, 179], ["the ViroCap probe", "TREATMENT", 221, 238]]], ["Details can be found in the Supplementary files.Sequencing and analysisCaptured reads were sequenced on one lane of the HiSeq2500 1 T as 2 \u00d7 126 bp reads generating on average 1.3Gb of data per sample.", [["HiSeq2500 1 T", "DNA", 120, 133], ["analysis", "TEST", 63, 71], ["bp reads", "TEST", 145, 153]]], ["The analysis workflow is similar to the one that was used in a study of the vaginal virome in preterm birth (Wylie et al., 2018b) .", [["vaginal", "ANATOMY", 76, 83], ["preterm birth", "DISEASE", 94, 107], ["vaginal", "ORGANISM_SUBDIVISION", 76, 83], ["The analysis workflow", "TEST", 0, 21], ["a study", "TEST", 61, 68], ["vaginal virome", "ANATOMY", 76, 90]]], ["Average genomic coverage (depth of coverage or DoC) was estimated from base representation by the extracted, deduplicated and aligned reads for each base of the genome.", [["Average genomic coverage (depth of coverage or DoC", "TREATMENT", 0, 50], ["coverage", "OBSERVATION_MODIFIER", 16, 24], ["genome", "OBSERVATION", 161, 167]]], ["Breadth of coverage (BoC) was estimated in SAMtools and was defined as the percent of bases of the reference viral genome that was covered by sequence reads at a level of 5x or higher.", [["reference viral genome", "DNA", 99, 121], ["coverage (BoC", "TREATMENT", 11, 24], ["bases", "ANATOMY_MODIFIER", 86, 91], ["viral genome", "OBSERVATION", 109, 121]]], ["The detection of false positives (e.g. by index swapping or contamination from sample handling) were minimized with the definition of strict coverage criteria.", [["false positives", "PROBLEM", 17, 32], ["index swapping", "PROBLEM", 42, 56], ["false positives", "OBSERVATION", 17, 32]]], ["Positive samples were defined as any sample that had \u22650.5x DoC.", [["samples", "ANATOMY", 9, 16], ["any sample", "TEST", 33, 43]]], ["Exceptions to this rule included samples that were manually reviewed for the presence of reads that were distributed across the viral genome to confirm presence of a virusPapillomavirus and Epstein Barr virus validationThe FAP59/FAP64 and BamHI W primers were used for papillomavirus and EBV respectively (Chiou et al., 2005; Forslund et al., 1999) .", [["samples", "ANATOMY", 33, 40], ["Papillomavirus", "ORGANISM", 171, 185], ["Epstein Barr virus", "ORGANISM", 190, 208], ["FAP59", "GENE_OR_GENE_PRODUCT", 223, 228], ["FAP64", "GENE_OR_GENE_PRODUCT", 229, 234], ["BamHI", "GENE_OR_GENE_PRODUCT", 239, 244], ["papillomavirus", "ORGANISM", 269, 283], ["EBV", "ORGANISM", 288, 291], ["viral genome", "DNA", 128, 140], ["FAP59/FAP64 and BamHI W primers", "DNA", 223, 254], ["Epstein Barr virus", "SPECIES", 190, 208], ["EBV", "SPECIES", 288, 291], ["a virusPapillomavirus", "PROBLEM", 164, 185], ["Epstein Barr virus validation", "TEST", 190, 219], ["The FAP59", "TEST", 219, 228], ["FAP64", "TEST", 229, 234], ["BamHI W primers", "TREATMENT", 239, 254], ["papillomavirus", "PROBLEM", 269, 283], ["viral genome", "OBSERVATION", 128, 140]]], ["Details of the PCR conditions can be found in Supplementary Table 3 .", [["the PCR conditions", "TEST", 11, 29]]], ["Each sample was amplified in duplicate and a no template control was included in each assay.", [["sample", "ANATOMY", 5, 11], ["a no template control", "TREATMENT", 43, 64]]], ["The EBV amplicon was sequenced.ResultsOf the 20 FOSCC samples, 12 (60%) were from the gingiva, 5 (25%) were from the tongue and the location of 3 (15%) samples was unknown.", [["FOSCC samples", "ANATOMY", 48, 61], ["gingiva", "ANATOMY", 86, 93], ["tongue", "ANATOMY", 117, 123], ["samples", "ANATOMY", 152, 159], ["EBV", "ORGANISM", 4, 7], ["FOSCC samples", "CANCER", 48, 61], ["gingiva", "ORGAN", 86, 93], ["tongue", "ORGAN", 117, 123], ["samples", "CANCER", 152, 159], ["EBV amplicon", "DNA", 4, 16], ["The EBV amplicon", "TREATMENT", 0, 16], ["the 20 FOSCC samples", "TEST", 41, 61], ["EBV amplicon", "OBSERVATION", 4, 16], ["gingiva", "ANATOMY", 86, 93], ["tongue", "ANATOMY", 117, 123]]], ["Sequence data for the 37 samples were deposited into the Sequence Read Archive (SRA) under BioProject PRJNA553834.Results3.1.", [["samples", "ANATOMY", 25, 32], ["Sequence Read Archive", "DNA", 57, 78], ["Sequence data", "TEST", 0, 13], ["the 37 samples", "TEST", 18, 32]]], ["The virome of the oral mucosa of cats consisted of foamy virus, torque teno virus, alphaherpesvirus, feline papillomavirus, FeLV, FIV and EBV but these viruses were not associated consistently with FOSCC FcaPV was found in 1/20 and 0/9 (p = 1.00, Fisher's exact test, 2tailed), feline foamy virus in 7/20 and 2/9 (p = 0.67), feline torque teno virus in 2/20 and 0/9 (p = 1.00), alphaherpesvirus in 2/20 and 0/ 9 (p = 1.00), FIV in 0/20 and 2/9, exogenous FeLV (exFeLV) in 0/20 and 1/9, Epstein-Barr virus in 1/20 and 0/9 (p = 1.00) respectively in FOSCC and normal oral mucosa samples (Fig. 1, Supplementary Fig. 1) .", [["oral mucosa", "ANATOMY", 18, 29], ["FOSCC", "ANATOMY", 548, 553], ["oral mucosa samples", "ANATOMY", 565, 584], ["feline papillomavirus, FeLV, FIV and EBV", "DISEASE", 101, 141], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 18, 29], ["cats", "ORGANISM", 33, 37], ["foamy virus", "ORGANISM", 51, 62], ["torque teno virus", "ORGANISM", 64, 81], ["alphaherpesvirus", "GENE_OR_GENE_PRODUCT", 83, 99], ["feline papillomavirus", "ORGANISM", 101, 122], ["FeLV", "ORGANISM", 124, 128], ["FIV", "ORGANISM", 130, 133], ["EBV", "ORGANISM", 138, 141], ["FcaPV", "GENE_OR_GENE_PRODUCT", 204, 209], ["feline", "ORGANISM", 278, 284], ["foamy virus", "ORGANISM", 285, 296], ["feline", "ORGANISM", 325, 331], ["torque teno virus", "ORGANISM", 332, 349], ["FIV", "ORGANISM", 424, 427], ["FeLV", "ORGANISM", 455, 459], ["Epstein-Barr virus", "ORGANISM", 486, 504], ["FOSCC", "CANCER", 548, 553], ["oral mucosa samples", "TISSUE", 565, 584], ["FOSCC FcaPV", "DNA", 198, 209], ["cats", "SPECIES", 33, 37], ["foamy virus", "SPECIES", 51, 62], ["teno virus", "SPECIES", 71, 81], ["feline papillomavirus", "SPECIES", 101, 122], ["feline foamy virus", "SPECIES", 278, 296], ["foamy virus", "SPECIES", 51, 62], ["torque teno virus", "SPECIES", 64, 81], ["feline papillomavirus", "SPECIES", 101, 122], ["FeLV", "SPECIES", 124, 128], ["FIV", "SPECIES", 130, 133], ["EBV", "SPECIES", 138, 141], ["FOSCC", "SPECIES", 198, 203], ["feline foamy virus", "SPECIES", 278, 296], ["feline torque teno virus", "SPECIES", 325, 349], ["Epstein-Barr virus", "SPECIES", 486, 504], ["foamy virus", "PROBLEM", 51, 62], ["torque teno virus", "PROBLEM", 64, 81], ["alphaherpesvirus", "PROBLEM", 83, 99], ["FeLV", "PROBLEM", 124, 128], ["FIV", "PROBLEM", 130, 133], ["EBV", "PROBLEM", 138, 141], ["these viruses", "PROBLEM", 146, 159], ["FOSCC FcaPV", "TEST", 198, 209], ["Fisher's exact test", "TEST", 247, 266], ["feline foamy virus", "TEST", 278, 296], ["feline torque teno virus", "TEST", 325, 349], ["alphaherpesvirus", "TEST", 378, 394], ["FIV", "TEST", 424, 427], ["Barr virus", "TEST", 494, 504], ["Supplementary Fig", "TREATMENT", 594, 611], ["oral mucosa", "ANATOMY", 18, 29], ["foamy virus", "OBSERVATION", 51, 62], ["foamy virus", "OBSERVATION", 285, 296], ["exogenous FeLV", "OBSERVATION", 445, 459], ["Barr virus", "OBSERVATION", 494, 504], ["oral mucosa", "ANATOMY", 565, 576]]], ["Probability values were not evaluated for FIV and FeLV since these viruses can be higher in the group of cats in the normal mucosa group that consisted of largely unowned cats that were euthanized for various reasons.Papillomavirus was not associated with FOSCCThe results of conventional PCR, and ViroCap were concordant for all samples except PV2, Supplementary Table 4 .", [["mucosa", "ANATOMY", 124, 130], ["samples", "ANATOMY", 330, 337], ["FIV", "ORGANISM", 42, 45], ["FeLV", "ORGANISM", 50, 54], ["cats", "ORGANISM", 105, 109], ["mucosa", "MULTI-TISSUE_STRUCTURE", 124, 130], ["cats", "ORGANISM", 171, 175], ["Papillomavirus", "ORGANISM", 217, 231], ["cats", "SPECIES", 105, 109], ["cats", "SPECIES", 171, 175], ["FIV", "SPECIES", 42, 45], ["FeLV", "SPECIES", 50, 54], ["Probability values", "TEST", 0, 18], ["FIV", "PROBLEM", 42, 45], ["FeLV", "PROBLEM", 50, 54], ["these viruses", "PROBLEM", 61, 74], ["Papillomavirus", "PROBLEM", 217, 231], ["conventional PCR", "TEST", 276, 292], ["ViroCap", "TEST", 298, 305], ["higher", "OBSERVATION_MODIFIER", 82, 88], ["normal mucosa", "ANATOMY", 117, 130], ["not associated with", "UNCERTAINTY", 236, 255]]], ["PV2 was a papilloma on the skin of a dog and contained CPV-6 by ViroCap.", [["papilloma", "ANATOMY", 10, 19], ["skin", "ANATOMY", 27, 31], ["papilloma", "DISEASE", 10, 19], ["PV2", "GENE_OR_GENE_PRODUCT", 0, 3], ["papilloma", "CANCER", 10, 19], ["skin", "ORGAN", 27, 31], ["dog", "ORGANISM", 37, 40], ["ViroCap", "SIMPLE_CHEMICAL", 64, 71], ["dog", "SPECIES", 37, 40], ["PV2", "TEST", 0, 3], ["a papilloma", "PROBLEM", 8, 19], ["CPV", "TEST", 55, 58], ["papilloma", "OBSERVATION", 10, 19], ["skin", "ANATOMY", 27, 31]]], ["PV2 was negative on PCR.", [["PV2", "GENE_OR_GENE_PRODUCT", 0, 3], ["PV2", "DNA", 0, 3], ["PV2", "TEST", 0, 3], ["PCR", "TEST", 20, 23], ["negative", "OBSERVATION", 8, 16]]], ["Even though the FAP59/64 primers were created for cutaneous adapted PVs, they have never been shown to amplify CPV-6 and this may explain PCR failure.", [["PVs", "ANATOMY", 68, 71], ["FAP59", "GENE_OR_GENE_PRODUCT", 16, 21], ["PVs", "MULTI-TISSUE_STRUCTURE", 68, 71], ["CPV-6", "ORGANISM", 111, 116], ["FAP59/64 primers", "DNA", 16, 32], ["CPV-6", "SPECIES", 111, 116], ["the FAP59/64 primers", "TEST", 12, 32], ["cutaneous adapted PVs", "PROBLEM", 50, 71], ["CPV", "TEST", 111, 114], ["PCR failure", "PROBLEM", 138, 149], ["may explain", "UNCERTAINTY", 126, 137], ["PCR failure", "OBSERVATION", 138, 149]]], ["The 1 FOSCC sample that had PV, OSCC8, had a high viral read count, > 2.1 million reads, with feline PV (FcaPV-3), likely indicative of a true infection.", [["FOSCC sample", "ANATOMY", 6, 18], ["infection", "DISEASE", 143, 152], ["FOSCC", "CANCER", 6, 11], ["feline", "ORGANISM", 94, 100], ["FcaPV-3", "GENE_OR_GENE_PRODUCT", 105, 112], ["PV", "SPECIES", 28, 30], ["PV", "SPECIES", 101, 103], ["The 1 FOSCC sample", "TEST", 0, 18], ["a high viral read count", "PROBLEM", 43, 66], ["feline PV", "TEST", 94, 103], ["FcaPV", "TEST", 105, 110], ["a true infection", "PROBLEM", 136, 152], ["feline PV", "ANATOMY", 94, 103], ["likely indicative of", "UNCERTAINTY", 115, 135], ["true", "OBSERVATION_MODIFIER", 138, 142], ["infection", "OBSERVATION", 143, 152]]], ["A normal mucosal sample, N6, had a very low PV read count, 56 reads, with a human PV (HPV-28) and likely represented contamination (Supplementary Table 5 , Supplementary Fig. 2) .", [["mucosal sample", "ANATOMY", 9, 23], ["mucosal sample", "CANCER", 9, 23], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human PV (HPV-28", "SPECIES", 76, 92], ["a human PV", "TEST", 74, 84], ["HPV", "TEST", 86, 89], ["Supplementary Fig", "TREATMENT", 156, 173], ["normal", "OBSERVATION", 2, 8], ["mucosal", "ANATOMY", 9, 16], ["likely represented", "UNCERTAINTY", 98, 116], ["contamination", "OBSERVATION", 117, 130]]], ["PV was not detected by any method for the following positive control samples, PV1, PV6, PV7 and PV8 (Supplementary Table 4 ).", [["samples", "ANATOMY", 69, 76], ["PV", "SPECIES", 0, 2], ["PV", "TEST", 0, 2], ["PV1", "TEST", 78, 81], ["PV6", "TEST", 83, 86], ["PV7", "TEST", 88, 91], ["PV8", "TEST", 96, 99]]], ["These samples were from feline lesions that were diagnosed as sarcoids (fibropapillomas) and oral papillomas via histopathology with hematoxylin and eosin staining.", [["samples", "ANATOMY", 6, 13], ["lesions", "ANATOMY", 31, 38], ["sarcoids", "ANATOMY", 62, 70], ["fibropapillomas", "ANATOMY", 72, 87], ["oral papillomas", "ANATOMY", 93, 108], ["feline lesions", "DISEASE", 24, 38], ["sarcoids", "DISEASE", 62, 70], ["fibropapillomas", "DISEASE", 72, 87], ["oral papillomas", "DISEASE", 93, 108], ["hematoxylin", "CHEMICAL", 133, 144], ["eosin", "CHEMICAL", 149, 154], ["samples", "CANCER", 6, 13], ["feline", "ORGANISM", 24, 30], ["lesions", "CANCER", 31, 38], ["sarcoids", "CANCER", 62, 70], ["fibropapillomas", "CANCER", 72, 87], ["oral papillomas", "CANCER", 93, 108], ["hematoxylin", "SIMPLE_CHEMICAL", 133, 144], ["feline", "SPECIES", 24, 30], ["These samples", "TEST", 0, 13], ["feline lesions", "PROBLEM", 24, 38], ["sarcoids (fibropapillomas)", "PROBLEM", 62, 88], ["oral papillomas", "PROBLEM", 93, 108], ["hematoxylin", "TREATMENT", 133, 144], ["eosin staining", "TEST", 149, 163], ["papillomas", "OBSERVATION", 98, 108]]], ["Five novel variants of PV were discovered with ViroCap (Table 2, Fig. 2, Supplementary Table 6 , and Supplementary Figures 3-6 ).", [["ViroCap", "PROTEIN", 47, 54], ["PV", "SPECIES", 23, 25], ["PV", "ANATOMY", 23, 25]]], ["GenBank accessions for the new variants are KY802017, KY825186, KY825187, KY825188, and KY886226.", [["KY802017", "CHEMICAL", 44, 52], ["KY825186", "CHEMICAL", 54, 62], ["KY825187", "CHEMICAL", 64, 72], ["KY825188", "CHEMICAL", 74, 82], ["KY886226", "CHEMICAL", 88, 96], ["KY802017", "CHEMICAL", 44, 52], ["KY825186", "CHEMICAL", 54, 62], ["KY825187", "CHEMICAL", 64, 72], ["KY825188", "CHEMICAL", 74, 82], ["KY886226", "CHEMICAL", 88, 96], ["KY802017", "SIMPLE_CHEMICAL", 44, 52], ["KY825186", "SIMPLE_CHEMICAL", 54, 62], ["KY886226", "SIMPLE_CHEMICAL", 88, 96]]], ["All SNPs in the L1 gene in the novel variants were synonymous.", [["L1 gene", "DNA", 16, 23], ["All SNPs", "TEST", 0, 8], ["SNPs", "OBSERVATION", 4, 8], ["L1", "ANATOMY", 16, 18], ["synonymous", "OBSERVATION", 51, 61]]], ["For the 5 novel PV variants, the reads that aligned to the ends of the reference genome contained overhangs that mapped to the other end of the genome.", [["genome", "CELLULAR_COMPONENT", 144, 150], ["5 novel PV variants", "DNA", 8, 27], ["reference genome", "DNA", 71, 87], ["the 5 novel PV variants", "PROBLEM", 4, 27], ["overhangs", "OBSERVATION_MODIFIER", 98, 107], ["genome", "OBSERVATION", 144, 150]]], ["This is consistent with a circularized virus and maintenance of the virus as an episome.Foamy virus was the most common virus in feline oral mucosaFoamy virus that was integrated into the host genome was found in 10 feline samples, N6, N9, PV7, OSCC1, 4, 9, 10, 11, 16, 18 (Supplementary Table 8 ).", [["oral", "ANATOMY", 136, 140], ["samples", "ANATOMY", 223, 230], ["Foamy virus", "ORGANISM", 88, 99], ["feline", "ORGANISM", 129, 135], ["oral mucosaFoamy virus", "ORGANISM", 136, 158], ["feline", "ORGANISM", 216, 222], ["PV7", "CELL", 240, 243], ["host genome", "DNA", 188, 199], ["feline oral mucosaFoamy virus", "SPECIES", 129, 158], ["Foamy virus", "SPECIES", 88, 99], ["feline oral mucosaFoamy virus", "SPECIES", 129, 158], ["a circularized virus", "PROBLEM", 24, 44], ["the virus", "PROBLEM", 64, 73], ["Foamy virus", "PROBLEM", 88, 99], ["common virus in feline oral mucosaFoamy virus", "PROBLEM", 113, 158], ["N9", "TEST", 236, 238], ["PV7", "TEST", 240, 243], ["OSCC1", "TEST", 245, 250], ["consistent with", "UNCERTAINTY", 8, 23], ["circularized", "OBSERVATION_MODIFIER", 26, 38], ["virus", "OBSERVATION", 39, 44], ["virus", "OBSERVATION", 68, 73], ["episome", "OBSERVATION", 80, 87], ["virus", "OBSERVATION", 94, 99], ["most common", "OBSERVATION_MODIFIER", 108, 119], ["mucosaFoamy virus", "OBSERVATION", 141, 158], ["host genome", "OBSERVATION", 188, 199], ["N9", "ANATOMY_MODIFIER", 236, 238], ["OSCC1", "ANATOMY_MODIFIER", 245, 250]]], ["The difficulties of mapping short reads to repeat regions (e.g. long terminal repeat) prevented prediction of the whole genome sequence and location of genomic integration sites.", [["long terminal repeat", "ANATOMY", 64, 84], ["long terminal repeat", "CELLULAR_COMPONENT", 64, 84], ["repeat regions", "DNA", 43, 57], ["long terminal repeat", "DNA", 64, 84], ["whole genome sequence", "DNA", 114, 135], ["genomic integration sites", "DNA", 152, 177], ["the whole genome sequence", "TREATMENT", 110, 135], ["genomic integration sites", "PROBLEM", 152, 177], ["genomic integration", "OBSERVATION", 152, 171]]], ["Many SNPs were detected throughout the foamy virus genomes when compared to the closest relative ( Supplementary Figures 7 and 8 ).Anelloviruses or torque teno viruses were present at low read countsAnellovirus was detected in 8 of 33 cats (23% in non-FOSCC patients and 25% in FOSCC patients) in the current study but the coverage was < 0.5x in all but 2 of the samples, OSCC1 and OSCC8, and thus insufficient to confidently conclude the presence of anellovirus, Supplementary Table 9 .Epstein Barr Virus was present in a FOSCC sampleOnly 2 cats, OSCC19 and OSCC20, had evidence of felid herpes virus 1 (FHV-1), which is an alphaherpesvirus that causes upper respiratory tract infections in cats (Supplementary Table 9 ).", [["FOSCC", "ANATOMY", 278, 283], ["samples", "ANATOMY", 363, 370], ["upper respiratory tract", "ANATOMY", 654, 677], ["non-FOSCC", "DISEASE", 248, 257], ["felid herpes virus", "DISEASE", 583, 601], ["respiratory tract infections", "DISEASE", 660, 688], ["foamy virus", "ORGANISM", 39, 50], ["Anelloviruses", "GENE_OR_GENE_PRODUCT", 131, 144], ["torque teno viruses", "ORGANISM", 148, 167], ["cats", "ORGANISM", 235, 239], ["patients", "ORGANISM", 258, 266], ["FOSCC", "CANCER", 278, 283], ["patients", "ORGANISM", 284, 292], ["Epstein Barr Virus", "ORGANISM", 487, 505], ["cats", "ORGANISM", 542, 546], ["felid herpes virus 1", "ORGANISM", 583, 603], ["FHV-1", "ORGANISM", 605, 610], ["upper", "ORGANISM_SUBDIVISION", 654, 659], ["respiratory tract", "ORGANISM_SUBDIVISION", 660, 677], ["cats", "ORGANISM", 692, 696], ["cats", "SPECIES", 235, 239], ["patients", "SPECIES", 258, 266], ["patients", "SPECIES", 284, 292], ["cats", "SPECIES", 542, 546], ["felid herpes virus 1", "SPECIES", 583, 603], ["cats", "SPECIES", 692, 696], ["foamy virus", "SPECIES", 39, 50], ["Anellovirus", "SPECIES", 199, 210], ["Epstein Barr Virus", "SPECIES", 487, 505], ["felid herpes virus 1", "SPECIES", 583, 603], ["FHV-1", "SPECIES", 605, 610], ["Many SNPs", "PROBLEM", 0, 9], ["Anelloviruses", "TREATMENT", 131, 144], ["torque teno viruses", "PROBLEM", 148, 167], ["Anellovirus", "TEST", 199, 210], ["the current study", "TEST", 297, 314], ["OSCC1", "TEST", 372, 377], ["OSCC8", "TEST", 382, 387], ["anellovirus", "PROBLEM", 451, 462], ["Epstein Barr Virus", "PROBLEM", 487, 505], ["felid herpes virus", "PROBLEM", 583, 601], ["an alphaherpesvirus", "PROBLEM", 622, 641], ["upper respiratory tract infections in cats", "PROBLEM", 654, 696], ["torque", "OBSERVATION", 148, 154], ["teno viruses", "OBSERVATION", 155, 167], ["Barr Virus", "OBSERVATION", 495, 505], ["evidence of", "UNCERTAINTY", 571, 582], ["felid herpes", "OBSERVATION", 583, 595], ["alphaherpesvirus", "OBSERVATION", 625, 641], ["upper", "ANATOMY_MODIFIER", 654, 659], ["respiratory tract", "ANATOMY", 660, 677], ["infections", "OBSERVATION", 678, 688]]], ["Epstein Barr Virus (EBV; Human herpesvirus-4; HHV-4), a gammaherpesvirus, was detected in 1 cat, OSCC8.", [["Epstein Barr Virus", "DISEASE", 0, 18], ["Epstein Barr Virus", "ORGANISM", 0, 18], ["EBV", "ORGANISM", 20, 23], ["Human herpesvirus-4", "ORGANISM", 25, 44], ["HHV-4", "ORGANISM", 46, 51], ["gammaherpesvirus", "ORGANISM", 56, 72], ["cat", "ORGANISM", 92, 95], ["Human herpesvirus", "SPECIES", 25, 42], ["cat", "SPECIES", 92, 95], ["Epstein Barr Virus", "SPECIES", 0, 18], ["EBV", "SPECIES", 20, 23], ["Human herpesvirus-4; HHV-4", "SPECIES", 25, 51], ["Epstein Barr Virus", "TEST", 0, 18], ["EBV", "TEST", 20, 23], ["Human herpesvirus", "TEST", 25, 42], ["HHV", "TEST", 46, 49], ["a gammaherpesvirus", "PROBLEM", 54, 72], ["Barr Virus", "OBSERVATION", 8, 18], ["gammaherpesvirus", "ANATOMY", 56, 72]]], ["None of the EBV reads aligned to FcaGHV-1, feline gammaherpesvirus, (GenBank accession NC_028099.1).", [["EBV", "ORGANISM", 12, 15], ["FcaGHV-1", "GENE_OR_GENE_PRODUCT", 33, 41], ["feline gammaherpesvirus", "ORGANISM", 43, 66], ["EBV reads", "DNA", 12, 21], ["FcaGHV-1", "DNA", 33, 41], ["feline", "SPECIES", 43, 49], ["EBV", "SPECIES", 12, 15], ["FcaGHV-1", "SPECIES", 33, 41], ["feline gammaherpesvirus", "SPECIES", 43, 66], ["the EBV reads", "TEST", 8, 21], ["FcaGHV", "TEST", 33, 39]]], ["The DoC and BoC of EBV were approximately 2x and 7.1% ( Fig. 3 and Supplementary Table 5 ).", [["EBV", "ORGANISM", 19, 22], ["EBV", "TEST", 19, 22]]], ["The presence of EBV was confirmed with PCR (Supplementary Figure 9a) .", [["EBV", "ORGANISM", 16, 19], ["EBV", "SPECIES", 16, 19], ["EBV", "PROBLEM", 16, 19], ["PCR", "TEST", 39, 42], ["EBV", "OBSERVATION", 16, 19]]], ["EBV was the sole match with BLAST analysis and the sequence was identical to > 100 deposited EBV isolates with complete genomes (Supplementary Figure 9b) .Exogenous FeLV and FIV were detected in normal oral mucosaThe FIV-positive cats were the FIV SNAP positive cat, N3, and a stray cat N9 where FIV testing was not done.", [["oral mucosa", "ANATOMY", 202, 213], ["SNAP", "CHEMICAL", 248, 252], ["EBV", "ORGANISM", 0, 3], ["EBV", "ORGANISM", 93, 96], ["FeLV", "ORGANISM", 165, 169], ["FIV", "ORGANISM", 174, 177], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 202, 213], ["FIV", "ORGANISM", 217, 220], ["cats", "ORGANISM", 230, 234], ["FIV", "ORGANISM", 244, 247], ["SNAP", "GENE_OR_GENE_PRODUCT", 248, 252], ["cat", "ORGANISM", 262, 265], ["cat", "ORGANISM", 283, 286], ["FIV", "ORGANISM", 296, 299], ["cats", "SPECIES", 230, 234], ["EBV", "SPECIES", 0, 3], ["FIV", "SPECIES", 174, 177], ["FIV", "SPECIES", 244, 247], ["FIV", "SPECIES", 296, 299], ["BLAST analysis", "TEST", 28, 42], ["the sequence", "TEST", 47, 59], ["EBV isolates", "TEST", 93, 105], ["Exogenous FeLV and FIV", "PROBLEM", 155, 177], ["The FIV", "TEST", 213, 220], ["a stray cat N9", "TEST", 275, 289], ["FIV testing", "TEST", 296, 307], ["FeLV", "OBSERVATION", 165, 169], ["oral mucosa", "ANATOMY", 202, 213]]], ["Integrated FIV was detected at low DoC, 0.8x and 0.3x in N3 and N9 respectively (Supplementary Table 8 and Supplementary Figure 10 ).", [["FIV", "ORGANISM", 11, 14], ["FIV", "SPECIES", 11, 14], ["FIV", "OBSERVATION", 11, 14]]], ["Exogenous FeLV (exFeLV) was not detected by ViroCap in the cat that was FeLV positive on SNAP test, N2.", [["SNAP", "CHEMICAL", 89, 93], ["N2", "CHEMICAL", 100, 102], ["FeLV", "ORGANISM", 10, 14], ["exFeLV", "GENE_OR_GENE_PRODUCT", 16, 22], ["ViroCap", "SIMPLE_CHEMICAL", 44, 51], ["cat", "ORGANISM", 59, 62], ["FeLV", "ORGANISM", 72, 76], ["SNAP", "SIMPLE_CHEMICAL", 89, 93], ["ViroCap", "PROTEIN", 44, 51], ["Exogenous FeLV (exFeLV)", "PROBLEM", 0, 23], ["SNAP test", "TEST", 89, 98], ["FeLV", "OBSERVATION", 10, 14]]], ["In addition, the region of the U3 long terminal repeat that contains the CCAAT enhancer and TATA boxes found in exFeLV did not contain aligned reads in any patient except N7 and there were gaps in coverage in ENV and the 5\u2032 end of the gap-propol polyprotein (Supplementary Figure 11a and b) .", [["U3", "CELLULAR_COMPONENT", 31, 33], ["long terminal repeat", "CELLULAR_COMPONENT", 34, 54], ["CCAAT", "GENE_OR_GENE_PRODUCT", 73, 78], ["patient", "ORGANISM", 156, 163], ["ENV", "CANCER", 209, 212], ["U3 long terminal repeat", "DNA", 31, 54], ["CCAAT enhancer", "DNA", 73, 87], ["TATA boxes", "DNA", 92, 102], ["exFeLV", "DNA", 112, 118], ["ENV", "DNA", 209, 212], ["5\u2032 end", "DNA", 221, 227], ["gap-propol polyprotein", "DNA", 235, 257], ["patient", "SPECIES", 156, 163], ["the U3 long terminal repeat", "PROBLEM", 27, 54], ["the CCAAT enhancer", "PROBLEM", 69, 87], ["TATA boxes", "TEST", 92, 102], ["gaps in coverage in ENV", "TREATMENT", 189, 212], ["the gap-propol polyprotein", "TREATMENT", 231, 257], ["region", "ANATOMY_MODIFIER", 17, 23], ["U3", "ANATOMY_MODIFIER", 31, 33], ["CCAAT enhancer", "OBSERVATION", 73, 87]]], ["In contrast, cat N7 had a high BoC, 95.3%, and was thus suspected to be infected with exFeLV.", [["cat", "ORGANISM", 13, 16], ["exFeLV", "GENE_OR_GENE_PRODUCT", 86, 92], ["exFeLV", "PROTEIN", 86, 92], ["a high BoC", "PROBLEM", 24, 34], ["suspected to be", "UNCERTAINTY", 56, 71], ["infected", "OBSERVATION", 72, 80]]], ["Cat N7 was not FeLV/FIV tested but was diagnosed with feline infectious peritonitis (FIP) on necropsy.", [["feline infectious peritonitis", "DISEASE", 54, 83], ["FIP", "DISEASE", 85, 88], ["FeLV", "ORGANISM", 15, 19], ["FIV", "ORGANISM", 20, 23], ["feline", "ORGANISM", 54, 60], ["feline", "SPECIES", 54, 60], ["FIV", "SPECIES", 20, 23], ["Cat N7", "TREATMENT", 0, 6], ["FeLV/FIV", "TREATMENT", 15, 23], ["feline infectious peritonitis", "PROBLEM", 54, 83], ["necropsy", "TREATMENT", 93, 101], ["feline", "OBSERVATION_MODIFIER", 54, 60], ["infectious", "OBSERVATION_MODIFIER", 61, 71], ["peritonitis", "OBSERVATION", 72, 83]]], ["FIP is caused by infection with a mutated feline coronavirus, a ssRNA virus, and immunosuppression by FeLV has been associated with increased risk of FIP.Contamination with ovine and avian virusesA turkey hemorrhagic enteritis like virus, in the siadenovirus genus, was detected in sample PV3, 1 of 3 canine samples.", [["sample PV3", "ANATOMY", 282, 292], ["samples", "ANATOMY", 308, 315], ["FIP", "DISEASE", 0, 3], ["infection", "DISEASE", 17, 26], ["feline coronavirus", "DISEASE", 42, 60], ["FeLV", "DISEASE", 102, 106], ["FIP", "DISEASE", 150, 153], ["hemorrhagic enteritis", "DISEASE", 205, 226], ["FIP", "GENE_OR_GENE_PRODUCT", 0, 3], ["feline coronavirus", "ORGANISM", 42, 60], ["FeLV", "ORGANISM", 102, 106], ["ovine", "ORGANISM", 173, 178], ["avian virusesA", "ORGANISM", 183, 197], ["turkey hemorrhagic enteritis like virus", "ORGANISM", 198, 237], ["canine", "ORGANISM", 301, 307], ["samples", "CANCER", 308, 315], ["feline coronavirus", "SPECIES", 42, 60], ["turkey hemorrhagic enteritis", "SPECIES", 198, 226], ["canine", "SPECIES", 301, 307], ["feline coronavirus", "SPECIES", 42, 60], ["FeLV", "SPECIES", 102, 106], ["A turkey hemorrhagic enteritis like virus", "SPECIES", 196, 237], ["canine", "SPECIES", 301, 307], ["FIP", "PROBLEM", 0, 3], ["infection", "PROBLEM", 17, 26], ["a mutated feline coronavirus", "PROBLEM", 32, 60], ["a ssRNA virus", "PROBLEM", 62, 75], ["immunosuppression", "TREATMENT", 81, 98], ["increased risk of FIP", "PROBLEM", 132, 153], ["ovine and avian viruses", "TREATMENT", 173, 196], ["A turkey hemorrhagic enteritis like virus", "PROBLEM", 196, 237], ["sample PV3", "TEST", 282, 292], ["infection", "OBSERVATION", 17, 26], ["ssRNA virus", "OBSERVATION", 64, 75], ["FIP", "OBSERVATION", 150, 153], ["hemorrhagic", "OBSERVATION_MODIFIER", 205, 216], ["enteritis", "OBSERVATION", 217, 226], ["virus", "OBSERVATION", 232, 237], ["siadenovirus genus", "ANATOMY", 246, 264]]], ["The DoC and BoC were low, 0.3x and 0% respectively (Supplementary Figure 12) .", [["The DoC and BoC", "TREATMENT", 0, 15]]], ["BLAST of the reads that mapped to the hexon and fiber genes aligned solely to the turkey hemorrhagic enteritis viruses.", [["hemorrhagic enteritis", "DISEASE", 89, 110], ["hexon", "GENE_OR_GENE_PRODUCT", 38, 43], ["fiber", "CELLULAR_COMPONENT", 48, 53], ["turkey hemorrhagic enteritis viruses", "ORGANISM", 82, 118], ["hexon and fiber genes", "DNA", 38, 59], ["turkey hemorrhagic enteritis", "SPECIES", 82, 110], ["turkey hemorrhagic enteritis viruses", "SPECIES", 82, 118], ["the hexon and fiber genes", "TREATMENT", 34, 59], ["hemorrhagic enteritis viruses", "PROBLEM", 89, 118], ["fiber genes", "OBSERVATION", 48, 59], ["hemorrhagic", "OBSERVATION_MODIFIER", 89, 100], ["enteritis", "OBSERVATION", 101, 110]]], ["A canine siadenovirus has not been previously reported.", [["canine", "ORGANISM", 2, 8], ["canine", "SPECIES", 2, 8], ["canine", "SPECIES", 2, 8], ["A canine siadenovirus", "PROBLEM", 0, 21]]], ["Gallid herpesvirus 3 (GaHV-3) was present in one sample, OSCC13 (Supplementary Table 5 ).", [["sample", "ANATOMY", 49, 55], ["Gallid herpesvirus 3", "ORGANISM", 0, 20], ["GaHV-3", "GENE_OR_GENE_PRODUCT", 22, 28], ["Gallid herpesvirus", "SPECIES", 0, 18], ["Gallid herpesvirus", "SPECIES", 0, 18], ["Gallid herpesvirus", "TEST", 0, 18]]], ["BLAST of representative aligned reads were a match only to the Marek's disease viruses (MDV-2 and MDV-3) that infect chickens.", [["Marek's disease", "DISEASE", 63, 78], ["Marek's disease viruses", "ORGANISM", 63, 86], ["MDV-2", "ORGANISM", 88, 93], ["MDV-3", "ORGANISM", 98, 103], ["chickens", "ORGANISM", 117, 125], ["MDV", "SPECIES", 88, 91], ["MDV", "SPECIES", 98, 101], ["chickens", "SPECIES", 117, 125], ["Marek's disease viruses", "SPECIES", 63, 86], ["MDV", "SPECIES", 88, 91], ["MDV", "SPECIES", 98, 101], ["chickens", "SPECIES", 117, 125], ["the Marek's disease viruses", "PROBLEM", 59, 86], ["MDV", "TEST", 88, 91]]], ["This sample also contained avian leucosis virus (ALV).", [["sample", "ANATOMY", 5, 11], ["avian leucosis", "DISEASE", 27, 41], ["avian leucosis virus", "ORGANISM", 27, 47], ["ALV", "ORGANISM", 49, 52], ["avian leucosis virus", "SPECIES", 27, 47], ["avian leucosis virus", "SPECIES", 27, 47], ["ALV", "SPECIES", 49, 52], ["This sample", "TEST", 0, 11], ["avian leucosis virus", "PROBLEM", 27, 47], ["avian leucosis virus", "OBSERVATION", 27, 47]]], ["To determine if these avian viruses were present as a contaminant from chicken tissues, all of the sequenced reads from OSCC13 were aligned to the Gallus gallus genome (Galgal4).", [["tissues", "ANATOMY", 79, 86], ["avian", "ORGANISM", 22, 27], ["chicken", "ORGANISM", 71, 78], ["tissues", "TISSUE", 79, 86], ["OSCC13", "GENE_OR_GENE_PRODUCT", 120, 126], ["Gallus gallus", "ORGANISM", 147, 160], ["Galgal4", "GENE_OR_GENE_PRODUCT", 169, 176], ["OSCC13", "DNA", 120, 126], ["Gallus gallus genome", "DNA", 147, 167], ["Galgal4", "DNA", 169, 176], ["chicken", "SPECIES", 71, 78], ["Gallus gallus", "SPECIES", 147, 160], ["chicken", "SPECIES", 71, 78], ["Gallus gallus", "SPECIES", 147, 160], ["these avian viruses", "PROBLEM", 16, 35], ["a contaminant from chicken tissues", "PROBLEM", 52, 86], ["viruses", "OBSERVATION", 28, 35], ["Gallus gallus", "ANATOMY", 147, 160]]], ["OSCC13 had 98,146 reads (deduplicated with a mapping quality of \u226560) that mapped to Galgal4 with a BoC of 0.011%.", [["Galgal4", "GENE_OR_GENE_PRODUCT", 84, 91], ["OSCC13", "DNA", 0, 6], ["98,146 reads", "DNA", 11, 23], ["Galgal4", "DNA", 84, 91], ["a mapping quality", "TEST", 43, 60], ["a BoC", "TEST", 97, 102]]], ["In comparison, representative FOSCC FFPE samples that did not contain avian viruses, OSCC12-14, had 9144-16,699 reads with a BoC of 0.001-0.002%.", [["FFPE samples", "ANATOMY", 36, 48], ["FOSCC FFPE samples", "CANCER", 30, 48], ["avian viruses", "ORGANISM", 70, 83], ["OSCC12-14", "CELL", 85, 94], ["representative FOSCC FFPE samples", "TEST", 15, 48], ["OSCC12", "TEST", 85, 91], ["a BoC", "TEST", 123, 128]]], ["GaHV-3 and ALV were thus likely contaminants in sample OSCC13.", [["sample", "ANATOMY", 48, 54], ["GaHV-3", "GENE_OR_GENE_PRODUCT", 0, 6], ["ALV", "ORGANISM", 11, 14], ["ALV", "SPECIES", 11, 14], ["GaHV", "TEST", 0, 4], ["ALV", "TREATMENT", 11, 14], ["ALV", "ANATOMY", 11, 14], ["thus likely", "UNCERTAINTY", 20, 31], ["contaminants", "OBSERVATION", 32, 44]]], ["A Jaagsiekte retrovirus (ovine pulmonary carcinoma virus) like virus was present in 4 samples, OSCC4, OSCC10 OSCC19 and OSCC20 (Supplementary Table 5 ).", [["samples", "ANATOMY", 86, 93], ["pulmonary carcinoma", "DISEASE", 31, 50], ["Jaagsiekte retrovirus", "ORGANISM", 2, 23], ["ovine pulmonary carcinoma virus", "ORGANISM", 25, 56], ["Jaagsiekte retrovirus (ovine pulmonary carcinoma virus", "SPECIES", 2, 56], ["A Jaagsiekte retrovirus (ovine pulmonary carcinoma virus", "PROBLEM", 0, 56], ["virus", "PROBLEM", 63, 68], ["OSCC4", "TEST", 95, 100], ["retrovirus", "OBSERVATION", 13, 23], ["pulmonary", "ANATOMY", 31, 40], ["carcinoma", "OBSERVATION", 41, 50], ["virus", "OBSERVATION", 63, 68]]], ["The pattern of SNPs was identical in all samples and thus the virus in all samples came from the same source (Supplementary Figure 13) .", [["samples", "ANATOMY", 41, 48], ["SNPs", "DNA", 15, 19], ["SNPs", "PROBLEM", 15, 19], ["the virus", "PROBLEM", 58, 67], ["all samples", "TEST", 71, 82], ["virus", "OBSERVATION", 62, 67]]], ["The viral load was highest in OSCC10.", [["The viral load", "TEST", 0, 14], ["viral load", "OBSERVATION", 4, 14]]], ["OSCC10 could have cross-contaminated the other samples or all of these samples could have been contaminated by the same sheep tissue source.DiscussionThis is the first study to use a comprehensive capture approach to characterize the virome of the oral mucosa of domestic cats.", [["samples", "ANATOMY", 47, 54], ["samples", "ANATOMY", 71, 78], ["tissue", "ANATOMY", 126, 132], ["oral mucosa", "ANATOMY", 248, 259], ["OSCC10", "CHEMICAL", 0, 6], ["OSCC10", "GENE_OR_GENE_PRODUCT", 0, 6], ["sheep", "ORGANISM", 120, 125], ["tissue", "TISSUE", 126, 132], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 248, 259], ["cats", "ORGANISM", 272, 276], ["OSCC10", "PROTEIN", 0, 6], ["sheep", "SPECIES", 120, 125], ["cats", "SPECIES", 272, 276], ["sheep", "SPECIES", 120, 125], ["the other samples", "PROBLEM", 37, 54], ["a comprehensive capture approach", "TREATMENT", 181, 213], ["sheep tissue", "OBSERVATION", 120, 132], ["oral mucosa", "ANATOMY", 248, 259], ["domestic cats", "OBSERVATION", 263, 276]]], ["To demonstrate that PV causes FOSCC, ideally all 3 of the following criteria would be met: (1) PV DNA in the lesion, (2) expression of oncogenes such as E6 and E7, (3) disruption of tumor suppressor gene, TP53 and RB1, function by viral oncoproteins.", [["FOSCC", "ANATOMY", 30, 35], ["lesion", "ANATOMY", 109, 115], ["tumor", "ANATOMY", 182, 187], ["FOSCC", "DISEASE", 30, 35], ["tumor", "DISEASE", 182, 187], ["FOSCC", "CANCER", 30, 35], ["PV", "CELLULAR_COMPONENT", 95, 97], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["lesion", "PATHOLOGICAL_FORMATION", 109, 115], ["E6", "GENE_OR_GENE_PRODUCT", 153, 155], ["E7", "GENE_OR_GENE_PRODUCT", 160, 162], ["tumor", "CANCER", 182, 187], ["TP53", "GENE_OR_GENE_PRODUCT", 205, 209], ["RB1", "GENE_OR_GENE_PRODUCT", 214, 217], ["PV DNA", "DNA", 95, 101], ["oncogenes", "DNA", 135, 144], ["E6", "DNA", 153, 155], ["E7", "PROTEIN", 160, 162], ["tumor suppressor gene", "DNA", 182, 203], ["TP53", "DNA", 205, 209], ["RB1", "DNA", 214, 217], ["viral oncoproteins", "PROTEIN", 231, 249], ["PV", "SPECIES", 20, 22], ["PV", "SPECIES", 95, 97], ["PV DNA in the lesion", "PROBLEM", 95, 115], ["oncogenes such as E6 and E7, (3) disruption of tumor suppressor gene", "PROBLEM", 135, 203], ["TP53 and RB1", "TEST", 205, 217], ["viral oncoproteins", "PROBLEM", 231, 249], ["lesion", "OBSERVATION", 109, 115], ["tumor", "OBSERVATION", 182, 187], ["viral oncoproteins", "OBSERVATION", 231, 249]]], ["The first criterion was specifically evaluated in this study and was not met.", [["this study", "TEST", 50, 60]]], ["FcaPV was only detected in 1 of 20 FOSCC samples.", [["FOSCC samples", "ANATOMY", 35, 48], ["FcaPV", "GENE_OR_GENE_PRODUCT", 0, 5], ["FOSCC samples", "CANCER", 35, 48], ["FcaPV", "PROTEIN", 0, 5]]], ["These results are consistent with all published literature that includes > 1 FOSCC patient, where PV infection was detected in only 0-6.9% of patients (Munday and French, 2015; Munday et al., 2019 Munday et al., , 2009 Munday et al., 2011b; O'Neill et al., 2011; Supsavhad et al., 2016; Yamashita-Kawanishi et al., 2018) .", [["PV infection", "DISEASE", 98, 110], ["patient", "ORGANISM", 83, 90], ["patients", "ORGANISM", 142, 150], ["patient", "SPECIES", 83, 90], ["patients", "SPECIES", 142, 150], ["PV", "SPECIES", 98, 100], ["PV infection", "PROBLEM", 98, 110], ["consistent with", "UNCERTAINTY", 18, 33], ["PV", "ANATOMY", 98, 100], ["infection", "OBSERVATION", 101, 110]]], ["It is possible that PV was not detected but causes FOSCC via a 'hit and run' mechanism, where E6 and E7 contribute to tumor initiation, the virus is lost in overt neoplasms, and it is not required to maintain the transformed phenotype.", [["tumor", "ANATOMY", 118, 123], ["neoplasms", "ANATOMY", 163, 172], ["tumor", "DISEASE", 118, 123], ["neoplasms", "DISEASE", 163, 172], ["PV", "ORGANISM_SUBSTANCE", 20, 22], ["FOSCC", "CANCER", 51, 56], ["E6", "GENE_OR_GENE_PRODUCT", 94, 96], ["E7", "GENE_OR_GENE_PRODUCT", 101, 103], ["tumor", "CANCER", 118, 123], ["neoplasms", "CANCER", 163, 172], ["E6", "PROTEIN", 94, 96], ["E7", "PROTEIN", 101, 103], ["PV", "SPECIES", 20, 22], ["PV", "PROBLEM", 20, 22], ["FOSCC", "PROBLEM", 51, 56], ["a 'hit and run' mechanism", "PROBLEM", 61, 86], ["E6 and E7", "TREATMENT", 94, 103], ["tumor initiation", "PROBLEM", 118, 134], ["the virus", "PROBLEM", 136, 145], ["overt neoplasms", "PROBLEM", 157, 172], ["the transformed phenotype", "PROBLEM", 209, 234], ["tumor", "OBSERVATION", 118, 123], ["overt", "OBSERVATION_MODIFIER", 157, 162], ["neoplasms", "OBSERVATION", 163, 172]]], ["The hit and run hypothesis is unlikely in FOSCC due to the rarity of detecting FcaPV in FOSCC and in the oral mucosa of cats, lack of in vivo evidence that FcaPV causes premalignant changes in the oral mucosa, and the fact that PV is usually detectable with sensitive methods such as NGS in HNSCC lesions that have a genetic signature consistent with PV induced lesions (Parfenov et al., 2014) .", [["FOSCC", "ANATOMY", 88, 93], ["oral mucosa", "ANATOMY", 105, 116], ["oral mucosa", "ANATOMY", 197, 208], ["HNSCC lesions", "ANATOMY", 291, 304], ["lesions", "ANATOMY", 362, 369], ["FOSCC", "DISEASE", 88, 93], ["HNSCC", "DISEASE", 291, 296], ["FOSCC", "CANCER", 42, 47], ["FcaPV", "GENE_OR_GENE_PRODUCT", 79, 84], ["FOSCC", "CANCER", 88, 93], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 105, 116], ["cats", "ORGANISM", 120, 124], ["FcaPV", "GENE_OR_GENE_PRODUCT", 156, 161], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 197, 208], ["HNSCC lesions", "CANCER", 291, 304], ["lesions", "PATHOLOGICAL_FORMATION", 362, 369], ["FcaPV", "PROTEIN", 79, 84], ["PV", "SPECIES", 228, 230], ["PV", "SPECIES", 351, 353], ["The hit and run hypothesis", "PROBLEM", 0, 26], ["FcaPV in FOSCC", "PROBLEM", 79, 93], ["premalignant changes in the oral mucosa", "PROBLEM", 169, 208], ["NGS in HNSCC lesions", "PROBLEM", 284, 304], ["PV induced lesions", "PROBLEM", 351, 369], ["hit", "OBSERVATION", 4, 7], ["oral mucosa", "ANATOMY", 105, 116], ["premalignant", "OBSERVATION", 169, 181], ["oral mucosa", "ANATOMY", 197, 208], ["consistent with", "UNCERTAINTY", 335, 350], ["lesions", "OBSERVATION", 362, 369]]], ["The only PV virus that was isolated from a FOSCC lesion was FcaPV-3.", [["FOSCC lesion", "ANATOMY", 43, 55], ["FOSCC", "DISEASE", 43, 48], ["PV virus", "ORGANISM", 9, 17], ["FOSCC lesion", "CANCER", 43, 55], ["FcaPV-3", "GENE_OR_GENE_PRODUCT", 60, 67], ["PV virus", "SPECIES", 9, 17], ["PV virus", "PROBLEM", 9, 17], ["a FOSCC lesion", "PROBLEM", 41, 55], ["FcaPV", "TEST", 60, 65], ["PV", "ANATOMY", 9, 11], ["virus", "OBSERVATION", 12, 17], ["lesion", "OBSERVATION", 49, 55]]], ["FcaPV-3 is not as commonly isolated as FcaPV-2 in cats (Supplementary Table 1 ).", [["FcaPV-3", "CHEMICAL", 0, 7], ["FcaPV-3", "GENE_OR_GENE_PRODUCT", 0, 7], ["FcaPV-2", "GENE_OR_GENE_PRODUCT", 39, 46], ["cats", "ORGANISM", 50, 54], ["FcaPV", "PROTEIN", 39, 44], ["cats", "SPECIES", 50, 54], ["FcaPV", "TEST", 0, 5], ["FcaPV", "TEST", 39, 44]]], ["FcaPV-3 infection has been found in cutaneous SCC, nasal planum SCCs and BISC lesions (Munday et al., 2013a (Munday et al., , 2016 Munday et al., 2013b, a; Yamashita-Kawanishi et al., 2018) .", [["cutaneous SCC", "ANATOMY", 36, 49], ["nasal planum SCCs", "ANATOMY", 51, 68], ["BISC lesions", "ANATOMY", 73, 85], ["infection", "DISEASE", 8, 17], ["SCC", "DISEASE", 46, 49], ["nasal planum SCCs", "DISEASE", 51, 68], ["FcaPV-3", "GENE_OR_GENE_PRODUCT", 0, 7], ["cutaneous SCC", "CANCER", 36, 49], ["nasal planum SCCs", "CANCER", 51, 68], ["BISC lesions", "CANCER", 73, 85], ["FcaPV", "TEST", 0, 5], ["3 infection", "PROBLEM", 6, 17], ["cutaneous SCC", "PROBLEM", 36, 49], ["nasal planum SCCs", "PROBLEM", 51, 68], ["BISC lesions", "PROBLEM", 73, 85], ["infection", "OBSERVATION", 8, 17], ["cutaneous", "ANATOMY", 36, 45], ["SCC", "OBSERVATION", 46, 49], ["nasal planum", "ANATOMY", 51, 63]]], ["FcaPV-3 could have been an incidental infection.", [["FcaPV-3", "CHEMICAL", 0, 7], ["infection", "DISEASE", 38, 47], ["FcaPV-3", "CHEMICAL", 0, 7], ["FcaPV-3", "GENE_OR_GENE_PRODUCT", 0, 7], ["an incidental infection", "PROBLEM", 24, 47], ["incidental", "OBSERVATION_MODIFIER", 27, 37], ["infection", "OBSERVATION", 38, 47]]], ["The authors plan to further investigate PV as a cause of FOSCC in patient OSCC8 by demonstrating evidence of criteria 2 and 3 through analysis of expression of oncogenes and interaction with host tumor suppressor genes in a future study.", [["FOSCC", "ANATOMY", 57, 62], ["tumor", "ANATOMY", 196, 201], ["FOSCC", "DISEASE", 57, 62], ["tumor", "DISEASE", 196, 201], ["FOSCC", "CANCER", 57, 62], ["patient", "ORGANISM", 66, 73], ["OSCC8", "CANCER", 74, 79], ["tumor", "CANCER", 196, 201], ["oncogenes", "DNA", 160, 169], ["host tumor suppressor genes", "DNA", 191, 218], ["patient", "SPECIES", 66, 73], ["PV", "SPECIES", 40, 42], ["expression of oncogenes", "PROBLEM", 146, 169], ["host tumor suppressor genes", "TREATMENT", 191, 218], ["a future study", "TEST", 222, 236]]], ["Increased expression of p16, E6 and E7 and decreased expression of pRb and p53 would be expected in high-risk PV induced lesions.", [["lesions", "ANATOMY", 121, 128], ["p16", "GENE_OR_GENE_PRODUCT", 24, 27], ["E6", "GENE_OR_GENE_PRODUCT", 29, 31], ["E7", "GENE_OR_GENE_PRODUCT", 36, 38], ["pRb", "GENE_OR_GENE_PRODUCT", 67, 70], ["p53", "GENE_OR_GENE_PRODUCT", 75, 78], ["lesions", "PATHOLOGICAL_FORMATION", 121, 128], ["p16", "PROTEIN", 24, 27], ["E6", "PROTEIN", 29, 31], ["E7", "PROTEIN", 36, 38], ["pRb", "PROTEIN", 67, 70], ["p53", "PROTEIN", 75, 78], ["PV", "SPECIES", 110, 112], ["Increased expression of p16, E6 and E7", "PROBLEM", 0, 38], ["pRb and p53", "TREATMENT", 67, 78], ["high-risk PV induced lesions", "PROBLEM", 100, 128], ["risk PV", "OBSERVATION_MODIFIER", 105, 112], ["induced", "OBSERVATION_MODIFIER", 113, 120], ["lesions", "OBSERVATION", 121, 128]]], ["Decreased p53 and pRB expression and increased p16 expression was found in only 2.3% of FOSCC samples and all samples with high p16 expression were negative for PV (Supsavhad et al., 2016) .", [["FOSCC samples", "ANATOMY", 88, 101], ["samples", "ANATOMY", 110, 117], ["p53", "GENE_OR_GENE_PRODUCT", 10, 13], ["pRB", "GENE_OR_GENE_PRODUCT", 18, 21], ["p16", "GENE_OR_GENE_PRODUCT", 47, 50], ["FOSCC samples", "CANCER", 88, 101], ["samples", "CANCER", 110, 117], ["p16", "GENE_OR_GENE_PRODUCT", 128, 131], ["p53", "PROTEIN", 10, 13], ["pRB", "PROTEIN", 18, 21], ["p16", "PROTEIN", 47, 50], ["p16", "PROTEIN", 128, 131], ["PV", "SPECIES", 161, 163], ["Decreased p53", "PROBLEM", 0, 13], ["pRB expression", "TREATMENT", 18, 32], ["increased p16 expression", "PROBLEM", 37, 61], ["FOSCC samples", "TEST", 88, 101], ["all samples", "TEST", 106, 117], ["high p16 expression", "TEST", 123, 142], ["PV", "PROBLEM", 161, 163], ["p53", "OBSERVATION", 10, 13], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["p16 expression", "OBSERVATION", 47, 61]]], ["Increased p16 expression has been identified as a positive prognostic factor in FOSCC but has only been seen in a minority of samples, 6.7% to 19%, and has not been associated with PV infection (Munday et al., 2019 (Munday et al., , 2011b .", [["FOSCC", "ANATOMY", 80, 85], ["samples", "ANATOMY", 126, 133], ["FOSCC", "DISEASE", 80, 85], ["PV infection", "DISEASE", 181, 193], ["p16", "GENE_OR_GENE_PRODUCT", 10, 13], ["FOSCC", "CANCER", 80, 85], ["samples", "CANCER", 126, 133], ["p16", "PROTEIN", 10, 13], ["PV", "SPECIES", 181, 183], ["Increased p16 expression", "PROBLEM", 0, 24], ["a positive prognostic factor", "PROBLEM", 48, 76], ["PV infection", "PROBLEM", 181, 193], ["p16 expression", "OBSERVATION", 10, 24], ["positive", "OBSERVATION_MODIFIER", 50, 58], ["not been associated with", "UNCERTAINTY", 156, 180], ["PV", "ANATOMY", 181, 183], ["infection", "OBSERVATION", 184, 193]]], ["High-risk PVs encode an E6 protein that binds to p53 sufficiently to induce ubiquitin proteolysis (Faraji et al., 2017) .", [["PVs", "MULTI-TISSUE_STRUCTURE", 10, 13], ["E6", "GENE_OR_GENE_PRODUCT", 24, 26], ["p53", "GENE_OR_GENE_PRODUCT", 49, 52], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 76, 85], ["E6 protein", "PROTEIN", 24, 34], ["p53", "PROTEIN", 49, 52], ["High-risk PVs", "PROBLEM", 0, 13], ["an E6 protein", "TREATMENT", 21, 34], ["ubiquitin proteolysis", "PROBLEM", 76, 97], ["risk PVs", "OBSERVATION_MODIFIER", 5, 13]]], ["E7 similarly induces pRb degradation.", [["E7", "GENE_OR_GENE_PRODUCT", 0, 2], ["pRb", "GENE_OR_GENE_PRODUCT", 21, 24], ["E7", "PROTEIN", 0, 2], ["pRb", "PROTEIN", 21, 24], ["pRb degradation", "PROBLEM", 21, 36], ["pRb degradation", "OBSERVATION", 21, 36]]], ["However, E7 of FcaPV-3 is not expected to behave like in high-risk HPVs.", [["HPVs", "DISEASE", 67, 71], ["E7", "GENE_OR_GENE_PRODUCT", 9, 11], ["FcaPV-3", "GENE_OR_GENE_PRODUCT", 15, 22], ["HPVs", "ORGANISM", 67, 71], ["E7", "PROTEIN", 9, 11], ["FcaPV", "PROTEIN", 15, 20], ["HPVs", "OBSERVATION", 67, 71]]], ["The critical cysteine amino acid in the LXCXE motif on E7, that is conserved in HPV-16, FcaPV-1 and FcaPV-2, and which is responsible for pRb binding, was not present in FcaPV-3 (Supplementary Figure 14) .", [["amino acid", "CHEMICAL", 22, 32], ["cysteine amino acid", "CHEMICAL", 13, 32], ["cysteine", "AMINO_ACID", 13, 21], ["amino acid", "AMINO_ACID", 22, 32], ["E7", "GENE_OR_GENE_PRODUCT", 55, 57], ["HPV-16", "ORGANISM", 80, 86], ["FcaPV-1", "GENE_OR_GENE_PRODUCT", 88, 95], ["FcaPV-2", "GENE_OR_GENE_PRODUCT", 100, 107], ["pRb", "GENE_OR_GENE_PRODUCT", 138, 141], ["FcaPV-3", "GENE_OR_GENE_PRODUCT", 170, 177], ["LXCXE motif", "PROTEIN", 40, 51], ["E7", "PROTEIN", 55, 57], ["pRb", "PROTEIN", 138, 141], ["FcaPV", "PROTEIN", 170, 175], ["HPV-16", "SPECIES", 80, 86], ["The critical cysteine amino acid", "TEST", 0, 32], ["the LXCXE motif", "TEST", 36, 51], ["HPV", "TEST", 80, 83], ["FcaPV", "TEST", 88, 93], ["FcaPV", "TEST", 100, 105], ["pRb binding", "PROBLEM", 138, 149], ["FcaPV", "TEST", 170, 175], ["amino acid", "OBSERVATION", 22, 32]]], ["FcaPV-3 either does not bind to pRb and cause its degradation or binds pRb in a yet to be discovered novel mechanism.DiscussionThere is thus currently no evidence that PV is associated with changes in oncoproteins or tumor suppressor proteins in FOSCC analogous to high-risk HPVs.", [["tumor", "ANATOMY", 217, 222], ["FOSCC", "ANATOMY", 246, 251], ["tumor", "DISEASE", 217, 222], ["HPVs", "DISEASE", 275, 279], ["FcaPV-3", "CHEMICAL", 0, 7], ["FcaPV-3", "GENE_OR_GENE_PRODUCT", 0, 7], ["pRb", "GENE_OR_GENE_PRODUCT", 32, 35], ["pRb", "GENE_OR_GENE_PRODUCT", 71, 74], ["tumor", "CANCER", 217, 222], ["FOSCC", "CANCER", 246, 251], ["HPVs", "ORGANISM", 275, 279], ["FcaPV", "PROTEIN", 0, 5], ["pRb", "PROTEIN", 32, 35], ["pRb", "PROTEIN", 71, 74], ["oncoproteins", "PROTEIN", 201, 213], ["tumor suppressor proteins", "PROTEIN", 217, 242], ["PV", "SPECIES", 168, 170], ["its degradation", "PROBLEM", 46, 61], ["binds pRb", "PROBLEM", 65, 74], ["PV", "PROBLEM", 168, 170], ["changes in oncoproteins", "PROBLEM", 190, 213], ["tumor suppressor proteins", "PROBLEM", 217, 242], ["no evidence", "UNCERTAINTY", 151, 162], ["PV", "OBSERVATION", 168, 170]]], ["Three other characteristics of FOSCC decrease the likelihood that FOSCC is a good model for high-risk PV induced SCC in people: (1) PV was maintained as a full-length episome compared to integration into the host genome in high-risk HPVs (Cancer Genome Atlas, 2015; Faraji et al., 2017; Parfenov et al., 2014) ; (2) FOSCC is almost exclusively a cancer of geriatric patients in contrast to PV-positive HNSCC being most prevalent in younger patients compared to carcinogen induced HNSCC; (3) FOSCC most commonly occurs in the oral cavity proper compared to HPV-positive tumors that are the most common in the oropharynx (e.g. tonsils) (Kang et al., 2015) .", [["SCC", "ANATOMY", 113, 116], ["cancer", "ANATOMY", 346, 352], ["HNSCC", "ANATOMY", 402, 407], ["HNSCC", "ANATOMY", 480, 485], ["oral cavity", "ANATOMY", 525, 536], ["tumors", "ANATOMY", 569, 575], ["oropharynx", "ANATOMY", 608, 618], ["tonsils", "ANATOMY", 625, 632], ["SCC", "DISEASE", 113, 116], ["HPVs", "DISEASE", 233, 237], ["Cancer", "DISEASE", 239, 245], ["cancer", "DISEASE", 346, 352], ["HNSCC", "DISEASE", 402, 407], ["HNSCC", "DISEASE", 480, 485], ["HPV-positive tumors", "DISEASE", 556, 575], ["FOSCC", "CANCER", 31, 36], ["FOSCC", "CANCER", 66, 71], ["SCC", "CANCER", 113, 116], ["people", "ORGANISM", 120, 126], ["HPVs", "ORGANISM", 233, 237], ["FOSCC", "CANCER", 316, 321], ["cancer", "CANCER", 346, 352], ["patients", "ORGANISM", 366, 374], ["HNSCC", "CANCER", 402, 407], ["patients", "ORGANISM", 440, 448], ["HNSCC", "CANCER", 480, 485], ["FOSCC", "CANCER", 491, 496], ["oral cavity", "ORGAN", 525, 536], ["HPV", "ORGANISM", 556, 559], ["tumors", "CANCER", 569, 575], ["oropharynx", "ORGAN", 608, 618], ["tonsils", "ORGAN", 625, 632], ["host genome", "DNA", 208, 219], ["people", "SPECIES", 120, 126], ["patients", "SPECIES", 366, 374], ["patients", "SPECIES", 440, 448], ["PV", "SPECIES", 102, 104], ["PV", "SPECIES", 132, 134], ["PV", "SPECIES", 390, 392], ["FOSCC decrease", "PROBLEM", 31, 45], ["a full-length episome", "TREATMENT", 153, 174], ["PV", "TEST", 390, 392], ["positive HNSCC", "PROBLEM", 393, 407], ["carcinogen induced HNSCC", "PROBLEM", 461, 485], ["HPV", "TEST", 556, 559], ["positive tumors", "PROBLEM", 560, 575], ["host genome", "OBSERVATION", 208, 219], ["cancer", "OBSERVATION", 346, 352], ["HNSCC", "OBSERVATION", 402, 407], ["oral cavity", "ANATOMY", 525, 536], ["positive", "OBSERVATION_MODIFIER", 560, 568], ["tumors", "OBSERVATION", 569, 575], ["most common", "OBSERVATION_MODIFIER", 589, 600], ["oropharynx", "ANATOMY", 608, 618], ["tonsils", "ANATOMY", 625, 632]]], ["There were no tonsillar FOSCC lesions included in this study, due to the rarity of this lesion at the MU VMTH.", [["tonsillar FOSCC lesions", "ANATOMY", 14, 37], ["lesion", "ANATOMY", 88, 94], ["tonsillar FOSCC lesions", "CANCER", 14, 37], ["lesion", "CANCER", 88, 94], ["tonsillar FOSCC lesions", "PROBLEM", 14, 37], ["this study", "TEST", 50, 60], ["this lesion", "PROBLEM", 83, 94], ["no", "UNCERTAINTY", 11, 13], ["tonsillar", "ANATOMY", 14, 23], ["FOSCC", "OBSERVATION_MODIFIER", 24, 29], ["lesions", "OBSERVATION", 30, 37], ["lesion", "OBSERVATION", 88, 94]]], ["None of the PV-positive FOSCC lesions from previous studies were classified as oropharyngeal (Supplementary Table 2 ).", [["FOSCC lesions", "ANATOMY", 24, 37], ["oropharyngeal", "ANATOMY", 79, 92], ["PV", "GENE_OR_GENE_PRODUCT", 12, 14], ["FOSCC lesions", "CANCER", 24, 37], ["the PV", "TEST", 8, 14], ["positive FOSCC lesions", "PROBLEM", 15, 37], ["previous studies", "TEST", 43, 59], ["PV", "ANATOMY", 12, 14], ["positive", "OBSERVATION_MODIFIER", 15, 23], ["FOSCC", "OBSERVATION_MODIFIER", 24, 29], ["lesions", "OBSERVATION", 30, 37], ["oropharyngeal", "ANATOMY", 79, 92]]], ["To the author's knowledge PV status of oropharyngeal FOSCC has been evaluated in only 15 cats to date (Munday and French, 2015; Munday et al., 2019 Munday et al., , 2009 Munday et al., 2011b; O'Neill et al., 2011) .", [["oropharyngeal FOSCC", "ANATOMY", 39, 58], ["oropharyngeal FOSCC", "DISEASE", 39, 58], ["oropharyngeal FOSCC", "CANCER", 39, 58], ["cats", "ORGANISM", 89, 93], ["oropharyngeal FOSCC", "ANATOMY", 39, 58]]], ["Tonsillar FOSCC lesions have been associated with a better prognosis, than FOSCC lesions located in the oral cavity, when treated with an accelerated radiation therapy and carboplatin protocol (Fidel et al., 2011) .", [["Tonsillar FOSCC lesions", "ANATOMY", 0, 23], ["FOSCC lesions", "ANATOMY", 75, 88], ["oral cavity", "ANATOMY", 104, 115], ["carboplatin", "CHEMICAL", 172, 183], ["carboplatin", "CHEMICAL", 172, 183], ["Tonsillar FOSCC lesions", "CANCER", 0, 23], ["FOSCC lesions", "CANCER", 75, 88], ["oral cavity", "ORGAN", 104, 115], ["carboplatin", "SIMPLE_CHEMICAL", 172, 183], ["Tonsillar FOSCC lesions", "PROBLEM", 0, 23], ["FOSCC lesions", "PROBLEM", 75, 88], ["an accelerated radiation therapy", "TREATMENT", 135, 167], ["carboplatin protocol", "TREATMENT", 172, 192], ["lesions", "OBSERVATION", 16, 23], ["lesions", "OBSERVATION", 81, 88], ["oral cavity", "ANATOMY", 104, 115]]], ["If there is a feline correlate with HPV-positive OPSCC, tonsillar FOSCC would likely be the best candidate.", [["OPSCC", "ANATOMY", 49, 54], ["tonsillar FOSCC", "ANATOMY", 56, 71], ["OPSCC", "DISEASE", 49, 54], ["feline", "ORGANISM", 14, 20], ["HPV", "ORGANISM", 36, 39], ["tonsillar FOSCC", "CANCER", 56, 71], ["HPV", "TEST", 36, 39], ["positive OPSCC", "PROBLEM", 40, 54], ["tonsillar FOSCC", "PROBLEM", 56, 71], ["tonsillar", "ANATOMY", 56, 65]]], ["Non-viral causes of FOSCC may include age, microbiota, genetics and exposure to carcinogens which can affect the oral cavity via ingestion or grooming.", [["oral cavity", "ANATOMY", 113, 124], ["FOSCC", "DISEASE", 20, 25], ["FOSCC", "CANCER", 20, 25], ["oral cavity", "ORGANISM_SUBDIVISION", 113, 124], ["carcinogens", "TREATMENT", 80, 91]]], ["Carcinogenic agents in HNSCC commonly cause oxidative damage (Altieri et al., 2004; Freedman et al., 2007; Guha et al., 2014) .", [["HNSCC", "ANATOMY", 23, 28], ["HNSCC", "DISEASE", 23, 28], ["HNSCC", "CANCER", 23, 28], ["Carcinogenic agents", "TREATMENT", 0, 19], ["oxidative damage", "PROBLEM", 44, 60]]], ["Future studies on the etiology of FOSCC should focus on carcinogen exposure.", [["FOSCC", "DISEASE", 34, 39], ["FOSCC", "CANCER", 34, 39], ["Future studies", "TEST", 0, 14], ["carcinogen exposure", "TREATMENT", 56, 75]]], ["PV was also not found in some lesions that commonly have a PV cause.", [["lesions", "ANATOMY", 30, 37], ["lesions", "PATHOLOGICAL_FORMATION", 30, 37], ["PV", "SPECIES", 0, 2], ["some lesions", "PROBLEM", 25, 37], ["lesions", "OBSERVATION", 30, 37], ["PV", "OBSERVATION", 59, 61]]], ["Based on these results, it appears that at least a portion of histologically diagnosed feline sarcoids and oral papillomas are not virally induced and histology alone may be insufficient to diagnose these lesions.", [["sarcoids", "ANATOMY", 94, 102], ["oral papillomas", "ANATOMY", 107, 122], ["lesions", "ANATOMY", 205, 212], ["feline sarcoids", "DISEASE", 87, 102], ["oral papillomas", "DISEASE", 107, 122], ["feline", "ORGANISM", 87, 93], ["sarcoids", "CANCER", 94, 102], ["oral papillomas", "CANCER", 107, 122], ["lesions", "PATHOLOGICAL_FORMATION", 205, 212], ["feline", "SPECIES", 87, 93], ["histologically diagnosed feline sarcoids", "PROBLEM", 62, 102], ["oral papillomas", "PROBLEM", 107, 122], ["histology", "TEST", 151, 160], ["these lesions", "PROBLEM", 199, 212], ["histologically", "OBSERVATION_MODIFIER", 62, 76], ["feline sarcoids", "OBSERVATION", 87, 102], ["papillomas", "OBSERVATION", 112, 122], ["lesions", "OBSERVATION", 205, 212]]], ["Foamy viruses are continuously shed from the oral mucosa in infected cats and it was the most prevalent virus in normal and FOSCC oral mucosa.", [["oral mucosa", "ANATOMY", 45, 56], ["FOSCC oral mucosa", "ANATOMY", 124, 141], ["Foamy viruses", "ORGANISM", 0, 13], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 45, 56], ["cats", "ORGANISM", 69, 73], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 130, 141], ["cats", "SPECIES", 69, 73], ["Foamy viruses", "PROBLEM", 0, 13], ["infected cats", "TREATMENT", 60, 73], ["viruses", "OBSERVATION", 6, 13], ["oral mucosa", "ANATOMY", 45, 56], ["infected cats", "OBSERVATION", 60, 73], ["normal", "OBSERVATION", 113, 119], ["oral mucosa", "ANATOMY", 130, 141]]], ["A prevalence of 36% was seen in homeless cats from South Australia (Winkler et al., 1998) , similar to the 30% observed in this study.", [["cats", "ORGANISM", 41, 45], ["cats", "SPECIES", 41, 45], ["this study", "TEST", 123, 133]]], ["Foamy viruses have been used in gene therapy due to their preferential integration into transcriptionally inactive regions and resulting apparent lack of association with clinical disease.", [["Foamy viruses", "ORGANISM", 0, 13], ["transcriptionally inactive regions", "DNA", 88, 122], ["Foamy viruses", "PROBLEM", 0, 13], ["gene therapy", "TREATMENT", 32, 44], ["clinical disease", "PROBLEM", 171, 187], ["viruses", "OBSERVATION", 6, 13], ["inactive", "OBSERVATION", 106, 114]]], ["Torque teno virus was the second most prevalent virus but was detected at very low coverage.", [["Torque teno virus", "ORGANISM", 0, 17], ["Torque teno virus", "SPECIES", 0, 17], ["Torque teno virus", "PROBLEM", 0, 17], ["teno virus", "OBSERVATION", 7, 17], ["most prevalent", "OBSERVATION_MODIFIER", 33, 47], ["virus", "OBSERVATION", 48, 53]]], ["Anelloviruses have been detected in cat feces, saliva and serum (Jarosova et al., 2015; Zhang et al., 2014) .", [["feces", "ANATOMY", 40, 45], ["saliva", "ANATOMY", 47, 53], ["serum", "ANATOMY", 58, 63], ["Anelloviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["cat", "ORGANISM", 36, 39], ["feces", "ORGANISM_SUBSTANCE", 40, 45], ["saliva", "ORGANISM_SUBSTANCE", 47, 53], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["Anelloviruses", "PROTEIN", 0, 13], ["cat", "SPECIES", 36, 39], ["cat", "SPECIES", 36, 39], ["Anelloviruses", "TREATMENT", 0, 13]]], ["Anelloviruses are not known to be pathogenic in cats and pathogenicity in other species is controversial with the exception of chicken anemia virus and porcine circovirus, which are closely related to anelloviruses.", [["chicken anemia", "DISEASE", 127, 141], ["Anelloviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["cats", "ORGANISM", 48, 52], ["chicken anemia virus", "ORGANISM", 127, 147], ["porcine circovirus", "ORGANISM", 152, 170], ["anelloviruses", "CANCER", 201, 214], ["cats", "SPECIES", 48, 52], ["chicken", "SPECIES", 127, 134], ["porcine circovirus", "SPECIES", 152, 170], ["chicken anemia virus", "SPECIES", 127, 147], ["porcine circovirus", "SPECIES", 152, 170], ["Anelloviruses", "TREATMENT", 0, 13], ["pathogenic in cats", "PROBLEM", 34, 52], ["pathogenicity in other species", "PROBLEM", 57, 87], ["chicken anemia virus", "PROBLEM", 127, 147], ["porcine circovirus", "PROBLEM", 152, 170], ["not known to be", "UNCERTAINTY", 18, 33], ["pathogenic", "OBSERVATION", 34, 44], ["cats", "OBSERVATION", 48, 52], ["anemia virus", "OBSERVATION", 135, 147], ["porcine circovirus", "OBSERVATION", 152, 170]]], ["Prevalence in feline serum of 12.5-43% has been seen worldwide, which is similar to the suspected prevalence in this study (Jarosova et al., 2015; Okamoto et al., 2002; Zhu et al., 2011) .", [["serum", "ANATOMY", 21, 26], ["feline", "ORGANISM", 14, 20], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["feline", "SPECIES", 14, 20], ["Prevalence in feline serum", "TEST", 0, 26], ["this study", "TEST", 112, 122]]], ["To confirm the suspected higher prevalence a targeted PCR approach could be done.", [["a targeted PCR approach", "TREATMENT", 43, 66]]], ["Studies evaluating FHV-1 with PCR in conjunctival and gingival samples of clinical and non-clinical cats reported that only 1-6% cats were positive for FHV-1 (Sjodahl-Essen et al., 2008) .", [["conjunctival", "ANATOMY", 37, 49], ["gingival samples", "ANATOMY", 54, 70], ["FHV-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["conjunctival", "TISSUE", 37, 49], ["gingival samples", "CANCER", 54, 70], ["cats", "ORGANISM", 100, 104], ["cats", "ORGANISM", 129, 133], ["FHV-1", "DNA", 19, 24], ["cats", "SPECIES", 100, 104], ["FHV-1", "SPECIES", 19, 24], ["FHV-1", "SPECIES", 152, 157], ["Studies", "TEST", 0, 7], ["FHV", "TEST", 19, 22], ["PCR", "TEST", 30, 33], ["gingival samples", "TEST", 54, 70], ["non-clinical cats", "TEST", 87, 104], ["FHV", "TEST", 152, 155], ["conjunctival", "ANATOMY", 37, 49], ["gingival", "ANATOMY", 54, 62]]], ["In the current study, a similarly low prevalence of 6% was found.", [["the current study", "TEST", 3, 20]]], ["EBV was detected at low levels in a cat with FOSCC and concurrent FcaPV-3 infection.", [["FOSCC", "DISEASE", 45, 50], ["infection", "DISEASE", 74, 83], ["EBV", "ORGANISM", 0, 3], ["cat", "ORGANISM", 36, 39], ["FOSCC", "CANCER", 45, 50], ["FcaPV-3", "GENE_OR_GENE_PRODUCT", 66, 73], ["EBV", "SPECIES", 0, 3], ["EBV", "TEST", 0, 3], ["FOSCC", "PROBLEM", 45, 50], ["concurrent FcaPV-3 infection", "PROBLEM", 55, 83], ["low levels", "OBSERVATION_MODIFIER", 20, 30], ["infection", "OBSERVATION", 74, 83]]], ["Contamination was deemed an unlikely source since EBV is shed via human saliva, plasma and blood and personal protective equipment was worn during surgery or necropsy.", [["saliva", "ANATOMY", 72, 78], ["plasma", "ANATOMY", 80, 86], ["blood", "ANATOMY", 91, 96], ["EBV", "ORGANISM", 50, 53], ["human", "ORGANISM", 66, 71], ["saliva", "ORGANISM_SUBSTANCE", 72, 78], ["plasma", "ORGANISM_SUBSTANCE", 80, 86], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["human", "SPECIES", 66, 71], ["EBV", "SPECIES", 50, 53], ["human", "SPECIES", 66, 71], ["EBV", "PROBLEM", 50, 53], ["plasma", "TREATMENT", 80, 86], ["personal protective equipment", "TREATMENT", 101, 130], ["surgery", "TREATMENT", 147, 154], ["necropsy", "TREATMENT", 158, 166]]], ["Cross contamination was unlikely since the MU VMDL does not process human samples.", [["samples", "ANATOMY", 74, 81], ["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["Cross contamination", "PROBLEM", 0, 19]]], ["The oral mucosal sampling route used in this study would have been appropriate for detection of an active EBV infection since EBV replicates in the B-lymphocytes and epithelial cells in the oropharynx and is transmitted via oral secretions.", [["oral", "ANATOMY", 4, 8], ["mucosal", "ANATOMY", 9, 16], ["B-lymphocytes", "ANATOMY", 148, 161], ["epithelial cells", "ANATOMY", 166, 182], ["oropharynx", "ANATOMY", 190, 200], ["oral secretions", "ANATOMY", 224, 239], ["EBV infection", "DISEASE", 106, 119], ["oral mucosal", "MULTI-TISSUE_STRUCTURE", 4, 16], ["EBV", "ORGANISM", 106, 109], ["EBV", "ORGANISM", 126, 129], ["B-lymphocytes", "CELL", 148, 161], ["epithelial cells", "CELL", 166, 182], ["oropharynx", "ORGAN", 190, 200], ["oral", "ORGANISM_SUBDIVISION", 224, 228], ["secretions", "ORGANISM_SUBSTANCE", 229, 239], ["B-lymphocytes", "CELL_TYPE", 148, 161], ["epithelial cells", "CELL_TYPE", 166, 182], ["EBV", "SPECIES", 106, 109], ["EBV", "SPECIES", 126, 129], ["The oral mucosal sampling route", "TREATMENT", 0, 31], ["this study", "TEST", 40, 50], ["an active EBV infection", "PROBLEM", 96, 119], ["EBV replicates", "TEST", 126, 140], ["the B-lymphocytes", "TEST", 144, 161], ["epithelial cells in the oropharynx", "PROBLEM", 166, 200], ["transmitted via oral secretions", "PROBLEM", 208, 239], ["active", "OBSERVATION_MODIFIER", 99, 105], ["EBV", "OBSERVATION_MODIFIER", 106, 109], ["infection", "OBSERVATION", 110, 119], ["lymphocytes", "ANATOMY", 150, 161], ["epithelial cells", "OBSERVATION", 166, 182], ["oropharynx", "ANATOMY", 190, 200], ["secretions", "OBSERVATION", 229, 239]]], ["EBV or an EBVlike virus has been detected previously in cats with serology (Milman et al., 2011) .", [["EBV", "ORGANISM", 0, 3], ["EBVlike virus", "ORGANISM", 10, 23], ["cats", "ORGANISM", 56, 60], ["cats", "SPECIES", 56, 60], ["EBV", "SPECIES", 0, 3], ["EBVlike virus", "SPECIES", 10, 23], ["EBV", "PROBLEM", 0, 3], ["an EBVlike virus", "PROBLEM", 7, 23], ["serology", "TEST", 66, 74], ["EBVlike virus", "OBSERVATION", 10, 23]]], ["False positives due to cross-reactivity with other herpes viruses are possible with serology (Heller et al., 1982; Milman et al., 2011) .", [["herpes viruses", "DISEASE", 51, 65], ["herpes viruses", "ORGANISM", 51, 65], ["False positives", "PROBLEM", 0, 15], ["cross-reactivity", "PROBLEM", 23, 39], ["other herpes viruses", "PROBLEM", 45, 65]]], ["The presence of circulating EBV DNA in the blood pre and post treatment and antibody titers have been shown to be independent negative prognostic indicators in nasopharyngeal carcinomas (Kang et al., 2015) .", [["blood", "ANATOMY", 43, 48], ["nasopharyngeal carcinomas", "ANATOMY", 160, 185], ["nasopharyngeal carcinomas", "DISEASE", 160, 185], ["EBV", "ORGANISM", 28, 31], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["nasopharyngeal carcinomas", "CANCER", 160, 185], ["EBV DNA", "DNA", 28, 35], ["EBV", "SPECIES", 28, 31], ["circulating EBV DNA", "PROBLEM", 16, 35], ["the blood", "TEST", 39, 48], ["treatment", "TREATMENT", 62, 71], ["antibody titers", "TEST", 76, 91], ["nasopharyngeal carcinomas", "PROBLEM", 160, 185], ["circulating", "OBSERVATION_MODIFIER", 16, 27], ["EBV DNA", "OBSERVATION", 28, 35], ["blood", "ANATOMY", 43, 48], ["nasopharyngeal", "ANATOMY", 160, 174], ["carcinomas", "OBSERVATION", 175, 185]]], ["EBV infection has also been shown to increase the risk of HOSCC (She et al., 2017) .", [["EBV infection", "DISEASE", 0, 13], ["HOSCC", "DISEASE", 58, 63], ["EBV", "ORGANISM", 0, 3], ["HOSCC", "CANCER", 58, 63], ["EBV", "SPECIES", 0, 3], ["EBV infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["increase", "OBSERVATION_MODIFIER", 37, 45]]], ["This is the first study to find EBV DNA in a feline tumor.", [["tumor", "ANATOMY", 52, 57], ["feline tumor", "DISEASE", 45, 57], ["EBV", "ORGANISM", 32, 35], ["DNA", "CELLULAR_COMPONENT", 36, 39], ["feline", "ORGANISM", 45, 51], ["tumor", "CANCER", 52, 57], ["EBV DNA", "DNA", 32, 39], ["feline", "SPECIES", 45, 51], ["EBV", "SPECIES", 32, 35], ["the first study", "TEST", 8, 23], ["EBV DNA", "PROBLEM", 32, 39], ["a feline tumor", "PROBLEM", 43, 57], ["EBV DNA", "OBSERVATION", 32, 39], ["feline", "OBSERVATION_MODIFIER", 45, 51], ["tumor", "OBSERVATION", 52, 57]]], ["The SNAP FeLV positive but ViroCap exFeLV negative cat could have been a false positive since a confirmatory test was not done and the screening test was not repeated.", [["SNAP", "CHEMICAL", 4, 8], ["SNAP", "GENE_OR_GENE_PRODUCT", 4, 8], ["FeLV", "ORGANISM", 9, 13], ["ViroCap", "GENE_OR_GENE_PRODUCT", 27, 34], ["cat", "ORGANISM", 51, 54], ["ViroCap exFeLV negative cat", "DNA", 27, 54], ["The SNAP FeLV", "TEST", 0, 13], ["ViroCap exFeLV", "TEST", 27, 41], ["a false positive", "PROBLEM", 71, 87], ["a confirmatory test", "TEST", 94, 113], ["the screening test", "TEST", 131, 149], ["FeLV positive", "OBSERVATION", 9, 22]]], ["Alternatively, if N2 was truly Alternatively, fresh frozen oral mucosal tissue with cDNA conversion would be a more suitable methodology since both of these viruses are shed in the saliva during active infection.", [["oral mucosal tissue", "ANATOMY", 59, 78], ["saliva", "ANATOMY", 181, 187], ["infection", "DISEASE", 202, 211], ["N2", "CHEMICAL", 18, 20], ["oral mucosal tissue", "TISSUE", 59, 78], ["saliva", "ORGANISM_SUBSTANCE", 181, 187], ["N2", "PROBLEM", 18, 20], ["fresh frozen oral mucosal tissue", "PROBLEM", 46, 78], ["cDNA conversion", "TREATMENT", 84, 99], ["these viruses", "PROBLEM", 151, 164], ["active infection", "PROBLEM", 195, 211], ["mucosal tissue", "ANATOMY", 64, 78], ["viruses", "OBSERVATION", 157, 164], ["active", "OBSERVATION_MODIFIER", 195, 201], ["infection", "OBSERVATION", 202, 211]]], ["One sample, OSCC13, contained two chicken viruses, GaHV-3 and ALV.", [["sample", "ANATOMY", 4, 10], ["chicken", "ORGANISM", 34, 41], ["GaHV-3", "GENE_OR_GENE_PRODUCT", 51, 57], ["ALV", "ORGANISM", 62, 65], ["chicken", "SPECIES", 34, 41], ["chicken", "SPECIES", 34, 41], ["One sample", "TEST", 0, 10], ["OSCC13", "TEST", 12, 18], ["two chicken viruses", "PROBLEM", 30, 49], ["two", "OBSERVATION_MODIFIER", 30, 33], ["chicken viruses", "OBSERVATION", 34, 49], ["ALV", "ANATOMY", 62, 65]]], ["GaHV-3 also known as MDV-2, is not oncogenic in chickens, and is used in the bivalent vaccine for protection against Marek's disease (MDV-1).", [["Marek's disease", "DISEASE", 117, 132], ["GaHV-3", "GENE_OR_GENE_PRODUCT", 0, 6], ["MDV-2", "GENE_OR_GENE_PRODUCT", 21, 26], ["chickens", "ORGANISM", 48, 56], ["Marek's disease", "ORGANISM", 117, 132], ["MDV-1", "ORGANISM", 134, 139], ["GaHV", "PROTEIN", 0, 4], ["MDV", "SPECIES", 21, 24], ["chickens", "SPECIES", 48, 56], ["Marek", "SPECIES", 117, 122], ["MDV", "SPECIES", 134, 137], ["MDV", "SPECIES", 21, 24], ["chickens", "SPECIES", 48, 56], ["Marek's disease (MDV-1", "SPECIES", 117, 139], ["the bivalent vaccine", "TREATMENT", 73, 93], ["Marek's disease", "PROBLEM", 117, 132], ["not", "UNCERTAINTY", 31, 34], ["oncogenic", "OBSERVATION_MODIFIER", 35, 44]]], ["It is likely that this sample was contaminated with materials from chickens during sample preparation.", [["sample", "ANATOMY", 23, 29], ["sample", "ANATOMY", 83, 89], ["chickens", "ORGANISM", 67, 75], ["chickens", "SPECIES", 67, 75], ["chickens", "SPECIES", 67, 75], ["this sample", "PROBLEM", 18, 29], ["chickens during sample preparation", "TREATMENT", 67, 101], ["is likely", "UNCERTAINTY", 3, 12]]], ["Similarly, PV3 contained an adenovirus possibly from contamination from turkeys and OSCC4, OSCC10, OSCC19 and OSCC20 contained retrovirus possibly from contamination from sheep.", [["PV3", "GENE_OR_GENE_PRODUCT", 11, 14], ["adenovirus", "ORGANISM", 28, 38], ["turkeys", "ORGANISM", 72, 79], ["OSCC4", "GENE_OR_GENE_PRODUCT", 84, 89], ["OSCC10", "GENE_OR_GENE_PRODUCT", 91, 97], ["OSCC19", "GENE_OR_GENE_PRODUCT", 99, 105], ["OSCC20", "GENE_OR_GENE_PRODUCT", 110, 116], ["retrovirus", "ORGANISM", 127, 137], ["sheep", "ORGANISM", 171, 176], ["PV3", "PROTEIN", 11, 14], ["turkeys", "SPECIES", 72, 79], ["sheep", "SPECIES", 171, 176], ["turkeys", "SPECIES", 72, 79], ["sheep", "SPECIES", 171, 176], ["PV3", "TEST", 11, 14], ["an adenovirus", "PROBLEM", 25, 38], ["contamination", "PROBLEM", 53, 66], ["OSCC4", "TEST", 84, 89], ["OSCC10", "TEST", 91, 97], ["OSCC19", "TEST", 99, 105], ["retrovirus", "PROBLEM", 127, 137], ["adenovirus", "OBSERVATION", 28, 38], ["possibly from", "UNCERTAINTY", 39, 52], ["contamination", "OBSERVATION", 53, 66], ["retrovirus", "OBSERVATION", 127, 137], ["contamination", "OBSERVATION", 152, 165]]], ["HPV-28 causes benign flat plane warts in humans and was likely present in N6 due to contamination from sample handling.", [["benign flat plane warts", "ANATOMY", 14, 37], ["sample", "ANATOMY", 103, 109], ["HPV-28", "CHEMICAL", 0, 6], ["warts", "DISEASE", 32, 37], ["HPV-28", "ORGANISM", 0, 6], ["plane warts", "PATHOLOGICAL_FORMATION", 26, 37], ["humans", "ORGANISM", 41, 47], ["humans", "SPECIES", 41, 47], ["HPV-28", "SPECIES", 0, 6], ["humans", "SPECIES", 41, 47], ["HPV", "TEST", 0, 3], ["benign flat plane warts", "PROBLEM", 14, 37], ["contamination", "PROBLEM", 84, 97], ["benign", "OBSERVATION_MODIFIER", 14, 20], ["contamination", "OBSERVATION", 84, 97]]], ["Forensic studies have shown that wiping down surfaces with ethanol are not sufficient to remove contamination.", [["ethanol", "CHEMICAL", 59, 66], ["ethanol", "CHEMICAL", 59, 66], ["ethanol", "SIMPLE_CHEMICAL", 59, 66], ["Forensic studies", "TEST", 0, 16], ["ethanol", "TREATMENT", 59, 66]]], ["In future studies, where sensitive genomic work is involved cleaning techniques with a dilute (0.9-6%) hypochlorite solution or commercial decontamination solution should be requested.DiscussionA limitation of the current study is that RNA viruses that had not integrated into the host genome would not have been detected.", [["hypochlorite", "CHEMICAL", 103, 115], ["hypochlorite", "CHEMICAL", 103, 115], ["hypochlorite", "SIMPLE_CHEMICAL", 103, 115], ["host genome", "DNA", 281, 292], ["future studies", "TEST", 3, 17], ["a dilute (0.9-6%) hypochlorite solution", "TREATMENT", 85, 124], ["commercial decontamination solution", "TREATMENT", 128, 163], ["the current study", "TEST", 210, 227], ["RNA viruses", "PROBLEM", 236, 247], ["host genome", "OBSERVATION", 281, 292]]], ["A future metagenomic study that includes cDNA conversion would be required to completely rule out a viral cause of FOSCC, but RNA viruses would be considered a highly unlikely cause of FOSCC since a non-integrated RNA virus has not caused oral squamous cell carcinoma in any species to date.", [["oral squamous cell carcinoma", "ANATOMY", 239, 267], ["FOSCC", "DISEASE", 115, 120], ["FOSCC", "DISEASE", 185, 190], ["squamous cell carcinoma", "DISEASE", 244, 267], ["FOSCC", "CANCER", 115, 120], ["FOSCC", "CANCER", 185, 190], ["oral squamous cell carcinoma", "CANCER", 239, 267], ["A future metagenomic study", "TEST", 0, 26], ["cDNA conversion", "TREATMENT", 41, 56], ["a viral cause of FOSCC", "PROBLEM", 98, 120], ["RNA viruses", "PROBLEM", 126, 137], ["FOSCC", "PROBLEM", 185, 190], ["a non-integrated RNA virus", "PROBLEM", 197, 223], ["oral squamous cell carcinoma", "PROBLEM", 239, 267], ["viral", "OBSERVATION", 100, 105], ["squamous cell carcinoma", "OBSERVATION", 244, 267]]], ["Another limitation is that differences in the tissue sample preparation methods could have led to a higher viral capture efficiency in the fresh frozen negative control samples compared to the FFPE positive control and FOSCC samples.", [["tissue sample", "ANATOMY", 46, 59], ["samples", "ANATOMY", 169, 176], ["FOSCC samples", "ANATOMY", 219, 232], ["tissue", "TISSUE", 46, 52], ["FOSCC samples", "CANCER", 219, 232], ["a higher viral capture efficiency", "PROBLEM", 98, 131], ["the FFPE", "TEST", 189, 197], ["FOSCC samples", "TEST", 219, 232], ["viral capture efficiency", "OBSERVATION", 107, 131]]], ["Ideally future studies should utilize fresh frozen samples and include a larger number of samples.Funding informationThis work was supported by a University of Missouri Phi Zeta Veterinary Honor Society resident grant.Declaration of Competing InterestThe authors declare that there are no conflicts of interest.Appendix A. Supplementary dataSupplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.vetmic.2019.108491.", [["samples", "ANATOMY", 51, 58], ["samples", "ANATOMY", 90, 97], ["samples", "CANCER", 90, 97], ["future studies", "TEST", 8, 22], ["fresh frozen samples", "TEST", 38, 58]]], ["Read alignment from the FOSCC sample OSCC8 to FcaPV-3 (GenBank NC_021472.1) are shown in the top coverage track.", [["FOSCC sample", "ANATOMY", 24, 36], ["FcaPV-3", "DNA", 46, 53], ["GenBank NC_021472.1", "DNA", 55, 74], ["FcaPV", "TEST", 46, 51], ["GenBank NC_", "TEST", 55, 66], ["alignment", "OBSERVATION_MODIFIER", 5, 14]]], ["Red, green, brown and blue vertical lines on the coverage track indicate SNPs.", [["blue vertical lines", "CELL", 22, 41], ["Red, green, brown and blue vertical lines", "CELL_LINE", 0, 41], ["SNPs", "DNA", 73, 77], ["Red, green, brown and blue vertical lines", "PROBLEM", 0, 41], ["SNPs", "PROBLEM", 73, 77], ["green", "OBSERVATION_MODIFIER", 5, 10], ["brown", "OBSERVATION_MODIFIER", 12, 17], ["blue", "OBSERVATION", 22, 26], ["vertical lines", "OBSERVATION", 27, 41], ["SNPs", "OBSERVATION", 73, 77]]], ["Gene annotations from GenBank are shown in the lower track (red and green boxes).", [["red and green boxes", "DNA", 60, 79], ["lower", "ANATOMY_MODIFIER", 47, 52]]], ["This variant was deposited into GenBank as KY825188, Felis catus papillomavirus 3, isolate Missouri, complete genome.", [["Felis catus papillomavirus 3", "ORGANISM", 53, 81], ["isolate Missouri, complete genome", "DNA", 83, 116], ["Felis catus papillomavirus", "SPECIES", 53, 79], ["Felis catus papillomavirus", "SPECIES", 53, 79], ["Felis catus papillomavirus", "PROBLEM", 53, 79]]], ["3.Read alignment with the 1544 deduplicated reads from the FOSCC sample OSCC8 to EBV are shown.", [["FOSCC sample", "ANATOMY", 59, 71], ["EBV", "ORGANISM", 81, 84], ["1544 deduplicated reads", "DNA", 26, 49]]], ["Due to the large size of the EBV genome SNPs cannot be seen with a whole genome scale.", [["EBV", "ORGANISM", 29, 32], ["EBV genome SNPs", "DNA", 29, 44], ["the EBV genome SNPs", "PROBLEM", 25, 44], ["a whole genome scale", "TREATMENT", 65, 85], ["large", "OBSERVATION_MODIFIER", 11, 16], ["size", "OBSERVATION_MODIFIER", 17, 21], ["EBV genome SNPs", "OBSERVATION", 29, 44]]], ["Coverage was seen throughout the EBV genome.", [["EBV", "ORGANISM", 33, 36], ["EBV genome", "DNA", 33, 43], ["Coverage", "TREATMENT", 0, 8], ["EBV genome", "OBSERVATION", 33, 43]]], ["The peak in coverage around 25,000 bp in the EBV genome corresponds to a poorly mapped repeat region in the EBNA gene.", [["EBV", "ORGANISM", 45, 48], ["EBNA", "GENE_OR_GENE_PRODUCT", 108, 112], ["EBV genome", "DNA", 45, 55], ["EBNA gene", "DNA", 108, 117], ["The peak in coverage", "TEST", 0, 20], ["bp", "TEST", 35, 37], ["a poorly mapped repeat region", "PROBLEM", 71, 100], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["EBV genome", "OBSERVATION", 45, 55], ["EBNA gene", "OBSERVATION", 108, 117]]]], "afa67c34e52aa31421d540d1ea7484f52b3318e2": [["IntroductionThe effectiveness of collaboration reflects a successful implementation of planned actions and procedures to coordinate join activities among seemingly independent set of private and public agencies.", [["planned actions", "TREATMENT", 87, 102], ["procedures", "TREATMENT", 107, 117]]], ["An effective collaboration captures not only meaningful interactions previously developed by agencies but also a set of planned actions and procedures contributing to an effective cooperation among various levels of public agencies and private organizations during a crisis [1, 2] .", [["procedures", "TREATMENT", 140, 150]]], ["An effective collaborative effort can be examined through three dimensions: the expectation that a collaborative effort is contributed by: (1) improved quality of services provision and production, (2) cost savings, and (3) coordination [3] [4] [5] .IntroductionHowever, current literatures on public health emergency response have been particularly silent on the relationship between social positions of organizations and the tangible or intangible advantages that individual organizations can gain from the positions [6] .", [["[3] [4", "SIMPLE_CHEMICAL", 237, 243]]], ["The benefits of interaction among first responders are assumed to reduce the cost of response when they can allocate risks through diversification of partners and take advantage of various expertise and skills within their networks [2, 6] .IntroductionThis study aims to develop theories to understand a self-organized mechanism to mitigate collective action dilemmas derived from public health network responding to an epidemic event in South Korea, which is known to have a strong hierarchically coordination.", [["This study", "TEST", 252, 262]]], ["The research question guiding this study is what communication strategies governmental agencies take to enhance the effectiveness of intergovernmental collaboration during public health emergency response.", [["this study", "TEST", 30, 40]]], ["The other argument is that the more positive the opinion an organization has on the flow/channel of information dissemination concerning an epidemic event, the more confident the organization has on the successful collaboration effort.", [["an epidemic event", "PROBLEM", 137, 154]]], ["A positive disposition implies favorable perception on successful collaboration even though organizations may have different experiences about how information is shared with the public, which in turns influences the opinion of first responders regarding the effectiveness of collaboration.IntroductionThis research contributes to a growing body of literature on interorganizational collaboration by focusing on public health emergency response in the arena of communicable diseases.", [["communicable diseases", "DISEASE", 460, 481], ["communicable diseases", "PROBLEM", 460, 481]]], ["Although the ICA dilemma is expected to vary across countries [1] , the ICA framework has been rarely applied in other governmental settings (except [6, 11, 12] ).Institutional Collective Action FrameworkPrevious research applying the ICA framework explained that, individual organizations do better than other organizations given the nature of their interactions [13] [14] [15] [16] [17] [18] .", [["[13] [14] [15] [16] [17", "SIMPLE_CHEMICAL", 364, 387], ["the ICA dilemma", "PROBLEM", 9, 24], ["the ICA framework", "TREATMENT", 68, 85], ["the ICA framework", "TREATMENT", 231, 248], ["ICA", "ANATOMY", 13, 16], ["dilemma", "OBSERVATION", 17, 24]]], ["Public officials representing their respective organization developed relationships with their partnered organizations.", [["respective organization", "OBSERVATION", 36, 59]]], ["While coordination is critical for provision of public services requiring interconnected efforts across jurisdictions, the risk of coordination failure can be high if the collective action involves a set of diverse actors and activities.", [["public services", "TREATMENT", 48, 63], ["coordination failure", "PROBLEM", 131, 151], ["coordination failure", "OBSERVATION", 131, 151]]], ["A linkage with a central actor that has critical information may help resolve a problem of incoordination [1] .Institutional Collective Action FrameworkMoreover, another challenge is that institutional actors may confront bargaining problems or effective monitoring mechanism if they do not have perfect information about other actors' behaviors [6, 9] .", [["incoordination", "DISEASE", 91, 105], ["incoordination", "PROBLEM", 91, 105]]], ["For example, cities in Georgia were less likely to enter interlocal service agreements when the difficulties measuring the services increase beyond a certain point [16] .Institutional Collective Action FrameworkWhile there are a few empirical studies applying the ICA framework [10, 18, 20] , few have examined ICA problems at the international setting.", [["a few empirical studies", "TEST", 227, 250], ["ICA problems", "PROBLEM", 311, 323]]], ["Even fewer has examined the ICA problems during public health emergency response.", [["the ICA problems", "PROBLEM", 24, 40]]], ["Most studies tend to focus on policy arenas in the realm of water conservation, public good markets, and local sustainable policy.", [["Most studies", "TEST", 0, 12]]], ["Here, the commitment of an individual organization to work jointly during a crisis illustrates the advantage of bonding when risks of inaction by its members can be minimized through sanctions and reputational effects [2] .", [["a crisis", "PROBLEM", 74, 82]]], ["During public health emergency responses, where risks of failure are shared, effective sanction and monitoring mechanisms become key to guide the collective action, i.e., acceptable and professional behaviors [21] .", [["failure", "PROBLEM", 57, 64], ["monitoring mechanisms", "TEST", 100, 121], ["failure", "OBSERVATION", 57, 64]]], ["The failure of one affects the ability of others to get the job done.Collaboration Effectiveness during Public Health Emergency Response: Bonding and Bridging EffectHowever, in the field of public health emergency response, the empirical studies on the effect of bonding have been sketchy.", [["the empirical studies", "TEST", 224, 245], ["sketchy", "PROBLEM", 281, 288], ["failure", "OBSERVATION", 4, 11]]], ["In presence of a crisis, the risk of failure of individual responders can contribute to the difficulty to make appropriate choices and set priorities.", [["a crisis", "PROBLEM", 15, 23], ["failure of individual responders", "PROBLEM", 37, 69], ["crisis", "OBSERVATION", 17, 23]]], ["For example, second hand information (especially to evaluate the situation) often leaves out contextual situation influencing outcomes [24] .", [["hand", "ANATOMY", 20, 24]]], ["For instance, the evaluation of success is shaped by group discussion/interactions [26] .", [["the evaluation", "TEST", 14, 28]]], ["If closed-knit groups have a positive view of the outcome, the likelihood of the individuals in the group to have a positive predisposition about the join efforts would be high.", [["a positive predisposition", "PROBLEM", 114, 139], ["high", "OBSERVATION_MODIFIER", 172, 176]]], ["According to Burt, a positive image of outcomes can lead to certain individuals to have favorable opinion about outcomes [27] .Network CentralityThe explanations for a network centrality-as a proxy for the bonding effect-on the level of perceived effectiveness of collaboration are as follows: network centrality, which is measured in terms of network size, provides an opportunity for an actor to access information and resources in a timely way from multiple actors and improve their task performance [28] [29] [30] [31] .", [["network", "MULTI-TISSUE_STRUCTURE", 294, 301], ["[28] [29] [30] [31]", "SIMPLE_CHEMICAL", 503, 522], ["the bonding effect", "PROBLEM", 202, 220], ["size", "OBSERVATION_MODIFIER", 352, 356]]], ["The focal actor is located at the central location of network can improve its reputation from others and can ensure cooperation from their partners [29] .", [["focal", "OBSERVATION_MODIFIER", 4, 9], ["central", "ANATOMY_MODIFIER", 34, 41]]], ["The prominent actors can access timely information from their partners and better exploit information.", [["prominent", "OBSERVATION_MODIFIER", 4, 13], ["actors", "OBSERVATION", 14, 20]]], ["The prominent actor also can develop capacity to use information and resources from their partners by expanding expericence of creating and maintaing linkage with other actors [30] .", [["prominent", "OBSERVATION_MODIFIER", 4, 13]]], ["The focal actor that has actual interaction with other actors and has better understandings about the availability of information and resources from their partners, develop innovative solutions, and improve its performance.Network CentralityA public agency that has linkage with multiple organizations is better able to access core timely information because the focal agency can receive information directly from them [32] .", [["innovative solutions", "TREATMENT", 173, 193], ["focal", "OBSERVATION_MODIFIER", 4, 9], ["focal", "OBSERVATION_MODIFIER", 363, 368]]], ["The agency can develop better understanding about a crisis by communicating with multiple organizations and provide better information to their partner agencies.", [["a crisis", "PROBLEM", 50, 58]]], ["The centralization of the focal agency can improve the effectiveness of the collaborative efforts with other organizations in preventing further crisis to occur.", [["further crisis", "PROBLEM", 137, 151], ["centralization", "OBSERVATION_MODIFIER", 4, 18], ["focal", "OBSERVATION_MODIFIER", 26, 31]]], ["The higher the level of network centrality of an organization, the higher the perceived level of collaboration effectiveness will be during a crisis.Network ConstraintThe quality of information deteriorates as more intermediaries are involved, however.", [["a crisis", "PROBLEM", 140, 148], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["higher", "OBSERVATION_MODIFIER", 67, 73]]], ["An organization that is constrained by partners that are directly connected is more likely to receive redundant information from their partners [33] .", [["organization", "OBSERVATION", 3, 15]]], ["The actor may not obtain innovative solutions from their homogenous partners.", [["innovative solutions", "TREATMENT", 25, 45]]], ["Organizations are constrained if they are positioned within a close-knit network.", [["knit network", "MULTI-TISSUE_STRUCTURE", 68, 80]]], ["The organizations that have high constraints or are densely connected to other organizations may not be able to access new risk information and may not collaborate effectively to prevent the further transmission of infectious disease.", [["infectious disease", "DISEASE", 215, 233], ["high constraints", "PROBLEM", 28, 44], ["infectious disease", "PROBLEM", 215, 233], ["infectious", "OBSERVATION", 215, 225]]], ["In other words, Burt's logic of network constraint explains that the higher the level of constraints, the lower the perceived level of collaboration effectiveness during the crisis [31] .Network ConstraintIn the context of interorganizational collaboration, the next best option for the organization is to interact with organizations in other groups.", [["interorganizational", "OBSERVATION_MODIFIER", 223, 242], ["collaboration", "OBSERVATION", 243, 256]]], ["This is important especially when the response agency is able to access information from multiple jurisdictions in responding to a virus outbreak.", [["a virus outbreak", "PROBLEM", 129, 145]]], ["The agency needs to understand the path of infectious disease transmission, which has a transboundary nature [37] .", [["infectious disease transmission", "DISEASE", 43, 74], ["infectious", "OBSERVATION", 43, 53]]], ["The agency will also be better able to access the transmission information and improve the effectiveness of interagency collaboration when the agency interacts with organizations in other regions.Hypothesis 2.The lower the level of constraints, the higher the perceived level of collaboration effectiveness will be during a crisis.Network HierarchyA public agency may choose an efficient mode of communication strategies by exchanging information only with key agencies.", [["a crisis", "PROBLEM", 322, 330], ["communication strategies", "TREATMENT", 396, 420], ["lower", "OBSERVATION_MODIFIER", 213, 218], ["higher", "OBSERVATION_MODIFIER", 249, 255]]], ["Network hierarchy refers to a closed form of network structure organized around a few prominent alters and allows a focal actor to leverage on others through the central actors [31, 33, 38] .", [["few", "OBSERVATION_MODIFIER", 82, 85], ["prominent", "OBSERVATION", 86, 95]]], ["A higher level of network hierarchy means less redundant ties and a more efficient communication ties to access new information.Network HierarchyThe argument is a direct criticism of the bonding effect, i.e., when the agency is surrounded with redundant ties, the agency can access novel information [8, 33] .", [["Hierarchy", "OBSERVATION", 136, 145]]], ["The linkage with the central actors, therefore, enables the focal actor to obtain diverse information from the prominent actor that received information from heterogeneous set of other actors and thus allowing the organization to save time and resources.Network HierarchyThe network hierarchy captures the logic of the bridging effect.", [["central", "ANATOMY_MODIFIER", 21, 28], ["Hierarchy", "OBSERVATION", 262, 271], ["bridging effect", "OBSERVATION", 319, 334]]], ["In other words, an organization will have a higher score on a network hierarchy suggests that the organization communicates with a higher-level agency or a prominent agency that already have information from higher level agencies.", [["a higher score", "PROBLEM", 42, 56]]], ["Interacting with these agencies not only give certain advantages to the organization, i.e., save time and resources for creating and maintaining the linkage with other multiple agencies, but also access to comprehensive information about the crisis.", [["the crisis", "PROBLEM", 238, 248]]], ["Considering the transboundary nature of an epidemic event, communication with a national or a regional agency will help the public agency at the local level to understand the nature of an epidemic event.", [["an epidemic event", "PROBLEM", 40, 57], ["an epidemic event", "PROBLEM", 185, 202], ["epidemic", "OBSERVATION", 43, 51], ["epidemic", "OBSERVATION", 188, 196]]], ["Local agencies will be better able to use limited resource for collaborating with other agencies in preventing secondary effect of hazard more efficiently.Hypothesis 3.The higher the level of network hierarchy, the higher the perceived level of collaboration effectiveness during the crisis.Social Media and CollaborationHow does effective dissemination of information affect interorganizational collaboration?", [["the crisis", "PROBLEM", 280, 290], ["higher", "OBSERVATION_MODIFIER", 172, 178], ["network hierarchy", "OBSERVATION", 192, 209]]], ["The ability of various organizations to disseminate information regarding a crisis also creates conditions that can promote interorganizational collaboration during responses [40, 41] .", [["a crisis", "PROBLEM", 74, 82]]], ["Collaboration among public agencies facilitates a culture of responsiveness among first responders and responsible agencies.", [["a culture", "TEST", 48, 57]]], ["Such a culture provides a condition that allows a highly productive team to work together in order to develop a cohesive response.Social Media and CollaborationScholars have argued that online information channels can expand ways to disseminate timely information to the target population as a new epidemic situation develops [43] [44] [45] [46] [47] .", [["[43] [44] [45] [46] [47]", "CHEMICAL", 326, 350], ["[43] [44] [45] [46] [47]", "SIMPLE_CHEMICAL", 326, 350], ["a culture", "TEST", 5, 14]]], ["For instance, following the Red River flooding of 2009, a Facebook group helped the city of Fargo (ND, USA) to recruit 5 percent of the total population when the city suffered from low response capabilities.Social Media and CollaborationThe literature on risk communication provides clues on the mechanisms to enhance the effectiveness of intergovernmental collaboration.", [["low response capabilities", "PROBLEM", 181, 206], ["low", "OBSERVATION_MODIFIER", 181, 184], ["response capabilities", "OBSERVATION", 185, 206]]], ["Effective risk communication is critical for informing the public of the very nature of hazards and governmental actions to avoid inaccurate perception of the hazard risk and unnecessary sufferings from the lack of knowledge [48] .", [["governmental actions", "TREATMENT", 100, 120], ["the hazard risk", "PROBLEM", 155, 170]]], ["Timely and reciprocal information provision can improve trust on governmental actions and help them follow guidance from governmental agencies while high levels of trust in governmental actions can discourage individuals to take personal protections [43, 49, 50] .Hypothesis 4.The more an organization employed the social media to disseminate information to the public, the higher the level of perceived effectiveness of interorganizational collaboration.The 2015 Middle East Respiratory Syndrome (MERS) Outbreak in South KoreaSouth Korea suffered from a MERS outbreak in 2015.", [["Middle East Respiratory Syndrome", "DISEASE", 464, 496], ["MERS", "DISEASE", 498, 502], ["governmental actions", "TREATMENT", 65, 85], ["Respiratory Syndrome", "PROBLEM", 476, 496], ["Middle", "ANATOMY_MODIFIER", 464, 470], ["Respiratory Syndrome", "OBSERVATION", 476, 496]]], ["One argument suggests that the country failed to control the transmission of the infectious disease from the first patient, who travelled internationally to the Middle East.", [["infectious disease", "DISEASE", 81, 99], ["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["the infectious disease", "PROBLEM", 77, 99], ["infectious", "OBSERVATION", 81, 91], ["Middle", "ANATOMY_MODIFIER", 161, 167]]], ["MERS was a novel pathogen at the time and most cases had been found in Saudi Arabia [51] .", [["MERS", "GENE_OR_GENE_PRODUCT", 0, 4], ["a novel pathogen", "PROBLEM", 9, 25]]], ["The disease is caused by a virus called by MERS Coronavirus, and the common symptoms include shortness of breath, cough, and fever [52, 53] .", [["shortness of breath", "DISEASE", 93, 112], ["cough", "DISEASE", 114, 119], ["fever", "DISEASE", 125, 130], ["The disease", "PROBLEM", 0, 11], ["a virus", "PROBLEM", 25, 32], ["MERS Coronavirus", "PROBLEM", 43, 59], ["the common symptoms", "PROBLEM", 65, 84], ["shortness of breath", "PROBLEM", 93, 112], ["cough", "PROBLEM", 114, 119], ["fever", "PROBLEM", 125, 130], ["disease", "OBSERVATION", 4, 11], ["virus", "OBSERVATION", 27, 32]]], ["Three in ten infected patients tend to die.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["infected", "OBSERVATION", 13, 21]]], ["Although the virus is thought to be transmitted through close contact with infected persons, there is no precise understanding of the mode(s) of transmission.", [["persons", "SPECIES", 84, 91], ["the virus", "PROBLEM", 9, 18], ["virus", "OBSERVATION", 13, 18], ["thought to be", "UNCERTAINTY", 22, 35], ["no", "UNCERTAINTY", 102, 104]]], ["There is currently no recommended vaccine or specific treatment for the virus infection.", [["infection", "DISEASE", 78, 87], ["vaccine", "TREATMENT", 34, 41], ["specific treatment", "TREATMENT", 45, 63], ["the virus infection", "PROBLEM", 68, 87]]], ["Most medical doctors and the national public health authority did not have knowledge about the nature or transmissibility of the virus.", [["the virus", "PROBLEM", 125, 134]]], ["The first-MERS patient who had traveled to Middle East found that he had fever and visited five hospitals but could not find the cause of the symptom in the first four hospitals [54] .", [["fever", "DISEASE", 73, 78], ["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22], ["fever", "PROBLEM", 73, 78], ["the symptom", "PROBLEM", 138, 149]]], ["Eventually, the last hospital he visited identified that he had become infected with MERS.", [["MERS", "DISEASE", 85, 89], ["infected", "OBSERVATION", 71, 79]]], ["The national public health authority was not also effective in controlling the transmission of infectious disease from the confirmation of the first case on 20 May 2015.", [["infectious disease", "DISEASE", 95, 113], ["infectious disease", "PROBLEM", 95, 113], ["the confirmation", "TEST", 119, 135], ["infectious", "OBSERVATION", 95, 105]]], ["Epidemic investigators from the South Korea Center for Disease Control (CDC) set a narrow quarantine range and missed other clinicians and family members who had come into contact with the patient [55] .The 2015 Middle East Respiratory Syndrome (MERS) Outbreak in South KoreaThe failure of the initial response led to further transmission that resulted in 186 confirmed cases, the death of 38 and the quarantine of about 17,000 people [56] .", [["Middle East Respiratory Syndrome", "DISEASE", 212, 244], ["MERS", "DISEASE", 246, 250], ["death", "DISEASE", 381, 386], ["patient", "ORGANISM", 189, 196], ["patient", "SPECIES", 189, 196], ["people", "SPECIES", 428, 434], ["Middle East Respiratory Syndrome", "PROBLEM", 212, 244], ["the death", "TEST", 377, 386], ["Middle", "ANATOMY_MODIFIER", 212, 218], ["Respiratory Syndrome", "OBSERVATION", 224, 244], ["failure", "OBSERVATION", 279, 286]]], ["The mortality rate was the second highest in the world.", [["The mortality rate", "TEST", 0, 18]]], ["People who were under quarantine were to stay at home for fourteen days to prevent potential transmission to others.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["When there was great anxiety of infection among people, about two thousand schools canceled the classes and people avoided visiting hospitals, shopping malls, and amusement parks [58] .", [["anxiety", "DISEASE", 21, 28], ["infection", "DISEASE", 32, 41], ["people", "ORGANISM", 48, 54], ["people", "ORGANISM", 108, 114], ["people", "SPECIES", 48, 54], ["people", "SPECIES", 108, 114], ["great anxiety of infection", "PROBLEM", 15, 41], ["infection", "OBSERVATION", 32, 41]]], ["Not only the high-risk patients and the isolated resident but also parents who had children with cancelled classes had difficulties to continue their existing economic activities [59] .", [["patients", "ORGANISM", 23, 31], ["children", "ORGANISM", 83, 91], ["patients", "SPECIES", 23, 31], ["children", "SPECIES", 83, 91]]], ["The outbreak, especially, damaged tourism industries and the country had two million tourists less than expected during the year of the outbreak [60] .The 2015 Middle East Respiratory Syndrome (MERS) Outbreak in South KoreaPublic agencies had several challenges in seeking risk information to prevent the further transmission during the outbreak response.", [["Middle East Respiratory Syndrome", "DISEASE", 160, 192], ["MERS", "DISEASE", 194, 198], ["Respiratory Syndrome", "PROBLEM", 172, 192], ["outbreak", "OBSERVATION_MODIFIER", 4, 12], ["Middle", "ANATOMY_MODIFIER", 160, 166], ["Respiratory Syndrome", "OBSERVATION", 172, 192]]], ["The national public health authority disclosed information about hospitals with MERS cases two weeks after the first patient was identified and was blamed for the further transmission [61] .", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124]]], ["Residents who had not known about the hospitals and visited the facilities became infected.", [["infected", "PROBLEM", 82, 90], ["infected", "OBSERVATION", 82, 90]]], ["The Seoul metropolitan government criticized the national government regarding the transparency regarding the hospitals with MERS infection [62] .", [["infection", "DISEASE", 130, 139], ["MERS infection", "PROBLEM", 125, 139]]], ["It is evident that South Korea public agencies were desperate to gain information about MERS in order to prevent the further transmission of infectious disease in their jurisdictions.", [["infectious disease", "DISEASE", 141, 159], ["infectious disease", "PROBLEM", 141, 159], ["infectious", "OBSERVATION", 141, 151]]], ["The MERS crisis reflects challenges in interorganizational collaboration, especially the effectiveness of collaboration among public agencies.", [["The MERS crisis", "PROBLEM", 0, 15], ["MERS crisis", "OBSERVATION", 4, 15]]], ["Along with information sharing, national, regional, and local public health agencies had challenges in cooperation for resource exchange.", [["resource exchange", "TREATMENT", 119, 136]]], ["For instance, one local public health agency of Seoul requested equipment (e.g., ambulance) and personnel to the regional agency to tackle with high risk patients in the local jurisdiction but the upper level agency did not respond to the low-level agency's demand immediately.", [["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162]]], ["The slow response was not beneficial for governmental agencies to prevent further transmission of the infectious disease [55] .DataThe data were collected in the Seoul metropolitan region and 25 other local jurisdictions with reported MERS cases in February 2016.", [["infectious disease", "DISEASE", 102, 120], ["governmental agencies", "TREATMENT", 41, 62], ["the infectious disease", "PROBLEM", 98, 120], ["The data", "TEST", 131, 139], ["infectious", "OBSERVATION", 102, 112]]], ["The regional and local agencies represent Seoul Metropolitan areas and 25 other local areas that had hospitals with MERS cases.", [["Seoul Metropolitan areas", "PROBLEM", 42, 66], ["regional", "OBSERVATION_MODIFIER", 4, 12], ["local", "OBSERVATION_MODIFIER", 17, 22], ["Seoul", "OBSERVATION_MODIFIER", 42, 47], ["Metropolitan", "OBSERVATION_MODIFIER", 48, 60]]], ["All local public agencies in the Seoul Metropolitan areas were selected because 64 percent of local jurisdictions had more than one MERS case and residents have high mobility within the region.DataLocal agencies in non-Seoul metropolitan areas were identified from a list of affected areas from the Ministry of Welfare and Health.", [["high mobility within the region", "PROBLEM", 161, 192], ["local", "OBSERVATION_MODIFIER", 4, 9], ["public agencies", "OBSERVATION", 10, 25], ["high", "OBSERVATION_MODIFIER", 161, 165], ["mobility", "OBSERVATION", 166, 174]]], ["The response rate was 71 percent.", [["The response rate", "TEST", 0, 17]]], ["Public officials from the selected agencies were asked to judge interagency effectiveness in the tree dimensions using the following survey items:Interagency Collaboration EffectivenessQuality of service and production: \"Please rate how much did interagency collaboration help your agency improve the service quality to address the needs of high risk patients and suspected residents during the first month of the outbreak response (20 May-14 June 2015)?\"", [["patients", "ORGANISM", 351, 359], ["patients", "SPECIES", 351, 359]]], ["Cost savings: \"Please rate how much did interagency collaboration help your agency to save costs regarding service quality to address the needs of high risk patients and suspected residents during the first month of the outbreak response (20 May-14 June 2015)?\"", [["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165]]], ["Coordination: \"Please rate how much did interagency collaboration help your agency to coordinate efforts to address the needs of high risk patients and suspected residents during the first month of the outbreak response (20 May-14 June 2015)?\"Interagency Collaboration EffectivenessThe response on each item is rating of each dimension and ranges from 0 (not at all) to 10 (very much helpful).", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147]]], ["The response categories are ratings of the responses and are summed as one index variable (Cronbach's alpha = 0.9102).", [["one index", "TEST", 71, 80], ["Cronbach's alpha", "TEST", 91, 107]]], ["As shown by the descriptive statistics in Table 2 , the average value is 21.44 and the standard error is 6.65.Interagency Collaboration EffectivenessAlthough there are various ways to measure interorganizational collaboration, we used two survey items asking the following question to measure collaboration:Interagency Collaboration EffectivenessSending information: \"To which organization did your organization send information regarding MERS during the outbreak directly (information about high risk patient, hospital, or response information).\"Interagency Collaboration EffectivenessReceiving information: \"To which organization did your organization receive information regarding MERS during the outbreak directly (information about high risk patient, hospital, or response information). \"", [["patient", "ORGANISM", 502, 509], ["patient", "ORGANISM", 747, 754], ["patient", "SPECIES", 502, 509], ["patient", "SPECIES", 747, 754], ["the average value", "TEST", 52, 69]]], ["The data were managed as a non-directed matrix after we merged the survey response in the same direction to make the most use of information about interagency communication.", [["matrix", "CELLULAR_COMPONENT", 40, 46]]], ["The average length of the shortest path is 2.97 and the distance-based cohesion is 0.31.Network CentralityThe network centrality is operationalized by calculating the normalized degree centrality score, which is the number of nodes adjacent to the focal node (i.e., degree) [64, 65] .", [["nodes", "ANATOMY", 226, 231], ["focal node", "ANATOMY", 248, 258], ["network", "MULTI-TISSUE_STRUCTURE", 110, 117], ["focal node", "MULTI-TISSUE_STRUCTURE", 248, 258], ["average", "OBSERVATION_MODIFIER", 4, 11], ["length", "OBSERVATION_MODIFIER", 12, 18], ["normalized degree", "OBSERVATION_MODIFIER", 167, 184], ["centrality", "OBSERVATION_MODIFIER", 185, 195], ["number", "OBSERVATION_MODIFIER", 216, 222], ["nodes", "OBSERVATION", 226, 231], ["focal", "OBSERVATION_MODIFIER", 248, 253], ["node", "OBSERVATION", 254, 258]]], ["The literature used degree centrality to measure the prominence of an actor in an interorganizational network.", [["interorganizational network", "MULTI-TISSUE_STRUCTURE", 82, 109], ["prominence", "OBSERVATION_MODIFIER", 53, 63]]], ["UCINET 6 (version 6.012, Analytic Technologies, Harvard, MA, USA) was employed to calculate the normalized score, which is degree divided by maximum possible number of nodes [64] .Network ConstraintsNetwork constraint is used to measure bridging effects that allow the focal actor to access heterogeneous information through directly connected alters [66] .", [["maximum", "OBSERVATION_MODIFIER", 141, 148], ["possible", "UNCERTAINTY", 149, 157], ["number", "OBSERVATION_MODIFIER", 158, 164], ["nodes", "OBSERVATION", 168, 173]]], ["Network constraint is the extent to which the focal node is connected to others that are connected to each other [29, 35] .", [["focal node", "ANATOMY", 46, 56], ["focal node", "MULTI-TISSUE_STRUCTURE", 46, 56], ["the focal node", "PROBLEM", 42, 56], ["focal", "OBSERVATION_MODIFIER", 46, 51], ["node", "OBSERVATION", 52, 56]]], ["A high level of network constraint means few structure holes and decreases the likelihood of a local bridging role between directly connected alters while a low level of the constraint means many structure holes increase the likelihood of local bridging role.", [["few structure holes", "PROBLEM", 41, 60], ["high", "OBSERVATION_MODIFIER", 2, 6], ["few", "OBSERVATION_MODIFIER", 41, 44], ["structure holes", "OBSERVATION", 45, 60], ["local", "OBSERVATION_MODIFIER", 95, 100], ["bridging", "OBSERVATION", 101, 109], ["low", "OBSERVATION_MODIFIER", 157, 160], ["structure holes", "OBSERVATION", 196, 211], ["local bridging", "OBSERVATION", 239, 253]]], ["UCINET 6 was employed to calculate the constraint score based on the undirected matrix [64] .Network HierarchyNetwork hierarchy measured as the extent which total constraints are located at the focal node's single other [33] .", [["focal node", "ANATOMY", 194, 204], ["matrix", "CELLULAR_COMPONENT", 80, 86], ["focal node", "MULTI-TISSUE_STRUCTURE", 194, 204], ["Hierarchy", "OBSERVATION", 101, 110], ["extent", "OBSERVATION_MODIFIER", 144, 150], ["focal", "OBSERVATION_MODIFIER", 194, 199], ["node", "OBSERVATION", 200, 204]]], ["The summative index has high reliability (Cronbach alpha = 0.990).Online Channel EffectivenessA set of control variables was also included at the organizational level, i.e., organizational types and socio-demographic characteristics of community served by the organizations.", [["The summative index", "TEST", 0, 19], ["Cronbach alpha", "TEST", 42, 56], ["high", "OBSERVATION_MODIFIER", 24, 28]]], ["We also added two socio-demographic variables: population density and elderly population.", [["elderly population", "PROBLEM", 70, 88], ["population", "OBSERVATION_MODIFIER", 47, 57], ["density", "OBSERVATION", 58, 65]]], ["Population density was measured as the total population divided by the land area (km 2 ) and elderly population was measured as the proportion of elderly population to total population.", [["Population density", "PROBLEM", 0, 18], ["the total population", "TREATMENT", 35, 55], ["elderly population", "PROBLEM", 93, 111], ["density", "OBSERVATION", 11, 18], ["total", "OBSERVATION_MODIFIER", 39, 44], ["population", "OBSERVATION_MODIFIER", 45, 55], ["land", "ANATOMY_MODIFIER", 71, 75]]], ["It was also expected that local agencies that served densely populated area or a large proportion of senior population will face challenges when responding to the outbreak because citizens are more vulnerable to the virus transmission via contact.Methods of AnalysisAn ordinary least square (OLS) regressions was used to test the effects of the three types of communication strategies and online channel on interagency collaboration effectiveness.", [["communication strategies", "TREATMENT", 360, 384], ["densely", "OBSERVATION_MODIFIER", 53, 60], ["populated", "OBSERVATION_MODIFIER", 61, 70], ["large", "OBSERVATION_MODIFIER", 81, 86], ["proportion", "OBSERVATION_MODIFIER", 87, 97]]], ["OLS regressions were applied to similar research that examine the relationship between network effects and outcomes [2, 6, 12] .", [["OLS regressions", "PROBLEM", 0, 15]]], ["Although all the models do not have multicollinearity issues (average variance inflation factor < 2), Breusch-Pagan tests show that the first models had issues of heteroscedasticity.", [["heteroscedasticity", "DISEASE", 163, 181], ["multicollinearity issues", "PROBLEM", 36, 60], ["average variance inflation factor", "TEST", 62, 95], ["Breusch-Pagan tests", "TEST", 102, 121], ["heteroscedasticity", "PROBLEM", 163, 181], ["heteroscedasticity", "OBSERVATION", 163, 181]]], ["We employed robust regressions to address the problem in estimating the first three models.Results and DiscussionsTables 4 and 5 present the OLS regression results testing the effects of network position and communication technology on the effectiveness of interagency collaboration.", [["the problem", "PROBLEM", 42, 53], ["communication technology", "TREATMENT", 208, 232]]], ["The regression results do not support the first hypothesis that the greater the network centrality, the higher the perceived level of collaboration effectiveness during the crisis.", [["the crisis", "PROBLEM", 169, 179], ["greater", "OBSERVATION_MODIFIER", 68, 75], ["higher", "OBSERVATION_MODIFIER", 104, 110]]], ["Although the coefficients of the variable are positive (0.362 and 0.146) in the Models 1 and 4, network centrality does not have a significant relationship with the effectiveness of interagency collaboration at the level of 0.1.", [["network", "MULTI-TISSUE_STRUCTURE", 96, 103], ["the Models", "TEST", 76, 86], ["positive", "OBSERVATION", 46, 54]]], ["Especially, different types of public agencies have different culture and information standards, which create challenges in expanding communication with multiple agencies [67, 68] .", [["different culture", "TEST", 52, 69]]], ["My local public health agency had confusion in sharing information about period and termination date of quarantines with police or fire agencies because the supporting agencies did not have the same information standard for reporting the quarantine start and termination dates.\"", [["confusion", "DISEASE", 34, 43], ["confusion", "PROBLEM", 34, 43]]], ["Model 2 results confirm the second hypothesis that the lower the level of constraints, the higher the perceived level of collaboration effectiveness during the crisis ( Table 4 ).", [["the second hypothesis", "PROBLEM", 24, 45]]], ["The coefficient of network constraint is \u22126.862 and is significant at the levels of 0.01 in Model 2.", [["significant", "OBSERVATION_MODIFIER", 55, 66]]], ["A public agency that communicates with agencies in other regions can have a better understanding of the infectious disease transmission and may be better able to collaborate with other agencies to address the immediate response needs.", [["the infectious disease transmission", "PROBLEM", 100, 135], ["infectious", "OBSERVATION", 104, 114]]], ["High mobility of residents may increase the importance of communication across regions to accurately identify the transmission path to prevent further transmission in their jurisdictions.", [["mobility", "OBSERVATION_MODIFIER", 5, 13]]], ["For instance, two residents lived in a region about 250 miles away from the hospital with tens of MERS cases and the two of them became infected.", [["infected", "PROBLEM", 136, 144], ["infected", "OBSERVATION", 136, 144]]], ["Most local public health agencies that led the outbreak response in their regions communicated with agencies in other jurisdictions or high-level agencies, so network constraints do not have differentiated effects on the levels of interagency collaboration effectiveness.Results and DiscussionsModel 3 result does not support the third hypothesis that the higher the level of network hierarchy, the higher the perceived level of collaboration effectiveness during the crisis.", [["the third hypothesis", "PROBLEM", 326, 346], ["the crisis", "PROBLEM", 464, 474]]], ["Although the coefficient of network hierarchy is positive (\u03b2 = 0.615), the coefficient is not statistically significant at the level of 0.1.", [["positive", "OBSERVATION_MODIFIER", 49, 57]]], ["The coefficient of network hierarchy is 13.53 and significant at the level of 0.05.", [["significant", "OBSERVATION_MODIFIER", 50, 61]]], ["When local public health agencies that represent their local jurisdictions communicate with national, regional, or other prominent agencies have better understanding about the infectious disease transmission and can develop better strategies to coordinate interagency efforts in preventing the further transmission in the jurisdictions.Results and DiscussionsThe first three model results support the fourth hypothesis that risk communication is positively associated with the perceived levels of interagency collaboration effectiveness.", [["the infectious disease transmission", "PROBLEM", 172, 207]]], ["The coefficients of the three models are each 0.042, 0.046, and 0.043 and are statistically significant at the level of 0.01.", [["significant", "OBSERVATION_MODIFIER", 92, 103]]], ["They can respond and improve interagency efforts to prevent further transmission of the virus within their local jurisdictions.", [["the virus", "PROBLEM", 84, 93]]], ["Online communication channels also helped improve the awareness of the public and contribute to interorganizational efforts toward the prevention of the transmission.Results and DiscussionsAdditionally, the results of the model show that organizations, locations, and demographic characteristics of local organizations do not have a significant effect on the perceived levels of interagency collaboration effectiveness.", [["interorganizational efforts", "TREATMENT", 96, 123]]], ["Elderly population served by local agencies has a positive effect on the dependent variable but the coefficient is not statistically significant.", [["a positive effect", "PROBLEM", 48, 65], ["positive effect", "OBSERVATION_MODIFIER", 50, 65]]], ["An agency serving densely populated residents, on average, reported to have favorable view on interagency collaboration (Model 6).", [["densely", "OBSERVATION_MODIFIER", 18, 25]]], ["Public agencies in the populous jurisdictions may be sensitive to potential widespread transmission and choose to collaborate better with other agencies than those jurisdictions that are serving less densely populated residents.ConclusionsThis study suggests that interagency risk communication strategies and online risk communication are important means to improve interagency effort toward a virus outbreak.", [["This study", "TEST", 239, 249], ["interagency risk communication strategies", "PROBLEM", 264, 305], ["online risk communication", "TREATMENT", 310, 335], ["a virus outbreak", "PROBLEM", 393, 409]]], ["Public agencies need to take adequate interagency risk communication strategies to access core information to prevent the transmission of an infectious disease that has a transboundary nature.", [["infectious disease", "DISEASE", 141, 159], ["an infectious disease", "PROBLEM", 138, 159], ["infectious", "OBSERVATION", 141, 151]]], ["Bridging strategies are useful for public agencies to access new risk information from other regions, understand the dissemination path of the disease, and exert better collective efforts toward the prevention of transmission.", [["the disease", "PROBLEM", 139, 150], ["disease", "OBSERVATION", 143, 150]]], ["Efficiency-based risk communication helps local public health agencies to obtain critical risk information and save time and resource for productive activities to prevent the further transmission of an infectious disease.", [["infectious disease", "DISEASE", 202, 220], ["an infectious disease", "PROBLEM", 199, 220], ["infectious", "OBSERVATION", 202, 212]]], ["Finally, when public agencies use online media, such as websites and social media, the agencies can expand the channel of public risk communication.", [["online media", "TREATMENT", 34, 46]]], ["The expanded communication channels help improve the public awareness of the outbreak response, individual protection actions, and contribute to interagency collaboration.ConclusionsThe findings have several practical implications for effective interagency communication and collaboration in response to epidemics that has a transboundary nature.", [["The expanded communication channels", "TREATMENT", 0, 35], ["epidemics", "PROBLEM", 304, 313], ["transboundary", "OBSERVATION_MODIFIER", 325, 338]]], ["Bridging strategies enable a public agency to access information, which is not available within or nearby local jurisdictions to understand better the path of infectious disease transmission.", [["infectious disease transmission", "DISEASE", 159, 190], ["infectious disease transmission", "PROBLEM", 159, 190], ["infectious", "OBSERVATION", 159, 169]]], ["Instead of creating multiple communication linkage, communication with the prominent agencies that exchange information with other regional or local agencies can obtain comprehensive information about the transmission path.ConclusionsFinally, expansion of communication channel is helpful for a public agency to raise the situational awareness of the public regarding local response status and improve interagency efforts to prevent the further transmission of the infectious disease.", [["infectious disease", "DISEASE", 465, 483], ["interagency efforts", "TREATMENT", 402, 421], ["the infectious disease", "PROBLEM", 461, 483], ["infectious", "OBSERVATION", 465, 475]]], ["Online media, such as websites, blogs, and other social media allows the public agency to disseminate up-to-date risk information to residents and help residents to understand how the individuals can take protective actions and contribute to interagency efforts toward the control of the transmission.", [["individuals", "ORGANISM", 184, 195], ["protective actions", "TREATMENT", 205, 223]]], ["When members of the public as co-producer of public services have better understandings of the response [69] , they can be better able to contribute to the control of the transmission.ConclusionsThe study has several limitations in testing the effects of the three communication strategies and online channel use on intergovernmental collaboration effectiveness.", [["The study", "TEST", 195, 204], ["the three communication strategies", "TREATMENT", 255, 289], ["intergovernmental collaboration effectiveness", "TREATMENT", 316, 361]]], ["First, the study does not use objective measures to assess the outcome variables.", [["the study", "TEST", 7, 16], ["objective measures", "TREATMENT", 30, 48]]], ["Because there is no archival data that assess agency or collaboration performance, this study used the perception of public officials who are knowledgeable about their agency response.", [["archival data", "TEST", 20, 33], ["this study", "TEST", 83, 93], ["no", "UNCERTAINTY", 17, 19]]], ["Even though it is hard to establish objective indicators for collaboration performance, future studies may develop objective measures for public health emergencies and compare the measure with the subjective measures.", [["collaboration performance", "TEST", 61, 86], ["future studies", "TEST", 88, 102], ["objective measures", "TREATMENT", 115, 133], ["the subjective measures", "TREATMENT", 193, 216]]], ["Second, the study might not be generalizable to all regions or local areas.", [["the study", "TEST", 8, 17]]], ["This study focused on Seoul metropolitan areas and other local areas that had MERS cases due to time and costs.", [["This study", "TEST", 0, 10], ["Seoul metropolitan areas", "TREATMENT", 22, 46]]], ["This study did not investigate other local areas or regions that were affected by the outbreak although the areas did not have confirmed cases.", [["This study", "TEST", 0, 10]]]], "1d030bbc967a85a8c064c022cbd2939765683951": [["IntroductionIn the past decade, we have learned that the lungs, previously considered sterile, in fact harbour a dynamic ecosystem of diverse bacteria, fungi and viruses [1] .", [["lungs", "ANATOMY", 57, 62], ["lungs", "ORGAN", 57, 62], ["diverse bacteria", "PROBLEM", 134, 150], ["fungi", "PROBLEM", 152, 157], ["viruses", "PROBLEM", 162, 169], ["lungs", "ANATOMY", 57, 62], ["diverse", "OBSERVATION_MODIFIER", 134, 141], ["bacteria", "OBSERVATION", 142, 150]]], ["This lung microbiota is detectable in health [2, 3] , altered in disease [4] , predictive of disease outcomes [5, 6] and correlates with variations in host immunity [7, 8] .", [["lung microbiota", "ANATOMY", 5, 20], ["lung", "ORGAN", 5, 9], ["altered in disease", "PROBLEM", 54, 72], ["disease outcomes", "PROBLEM", 93, 109], ["lung", "ANATOMY", 5, 9], ["microbiota", "OBSERVATION", 10, 20], ["detectable", "OBSERVATION_MODIFIER", 24, 34]]], ["Recent insights, based on studies in both humans [8] and mice [7] , are that the baseline immune tone of the lungs, even in health, is closely linked to the local microbial milieu [9] .", [["lungs", "ANATOMY", 109, 114], ["humans", "ORGANISM", 42, 48], ["mice", "ORGANISM", 57, 61], ["lungs", "ORGAN", 109, 114], ["humans", "SPECIES", 42, 48], ["mice", "SPECIES", 57, 61], ["humans", "SPECIES", 42, 48], ["studies", "TEST", 26, 33], ["lungs", "ANATOMY", 109, 114]]], ["This hypothesis that the \"immune tone\" in the airways and alveoli is at least in part regulated by the microbiota is a radical departure from our conventional, dichotomous understanding of lung immunity: dormant in health, activated in infection.", [["airways", "ANATOMY", 46, 53], ["alveoli", "ANATOMY", 58, 65], ["lung", "ANATOMY", 189, 193], ["infection", "DISEASE", 236, 245], ["airways", "MULTI-TISSUE_STRUCTURE", 46, 53], ["alveoli", "MULTI-TISSUE_STRUCTURE", 58, 65], ["lung", "ORGAN", 189, 193], ["the \"immune tone", "PROBLEM", 21, 37], ["alveoli", "PROBLEM", 58, 65], ["infection", "PROBLEM", 236, 245], ["airways", "ANATOMY", 46, 53], ["alveoli", "ANATOMY", 58, 65], ["lung", "ANATOMY", 189, 193], ["immunity", "OBSERVATION", 194, 202], ["infection", "OBSERVATION", 236, 245]]], ["Next to known changes in the inflammatory milieu of the lungs, most lung diseases, such as asthma [10] , COPD [11] , cystic fibrosis [12] , idiopathic pulmonary fibrosis (IPF) [13] and, recently, lung cancer [14] have been associated with a microbial dysbiosis in the lung.", [["lungs", "ANATOMY", 56, 61], ["lung", "ANATOMY", 68, 72], ["cystic", "ANATOMY", 117, 123], ["pulmonary", "ANATOMY", 151, 160], ["lung cancer", "ANATOMY", 196, 207], ["lung", "ANATOMY", 268, 272], ["lung diseases", "DISEASE", 68, 81], ["asthma", "DISEASE", 91, 97], ["COPD", "DISEASE", 105, 109], ["cystic fibrosis", "DISEASE", 117, 132], ["idiopathic pulmonary fibrosis", "DISEASE", 140, 169], ["IPF", "DISEASE", 171, 174], ["lung cancer", "DISEASE", 196, 207], ["microbial dysbiosis", "DISEASE", 241, 260], ["lungs", "ORGAN", 56, 61], ["lung", "ORGAN", 68, 72], ["pulmonary", "ORGAN", 151, 160], ["lung cancer", "CANCER", 196, 207], ["lung", "ORGAN", 268, 272], ["known changes in the inflammatory milieu of the lungs", "PROBLEM", 8, 61], ["most lung diseases", "PROBLEM", 63, 81], ["asthma", "PROBLEM", 91, 97], ["COPD", "PROBLEM", 105, 109], ["cystic fibrosis", "PROBLEM", 117, 132], ["idiopathic pulmonary fibrosis (IPF)", "PROBLEM", 140, 175], ["lung cancer", "PROBLEM", 196, 207], ["a microbial dysbiosis in the lung", "PROBLEM", 239, 272], ["inflammatory", "OBSERVATION", 29, 41], ["lungs", "ANATOMY", 56, 61], ["lung", "ANATOMY", 68, 72], ["diseases", "OBSERVATION", 73, 81], ["cystic", "OBSERVATION_MODIFIER", 117, 123], ["fibrosis", "OBSERVATION", 124, 132], ["idiopathic", "OBSERVATION_MODIFIER", 140, 150], ["pulmonary", "ANATOMY", 151, 160], ["fibrosis", "OBSERVATION", 161, 169], ["IPF", "OBSERVATION", 171, 174], ["lung", "ANATOMY", 196, 200], ["cancer", "OBSERVATION", 201, 207], ["microbial", "OBSERVATION_MODIFIER", 241, 250], ["dysbiosis", "OBSERVATION", 251, 260], ["lung", "ANATOMY", 268, 272]]], ["However, it is unknown if changes in the bacterial composition drive disease pathogenesis or if they are rather a reflection of alterations of the ecological niche [9, 15] .", [["the bacterial composition drive disease pathogenesis", "PROBLEM", 37, 89]]], ["Thus, it is of utmost importance to understand the underlying molecular mechanisms at the host-microbiome interface to develop novel targeted therapies or preventative approaches.IntroductionHere, we discuss the impact of host-microbiome cross-talk on respiratory health and disease, while focusing on how the local microbiota and the host interact at the epithelial surface.", [["respiratory", "ANATOMY", 252, 263], ["epithelial surface", "ANATOMY", 356, 374], ["epithelial surface", "CELLULAR_COMPONENT", 356, 374], ["novel targeted therapies", "TREATMENT", 127, 151], ["preventative approaches", "TREATMENT", 155, 178], ["disease", "PROBLEM", 275, 282], ["epithelial", "ANATOMY_MODIFIER", 356, 366], ["surface", "ANATOMY_MODIFIER", 367, 374]]], ["Furthermore, we review current therapeutic approaches, and suggest a more holistic approach for treating lung disease in the future.", [["lung", "ANATOMY", 105, 109], ["lung disease", "DISEASE", 105, 117], ["lung", "ORGAN", 105, 109], ["lung disease", "PROBLEM", 105, 117], ["lung", "ANATOMY", 105, 109], ["disease", "OBSERVATION", 110, 117]]], ["This review is a follow-up of presentations and discussions at and after the ERS Research Seminar \"Cross-talk in the lung microenvironment: implications for understanding chronic lung disease\" (Berlin, February 2018).The mucosal niche in the lungAll external interfaces of the human body, such as gut, skin, reproductive and respiratory tracts, are colonised by a distinct microbial flora [16] .", [["lung", "ANATOMY", 117, 121], ["lung", "ANATOMY", 179, 183], ["mucosal niche", "ANATOMY", 221, 234], ["lung", "ANATOMY", 242, 246], ["body", "ANATOMY", 283, 287], ["gut", "ANATOMY", 297, 300], ["skin", "ANATOMY", 302, 306], ["respiratory tracts", "ANATOMY", 325, 343], ["chronic lung disease", "DISEASE", 171, 191], ["lung", "ORGAN", 117, 121], ["lung", "ORGAN", 179, 183], ["mucosal niche", "MULTI-TISSUE_STRUCTURE", 221, 234], ["lung", "ORGAN", 242, 246], ["human", "ORGANISM", 277, 282], ["body", "ORGANISM_SUBDIVISION", 283, 287], ["gut", "ORGANISM_SUBDIVISION", 297, 300], ["skin", "ORGAN", 302, 306], ["human", "SPECIES", 277, 282], ["human", "SPECIES", 277, 282], ["chronic lung disease", "PROBLEM", 171, 191], ["gut, skin, reproductive and respiratory tracts", "PROBLEM", 297, 343], ["a distinct microbial flora", "PROBLEM", 362, 388], ["lung", "ANATOMY", 117, 121], ["chronic", "OBSERVATION_MODIFIER", 171, 178], ["lung", "ANATOMY", 179, 183], ["disease", "OBSERVATION", 184, 191], ["mucosal niche", "OBSERVATION", 221, 234], ["lung", "ANATOMY", 242, 246], ["All", "ANATOMY_MODIFIER", 246, 249], ["external interfaces", "OBSERVATION", 250, 269], ["human", "ANATOMY", 277, 282], ["body", "ANATOMY_MODIFIER", 283, 287], ["gut", "ANATOMY", 297, 300], ["skin", "ANATOMY", 302, 306], ["respiratory tracts", "ANATOMY", 325, 343]]], ["The microbial communities differ at the various body sites due to local factors (e.g. oxygen, carbon dioxide, pH, nutrients, host defence factors, inhaled pollutants) that shape the niche.", [["communities", "ANATOMY", 14, 25], ["body sites", "ANATOMY", 48, 58], ["oxygen", "CHEMICAL", 86, 92], ["carbon dioxide", "CHEMICAL", 94, 108], ["oxygen", "CHEMICAL", 86, 92], ["carbon dioxide", "CHEMICAL", 94, 108], ["body sites", "MULTI-TISSUE_STRUCTURE", 48, 58], ["oxygen", "SIMPLE_CHEMICAL", 86, 92], ["carbon dioxide", "SIMPLE_CHEMICAL", 94, 108], ["host defence factors", "PROTEIN", 125, 145], ["local factors", "PROBLEM", 66, 79], ["e.g. oxygen", "TREATMENT", 81, 92], ["carbon dioxide", "TREATMENT", 94, 108], ["host defence factors", "TREATMENT", 125, 145], ["microbial", "OBSERVATION_MODIFIER", 4, 13], ["communities", "OBSERVATION", 14, 25], ["niche", "OBSERVATION_MODIFIER", 182, 187]]], ["As examples, the lumen of the lower gastrointestinal tract represents a low-oxygen, nutrient-rich environment and is thus commonly populated by high-abundance communities of anaerobic organisms; by contrast, the skin is a low-nutrient environment directly exposed to environmental oxygen and is thus more commonly populated by relatively sparse communities of oxygen-tolerant bacteria.", [["lumen", "ANATOMY", 17, 22], ["lower gastrointestinal tract", "ANATOMY", 30, 58], ["skin", "ANATOMY", 212, 216], ["oxygen", "CHEMICAL", 76, 82], ["oxygen", "CHEMICAL", 281, 287], ["oxygen", "CHEMICAL", 360, 366], ["oxygen", "CHEMICAL", 76, 82], ["oxygen", "CHEMICAL", 281, 287], ["oxygen", "CHEMICAL", 360, 366], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 17, 22], ["lower", "ORGANISM_SUBDIVISION", 30, 35], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 36, 58], ["oxygen", "SIMPLE_CHEMICAL", 76, 82], ["skin", "ORGAN", 212, 216], ["oxygen", "SIMPLE_CHEMICAL", 281, 287], ["oxygen", "SIMPLE_CHEMICAL", 360, 366], ["anaerobic organisms", "PROBLEM", 174, 193], ["environmental oxygen", "TREATMENT", 267, 287], ["tolerant bacteria", "PROBLEM", 367, 384], ["lumen", "ANATOMY_MODIFIER", 17, 22], ["lower", "ANATOMY_MODIFIER", 30, 35], ["gastrointestinal tract", "ANATOMY", 36, 58], ["low", "OBSERVATION_MODIFIER", 72, 75], ["skin", "ANATOMY", 212, 216], ["environmental oxygen", "OBSERVATION", 267, 287]]], ["Thus, the local environment is a crucial determinant of the formation of microbial communities early in development, but also at later stages [17] .The mucosal niche in the lungConsequently, the lung microenvironment creates a special ecological niche for microbes that differs from other body sites and will presumably influence niche-specific colonisation.", [["communities", "ANATOMY", 83, 94], ["mucosal niche", "ANATOMY", 152, 165], ["lung", "ANATOMY", 173, 177], ["lung", "ANATOMY", 195, 199], ["body sites", "ANATOMY", 289, 299], ["mucosal niche", "MULTI-TISSUE_STRUCTURE", 152, 165], ["lung", "ORGAN", 173, 177], ["lung", "ORGAN", 195, 199], ["body sites", "MULTI-TISSUE_STRUCTURE", 289, 299], ["microbial", "OBSERVATION_MODIFIER", 73, 82], ["communities", "OBSERVATION_MODIFIER", 83, 94], ["mucosal niche", "OBSERVATION", 152, 165], ["lung", "ANATOMY", 173, 177], ["lung", "ANATOMY", 195, 199], ["microenvironment", "OBSERVATION", 200, 216], ["colonisation", "OBSERVATION", 345, 357]]], ["Accordingly, airway epithelial cells are a principle contributor in shaping this niche, as they are strategically located to be the first contact between inhaled substances (including micro-organisms) and host tissues.", [["airway epithelial cells", "ANATOMY", 13, 36], ["tissues", "ANATOMY", 210, 217], ["airway epithelial cells", "CELL", 13, 36], ["host tissues", "TISSUE", 205, 217], ["airway epithelial cells", "CELL_TYPE", 13, 36], ["airway epithelial cells", "PROBLEM", 13, 36], ["inhaled substances", "TREATMENT", 154, 172], ["micro-organisms", "PROBLEM", 184, 199], ["airway", "ANATOMY", 13, 19], ["epithelial cells", "OBSERVATION", 20, 36], ["host tissues", "ANATOMY", 205, 217]]], ["Various mechanisms are employed by the airway epithelium in host defences against infection, including its barrier function, mucociliary clearance, production of antimicrobial peptides and other substances, pro-and anti-inflammatory mediators and ability to transport (e.g. polymeric IgA and IgM from the basal to the apical side of the epithelium through the polymeric immunoglobulin receptor ( pIgR)) [18] [19] [20] [21] .", [["airway epithelium", "ANATOMY", 39, 56], ["barrier", "ANATOMY", 107, 114], ["mucociliary", "ANATOMY", 125, 136], ["apical side", "ANATOMY", 318, 329], ["epithelium", "ANATOMY", 337, 347], ["infection", "DISEASE", 82, 91], ["airway epithelium", "TISSUE", 39, 56], ["barrier", "TISSUE", 107, 114], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 125, 136], ["IgA", "GENE_OR_GENE_PRODUCT", 284, 287], ["IgM", "GENE_OR_GENE_PRODUCT", 292, 295], ["epithelium", "TISSUE", 337, 347], ["immunoglobulin receptor", "GENE_OR_GENE_PRODUCT", 370, 393], ["pIgR", "GENE_OR_GENE_PRODUCT", 396, 400], ["IgA", "PROTEIN", 284, 287], ["IgM", "PROTEIN", 292, 295], ["polymeric immunoglobulin receptor", "PROTEIN", 360, 393], ["pIgR", "PROTEIN", 396, 400], ["the airway epithelium", "PROBLEM", 35, 56], ["infection", "PROBLEM", 82, 91], ["its barrier function", "TREATMENT", 103, 123], ["mucociliary clearance", "TREATMENT", 125, 146], ["antimicrobial peptides", "TREATMENT", 162, 184], ["pro-and anti-inflammatory mediators", "TREATMENT", 207, 242], ["e.g. polymeric IgA", "TEST", 269, 287], ["IgM", "TEST", 292, 295], ["airway", "ANATOMY", 39, 45], ["infection", "OBSERVATION", 82, 91], ["apical", "ANATOMY_MODIFIER", 318, 324], ["epithelium", "ANATOMY_MODIFIER", 337, 347]]], ["It is likely that similar mechanisms contribute to the formation of niche-specific communities along the respiratory tract, and such local conditions are crucial for allowing beneficial microbiota to persist at epithelial surfaces.", [["communities", "ANATOMY", 83, 94], ["respiratory tract", "ANATOMY", 105, 122], ["epithelial surfaces", "ANATOMY", 211, 230], ["respiratory tract", "ORGANISM_SUBDIVISION", 105, 122], ["epithelial surfaces", "TISSUE", 211, 230], ["such local conditions", "PROBLEM", 128, 149], ["respiratory tract", "ANATOMY", 105, 122], ["epithelial", "ANATOMY_MODIFIER", 211, 221]]], ["The involvement of such host-microbiota interactions in disease is well illustrated in cystic fibrosis.", [["cystic", "ANATOMY", 87, 93], ["fibrosis", "DISEASE", 94, 102], ["cystic fibrosis", "PATHOLOGICAL_FORMATION", 87, 102], ["disease", "PROBLEM", 56, 63], ["cystic fibrosis", "PROBLEM", 87, 102], ["cystic", "OBSERVATION_MODIFIER", 87, 93], ["fibrosis", "OBSERVATION", 94, 102]]], ["In cystic fibrosis, mutational dysfunction of the cystic fibrosis transmembrane regulator (CFTR) protein results in a reduction of anion (mostly bicarbonate and chloride) exchange across the epithelial surface, resulting in a dehydrated surface and sticky mucus.", [["cystic", "ANATOMY", 3, 9], ["epithelial surface", "ANATOMY", 191, 209], ["surface", "ANATOMY", 237, 244], ["mucus", "ANATOMY", 256, 261], ["cystic fibrosis", "DISEASE", 3, 18], ["fibrosis", "DISEASE", 57, 65], ["bicarbonate", "CHEMICAL", 145, 156], ["chloride", "CHEMICAL", 161, 169], ["bicarbonate", "CHEMICAL", 145, 156], ["chloride", "CHEMICAL", 161, 169], ["cystic fibrosis transmembrane regulator", "GENE_OR_GENE_PRODUCT", 50, 89], ["CFTR", "GENE_OR_GENE_PRODUCT", 91, 95], ["anion", "SIMPLE_CHEMICAL", 131, 136], ["bicarbonate", "SIMPLE_CHEMICAL", 145, 156], ["chloride", "SIMPLE_CHEMICAL", 161, 169], ["epithelial surface", "CELLULAR_COMPONENT", 191, 209], ["surface", "CELLULAR_COMPONENT", 237, 244], ["cystic fibrosis transmembrane regulator (CFTR) protein", "PROTEIN", 50, 104], ["cystic fibrosis", "PROBLEM", 3, 18], ["mutational dysfunction of the cystic fibrosis transmembrane regulator", "PROBLEM", 20, 89], ["a reduction of anion (mostly bicarbonate and chloride) exchange", "TREATMENT", 116, 179], ["a dehydrated surface", "PROBLEM", 224, 244], ["sticky mucus", "PROBLEM", 249, 261], ["cystic", "OBSERVATION_MODIFIER", 3, 9], ["fibrosis", "OBSERVATION", 10, 18], ["cystic", "OBSERVATION_MODIFIER", 50, 56], ["fibrosis", "OBSERVATION", 57, 65], ["epithelial", "ANATOMY", 191, 201], ["surface", "ANATOMY_MODIFIER", 202, 209], ["dehydrated", "OBSERVATION_MODIFIER", 226, 236], ["surface", "OBSERVATION_MODIFIER", 237, 244], ["sticky mucus", "OBSERVATION", 249, 261]]], ["This mucus cannot be readily cleared from the airways, which helps to explain why CFTR mutations are associated with alterations of the resident microbiota, including frequent colonisation with Staphylococcus aureus and Pseudomonas aeruginosa (as recently reviewed in [22] ).", [["mucus", "ANATOMY", 5, 10], ["airways", "ANATOMY", 46, 53], ["Staphylococcus aureus", "DISEASE", 194, 215], ["mucus", "MULTI-TISSUE_STRUCTURE", 5, 10], ["airways", "MULTI-TISSUE_STRUCTURE", 46, 53], ["CFTR", "GENE_OR_GENE_PRODUCT", 82, 86], ["Staphylococcus aureus", "ORGANISM", 194, 215], ["Pseudomonas aeruginosa", "ORGANISM", 220, 242], ["CFTR", "PROTEIN", 82, 86], ["Staphylococcus aureus", "SPECIES", 194, 215], ["Pseudomonas aeruginosa", "SPECIES", 220, 242], ["Staphylococcus aureus", "SPECIES", 194, 215], ["Pseudomonas aeruginosa", "SPECIES", 220, 242], ["CFTR mutations", "PROBLEM", 82, 96], ["frequent colonisation", "PROBLEM", 167, 188], ["Staphylococcus aureus", "PROBLEM", 194, 215], ["Pseudomonas aeruginosa", "PROBLEM", 220, 242], ["airways", "ANATOMY", 46, 53], ["Staphylococcus aureus", "OBSERVATION", 194, 215]]], ["However, we are still lacking knowledge on the underlying mechanisms of the niche alterations in more complex genetic lung diseases, such as asthma and COPD.The mucosal niche in the lungAdditionally, the epithelium transmits environmental and microbial signals to the immune system, allowing it to mount appropriate responses or develop tolerance [21, 23, 24] .The mucosal niche in the lungVarious mechanisms of sensing microbial presence include pattern recognition receptors such as the Toll-like receptors [20] , and other processes not mediated via classical receptor-mediated signalling, e.g. the integrated stress response [25] .", [["lung", "ANATOMY", 118, 122], ["mucosal niche", "ANATOMY", 161, 174], ["lung", "ANATOMY", 182, 186], ["epithelium", "ANATOMY", 204, 214], ["immune system", "ANATOMY", 268, 281], ["mucosal niche", "ANATOMY", 365, 378], ["lung diseases", "DISEASE", 118, 131], ["asthma", "DISEASE", 141, 147], ["COPD", "DISEASE", 152, 156], ["lung", "ORGAN", 118, 122], ["mucosal niche", "MULTI-TISSUE_STRUCTURE", 161, 174], ["lung", "ORGAN", 182, 186], ["epithelium", "TISSUE", 204, 214], ["immune system", "ANATOMICAL_SYSTEM", 268, 281], ["mucosal niche", "MULTI-TISSUE_STRUCTURE", 365, 378], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 489, 508], ["pattern recognition receptors", "PROTEIN", 447, 476], ["Toll-like receptors", "PROTEIN", 489, 508], ["the niche alterations", "PROBLEM", 72, 93], ["more complex genetic lung diseases", "PROBLEM", 97, 131], ["asthma", "PROBLEM", 141, 147], ["COPD", "PROBLEM", 152, 156], ["niche alterations", "OBSERVATION", 76, 93], ["more complex", "OBSERVATION_MODIFIER", 97, 109], ["genetic", "OBSERVATION", 110, 117], ["lung", "ANATOMY", 118, 122], ["diseases", "OBSERVATION", 123, 131], ["asthma", "OBSERVATION", 141, 147], ["COPD", "OBSERVATION", 152, 156], ["mucosal niche", "OBSERVATION", 161, 174], ["lung", "ANATOMY", 182, 186], ["epithelium", "ANATOMY_MODIFIER", 204, 214], ["mucosal niche", "OBSERVATION", 365, 378]]], ["Upon sensing microbial, environmental or endogenous challenges, epithelial cells mount active responses by increasing defence molecules, such as antimicrobial peptides, cytokines and chemokines.", [["epithelial cells", "ANATOMY", 64, 80], ["epithelial cells", "CELL", 64, 80], ["epithelial cells", "CELL_TYPE", 64, 80], ["defence molecules", "PROTEIN", 118, 135], ["cytokines", "PROTEIN", 169, 178], ["chemokines", "PROTEIN", 183, 193], ["endogenous challenges", "TREATMENT", 41, 62], ["epithelial cells", "PROBLEM", 64, 80], ["increasing defence molecules", "PROBLEM", 107, 135], ["antimicrobial peptides", "TREATMENT", 145, 167], ["cytokines and chemokines", "TREATMENT", 169, 193], ["epithelial cells", "OBSERVATION", 64, 80]]], ["These enhance the defence against respiratory pathogens, while simultaneously changing the ecological niche of complex microbial communities, indicating that the properties of the ecological niche encountered by micro-organisms changes as a result of environmental exposures.The mucosal niche in the lungAnatomical differences along the respiratory tract such as differences in epithelial cell composition shape this ecological niche.", [["communities", "ANATOMY", 129, 140], ["mucosal niche", "ANATOMY", 279, 292], ["lung", "ANATOMY", 300, 304], ["respiratory tract", "ANATOMY", 337, 354], ["epithelial cell", "ANATOMY", 378, 393], ["respiratory pathogens", "DISEASE", 34, 55], ["mucosal niche", "MULTI-TISSUE_STRUCTURE", 279, 292], ["lung", "ORGAN", 300, 304], ["respiratory tract", "ORGANISM_SUBDIVISION", 337, 354], ["epithelial cell", "CELL", 378, 393], ["respiratory pathogens", "PROBLEM", 34, 55], ["micro-organisms changes", "PROBLEM", 212, 235], ["respiratory pathogens", "OBSERVATION", 34, 55], ["micro-organisms", "OBSERVATION", 212, 227], ["mucosal niche", "OBSERVATION", 279, 292], ["lung", "ANATOMY", 300, 304], ["Anatomical", "ANATOMY_MODIFIER", 304, 314], ["respiratory tract", "ANATOMY", 337, 354], ["epithelial cell", "OBSERVATION", 378, 393], ["composition", "OBSERVATION_MODIFIER", 394, 405], ["shape", "OBSERVATION_MODIFIER", 406, 411], ["ecological niche", "OBSERVATION", 417, 433]]], ["While the epithelium contributes to local conditions that shape the microbiota, epithelial exposure to microbes and their products has marked effects on its function.", [["epithelium", "ANATOMY", 10, 20], ["epithelial", "ANATOMY", 80, 90], ["epithelium", "TISSUE", 10, 20], ["epithelial", "TISSUE", 80, 90], ["local conditions", "PROBLEM", 36, 52], ["epithelial exposure", "PROBLEM", 80, 99], ["local conditions", "OBSERVATION", 36, 52], ["shape", "OBSERVATION_MODIFIER", 58, 63], ["microbiota", "OBSERVATION_MODIFIER", 68, 78], ["epithelial exposure", "OBSERVATION", 80, 99], ["marked", "OBSERVATION_MODIFIER", 135, 141], ["effects", "OBSERVATION_MODIFIER", 142, 149]]], ["Consequently, human epithelia and the microbiota have developed interactions that are of mutual benefit, responding to pathogens and tolerating innocuous substances [26] .", [["epithelia", "ANATOMY", 20, 29], ["human", "ORGANISM", 14, 19], ["epithelia", "TISSUE", 20, 29], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["pathogens", "PROBLEM", 119, 128], ["innocuous substances", "TREATMENT", 144, 164]]], ["This concept is important to understand how inhaled environmental triggers regulate immunity, since microbial components contribute to the response to environmental exposures, such as farm [27] and geogenic (earth-derived) dust [28] .", [["microbial components", "PROBLEM", 100, 120]]], ["However, how the epithelium integrates these microbial and nonmicrobial signals into a fine-tuned response is incompletely understood.The mucosal niche in the lungIn order to transmit signals from the environment, epithelial cells use sophisticated communication systems with other lung cell types.", [["epithelium", "ANATOMY", 17, 27], ["mucosal niche", "ANATOMY", 138, 151], ["lung", "ANATOMY", 159, 163], ["epithelial cells", "ANATOMY", 214, 230], ["lung cell", "ANATOMY", 282, 291], ["epithelium", "TISSUE", 17, 27], ["mucosal niche", "MULTI-TISSUE_STRUCTURE", 138, 151], ["lung", "ORGAN", 159, 163], ["epithelial cells", "CELL", 214, 230], ["lung cell", "CELL", 282, 291], ["epithelial cells", "CELL_TYPE", 214, 230], ["lung cell types", "CELL_TYPE", 282, 297], ["epithelial cells", "PROBLEM", 214, 230], ["mucosal niche", "OBSERVATION", 138, 151], ["lung", "ANATOMY", 159, 163], ["epithelial cells", "OBSERVATION", 214, 230], ["lung", "ANATOMY", 282, 286], ["cell types", "OBSERVATION", 287, 297]]], ["The airway epithelium (and that of gut and skin) plays key roles in transmitting signals from micro-organisms and environmental stimuli to instruct antigen-presenting dendritic cells to direct immunity towards inflammation or tolerance [24] .", [["airway epithelium", "ANATOMY", 4, 21], ["gut", "ANATOMY", 35, 38], ["skin", "ANATOMY", 43, 47], ["dendritic cells", "ANATOMY", 167, 182], ["inflammation", "DISEASE", 210, 222], ["airway epithelium", "TISSUE", 4, 21], ["gut", "ORGANISM_SUBDIVISION", 35, 38], ["skin", "ORGAN", 43, 47], ["dendritic cells", "CELL", 167, 182], ["antigen-presenting dendritic cells", "CELL_TYPE", 148, 182], ["The airway epithelium", "PROBLEM", 0, 21], ["micro-organisms", "PROBLEM", 94, 109], ["environmental stimuli", "TEST", 114, 135], ["inflammation", "PROBLEM", 210, 222], ["airway", "ANATOMY", 4, 10], ["epithelium", "ANATOMY_MODIFIER", 11, 21], ["gut", "ANATOMY", 35, 38], ["skin", "ANATOMY", 43, 47]]], ["Epithelial cells interact not only with other immune cells, such as macrophages, neutrophils, innate lymphoid cells and T-cells, but also with structural cells such as fibroblasts, airway smooth muscle cells and endothelial cells via a plethora of different mechanisms (figure 1) [18, 20, 24] .", [["Epithelial cells", "ANATOMY", 0, 16], ["immune cells", "ANATOMY", 46, 58], ["macrophages", "ANATOMY", 68, 79], ["neutrophils", "ANATOMY", 81, 92], ["lymphoid cells", "ANATOMY", 101, 115], ["T-cells", "ANATOMY", 120, 127], ["cells", "ANATOMY", 154, 159], ["fibroblasts", "ANATOMY", 168, 179], ["airway smooth muscle cells", "ANATOMY", 181, 207], ["endothelial cells", "ANATOMY", 212, 229], ["Epithelial cells", "CELL", 0, 16], ["immune cells", "CELL", 46, 58], ["macrophages", "CELL", 68, 79], ["neutrophils", "CELL", 81, 92], ["innate lymphoid cells", "CELL", 94, 115], ["T-cells", "CELL", 120, 127], ["cells", "CELL", 154, 159], ["fibroblasts", "CELL", 168, 179], ["airway smooth muscle cells", "CELL", 181, 207], ["endothelial cells", "CELL", 212, 229], ["Epithelial cells", "CELL_TYPE", 0, 16], ["immune cells", "CELL_TYPE", 46, 58], ["macrophages", "CELL_TYPE", 68, 79], ["neutrophils", "CELL_TYPE", 81, 92], ["innate lymphoid cells", "CELL_TYPE", 94, 115], ["T-cells", "CELL_TYPE", 120, 127], ["structural cells", "CELL_TYPE", 143, 159], ["fibroblasts", "CELL_TYPE", 168, 179], ["airway smooth muscle cells", "CELL_TYPE", 181, 207], ["endothelial cells", "CELL_TYPE", 212, 229], ["Epithelial cells", "PROBLEM", 0, 16], ["other immune cells", "PROBLEM", 40, 58], ["macrophages", "PROBLEM", 68, 79], ["neutrophils", "TEST", 81, 92], ["innate lymphoid cells", "PROBLEM", 94, 115], ["T-cells", "PROBLEM", 120, 127], ["structural cells", "PROBLEM", 143, 159], ["fibroblasts, airway smooth muscle cells", "PROBLEM", 168, 207], ["endothelial cells", "PROBLEM", 212, 229], ["immune cells", "OBSERVATION", 46, 58], ["macrophages", "OBSERVATION", 68, 79], ["neutrophils", "ANATOMY", 81, 92], ["innate lymphoid cells", "OBSERVATION", 94, 115], ["structural cells", "OBSERVATION", 143, 159], ["fibroblasts", "OBSERVATION", 168, 179], ["airway", "ANATOMY", 181, 187], ["smooth muscle cells", "OBSERVATION", 188, 207], ["endothelial cells", "OBSERVATION", 212, 229]]], ["This array of interactions with environmental triggers, micro-organisms and lung cells allows epithelial cells to orchestrate host defence and immunity, and to maintain epithelial integrity and mediate pathologic airway remodelling (figure 1) [21] .Establishment and maintenance of the lung microbiotaThe establishment of the lung microbiota likely occurs in the first days and weeks of life.", [["micro-organisms", "ANATOMY", 56, 71], ["lung cells", "ANATOMY", 76, 86], ["epithelial cells", "ANATOMY", 94, 110], ["epithelial", "ANATOMY", 169, 179], ["airway", "ANATOMY", 213, 219], ["lung", "ANATOMY", 286, 290], ["lung microbiota", "ANATOMY", 326, 341], ["micro-organisms", "CELL", 56, 71], ["lung cells", "CELL", 76, 86], ["epithelial cells", "CELL", 94, 110], ["epithelial", "TISSUE", 169, 179], ["airway", "MULTI-TISSUE_STRUCTURE", 213, 219], ["lung", "ORGAN", 286, 290], ["lung", "ORGAN", 326, 330], ["lung cells", "CELL_TYPE", 76, 86], ["epithelial cells", "CELL_TYPE", 94, 110], ["micro-organisms", "PROBLEM", 56, 71], ["lung cells", "PROBLEM", 76, 86], ["epithelial cells", "PROBLEM", 94, 110], ["mediate pathologic airway remodelling", "PROBLEM", 194, 231], ["the lung microbiota", "TREATMENT", 282, 301], ["lung", "ANATOMY", 76, 80], ["epithelial cells", "OBSERVATION", 94, 110], ["epithelial", "ANATOMY", 169, 179], ["pathologic", "OBSERVATION_MODIFIER", 202, 212], ["airway", "ANATOMY", 213, 219], ["lung", "ANATOMY", 286, 290], ["microbiota", "ANATOMY_MODIFIER", 291, 301], ["lung", "ANATOMY", 326, 330], ["microbiota", "OBSERVATION", 331, 341]]], ["Although early high-profile reports suggested the presence of a \"placental microbiome\" that could influence prepartum lung development [29] , subsequent well-controlled studies have failed to detect bacterial signals distinct from contaminating DNA present in negative controls [30] .", [["placental microbiome", "ANATOMY", 65, 85], ["lung", "ANATOMY", 118, 122], ["placental microbiome", "TISSUE", 65, 85], ["lung", "ORGAN", 118, 122], ["DNA", "CELLULAR_COMPONENT", 245, 248], ["a \"placental microbiome", "PROBLEM", 62, 85], ["bacterial signals", "PROBLEM", 199, 216], ["contaminating DNA", "PROBLEM", 231, 248]]], ["The lung microbiota of newborn mice is below the limit of detection (via quantitative PCR), and increase in total burden in the following days and weeks [31, 32] .", [["lung", "ANATOMY", 4, 8], ["lung microbiota", "MULTI-TISSUE_STRUCTURE", 4, 19], ["mice", "ORGANISM", 31, 35], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["quantitative PCR", "TEST", 73, 89], ["lung", "ANATOMY", 4, 8], ["microbiota", "ANATOMY_MODIFIER", 9, 19], ["newborn mice", "OBSERVATION", 23, 35], ["increase", "OBSERVATION_MODIFIER", 96, 104], ["total", "OBSERVATION_MODIFIER", 108, 113], ["burden", "OBSERVATION_MODIFIER", 114, 120]]], ["In human infants, the composition of the respiratory microbiome seems to mature in a predictable, well-characterised pattern during the first year of life [32] .", [["respiratory microbiome", "ANATOMY", 41, 63], ["human", "ORGANISM", 3, 8], ["infants", "ORGANISM", 9, 16], ["human", "SPECIES", 3, 8], ["infants", "SPECIES", 9, 16], ["human", "SPECIES", 3, 8]]], ["Besides the special niche characteristics of the lung, early-life respiratory microbiota are influenced by mode of delivery (vaginal versus caesarean), method of feeding (breast versus bottle), and exposures (siblings, day-care attendance) [32] .", [["lung", "ANATOMY", 49, 53], ["respiratory", "ANATOMY", 66, 77], ["vaginal", "ANATOMY", 125, 132], ["breast", "ANATOMY", 171, 177], ["lung", "ORGAN", 49, 53], ["vaginal", "ORGANISM_SUBDIVISION", 125, 132], ["breast", "ORGANISM_SUBDIVISION", 171, 177], ["delivery (vaginal versus caesarean", "TREATMENT", 115, 149], ["method of feeding (breast versus bottle", "TREATMENT", 152, 191], ["lung", "ANATOMY", 49, 53], ["early", "OBSERVATION_MODIFIER", 55, 60], ["breast", "ANATOMY", 171, 177]]], ["Provocatively, early-life respiratory microbiota may predict subsequent susceptibility to respiratory tract infections [32, 33] , suggesting roles of the local microbes in immune homeostasis and resistance to pathogens.", [["respiratory", "ANATOMY", 26, 37], ["respiratory tract", "ANATOMY", 90, 107], ["respiratory tract infections", "DISEASE", 90, 118], ["tract", "ORGANISM_SUBDIVISION", 102, 107], ["respiratory tract infections", "PROBLEM", 90, 118], ["immune homeostasis", "PROBLEM", 172, 190], ["pathogens", "PROBLEM", 209, 218], ["respiratory tract", "ANATOMY", 90, 107], ["immune homeostasis", "OBSERVATION", 172, 190]]], ["In contrast, being exposed to an increased microbial diversity during childhood promotes the development of balanced immunity and is protective against inflammatory responses to allergens and asthma development [34, 35] .", [["asthma", "DISEASE", 192, 198], ["an increased microbial diversity", "PROBLEM", 30, 62], ["inflammatory responses", "PROBLEM", 152, 174], ["asthma development", "PROBLEM", 192, 210], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["microbial diversity", "OBSERVATION", 43, 62]]], ["This protection is partly associated with distinct farm dust, which in vitro increases epithelial barrier function and antiviral defences [27] .Establishment and maintenance of the lung microbiotaOnce established, the composition of the lung microbiome is determined by three ecological factors: immigration, elimination and relative growth rates of community members (figure 1) [36] .", [["epithelial barrier", "ANATOMY", 87, 105], ["lung", "ANATOMY", 181, 185], ["lung microbiome", "ANATOMY", 237, 252], ["epithelial barrier", "TISSUE", 87, 105], ["lung", "ORGAN", 181, 185], ["lung", "ORGAN", 237, 241], ["distinct farm dust", "PROBLEM", 42, 60], ["antiviral defences", "TREATMENT", 119, 137], ["the lung microbiotaOnce", "TREATMENT", 177, 200], ["partly associated with", "UNCERTAINTY", 19, 41], ["distinct", "OBSERVATION_MODIFIER", 42, 50], ["farm dust", "OBSERVATION", 51, 60], ["increases", "OBSERVATION_MODIFIER", 77, 86], ["epithelial barrier function", "OBSERVATION", 87, 114], ["lung", "ANATOMY", 181, 185], ["lung", "ANATOMY", 237, 241]]], ["In health, lung communities are sparse and dynamic, largely determined by the equilibrium between immigration (via microaspiration [3] ) and elimination (via cough, mucociliary clearance and immune defences).", [["lung communities", "ANATOMY", 11, 27], ["mucociliary", "ANATOMY", 165, 176], ["cough", "DISEASE", 158, 163], ["lung", "ORGAN", 11, 15], ["mucociliary", "ORGAN", 165, 176], ["cough", "PROBLEM", 158, 163], ["mucociliary clearance", "TEST", 165, 186], ["lung", "ANATOMY", 11, 15], ["communities", "ANATOMY_MODIFIER", 16, 27], ["dynamic", "OBSERVATION_MODIFIER", 43, 50]]], ["Little evidence supports the presence of resident lung bacteria in health that reproduce and survive selective pressures [1, 4, 9] .", [["lung", "ANATOMY", 50, 54], ["lung", "ORGAN", 50, 54], ["resident lung bacteria", "PROBLEM", 41, 63], ["selective pressures", "TEST", 101, 120], ["lung", "ANATOMY", 50, 54], ["bacteria", "OBSERVATION", 55, 63]]], ["Nevertheless, the transient and dynamic communities detected in health are largely viable [37] , and exert a detectable effect on the immune constitution of the lower respiratory tract [7, 8] .Establishment and maintenance of the lung microbiotaThe establishment of a diverse respiratory microbial flora is influenced by many different factors.", [["lower respiratory tract", "ANATOMY", 161, 184], ["lung", "ANATOMY", 230, 234], ["lower respiratory", "ORGANISM_SUBDIVISION", 161, 178], ["tract", "ORGANISM_SUBDIVISION", 179, 184], ["lung", "ORGAN", 230, 234], ["the transient and dynamic communities", "PROBLEM", 14, 51], ["a detectable effect", "PROBLEM", 107, 126], ["the lung microbiota", "TREATMENT", 226, 245], ["a diverse respiratory microbial flora", "PROBLEM", 266, 303], ["transient", "OBSERVATION_MODIFIER", 18, 27], ["dynamic", "OBSERVATION_MODIFIER", 32, 39], ["communities", "OBSERVATION_MODIFIER", 40, 51], ["detectable effect", "OBSERVATION", 109, 126], ["lower", "ANATOMY_MODIFIER", 161, 166], ["respiratory tract", "ANATOMY", 167, 184], ["lung", "ANATOMY", 230, 234], ["microbiota", "ANATOMY_MODIFIER", 235, 245], ["diverse", "OBSERVATION_MODIFIER", 268, 275], ["respiratory microbial flora", "OBSERVATION", 276, 303]]], ["There is a fine-tuned balance between tolerance of commensal or \"beneficial\" bacteria at the epithelial surface, and the development of active immune responses to pathogens.", [["epithelial surface", "ANATOMY", 93, 111], ["epithelial surface", "TISSUE", 93, 111], ["bacteria at the epithelial surface", "PROBLEM", 77, 111], ["active immune responses", "PROBLEM", 136, 159], ["pathogens", "PROBLEM", 163, 172], ["fine", "OBSERVATION_MODIFIER", 11, 15], ["-tuned", "OBSERVATION_MODIFIER", 15, 21], ["epithelial surface", "ANATOMY", 93, 111], ["active", "OBSERVATION_MODIFIER", 136, 142], ["immune responses", "OBSERVATION", 143, 159]]], ["Sudden shifts in this tightly controlled equilibrium, such as outgrowth of specific pathogens or, for example, virally induced damage to the airway epithelium destroying the barrier and inducing local immune responses, can have detrimental effects on both the host and the microbiome, and might therefore contribute to the pathogenesis of respiratory diseases.Establishment and maintenance of the lung microbiotaRole of the environment in shaping the lung microbiome Environmental influences play pivotal roles in the development of lung diseases.", [["airway epithelium", "ANATOMY", 141, 158], ["barrier", "ANATOMY", 174, 181], ["respiratory", "ANATOMY", 339, 350], ["lung", "ANATOMY", 397, 401], ["lung", "ANATOMY", 451, 455], ["lung", "ANATOMY", 533, 537], ["respiratory diseases", "DISEASE", 339, 359], ["lung diseases", "DISEASE", 533, 546], ["airway epithelium", "TISSUE", 141, 158], ["lung", "ORGAN", 397, 401], ["lung", "ORGAN", 451, 455], ["lung", "ORGAN", 533, 537], ["Sudden shifts", "PROBLEM", 0, 13], ["this tightly controlled equilibrium", "PROBLEM", 17, 52], ["specific pathogens", "PROBLEM", 75, 93], ["virally induced damage", "PROBLEM", 111, 133], ["the airway epithelium", "PROBLEM", 137, 158], ["the barrier", "TREATMENT", 170, 181], ["respiratory diseases", "PROBLEM", 339, 359], ["lung diseases", "PROBLEM", 533, 546], ["tightly controlled", "OBSERVATION_MODIFIER", 22, 40], ["equilibrium", "OBSERVATION", 41, 52], ["airway", "ANATOMY", 141, 147], ["epithelium", "ANATOMY_MODIFIER", 148, 158], ["respiratory diseases", "OBSERVATION", 339, 359], ["lung", "ANATOMY", 397, 401], ["microbiotaRole", "OBSERVATION", 402, 416], ["environment", "OBSERVATION_MODIFIER", 424, 435], ["lung", "ANATOMY", 451, 455], ["lung", "ANATOMY", 533, 537], ["diseases", "OBSERVATION", 538, 546]]], ["This might be due to direct effects on the host epithelial barrier and immune responses, but most known risk factors, such as cigarette smoke, air pollution [38, 39] , viral infections and diet also directly impact the microbiota [11, [40] [41] [42] .", [["epithelial barrier", "ANATOMY", 48, 66], ["viral infections", "DISEASE", 168, 184], ["epithelial barrier", "TISSUE", 48, 66], ["direct effects", "PROBLEM", 21, 35], ["the host epithelial barrier", "TREATMENT", 39, 66], ["viral infections", "PROBLEM", 168, 184], ["infections", "OBSERVATION", 174, 184]]], ["Thus, a combination of both might be critical for disease development.Establishment and maintenance of the lung microbiotaFor example, one of the most studied inhaled toxins, cigarette smoke, supposedly has a detrimental effect on both the host and microbial communities.", [["lung", "ANATOMY", 107, 111], ["communities", "ANATOMY", 259, 270], ["smoke", "CHEMICAL", 185, 190], ["lung", "ORGAN", 107, 111], ["cigarette", "ORGANISM", 175, 184], ["disease development", "PROBLEM", 50, 69], ["the lung microbiota", "TREATMENT", 103, 122], ["lung", "ANATOMY", 107, 111], ["microbiota", "ANATOMY_MODIFIER", 112, 122]]], ["Prolonged cigarette smoke exposure contributes to increased baseline inflammation in the airways and epithelial remodelling towards goblet cell hyperplasia and a reduction in cilia and ciliary activity [19] and can reduce the antimicrobial defence provided by the airway epithelium [43] .", [["airways", "ANATOMY", 89, 96], ["epithelial", "ANATOMY", 101, 111], ["goblet cell", "ANATOMY", 132, 143], ["cilia", "ANATOMY", 175, 180], ["ciliary", "ANATOMY", 185, 192], ["airway epithelium", "ANATOMY", 264, 281], ["smoke", "CHEMICAL", 20, 25], ["inflammation", "DISEASE", 69, 81], ["airways", "MULTI-TISSUE_STRUCTURE", 89, 96], ["epithelial", "TISSUE", 101, 111], ["goblet cell", "CELL", 132, 143], ["cilia", "CELLULAR_COMPONENT", 175, 180], ["ciliary", "MULTI-TISSUE_STRUCTURE", 185, 192], ["airway epithelium", "TISSUE", 264, 281], ["increased baseline inflammation in the airways", "PROBLEM", 50, 96], ["epithelial remodelling", "PROBLEM", 101, 123], ["goblet cell hyperplasia", "PROBLEM", 132, 155], ["a reduction in cilia and ciliary activity", "PROBLEM", 160, 201], ["the antimicrobial defence", "TREATMENT", 222, 247], ["cigarette smoke", "OBSERVATION", 10, 25], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["baseline", "OBSERVATION_MODIFIER", 60, 68], ["inflammation", "OBSERVATION", 69, 81], ["airways", "ANATOMY", 89, 96], ["epithelial", "ANATOMY_MODIFIER", 101, 111], ["goblet cell hyperplasia", "OBSERVATION", 132, 155], ["reduction", "OBSERVATION_MODIFIER", 162, 171], ["cilia", "ANATOMY_MODIFIER", 175, 180], ["ciliary activity", "OBSERVATION", 185, 201], ["antimicrobial defence", "OBSERVATION", 226, 247], ["airway", "ANATOMY", 264, 270]]], ["In patients with COPD, it has been shown to be associated with reduced lung Bacilli and increased Haemophilus influenzae and Streptococcus pneumoniae [44] , but the largest study to date in \"healthy\" smokers has not found a significant effect of cigarette smoke on the lung microbiome [45] .", [["lung", "ANATOMY", 71, 75], ["lung", "ANATOMY", 269, 273], ["COPD", "DISEASE", 17, 21], ["Haemophilus influenzae", "DISEASE", 98, 120], ["patients", "ORGANISM", 3, 11], ["lung", "ORGAN", 71, 75], ["Haemophilus influenzae", "ORGANISM", 98, 120], ["Streptococcus pneumoniae", "ORGANISM", 125, 149], ["cigarette", "ORGANISM", 246, 255], ["lung", "ORGAN", 269, 273], ["patients", "SPECIES", 3, 11], ["Haemophilus influenzae", "SPECIES", 98, 120], ["Streptococcus pneumoniae", "SPECIES", 125, 149], ["Haemophilus influenzae", "SPECIES", 98, 120], ["Streptococcus pneumoniae", "SPECIES", 125, 149], ["COPD", "PROBLEM", 17, 21], ["reduced lung Bacilli", "PROBLEM", 63, 83], ["increased Haemophilus influenzae", "PROBLEM", 88, 120], ["Streptococcus pneumoniae", "PROBLEM", 125, 149], ["the largest study", "TEST", 161, 178], ["COPD", "OBSERVATION", 17, 21], ["lung", "ANATOMY", 71, 75], ["Bacilli", "OBSERVATION", 76, 83], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["Haemophilus influenzae", "OBSERVATION", 98, 120], ["Streptococcus pneumoniae", "OBSERVATION", 125, 149], ["cigarette smoke", "OBSERVATION", 246, 261], ["lung", "ANATOMY", 269, 273]]], ["Thus, it is intriguing to speculate that cigarette smoke primarily affects the host system, which over time and upon disease (COPD) development in susceptible individuals may also affect the microbiome.Establishment and maintenance of the lung microbiotaAnother example of environmental influence on respiratory disease is diet, which has profound effects on both microbiota and health, even in the short term [46] .", [["lung", "ANATOMY", 239, 243], ["respiratory", "ANATOMY", 300, 311], ["smoke", "CHEMICAL", 51, 56], ["COPD", "DISEASE", 126, 130], ["respiratory disease", "DISEASE", 300, 319], ["cigarette", "ORGANISM", 41, 50], ["lung", "ORGAN", 239, 243], ["disease (COPD) development in susceptible individuals", "PROBLEM", 117, 170], ["respiratory disease", "PROBLEM", 300, 319], ["host system", "ANATOMY", 79, 90], ["lung", "ANATOMY", 239, 243], ["respiratory disease", "OBSERVATION", 300, 319]]], ["The intake of dietary fibre induces similar beneficial microbiota changes in the lung and gut [47] .", [["lung", "ANATOMY", 81, 85], ["gut", "ANATOMY", 90, 93], ["lung", "ORGAN", 81, 85], ["gut", "ORGANISM_SUBDIVISION", 90, 93], ["beneficial", "OBSERVATION_MODIFIER", 44, 54], ["microbiota", "OBSERVATION", 55, 65], ["lung", "ANATOMY", 81, 85], ["gut", "ANATOMY", 90, 93]]], ["While low-fibre diets change the gut microbial community over multiple generations in mice [48] , high-fibre diets have beneficial effects in pregnant mice and suppress allergic airway disease (AAD) in mothers and their offspring [49] .", [["gut microbial community", "ANATOMY", 33, 56], ["airway", "ANATOMY", 178, 184], ["allergic airway disease", "DISEASE", 169, 192], ["AAD", "DISEASE", 194, 197], ["gut microbial", "MULTI-TISSUE_STRUCTURE", 33, 46], ["mice", "ORGANISM", 86, 90], ["mice", "ORGANISM", 151, 155], ["allergic airway", "MULTI-TISSUE_STRUCTURE", 169, 184], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 151, 155], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 151, 155], ["high-fibre diets", "TREATMENT", 98, 114], ["suppress allergic airway disease", "PROBLEM", 160, 192], ["allergic airway disease", "OBSERVATION", 169, 192]]], ["This also highlights the importance of cross-talk between the gut and lung.", [["gut", "ANATOMY", 62, 65], ["lung", "ANATOMY", 70, 74], ["gut", "ORGANISM_SUBDIVISION", 62, 65], ["lung", "ORGAN", 70, 74], ["gut", "ANATOMY", 62, 65], ["lung", "ANATOMY", 70, 74]]], ["High-fibre diets induce the production of short-chain fatty acids by gut bacteria, which are transported systemically to the lung, where they exert anti-inflammatory actions and ameliorate AAD in mice [47] .", [["lung", "ANATOMY", 125, 129], ["fatty acids", "CHEMICAL", 54, 65], ["AAD", "DISEASE", 189, 192], ["short-chain fatty acids", "CHEMICAL", 42, 65], ["short-chain fatty acids", "SIMPLE_CHEMICAL", 42, 65], ["lung", "ORGAN", 125, 129], ["mice", "ORGANISM", 196, 200], ["mice", "SPECIES", 196, 200], ["mice", "SPECIES", 196, 200], ["High-fibre diets", "TREATMENT", 0, 16], ["short-chain fatty acids", "PROBLEM", 42, 65], ["gut bacteria", "PROBLEM", 69, 81], ["anti-inflammatory actions", "TREATMENT", 148, 173], ["AAD", "PROBLEM", 189, 192], ["fibre diets", "OBSERVATION_MODIFIER", 5, 16], ["lung", "ANATOMY", 125, 129]]], ["In contrast, a lipid-rich diet alters the microbiota and promotes metabolic inflammation [50] , and has been associated with premetastatic niche development in lung cancer [51] .", [["premetastatic niche", "ANATOMY", 125, 144], ["lung cancer", "ANATOMY", 160, 171], ["inflammation", "DISEASE", 76, 88], ["lung cancer", "DISEASE", 160, 171], ["lipid", "SIMPLE_CHEMICAL", 15, 20], ["lung cancer", "CANCER", 160, 171], ["a lipid-rich diet alters", "TREATMENT", 13, 37], ["metabolic inflammation", "PROBLEM", 66, 88], ["lung cancer", "PROBLEM", 160, 171], ["metabolic inflammation", "OBSERVATION", 66, 88], ["associated with", "UNCERTAINTY", 109, 124], ["lung", "ANATOMY", 160, 164], ["cancer", "OBSERVATION", 165, 171]]], ["However, the detailed mechanisms of action remain unclear.Establishment and maintenance of the lung microbiotaAlong with bacteria, common major respiratory viruses, including respiratory syncytial virus, rhinovirus, coronaviruses, influenza and adenoviruses are part of the respiratory microbiome [52] and contribute to the pathogenesis of chronic respiratory diseases.", [["lung", "ANATOMY", 95, 99], ["respiratory", "ANATOMY", 274, 285], ["respiratory", "ANATOMY", 348, 359], ["respiratory viruses", "DISEASE", 144, 163], ["respiratory syncytial virus", "DISEASE", 175, 202], ["rhinovirus, coronaviruses", "DISEASE", 204, 229], ["influenza", "DISEASE", 231, 240], ["chronic respiratory diseases", "DISEASE", 340, 368], ["lung", "ORGAN", 95, 99], ["respiratory syncytial virus", "ORGANISM", 175, 202], ["rhinovirus", "ORGANISM", 204, 214], ["adenoviruses", "ORGANISM", 245, 257], ["respiratory syncytial virus", "SPECIES", 175, 202], ["respiratory syncytial virus", "SPECIES", 175, 202], ["bacteria", "PROBLEM", 121, 129], ["common major respiratory viruses", "PROBLEM", 131, 163], ["respiratory syncytial virus", "PROBLEM", 175, 202], ["rhinovirus", "PROBLEM", 204, 214], ["coronaviruses", "PROBLEM", 216, 229], ["influenza", "PROBLEM", 231, 240], ["adenoviruses", "PROBLEM", 245, 257], ["chronic respiratory diseases", "PROBLEM", 340, 368], ["lung", "ANATOMY", 95, 99], ["bacteria", "OBSERVATION", 121, 129], ["respiratory viruses", "OBSERVATION", 144, 163], ["respiratory syncytial virus", "OBSERVATION", 175, 202], ["chronic", "OBSERVATION_MODIFIER", 340, 347], ["respiratory diseases", "OBSERVATION", 348, 368]]], ["This may result from complex interactions of viruses with the host's immune system and the microbiota including other pathogens.", [["immune system", "ANATOMY", 69, 82], ["immune system", "ANATOMICAL_SYSTEM", 69, 82], ["complex interactions of viruses", "PROBLEM", 21, 52], ["other pathogens", "PROBLEM", 112, 127]]], ["These interactions can influence the prevalence of bacterial pathogens by increasing the expression of adhesion molecules on the respiratory epithelium, damaging respiratory epithelial cells compromising barrier function, impairing mucociliary clearance and altering host immunity and the lung microenvironment [53] [54] [55] .", [["respiratory epithelium", "ANATOMY", 129, 151], ["respiratory epithelial cells", "ANATOMY", 162, 190], ["barrier", "ANATOMY", 204, 211], ["mucociliary", "ANATOMY", 232, 243], ["lung", "ANATOMY", 289, 293], ["respiratory epithelium", "TISSUE", 129, 151], ["respiratory epithelial cells", "CELL", 162, 190], ["barrier", "TISSUE", 204, 211], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 232, 243], ["lung", "ORGAN", 289, 293], ["adhesion molecules", "PROTEIN", 103, 121], ["respiratory epithelial cells", "CELL_TYPE", 162, 190], ["bacterial pathogens", "PROBLEM", 51, 70], ["adhesion molecules", "PROBLEM", 103, 121], ["the respiratory epithelium", "PROBLEM", 125, 151], ["damaging respiratory epithelial cells", "PROBLEM", 153, 190], ["impairing mucociliary clearance", "PROBLEM", 222, 253], ["respiratory epithelium", "ANATOMY", 129, 151], ["respiratory epithelial cells", "OBSERVATION", 162, 190], ["lung", "ANATOMY", 289, 293]]], ["Interestingly, it has been suggested that viruses (and bacteriophages) induce consistent and reproducible changes in respiratory microbiomes in chronic disease, but not the healthy state, and have been shown to increase microbial diversity in the nasopharynx [53, 56, 57] .", [["nasopharynx", "ANATOMY", 247, 258], ["chronic disease", "DISEASE", 144, 159], ["nasopharynx", "ORGAN", 247, 258], ["viruses (and bacteriophages)", "PROBLEM", 42, 70], ["reproducible changes in respiratory microbiomes", "PROBLEM", 93, 140], ["chronic disease", "PROBLEM", 144, 159], ["viruses", "OBSERVATION", 42, 49], ["reproducible", "OBSERVATION_MODIFIER", 93, 105], ["respiratory microbiomes", "OBSERVATION", 117, 140], ["chronic", "OBSERVATION_MODIFIER", 144, 151], ["disease", "OBSERVATION", 152, 159], ["increase", "OBSERVATION_MODIFIER", 211, 219], ["microbial diversity", "OBSERVATION", 220, 239], ["nasopharynx", "ANATOMY", 247, 258]]], ["Furthermore, fungi such as Aspergillus spp. contribute to the pathogenesis of chronic respiratory diseases as pathogens on their own, but also by activation of the immune system, and probably through their interactions with microbiota, particularly with nontuberculous mycobacteria [9, 58] .Establishment and maintenance of the lung microbiotaImportantly, the absence of certain members from the microbiome can have detrimental influences on lung health.", [["respiratory", "ANATOMY", 86, 97], ["immune system", "ANATOMY", 164, 177], ["lung", "ANATOMY", 328, 332], ["lung", "ANATOMY", 442, 446], ["respiratory diseases", "DISEASE", 86, 106], ["nontuberculous mycobacteria", "DISEASE", 254, 281], ["Aspergillus spp", "ORGANISM", 27, 42], ["lung", "ORGAN", 328, 332], ["lung", "ORGAN", 442, 446], ["Aspergillus spp", "SPECIES", 27, 42], ["Aspergillus spp", "SPECIES", 27, 42], ["fungi", "PROBLEM", 13, 18], ["Aspergillus spp", "PROBLEM", 27, 42], ["chronic respiratory diseases", "PROBLEM", 78, 106], ["nontuberculous mycobacteria", "PROBLEM", 254, 281], ["the lung microbiotaImportantly", "TREATMENT", 324, 354], ["fungi", "OBSERVATION", 13, 18], ["Aspergillus spp", "OBSERVATION", 27, 42], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["respiratory diseases", "OBSERVATION", 86, 106], ["lung", "ANATOMY", 328, 332], ["lung", "ANATOMY", 442, 446]]], ["This is illustrated by the relative disappearance of parasitic worms, which have been a constant part of our gut microbiome and have even been found in fossils from the period of jawed fish [59] .", [["gut microbiome", "ANATOMY", 109, 123], ["gut", "ORGANISM_SUBDIVISION", 109, 112], ["worms", "SPECIES", 63, 68], ["parasitic worms", "PROBLEM", 53, 68], ["disappearance", "OBSERVATION_MODIFIER", 36, 49], ["parasitic worms", "OBSERVATION", 53, 68]]], ["In fact, our Host-microbiome cross-talk in the lung microenvironment.", [["lung", "ANATOMY", 47, 51], ["lung", "ORGAN", 47, 51], ["lung", "ANATOMY", 47, 51]]], ["The lung microenvironment consists of different cell types, depending on the location in the proximal-to-distal airway tree.", [["lung", "ANATOMY", 4, 8], ["cell", "ANATOMY", 48, 52], ["distal airway tree", "ANATOMY", 105, 123], ["lung", "ORGAN", 4, 8], ["cell", "CELL", 48, 52], ["airway tree", "MULTI-TISSUE_STRUCTURE", 112, 123], ["different cell types", "PROBLEM", 38, 58], ["lung", "ANATOMY", 4, 8], ["microenvironment", "OBSERVATION", 9, 25], ["different cell types", "OBSERVATION", 38, 58], ["proximal", "ANATOMY_MODIFIER", 93, 101], ["distal", "ANATOMY_MODIFIER", 105, 111], ["airway", "ANATOMY", 112, 118], ["tree", "ANATOMY_MODIFIER", 119, 123]]], ["The epithelial layer in larger airways is constantly exposed to a variety of different microbes of the local microbiota.", [["epithelial layer", "ANATOMY", 4, 20], ["airways", "ANATOMY", 31, 38], ["epithelial layer", "TISSUE", 4, 20], ["airways", "MULTI-TISSUE_STRUCTURE", 31, 38], ["epithelial", "ANATOMY_MODIFIER", 4, 14], ["layer", "OBSERVATION_MODIFIER", 15, 20], ["larger", "OBSERVATION_MODIFIER", 24, 30], ["airways", "ANATOMY", 31, 38], ["variety", "OBSERVATION_MODIFIER", 66, 73], ["different", "OBSERVATION_MODIFIER", 77, 86], ["microbes", "OBSERVATION_MODIFIER", 87, 95], ["local microbiota", "OBSERVATION", 103, 119]]], ["While the composition of the latter is influenced by host factors such as elimination via mucociliary clearance, it also depends on the competition among the microbial inhabitants.", [["mucociliary", "ANATOMY", 90, 101], ["mucociliary", "ORGAN", 90, 101], ["mucociliary clearance", "TEST", 90, 111]]], ["Accordingly, bacterial metabolites or outer membrane vesicles can influence the host status, while antimicrobial peptides or cytokines can shape the composition of the microbiota.", [["outer membrane vesicles", "ANATOMY", 38, 61], ["outer membrane vesicles", "CELLULAR_COMPONENT", 38, 61], ["cytokines", "PROTEIN", 125, 134], ["bacterial metabolites", "PROBLEM", 13, 34], ["outer membrane vesicles", "PROBLEM", 38, 61], ["antimicrobial peptides", "TREATMENT", 99, 121], ["cytokines", "TREATMENT", 125, 134], ["bacterial metabolites", "OBSERVATION", 13, 34], ["outer", "ANATOMY_MODIFIER", 38, 43], ["membrane vesicles", "OBSERVATION", 44, 61]]], ["As virtually all of these single factors are altered in chronic respiratory disease, it is of utmost importance to appreciate and assess the complexity of this system in future studies.Establishment and maintenance of the lung microbiotahttps://doi.org/10.1183/13993003.02320-2019Establishment and maintenance of the lung microbiota\"modern\" immune system developed in the continuous presence of helminths [60] , which may explain their important regulatory role in immunity.", [["respiratory", "ANATOMY", 64, 75], ["lung", "ANATOMY", 222, 226], ["lung", "ANATOMY", 317, 321], ["immune system", "ANATOMY", 341, 354], ["chronic respiratory disease", "DISEASE", 56, 83], ["lung", "ORGAN", 222, 226], ["lung", "ORGAN", 317, 321], ["immune system", "ANATOMICAL_SYSTEM", 341, 354], ["chronic respiratory disease", "PROBLEM", 56, 83], ["future studies", "TEST", 170, 184], ["the lung microbiotahttps://doi.org/10.1183/13993003.02320-2019Establishment", "TREATMENT", 218, 293], ["the lung microbiota", "TREATMENT", 313, 332], ["altered", "OBSERVATION_MODIFIER", 45, 52], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["respiratory disease", "OBSERVATION", 64, 83], ["lung", "ANATOMY", 222, 226], ["microbiotahttps://doi.org/10.1183/13993003.02320-2019Establishment", "OBSERVATION", 227, 293], ["lung", "ANATOMY", 317, 321]]], ["Typically, worms induce type-2 immune responses which are considered instrumental in host defence against these parasitic infections.", [["worms", "ANATOMY", 11, 16], ["parasitic infections", "DISEASE", 112, 132], ["worms", "SPECIES", 11, 16], ["these parasitic infections", "PROBLEM", 106, 132], ["parasitic", "OBSERVATION_MODIFIER", 112, 121], ["infections", "OBSERVATION", 122, 132]]], ["However, worm infections induce regulatory responses that are aimed to suppress immune responses directed at worm antigens, which allows worms to live in their host for years.", [["worm", "ANATOMY", 9, 13], ["worm infections", "DISEASE", 9, 24], ["worm infections", "ORGANISM", 9, 24], ["worm antigens", "PROTEIN", 109, 122], ["worms", "SPECIES", 137, 142], ["worm infections", "PROBLEM", 9, 24], ["immune responses", "PROBLEM", 80, 96]]], ["This is illustrated by studies in mouse models, in which various helminth infections have been shown to provide protection against the development of allergic asthma [62] .", [["helminth infections", "DISEASE", 65, 84], ["allergic asthma", "DISEASE", 150, 165], ["mouse", "ORGANISM", 34, 39], ["mouse", "SPECIES", 34, 39], ["mouse", "SPECIES", 34, 39], ["various helminth infections", "PROBLEM", 57, 84], ["allergic asthma", "PROBLEM", 150, 165], ["allergic asthma", "OBSERVATION", 150, 165]]], ["The range of helminth-induced protective mechanisms includes the inhibition of interleukin (IL)-33 [63] in the airways, and the induction of regulatory T-cells [64, 65] , B-cells [66, 67] and macrophages [68] .", [["airways", "ANATOMY", 111, 118], ["regulatory T-cells", "ANATOMY", 141, 159], ["B-cells", "ANATOMY", 171, 178], ["macrophages", "ANATOMY", 192, 203], ["interleukin (IL)-33", "GENE_OR_GENE_PRODUCT", 79, 98], ["airways", "MULTI-TISSUE_STRUCTURE", 111, 118], ["T-cells", "CELL", 152, 159], ["B-cells", "CELL", 171, 178], ["macrophages", "CELL", 192, 203], ["regulatory T-cells", "CELL_TYPE", 141, 159], ["B-cells", "CELL_TYPE", 171, 178], ["macrophages", "CELL_TYPE", 192, 203], ["interleukin (IL)", "TREATMENT", 79, 95], ["B-cells", "TEST", 171, 178], ["macrophages", "TEST", 192, 203], ["airways", "ANATOMY", 111, 118]]], ["Intriguingly, the presence of helminths also affects the composition of the bacterial community, which might be important for the protection against allergic airway disease in mice [69] .Niche and microbiome alterations in respiratory diseaseIn disease, the ecology of the lower respiratory tract changes dramatically.", [["community", "ANATOMY", 86, 95], ["airway", "ANATOMY", 158, 164], ["respiratory", "ANATOMY", 223, 234], ["lower respiratory tract", "ANATOMY", 273, 296], ["helminths", "DISEASE", 30, 39], ["allergic airway disease", "DISEASE", 149, 172], ["respiratory disease", "DISEASE", 223, 242], ["airway", "ORGAN", 158, 164], ["mice", "ORGANISM", 176, 180], ["lower", "ORGANISM_SUBDIVISION", 273, 278], ["respiratory tract", "ORGANISM_SUBDIVISION", 279, 296], ["mice", "SPECIES", 176, 180], ["mice", "SPECIES", 176, 180], ["allergic airway disease", "PROBLEM", 149, 172], ["microbiome alterations", "PROBLEM", 197, 219], ["respiratory disease", "PROBLEM", 223, 242], ["the lower respiratory tract changes", "PROBLEM", 269, 304], ["helminths", "OBSERVATION", 30, 39], ["bacterial", "OBSERVATION_MODIFIER", 76, 85], ["respiratory disease", "OBSERVATION", 223, 242], ["disease", "OBSERVATION", 245, 252], ["lower", "ANATOMY_MODIFIER", 273, 278], ["respiratory tract", "ANATOMY", 279, 296]]], ["The airways and alveoli, normally inhospitable to bacterial reproduction [3] , are radically altered by the influx of nutrient-rich oedema and mucus, establishment of stark oxygen gradients, surge of bacterial growth-promoting inflammatory responses [70, 71] and impairment of local host defences [36, 72] .", [["airways", "ANATOMY", 4, 11], ["alveoli", "ANATOMY", 16, 23], ["mucus", "ANATOMY", 143, 148], ["oedema", "DISEASE", 132, 138], ["oxygen", "CHEMICAL", 173, 179], ["oxygen", "CHEMICAL", 173, 179], ["airways", "MULTI-TISSUE_STRUCTURE", 4, 11], ["alveoli", "MULTI-TISSUE_STRUCTURE", 16, 23], ["oedema", "PATHOLOGICAL_FORMATION", 132, 138], ["mucus", "ORGANISM_SUBSTANCE", 143, 148], ["oxygen", "SIMPLE_CHEMICAL", 173, 179], ["bacterial reproduction", "PROBLEM", 50, 72], ["rich oedema", "PROBLEM", 127, 138], ["mucus", "PROBLEM", 143, 148], ["stark oxygen gradients", "PROBLEM", 167, 189], ["bacterial growth", "PROBLEM", 200, 216], ["airways", "ANATOMY", 4, 11], ["alveoli", "ANATOMY", 16, 23], ["rich", "OBSERVATION_MODIFIER", 127, 131], ["oedema", "OBSERVATION", 132, 138], ["mucus", "OBSERVATION_MODIFIER", 143, 148], ["bacterial growth", "OBSERVATION_MODIFIER", 200, 216], ["inflammatory", "OBSERVATION_MODIFIER", 227, 239]]], ["Thus, it is unsurprising that cross-sectional studies have identified altered lung microbiomes in established lung diseases, as changes in ecological niches supposedly result in different microbial communities due to selective pressure.", [["lung", "ANATOMY", 78, 82], ["lung", "ANATOMY", 110, 114], ["communities", "ANATOMY", 198, 209], ["lung diseases", "DISEASE", 110, 123], ["lung", "ORGAN", 78, 82], ["lung", "ORGAN", 110, 114], ["cross-sectional studies", "TEST", 30, 53], ["altered lung microbiomes", "PROBLEM", 70, 94], ["established lung diseases", "PROBLEM", 98, 123], ["selective pressure", "TEST", 217, 235], ["altered", "OBSERVATION_MODIFIER", 70, 77], ["lung", "ANATOMY", 78, 82], ["lung", "ANATOMY", 110, 114], ["diseases", "OBSERVATION", 115, 123], ["selective", "OBSERVATION_MODIFIER", 217, 226], ["pressure", "OBSERVATION", 227, 235]]], ["The composition of the lung microbiome then becomes increasingly determined by the relative growth rates of its constituents.Niche and microbiome alterations in respiratory diseaseWhile there are some studies on the role of the microbiome in IPF [13] and lung cancer [14] , most knowledge is based on studies of chronic inflammatory respiratory diseases, such as asthma, COPD and cystic fibrosis.", [["lung microbiome", "ANATOMY", 23, 38], ["lung cancer", "ANATOMY", 255, 266], ["respiratory", "ANATOMY", 333, 344], ["cystic", "ANATOMY", 380, 386], ["respiratory diseaseWhile", "DISEASE", 161, 185], ["IPF", "DISEASE", 242, 245], ["lung cancer", "DISEASE", 255, 266], ["respiratory diseases", "DISEASE", 333, 353], ["asthma", "DISEASE", 363, 369], ["COPD", "DISEASE", 371, 375], ["cystic fibrosis", "DISEASE", 380, 395], ["lung", "ORGAN", 23, 27], ["lung cancer", "CANCER", 255, 266], ["microbiome alterations in respiratory diseaseWhile", "PROBLEM", 135, 185], ["lung cancer", "PROBLEM", 255, 266], ["chronic inflammatory respiratory diseases", "PROBLEM", 312, 353], ["asthma", "PROBLEM", 363, 369], ["COPD", "PROBLEM", 371, 375], ["cystic fibrosis", "PROBLEM", 380, 395], ["lung", "ANATOMY", 23, 27], ["microbiome", "OBSERVATION", 28, 38], ["growth", "OBSERVATION_MODIFIER", 92, 98], ["respiratory diseaseWhile", "OBSERVATION", 161, 185], ["IPF", "OBSERVATION", 242, 245], ["lung", "ANATOMY", 255, 259], ["cancer", "OBSERVATION", 260, 266], ["chronic", "OBSERVATION_MODIFIER", 312, 319], ["inflammatory", "OBSERVATION_MODIFIER", 320, 332], ["respiratory diseases", "OBSERVATION", 333, 353], ["asthma", "OBSERVATION", 363, 369], ["COPD", "OBSERVATION", 371, 375], ["cystic", "OBSERVATION_MODIFIER", 380, 386], ["fibrosis", "OBSERVATION", 387, 395]]], ["Generally, those patients have increased susceptibility to infections and exacerbations that again affect the microbiome [4, 73, 74] .", [["infections", "DISEASE", 59, 69], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["increased susceptibility to infections", "PROBLEM", 31, 69], ["exacerbations", "PROBLEM", 74, 87], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["infections", "OBSERVATION", 59, 69]]], ["H. influenzae, Moraxella catarrhalis and S. pneumoniae are associated with the development of (severe) asthma and COPD.", [["asthma", "DISEASE", 103, 109], ["COPD", "DISEASE", 114, 118], ["H. influenzae", "ORGANISM", 0, 13], ["Moraxella catarrhalis", "ORGANISM", 15, 36], ["S. pneumoniae", "ORGANISM", 41, 54], ["H. influenzae", "SPECIES", 0, 13], ["Moraxella catarrhalis", "SPECIES", 15, 36], ["S. pneumoniae", "SPECIES", 41, 54], ["H. influenzae", "SPECIES", 0, 13], ["Moraxella catarrhalis", "SPECIES", 15, 36], ["S. pneumoniae", "SPECIES", 41, 54], ["H. influenzae", "PROBLEM", 0, 13], ["Moraxella catarrhalis", "PROBLEM", 15, 36], ["S. pneumoniae", "PROBLEM", 41, 54], ["(severe) asthma", "PROBLEM", 94, 109], ["COPD", "PROBLEM", 114, 118], ["influenzae", "OBSERVATION", 3, 13], ["Moraxella catarrhalis", "OBSERVATION", 15, 36], ["pneumoniae", "OBSERVATION", 44, 54], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["asthma", "OBSERVATION", 103, 109], ["COPD", "OBSERVATION", 114, 118]]], ["They modify the lung microbiome and drive inflammation, oxidative stress, symptoms and exacerbations [44, [75] [76] [77] [78] [79] [80] , which may form a vicious circle perpetuating the disease.", [["lung", "ANATOMY", 16, 20], ["inflammation", "DISEASE", 42, 54], ["lung", "ORGAN", 16, 20], ["[75] [76] [77] [78] [79] [80]", "SIMPLE_CHEMICAL", 106, 135], ["drive inflammation", "PROBLEM", 36, 54], ["oxidative stress", "PROBLEM", 56, 72], ["symptoms", "PROBLEM", 74, 82], ["exacerbations", "PROBLEM", 87, 100], ["the disease", "PROBLEM", 183, 194], ["lung", "ANATOMY", 16, 20], ["microbiome", "OBSERVATION", 21, 31], ["disease", "OBSERVATION", 187, 194]]], ["M. catarrhalis and H. influenzae in particular induce neutrophilic inflammation, more severe disease, and steroid resistance [79] [80] [81] [82] [83] [84] .", [["neutrophilic", "ANATOMY", 54, 66], ["inflammation", "DISEASE", 67, 79], ["steroid", "CHEMICAL", 106, 113], ["steroid", "CHEMICAL", 106, 113], ["[79] [80] [81] [82] [83]", "CHEMICAL", 125, 149], ["M. catarrhalis", "ORGANISM", 0, 14], ["H. influenzae", "ORGANISM", 19, 32], ["steroid", "SIMPLE_CHEMICAL", 106, 113], ["M. catarrhalis", "SPECIES", 0, 14], ["H. influenzae", "SPECIES", 19, 32], ["M. catarrhalis", "SPECIES", 0, 14], ["H. influenzae", "SPECIES", 19, 32], ["M. catarrhalis", "PROBLEM", 0, 14], ["H. influenzae", "PROBLEM", 19, 32], ["neutrophilic inflammation", "PROBLEM", 54, 79], ["more severe disease", "PROBLEM", 81, 100], ["steroid resistance", "TEST", 106, 124], ["catarrhalis", "OBSERVATION", 3, 14], ["neutrophilic", "OBSERVATION_MODIFIER", 54, 66], ["inflammation", "OBSERVATION", 67, 79], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["disease", "OBSERVATION", 93, 100]]], ["Furthermore, in asthma, altered respiratory microbiome profiles are associated with asthma phenotype [85] and severity [86] , responses to allergens [87] and treatment [88] .Niche and microbiome alterations in respiratory diseaseIn cystic fibrosis and bronchiectasis, Haemophilus and Pseudomonas spp. increasingly dominate the lung microbiota [89, 90] .", [["respiratory", "ANATOMY", 32, 43], ["lung", "ANATOMY", 327, 331], ["asthma", "DISEASE", 16, 22], ["asthma", "DISEASE", 84, 90], ["cystic fibrosis", "DISEASE", 232, 247], ["bronchiectasis", "DISEASE", 252, 266], ["Pseudomonas spp", "ORGANISM", 284, 299], ["lung", "ORGAN", 327, 331], ["Pseudomonas spp", "SPECIES", 284, 299], ["asthma", "PROBLEM", 16, 22], ["altered respiratory microbiome profiles", "PROBLEM", 24, 63], ["asthma phenotype", "PROBLEM", 84, 100], ["treatment", "TREATMENT", 158, 167], ["microbiome alterations", "PROBLEM", 184, 206], ["respiratory diseaseIn cystic fibrosis", "PROBLEM", 210, 247], ["bronchiectasis", "PROBLEM", 252, 266], ["Haemophilus", "PROBLEM", 268, 279], ["Pseudomonas spp", "PROBLEM", 284, 299], ["asthma", "OBSERVATION", 16, 22], ["respiratory microbiome", "OBSERVATION", 32, 54], ["respiratory diseaseIn", "OBSERVATION", 210, 231], ["cystic", "OBSERVATION_MODIFIER", 232, 238], ["fibrosis", "OBSERVATION", 239, 247], ["bronchiectasis", "OBSERVATION", 252, 266], ["Haemophilus", "OBSERVATION_MODIFIER", 268, 279], ["Pseudomonas spp", "OBSERVATION", 284, 299], ["lung", "ANATOMY", 327, 331]]], ["Genetic association studies in Phe508del cystic fibrosis-affected homozygous individuals have shown associations of single nucleotide polymorphisms with important disease features related to bacterial colonisation.", [["cystic fibrosis", "DISEASE", 41, 56], ["Phe508del cystic", "PATHOLOGICAL_FORMATION", 31, 47], ["Genetic association studies", "TEST", 0, 27], ["Phe508del cystic fibrosis", "PROBLEM", 31, 56], ["affected homozygous individuals", "PROBLEM", 57, 88], ["single nucleotide polymorphisms", "PROBLEM", 116, 147], ["important disease features", "PROBLEM", 153, 179], ["bacterial colonisation", "PROBLEM", 191, 213], ["cystic", "OBSERVATION_MODIFIER", 41, 47], ["fibrosis", "OBSERVATION", 48, 56], ["bacterial colonisation", "OBSERVATION", 191, 213]]], ["For example, gene variants of human leukocyte antigen class II genes (implicating a role for T-cell and B-cell immunity) associate with age of onset of persistent P. aeruginosa infection, indicating the role of the host's immune system in selecting a distinct microbiota [91].Niche and microbiome alterations in respiratory diseaseLike the bacterial composition of the lung microbiome, antiviral responses are altered in chronic respiratory diseases.", [["T-cell", "ANATOMY", 93, 99], ["B-cell", "ANATOMY", 104, 110], ["respiratory", "ANATOMY", 312, 323], ["lung microbiome", "ANATOMY", 369, 384], ["respiratory", "ANATOMY", 429, 440], ["P. aeruginosa infection", "DISEASE", 163, 186], ["chronic respiratory diseases", "DISEASE", 421, 449], ["human leukocyte antigen class II", "GENE_OR_GENE_PRODUCT", 30, 62], ["T-cell", "CELL", 93, 99], ["B-cell", "CELL", 104, 110], ["P. aeruginosa", "ORGANISM", 163, 176], ["immune system", "ANATOMICAL_SYSTEM", 222, 235], ["lung", "ORGAN", 369, 373], ["human leukocyte antigen class II genes", "DNA", 30, 68], ["human", "SPECIES", 30, 35], ["P. aeruginosa", "SPECIES", 163, 176], ["human", "SPECIES", 30, 35], ["P. aeruginosa", "SPECIES", 163, 176], ["human leukocyte antigen class II genes", "PROBLEM", 30, 68], ["B-cell immunity", "TREATMENT", 104, 119], ["persistent P. aeruginosa infection", "PROBLEM", 152, 186], ["microbiome alterations", "PROBLEM", 286, 308], ["chronic respiratory diseases", "PROBLEM", 421, 449], ["persistent", "OBSERVATION_MODIFIER", 152, 162], ["P. aeruginosa infection", "OBSERVATION", 163, 186], ["respiratory diseaseLike", "OBSERVATION", 312, 335], ["bacterial composition", "OBSERVATION", 340, 361], ["lung", "ANATOMY", 369, 373], ["chronic", "OBSERVATION_MODIFIER", 421, 428], ["respiratory diseases", "OBSERVATION", 429, 449]]], ["In asthma, where airway epithelial repair in response to viral infection is aberrant due to changes in genes regulating epithelial barrier function and repair [92] , the airway epithelium has reduced innate immunity to common viruses such as rhinovirus [79, 93] .", [["airway epithelial", "ANATOMY", 17, 34], ["epithelial barrier", "ANATOMY", 120, 138], ["airway epithelium", "ANATOMY", 170, 187], ["asthma", "DISEASE", 3, 9], ["viral infection", "DISEASE", 57, 72], ["airway epithelial", "TISSUE", 17, 34], ["epithelial barrier", "TISSUE", 120, 138], ["airway epithelium", "TISSUE", 170, 187], ["rhinovirus", "ORGANISM", 242, 252], ["asthma", "PROBLEM", 3, 9], ["airway epithelial repair", "TREATMENT", 17, 41], ["viral infection", "PROBLEM", 57, 72], ["changes in genes", "PROBLEM", 92, 108], ["epithelial barrier function", "TREATMENT", 120, 147], ["repair", "TREATMENT", 152, 158], ["the airway epithelium", "PROBLEM", 166, 187], ["common viruses", "PROBLEM", 219, 233], ["rhinovirus", "PROBLEM", 242, 252], ["asthma", "OBSERVATION", 3, 9], ["airway", "ANATOMY", 17, 23], ["epithelial repair", "OBSERVATION", 24, 41], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 63, 72], ["epithelial barrier", "OBSERVATION", 120, 138], ["airway", "ANATOMY", 170, 176], ["epithelium", "ANATOMY_MODIFIER", 177, 187]]], ["This is due to reduced type I and III interferon and increased miRNA levels [94, 95] .", [["type I and III interferon", "GENE_OR_GENE_PRODUCT", 23, 48], ["type I and III interferon", "PROTEIN", 23, 48], ["reduced type I and III interferon", "PROBLEM", 15, 48], ["increased miRNA levels", "PROBLEM", 53, 75]]], ["Transforming growth factor (TGF)-\u03b2, a cytokine commonly upregulated in asthma, suppresses airway epithelial innate immune responses through suppressor of cytokine signalling (SOCS)-1 and SOCS-3, contributing to impaired antiviral immunity [96] .", [["airway epithelial", "ANATOMY", 90, 107], ["asthma", "DISEASE", 71, 77], ["impaired antiviral immunity", "DISEASE", 211, 238], ["Transforming growth factor (TGF)-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 34], ["airway epithelial", "CELL", 90, 107], ["suppressor of cytokine signalling (SOCS)-1", "GENE_OR_GENE_PRODUCT", 140, 182], ["SOCS-3", "GENE_OR_GENE_PRODUCT", 187, 193], ["Transforming growth factor (TGF)-\u03b2", "PROTEIN", 0, 34], ["cytokine", "PROTEIN", 38, 46], ["cytokine signalling (SOCS)-1", "PROTEIN", 154, 182], ["SOCS-3", "PROTEIN", 187, 193], ["asthma", "PROBLEM", 71, 77], ["cytokine signalling", "PROBLEM", 154, 173], ["impaired antiviral immunity", "PROBLEM", 211, 238], ["asthma", "OBSERVATION", 71, 77], ["airway", "ANATOMY", 90, 96], ["epithelial", "ANATOMY_MODIFIER", 97, 107]]], ["This impaired antiviral immunity may also alter the bacterial microbiome and contribute to co-infections by bacteria [97] .", [["co-infections", "DISEASE", 91, 104], ["This impaired antiviral immunity", "TREATMENT", 0, 32], ["the bacterial microbiome", "PROBLEM", 48, 72], ["co-infections", "PROBLEM", 91, 104], ["bacteria", "PROBLEM", 108, 116], ["antiviral immunity", "OBSERVATION", 14, 32]]], ["Rhinovirus infection can also impair the phagocytosis of bacteria by alveolar macrophages which can lead to bacterial outgrowth in COPD [98] .", [["alveolar macrophages", "ANATOMY", 69, 89], ["Rhinovirus", "CHEMICAL", 0, 10], ["infection", "DISEASE", 11, 20], ["COPD", "DISEASE", 131, 135], ["alveolar macrophages", "CELL", 69, 89], ["alveolar macrophages", "CELL_TYPE", 69, 89], ["Rhinovirus", "SPECIES", 0, 10], ["Rhinovirus infection", "PROBLEM", 0, 20], ["the phagocytosis of bacteria", "PROBLEM", 37, 65], ["alveolar macrophages", "PROBLEM", 69, 89], ["bacterial outgrowth", "PROBLEM", 108, 127], ["COPD", "PROBLEM", 131, 135], ["infection", "OBSERVATION", 11, 20], ["phagocytosis", "OBSERVATION_MODIFIER", 41, 53], ["alveolar macrophages", "OBSERVATION", 69, 89], ["bacterial", "OBSERVATION_MODIFIER", 108, 117], ["outgrowth", "OBSERVATION_MODIFIER", 118, 127], ["COPD", "OBSERVATION", 131, 135]]], ["Murine studies showed that influenza-infected epithelial progenitors of the distal lung exhibited severely impaired renewal capacity due to virus-induced blockade of \u03b2-catenin-dependent Fgfr2b signalling [99] .", [["epithelial progenitors", "ANATOMY", 46, 68], ["distal lung", "ANATOMY", 76, 87], ["influenza-infected", "DISEASE", 27, 45], ["Murine", "ORGANISM", 0, 6], ["epithelial progenitors", "CELL", 46, 68], ["lung", "ORGAN", 83, 87], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 166, 175], ["Fgfr2b", "GENE_OR_GENE_PRODUCT", 186, 192], ["influenza-infected epithelial progenitors", "CELL_TYPE", 27, 68], ["\u03b2-catenin", "PROTEIN", 166, 175], ["Fgfr2b", "PROTEIN", 186, 192], ["Murine studies", "TEST", 0, 14], ["influenza", "PROBLEM", 27, 36], ["infected epithelial progenitors of the distal lung", "PROBLEM", 37, 87], ["severely impaired renewal capacity", "PROBLEM", 98, 132], ["virus", "PROBLEM", 140, 145], ["\u03b2-catenin", "TEST", 166, 175], ["influenza", "OBSERVATION", 27, 36], ["infected", "OBSERVATION_MODIFIER", 37, 45], ["epithelial progenitors", "OBSERVATION", 46, 68], ["distal", "ANATOMY_MODIFIER", 76, 82], ["lung", "ANATOMY", 83, 87], ["severely", "OBSERVATION_MODIFIER", 98, 106], ["impaired", "OBSERVATION_MODIFIER", 107, 115], ["renewal capacity", "OBSERVATION", 116, 132]]], ["This could contribute to impaired repair of the distal lung in COPD, although its involvement in human disease is still unclear.Niche and microbiome alterations in respiratory diseaseThus, viral and bacterial infections, and the inability to resolve them, may aggravate impaired airway and alveolar repair.", [["distal lung", "ANATOMY", 48, 59], ["respiratory", "ANATOMY", 164, 175], ["airway", "ANATOMY", 279, 285], ["alveolar", "ANATOMY", 290, 298], ["impaired repair of the distal lung", "DISEASE", 25, 59], ["COPD", "DISEASE", 63, 67], ["respiratory diseaseThus", "DISEASE", 164, 187], ["viral and bacterial infections", "DISEASE", 189, 219], ["impaired airway and alveolar repair", "DISEASE", 270, 305], ["lung", "ORGAN", 55, 59], ["human", "ORGANISM", 97, 102], ["airway", "MULTI-TISSUE_STRUCTURE", 279, 285], ["alveolar", "MULTI-TISSUE_STRUCTURE", 290, 298], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["impaired repair", "TREATMENT", 25, 40], ["COPD", "PROBLEM", 63, 67], ["human disease", "PROBLEM", 97, 110], ["microbiome alterations", "PROBLEM", 138, 160], ["respiratory diseaseThus", "PROBLEM", 164, 187], ["viral and bacterial infections", "PROBLEM", 189, 219], ["aggravate impaired airway", "PROBLEM", 260, 285], ["alveolar repair", "TREATMENT", 290, 305], ["impaired", "OBSERVATION_MODIFIER", 25, 33], ["repair", "OBSERVATION", 34, 40], ["distal", "ANATOMY_MODIFIER", 48, 54], ["lung", "ANATOMY", 55, 59], ["COPD", "OBSERVATION", 63, 67], ["human disease", "OBSERVATION", 97, 110], ["respiratory diseaseThus", "OBSERVATION", 164, 187], ["bacterial", "OBSERVATION_MODIFIER", 199, 208], ["infections", "OBSERVATION", 209, 219], ["airway", "ANATOMY", 279, 285], ["alveolar repair", "OBSERVATION", 290, 305]]], ["Combined with a heightened airway and/or alveolar immune tone, aberrant repair mechanisms following pathogen exposures in vulnerable individuals might represent a mechanism for how host-microbiome interactions contribute to disease progression.", [["airway", "ANATOMY", 27, 33], ["alveolar", "ANATOMY", 41, 49], ["airway", "MULTI-TISSUE_STRUCTURE", 27, 33], ["alveolar", "MULTI-TISSUE_STRUCTURE", 41, 49], ["a heightened airway", "PROBLEM", 14, 33], ["alveolar immune tone", "PROBLEM", 41, 61], ["aberrant repair mechanisms", "TREATMENT", 63, 89], ["pathogen exposures in vulnerable individuals", "PROBLEM", 100, 144], ["disease progression", "PROBLEM", 224, 243], ["airway", "ANATOMY", 27, 33], ["alveolar", "ANATOMY", 41, 49], ["aberrant", "OBSERVATION_MODIFIER", 63, 71], ["repair", "OBSERVATION", 72, 78]]], ["It is currently unclear if alterations in the lung microbiome can also precede lung structural changes and inflammation and thereby contribute to onset of disease.Niche and microbiome alterations in respiratory diseaseAs discussed earlier, the relationship between lung dysbiosis and lung inflammation is bidirectional: disordered lung communities trigger epithelial and luminal inflammation, further altering growth conditions of the lung microenvironment, chronic inflammation and perpetuating dysbiosis [4, 36] .", [["lung", "ANATOMY", 46, 50], ["lung", "ANATOMY", 79, 83], ["respiratory", "ANATOMY", 199, 210], ["lung", "ANATOMY", 265, 269], ["lung", "ANATOMY", 284, 288], ["lung communities", "ANATOMY", 331, 347], ["epithelial", "ANATOMY", 356, 366], ["luminal", "ANATOMY", 371, 378], ["lung", "ANATOMY", 435, 439], ["inflammation", "DISEASE", 107, 119], ["respiratory disease", "DISEASE", 199, 218], ["lung dysbiosis", "DISEASE", 265, 279], ["lung inflammation", "DISEASE", 284, 301], ["luminal", "CHEMICAL", 371, 378], ["inflammation", "DISEASE", 379, 391], ["inflammation", "DISEASE", 466, 478], ["dysbiosis", "DISEASE", 496, 505], ["lung", "ORGAN", 46, 50], ["lung", "ORGAN", 79, 83], ["lung", "ORGAN", 265, 269], ["lung", "ORGAN", 284, 288], ["lung", "ORGAN", 331, 335], ["epithelial", "TISSUE", 356, 366], ["luminal", "IMMATERIAL_ANATOMICAL_ENTITY", 371, 378], ["lung", "ORGAN", 435, 439], ["alterations in the lung microbiome", "PROBLEM", 27, 61], ["lung structural changes", "PROBLEM", 79, 102], ["inflammation", "PROBLEM", 107, 119], ["disease", "PROBLEM", 155, 162], ["microbiome alterations", "PROBLEM", 173, 195], ["respiratory disease", "PROBLEM", 199, 218], ["lung dysbiosis", "PROBLEM", 265, 279], ["lung inflammation", "PROBLEM", 284, 301], ["epithelial and luminal inflammation", "PROBLEM", 356, 391], ["further altering growth conditions of the lung microenvironment", "PROBLEM", 393, 456], ["chronic inflammation", "PROBLEM", 458, 478], ["perpetuating dysbiosis", "PROBLEM", 483, 505], ["lung", "ANATOMY", 46, 50], ["lung", "ANATOMY", 79, 83], ["inflammation", "OBSERVATION", 107, 119], ["disease", "OBSERVATION", 155, 162], ["respiratory disease", "OBSERVATION", 199, 218], ["lung", "ANATOMY", 265, 269], ["dysbiosis", "OBSERVATION", 270, 279], ["lung", "ANATOMY", 284, 288], ["inflammation", "OBSERVATION", 289, 301], ["lung", "ANATOMY", 331, 335], ["epithelial", "ANATOMY_MODIFIER", 356, 366], ["luminal", "ANATOMY_MODIFIER", 371, 378], ["inflammation", "OBSERVATION", 379, 391], ["growth", "OBSERVATION_MODIFIER", 410, 416], ["lung", "ANATOMY", 435, 439], ["chronic", "OBSERVATION_MODIFIER", 458, 465], ["inflammation", "OBSERVATION", 466, 478]]], ["A common finding across inflammatory lung conditions is the outgrowth of the inflammation-associated Proteobacteria phylum [4] , and in mice the lung microbiome has been shown to be associated with pulmonary levels of the innate cytokine IL-1\u03b1 [7] .", [["lung", "ANATOMY", 37, 41], ["lung microbiome", "ANATOMY", 145, 160], ["pulmonary", "ANATOMY", 198, 207], ["inflammation", "DISEASE", 77, 89], ["lung", "ORGAN", 37, 41], ["mice", "ORGANISM", 136, 140], ["lung", "ORGAN", 145, 149], ["pulmonary", "ORGAN", 198, 207], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 238, 243], ["innate cytokine IL-1\u03b1", "PROTEIN", 222, 243], ["mice", "SPECIES", 136, 140], ["mice", "SPECIES", 136, 140], ["A common finding across inflammatory lung conditions", "PROBLEM", 0, 52], ["the inflammation", "PROBLEM", 73, 89], ["Proteobacteria phylum", "PROBLEM", 101, 122], ["pulmonary levels", "PROBLEM", 198, 214], ["the innate cytokine IL", "TREATMENT", 218, 240], ["inflammatory", "OBSERVATION_MODIFIER", 24, 36], ["lung", "ANATOMY", 37, 41], ["conditions", "OBSERVATION", 42, 52], ["outgrowth", "OBSERVATION_MODIFIER", 60, 69], ["inflammation", "OBSERVATION", 77, 89], ["Proteobacteria phylum", "OBSERVATION", 101, 122], ["lung", "ANATOMY", 145, 149], ["shown to be associated with", "UNCERTAINTY", 170, 197], ["pulmonary", "ANATOMY", 198, 207]]], ["Additionally, alterations in the microbiome of the gut might influence the immune tone of the lung, which is shown by the development of more severe experimental asthma in germ-free mice [31, 47] or mice with disturbed microbiomes due to early-life antibiotic treatment [100, 101] .", [["gut", "ANATOMY", 51, 54], ["lung", "ANATOMY", 94, 98], ["asthma", "DISEASE", 162, 168], ["gut", "ORGANISM_SUBDIVISION", 51, 54], ["lung", "ORGAN", 94, 98], ["mice", "ORGANISM", 182, 186], ["mice", "ORGANISM", 199, 203], ["mice", "SPECIES", 182, 186], ["mice", "SPECIES", 199, 203], ["mice", "SPECIES", 182, 186], ["mice", "SPECIES", 199, 203], ["more severe experimental asthma", "PROBLEM", 137, 168], ["disturbed microbiomes", "PROBLEM", 209, 230], ["early-life antibiotic treatment", "TREATMENT", 238, 269], ["lung", "ANATOMY", 94, 98], ["severe", "OBSERVATION_MODIFIER", 142, 148], ["experimental", "OBSERVATION_MODIFIER", 149, 161], ["asthma", "OBSERVATION", 162, 168]]], ["In contrast, the absence of microbiota in germ-free mice or due to antibiotic treatment has recently been shown to protect mice with Kras mutations and p53 loss from lung cancer development [102] .", [["lung cancer", "ANATOMY", 166, 177], ["lung cancer", "DISEASE", 166, 177], ["mice", "ORGANISM", 52, 56], ["mice", "ORGANISM", 123, 127], ["Kras", "GENE_OR_GENE_PRODUCT", 133, 137], ["p53", "GENE_OR_GENE_PRODUCT", 152, 155], ["lung cancer", "CANCER", 166, 177], ["Kras", "PROTEIN", 133, 137], ["p53", "PROTEIN", 152, 155], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 123, 127], ["antibiotic treatment", "TREATMENT", 67, 87], ["Kras mutations", "PROBLEM", 133, 147], ["p53 loss", "PROBLEM", 152, 160], ["lung cancer development", "PROBLEM", 166, 189], ["lung", "ANATOMY", 166, 170], ["cancer", "OBSERVATION", 171, 177]]], ["According to the authors, this effect was due to the induction of IL-1\u03b2 and IL-23 through the microbiota that led to IL-17 production by \u03b3\u03b4-T cells and tumorigenesis.Niche and microbiome alterations in respiratory diseaseIn humans, COPD patients are two to three times more likely to have Crohn's colitis, and 50% of people with inflammatory bowel disease also have pulmonary inflammation [103] [104] [105] [106] .", [["\u03b3\u03b4-T cells", "ANATOMY", 137, 147], ["bowel", "ANATOMY", 342, 347], ["pulmonary", "ANATOMY", 366, 375], ["respiratory diseaseIn", "DISEASE", 202, 223], ["COPD", "DISEASE", 232, 236], ["Crohn's colitis", "DISEASE", 289, 304], ["inflammatory bowel disease", "DISEASE", 329, 355], ["pulmonary inflammation", "DISEASE", 366, 388], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 66, 71], ["IL-23", "GENE_OR_GENE_PRODUCT", 76, 81], ["IL-17", "GENE_OR_GENE_PRODUCT", 117, 122], ["\u03b3\u03b4-T cells", "CELL", 137, 147], ["humans", "ORGANISM", 224, 230], ["patients", "ORGANISM", 237, 245], ["people", "ORGANISM", 317, 323], ["bowel", "ORGAN", 342, 347], ["pulmonary", "ORGAN", 366, 375], ["IL-1\u03b2", "PROTEIN", 66, 71], ["IL-23", "PROTEIN", 76, 81], ["\u03b3\u03b4-T cells", "CELL_TYPE", 137, 147], ["humans", "SPECIES", 224, 230], ["patients", "SPECIES", 237, 245], ["people", "SPECIES", 317, 323], ["humans", "SPECIES", 224, 230], ["the induction of IL", "TREATMENT", 49, 68], ["IL", "TREATMENT", 76, 78], ["IL", "TEST", 117, 119], ["tumorigenesis", "PROBLEM", 152, 165], ["microbiome alterations", "PROBLEM", 176, 198], ["respiratory diseaseIn humans", "PROBLEM", 202, 230], ["COPD", "PROBLEM", 232, 236], ["Crohn's colitis", "PROBLEM", 289, 304], ["inflammatory bowel disease", "PROBLEM", 329, 355], ["pulmonary inflammation", "PROBLEM", 366, 388], ["respiratory diseaseIn", "OBSERVATION", 202, 223], ["COPD", "OBSERVATION", 232, 236], ["Crohn", "OBSERVATION", 289, 294], ["colitis", "OBSERVATION", 297, 304], ["inflammatory", "OBSERVATION_MODIFIER", 329, 341], ["bowel", "ANATOMY", 342, 347], ["disease", "OBSERVATION", 348, 355], ["pulmonary", "ANATOMY", 366, 375], ["inflammation", "OBSERVATION", 376, 388]]], ["The gastrointestinal tract has by far the highest microbial content, and thus an interaction of gut microbiota and their metabolites with the gastric mucosa affects systemic immunity, which may in turn impact the lung [107] .", [["gastrointestinal tract", "ANATOMY", 4, 26], ["gut", "ANATOMY", 96, 99], ["gastric mucosa", "ANATOMY", 142, 156], ["lung", "ANATOMY", 213, 217], ["gastrointestinal tract", "ORGAN", 4, 26], ["gut", "ORGANISM_SUBDIVISION", 96, 99], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 142, 156], ["lung", "ORGAN", 213, 217], ["gastrointestinal tract", "ANATOMY", 4, 26], ["highest", "OBSERVATION_MODIFIER", 42, 49], ["microbial content", "OBSERVATION", 50, 67], ["gastric mucosa", "ANATOMY", 142, 156], ["systemic immunity", "OBSERVATION", 165, 182], ["lung", "ANATOMY", 213, 217]]], ["Consequently, alterations in gut microbiota and physiology might contribute to respiratory disease and vice versa, possibly via the gut-lung axis.", [["gut microbiota", "ANATOMY", 29, 43], ["respiratory", "ANATOMY", 79, 90], ["gut", "ANATOMY", 132, 135], ["lung", "ANATOMY", 136, 140], ["respiratory disease", "DISEASE", 79, 98], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 29, 43], ["gut", "ORGANISM_SUBDIVISION", 132, 135], ["lung", "ORGAN", 136, 140], ["respiratory disease and vice versa", "PROBLEM", 79, 113], ["respiratory disease", "OBSERVATION", 79, 98], ["gut", "ANATOMY", 132, 135], ["lung axis", "ANATOMY", 136, 145]]], ["However, it is important to note that germ-free breeding, and to some extent antibiotic treatment, will affect both the gut and the lung microbiome, so it is still not completely clear whether these effects can fully be explained by gut-lung cross-talk or if they are influenced by aberrant local microbiota-immune cross-talk.", [["germ", "ANATOMY", 38, 42], ["gut", "ANATOMY", 120, 123], ["lung microbiome", "ANATOMY", 132, 147], ["gut", "ANATOMY", 233, 236], ["lung", "ANATOMY", 237, 241], ["gut", "ORGANISM_SUBDIVISION", 120, 123], ["lung", "ORGAN", 132, 136], ["gut", "ORGANISM_SUBDIVISION", 233, 236], ["lung", "ORGAN", 237, 241], ["some extent antibiotic treatment", "TREATMENT", 65, 97], ["gut", "ANATOMY", 120, 123], ["lung", "ANATOMY", 132, 136], ["lung", "ANATOMY", 237, 241]]], ["Along this line, in mice the lung immune tone has been suggested to be more correlated to lung bacteria than gut bacteria [7] .Niche and microbiome alterations in respiratory diseaseIn contrast, in mice, colitis-induced pulmonary pathology was associated with increased inflammation and Gram-negative bacterial endotoxins in the lung, that probably emanate from the gut [104] .", [["lung", "ANATOMY", 29, 33], ["lung bacteria", "ANATOMY", 90, 103], ["respiratory", "ANATOMY", 163, 174], ["pulmonary", "ANATOMY", 220, 229], ["lung", "ANATOMY", 329, 333], ["gut", "ANATOMY", 366, 369], ["respiratory disease", "DISEASE", 163, 182], ["colitis", "DISEASE", 204, 211], ["inflammation", "DISEASE", 270, 282], ["mice", "ORGANISM", 20, 24], ["lung", "ORGAN", 29, 33], ["lung", "ORGAN", 90, 94], ["gut", "ORGANISM_SUBDIVISION", 109, 112], ["mice", "ORGANISM", 198, 202], ["colitis", "PATHOLOGICAL_FORMATION", 204, 211], ["pulmonary", "ORGAN", 220, 229], ["lung", "ORGAN", 329, 333], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 198, 202], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 198, 202], ["this line", "TREATMENT", 6, 15], ["lung bacteria", "PROBLEM", 90, 103], ["gut bacteria", "PROBLEM", 109, 121], ["microbiome alterations", "PROBLEM", 137, 159], ["respiratory disease", "PROBLEM", 163, 182], ["colitis", "PROBLEM", 204, 211], ["pulmonary pathology", "PROBLEM", 220, 239], ["increased inflammation", "PROBLEM", 260, 282], ["Gram", "TEST", 287, 291], ["negative bacterial endotoxins in the lung", "PROBLEM", 292, 333], ["line", "OBSERVATION", 11, 15], ["lung", "ANATOMY", 29, 33], ["immune tone", "OBSERVATION", 34, 45], ["lung", "ANATOMY", 90, 94], ["bacteria", "OBSERVATION", 95, 103], ["respiratory disease", "OBSERVATION", 163, 182], ["colitis", "OBSERVATION", 204, 211], ["pulmonary", "ANATOMY", 220, 229], ["pathology", "OBSERVATION", 230, 239], ["increased", "OBSERVATION_MODIFIER", 260, 269], ["inflammation", "OBSERVATION", 270, 282], ["negative bacterial", "OBSERVATION_MODIFIER", 292, 310], ["endotoxins", "OBSERVATION", 311, 321], ["lung", "ANATOMY", 329, 333], ["gut", "ANATOMY", 366, 369]]], ["Furthermore, cigarette smoke-induced experimental COPD models [108] [109] [110] indicate that reduced gas exchange and hypoxia in the lung is associated with hypoxia in the gut, causing colon remodelling, cell death, inflammation and impaired barrier function [111] .", [["lung", "ANATOMY", 134, 138], ["gut", "ANATOMY", 173, 176], ["colon", "ANATOMY", 186, 191], ["cell", "ANATOMY", 205, 209], ["barrier", "ANATOMY", 243, 250], ["smoke", "CHEMICAL", 23, 28], ["COPD", "DISEASE", 50, 54], ["hypoxia", "DISEASE", 119, 126], ["hypoxia", "DISEASE", 158, 165], ["death", "DISEASE", 210, 215], ["inflammation", "DISEASE", 217, 229], ["lung", "ORGAN", 134, 138], ["gut", "ORGANISM_SUBDIVISION", 173, 176], ["colon", "MULTI-TISSUE_STRUCTURE", 186, 191], ["cell", "CELL", 205, 209], ["experimental COPD models", "PROBLEM", 37, 61], ["reduced gas exchange", "PROBLEM", 94, 114], ["hypoxia in the lung", "PROBLEM", 119, 138], ["hypoxia in the gut", "PROBLEM", 158, 176], ["colon remodelling", "PROBLEM", 186, 203], ["cell death", "PROBLEM", 205, 215], ["inflammation", "PROBLEM", 217, 229], ["impaired barrier function", "PROBLEM", 234, 259], ["reduced", "OBSERVATION_MODIFIER", 94, 101], ["gas exchange", "OBSERVATION", 102, 114], ["hypoxia", "OBSERVATION", 119, 126], ["lung", "ANATOMY", 134, 138], ["hypoxia", "OBSERVATION", 158, 165], ["gut", "ANATOMY", 173, 176], ["colon", "ANATOMY", 186, 191], ["cell death", "OBSERVATION", 205, 215], ["inflammation", "OBSERVATION", 217, 229], ["impaired", "OBSERVATION_MODIFIER", 234, 242], ["barrier function", "OBSERVATION", 243, 259]]], ["Additionally, activation of NOD-like receptors by bacteria in the gut increase production of reactive oxygen species by alveolar macrophages, suggesting that the gastrointestinal microbiome contributes to oxidative stress in the lung [112] .", [["gut", "ANATOMY", 66, 69], ["alveolar macrophages", "ANATOMY", 120, 140], ["gastrointestinal", "ANATOMY", 162, 178], ["lung", "ANATOMY", 229, 233], ["oxygen", "CHEMICAL", 102, 108], ["oxygen", "CHEMICAL", 102, 108], ["NOD-like receptors", "GENE_OR_GENE_PRODUCT", 28, 46], ["gut", "ORGANISM_SUBDIVISION", 66, 69], ["reactive oxygen species", "SIMPLE_CHEMICAL", 93, 116], ["alveolar macrophages", "CELL", 120, 140], ["gastrointestinal", "ORGAN", 162, 178], ["lung", "ORGAN", 229, 233], ["NOD-like receptors", "PROTEIN", 28, 46], ["alveolar macrophages", "CELL_TYPE", 120, 140], ["NOD-like receptors", "PROBLEM", 28, 46], ["bacteria", "PROBLEM", 50, 58], ["reactive oxygen species", "PROBLEM", 93, 116], ["alveolar macrophages", "PROBLEM", 120, 140], ["the gastrointestinal microbiome", "PROBLEM", 158, 189], ["oxidative stress in the lung", "PROBLEM", 205, 233], ["gut", "ANATOMY", 66, 69], ["increase", "OBSERVATION_MODIFIER", 70, 78], ["production", "OBSERVATION_MODIFIER", 79, 89], ["reactive oxygen species", "OBSERVATION", 93, 116], ["alveolar macrophages", "OBSERVATION", 120, 140], ["gastrointestinal", "ANATOMY", 162, 178], ["oxidative stress", "OBSERVATION", 205, 221], ["lung", "ANATOMY", 229, 233]]], ["Conversely, oral application of beneficial probiotic bacteria (Bifidobacterium-and Lactobacillus-based) reduced airway inflammation and emphysema in cigarette smoke-exposed mice [113] .Niche and microbiome alterations in respiratory diseaseA large Canadian study reported that four bacterial genera Lachnospira, Veillonella, Faecalibacterium and Rothia were reduced in the faeces of human infants that subsequently developed asthma, and inoculating a human faecal microbiome supplemented with these four taxa into germ-free mice partially protected their F1 progeny from experimentally induced AAD [114] .", [["oral", "ANATOMY", 12, 16], ["airway", "ANATOMY", 112, 118], ["faeces", "ANATOMY", 373, 379], ["faecal microbiome", "ANATOMY", 457, 474], ["Bifidobacterium-and Lactobacillus", "CHEMICAL", 63, 96], ["airway inflammation", "DISEASE", 112, 131], ["emphysema", "DISEASE", 136, 145], ["smoke", "CHEMICAL", 159, 164], ["respiratory diseaseA", "DISEASE", 221, 241], ["Lachnospira", "CHEMICAL", 299, 310], ["asthma", "DISEASE", 425, 431], ["AAD", "DISEASE", 594, 597], ["oral", "ORGANISM_SUBDIVISION", 12, 16], ["Bifidobacterium", "SIMPLE_CHEMICAL", 63, 78], ["Lactobacillus", "SIMPLE_CHEMICAL", 83, 96], ["airway", "MULTI-TISSUE_STRUCTURE", 112, 118], ["cigarette", "ORGANISM_SUBDIVISION", 149, 158], ["mice", "ORGANISM", 173, 177], ["Veillonella", "SIMPLE_CHEMICAL", 312, 323], ["Faecalibacterium", "ORGANISM", 325, 341], ["Rothia", "GENE_OR_GENE_PRODUCT", 346, 352], ["faeces", "ORGANISM_SUBDIVISION", 373, 379], ["human", "ORGANISM", 383, 388], ["infants", "ORGANISM", 389, 396], ["human", "ORGANISM", 451, 456], ["faecal", "ORGANISM_SUBDIVISION", 457, 463], ["mice", "ORGANISM", 524, 528], ["F1 progeny", "CELL_LINE", 555, 565], ["mice", "SPECIES", 173, 177], ["human", "SPECIES", 383, 388], ["infants", "SPECIES", 389, 396], ["human", "SPECIES", 451, 456], ["mice", "SPECIES", 524, 528], ["human", "SPECIES", 383, 388], ["human", "SPECIES", 451, 456], ["mice", "SPECIES", 524, 528], ["beneficial probiotic bacteria", "PROBLEM", 32, 61], ["Bifidobacterium", "TEST", 63, 78], ["Lactobacillus", "TREATMENT", 83, 96], ["reduced airway inflammation", "PROBLEM", 104, 131], ["emphysema", "PROBLEM", 136, 145], ["microbiome alterations", "PROBLEM", 195, 217], ["Canadian study", "TEST", 248, 262], ["four bacterial genera Lachnospira", "TEST", 277, 310], ["Veillonella", "PROBLEM", 312, 323], ["Faecalibacterium", "PROBLEM", 325, 341], ["asthma", "PROBLEM", 425, 431], ["a human faecal microbiome", "TREATMENT", 449, 474], ["airway", "ANATOMY", 112, 118], ["inflammation", "OBSERVATION", 119, 131], ["emphysema", "OBSERVATION", 136, 145], ["asthma", "OBSERVATION", 425, 431]]], ["Thus, there are encouraging studies in mouse models highlighting cause and effect of the gut-lung axis in respiratory disease.", [["gut", "ANATOMY", 89, 92], ["lung", "ANATOMY", 93, 97], ["respiratory", "ANATOMY", 106, 117], ["respiratory disease", "DISEASE", 106, 125], ["mouse", "ORGANISM", 39, 44], ["gut", "ORGANISM_SUBDIVISION", 89, 92], ["lung", "ORGAN", 93, 97], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 39, 44], ["encouraging studies", "TEST", 16, 35], ["respiratory disease", "PROBLEM", 106, 125], ["lung", "ANATOMY", 93, 97], ["axis", "ANATOMY_MODIFIER", 98, 102], ["respiratory disease", "OBSERVATION", 106, 125]]], ["However, findings first need to be validated in humans before proposing this cross-talk as a treatable trait for respiratory disease.Niche and microbiome alterations in respiratory diseaseIn summary, at the host-microbiome interface, disordered communities are probably both cause and effects of host inflammation.", [["respiratory", "ANATOMY", 113, 124], ["respiratory", "ANATOMY", 169, 180], ["communities", "ANATOMY", 245, 256], ["respiratory disease", "DISEASE", 113, 132], ["respiratory disease", "DISEASE", 169, 188], ["inflammation", "DISEASE", 301, 313], ["humans", "ORGANISM", 48, 54], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 48, 54], ["a treatable trait", "PROBLEM", 91, 108], ["respiratory disease", "PROBLEM", 113, 132], ["microbiome alterations", "PROBLEM", 143, 165], ["respiratory disease", "PROBLEM", 169, 188], ["host inflammation", "PROBLEM", 296, 313], ["respiratory disease", "OBSERVATION", 113, 132], ["respiratory disease", "OBSERVATION", 169, 188], ["host", "OBSERVATION_MODIFIER", 296, 300], ["inflammation", "OBSERVATION", 301, 313]]], ["However, given the close reciprocal interactions between the microbiome and host at all times, it might be impossible to determine the real cause of the very first changes in disease development, as host and microbiome factors are coinciding and closely intertwined.Implications for the development of novel therapiesDue to the strong and dynamic interdependency between host and microbiome in local niches, it is unsurprising that most drugs used in clinical practice that were designed to target the host also affect the microbiome.", [["the very first changes in disease development", "PROBLEM", 149, 194], ["novel therapies", "TREATMENT", 302, 317], ["disease", "OBSERVATION", 175, 182]]], ["Accordingly, inhaled corticosteroids and proton pump inhibitors affect the lung microbiota [115] [116] [117] , as well as subsequent pneumonia risk [118, 119] .", [["lung", "ANATOMY", 75, 79], ["pneumonia", "DISEASE", 133, 142], ["corticosteroids", "CHEMICAL", 21, 36], ["lung", "ORGAN", 75, 79], ["inhaled corticosteroids", "TREATMENT", 13, 36], ["proton pump inhibitors", "TREATMENT", 41, 63], ["subsequent pneumonia risk", "PROBLEM", 122, 147], ["lung", "ANATOMY", 75, 79], ["pneumonia", "OBSERVATION", 133, 142]]], ["Macrolide antibiotics, broadly effective across chronic lung conditions such as COPD [120] , affect both lung microbiota and host immunity.", [["lung", "ANATOMY", 56, 60], ["lung", "ANATOMY", 105, 109], ["Macrolide", "CHEMICAL", 0, 9], ["COPD", "DISEASE", 80, 84], ["Macrolide", "CHEMICAL", 0, 9], ["Macrolide", "SIMPLE_CHEMICAL", 0, 9], ["lung", "ORGAN", 56, 60], ["lung", "ORGAN", 105, 109], ["Macrolide antibiotics", "TREATMENT", 0, 21], ["chronic lung conditions", "PROBLEM", 48, 71], ["COPD", "PROBLEM", 80, 84], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["lung", "ANATOMY", 56, 60], ["conditions", "OBSERVATION", 61, 71], ["COPD", "OBSERVATION", 80, 84], ["lung", "ANATOMY", 105, 109], ["host immunity", "OBSERVATION", 125, 138]]], ["Perhaps most provocatively, baseline differences in lung microbiota appear to predict patient responsiveness to therapies such as inhaled corticosteroids [10] , suggesting that variation in lung microbiota may represent an untapped phenotype of \"precision medicine\" in the lung.", [["lung", "ANATOMY", 52, 56], ["lung", "ANATOMY", 190, 194], ["lung", "ANATOMY", 273, 277], ["corticosteroids", "CHEMICAL", 138, 153], ["lung", "ORGAN", 52, 56], ["patient", "ORGANISM", 86, 93], ["lung", "ORGAN", 190, 194], ["lung", "ORGAN", 273, 277], ["patient", "SPECIES", 86, 93], ["baseline differences in lung microbiota", "PROBLEM", 28, 67], ["therapies", "TREATMENT", 112, 121], ["inhaled corticosteroids", "TREATMENT", 130, 153], ["variation in lung microbiota", "PROBLEM", 177, 205], ["lung", "ANATOMY", 52, 56], ["lung", "ANATOMY", 190, 194], ["lung", "ANATOMY", 273, 277]]], ["This opens new possibilities to exploit this important cross-talk in therapeutic interventions, but in order to do so, we first need to improve our understanding of the molecular mechanisms.Implications for the development of novel therapiesIncreasing evidence of the importance of the microbiome raises the concept of restoring \"diseased\" microbiomes to prevent or treat diseases using microbiota-directed therapies or host-targeted therapies, such as probiotics, metabolites, lung microbiota transplantation or vitamin D therapy, which we discuss here in more detail.Implications for the development of novel therapiesMany clinical studies have investigated the efficacy of probiotic bacteria, which are supposedly beneficial for the host, to prevent chronic diseases such as asthma or allergic rhinitis.", [["lung", "ANATOMY", 478, 482], ["vitamin D", "CHEMICAL", 513, 522], ["asthma", "DISEASE", 778, 784], ["allergic rhinitis", "DISEASE", 788, 805], ["vitamin D", "CHEMICAL", 513, 522], ["lung", "ORGAN", 478, 482], ["vitamin D", "SIMPLE_CHEMICAL", 513, 522], ["therapeutic interventions", "TREATMENT", 69, 94], ["novel therapies", "TREATMENT", 226, 241], ["restoring \"diseased\" microbiomes", "PROBLEM", 319, 351], ["treat diseases", "PROBLEM", 366, 380], ["microbiota-directed therapies", "TREATMENT", 387, 416], ["host-targeted therapies", "TREATMENT", 420, 443], ["probiotics", "TREATMENT", 453, 463], ["metabolites", "TREATMENT", 465, 476], ["lung microbiota transplantation", "TREATMENT", 478, 509], ["vitamin D therapy", "TREATMENT", 513, 530], ["novel therapies", "TREATMENT", 605, 620], ["Many clinical studies", "TEST", 620, 641], ["probiotic bacteria", "PROBLEM", 676, 694], ["chronic diseases", "PROBLEM", 753, 769], ["asthma", "PROBLEM", 778, 784], ["allergic rhinitis", "PROBLEM", 788, 805], ["lung", "ANATOMY", 478, 482], ["chronic", "OBSERVATION_MODIFIER", 753, 760], ["diseases", "OBSERVATION", 761, 769], ["asthma", "OBSERVATION", 778, 784], ["allergic rhinitis", "OBSERVATION", 788, 805]]], ["However, these studies have largely produced contradictory outcomes [121] , which might be due to the fact that the used probiotics were not selected based on potential mechanistic effects and may not be ideal.", [["these studies", "TEST", 9, 22], ["probiotics", "TREATMENT", 121, 131], ["may not be", "UNCERTAINTY", 193, 203]]], ["The microbiome is a complex ecosystem comprised of a variety of different inhabitants and influenced by many external (host-derived) factors; thus, the addition of single strains may not make a profound difference.", [["single strains", "PROBLEM", 164, 178], ["a profound difference", "PROBLEM", 192, 213], ["complex", "OBSERVATION_MODIFIER", 20, 27], ["ecosystem", "OBSERVATION", 28, 37], ["variety", "OBSERVATION_MODIFIER", 53, 60]]], ["Thus, the transfer of whole microbiomes via faecal microbiota transplantation (FMT) could be a more promising approach.", [["faecal microbiota", "ANATOMY", 44, 61], ["faecal microbiota", "MULTI-TISSUE_STRUCTURE", 44, 61], ["whole microbiomes via faecal microbiota transplantation", "TREATMENT", 22, 77]]], ["The introduction of healthy microbiota into diseased hosts has restored immunity and physiology [122] , demonstrating that intestinal microbiota and their products can modulate host immunity locally and systemically, and that FMT can replace disease-related microbiomes with healthy ones [40, 107] .", [["intestinal microbiota", "ANATOMY", 123, 144], ["FMT", "CHEMICAL", 226, 229], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 123, 144], ["FMT", "SIMPLE_CHEMICAL", 226, 229], ["disease", "PROBLEM", 242, 249], ["intestinal microbiota", "ANATOMY", 123, 144]]], ["FMT is remarkably (90%) successful in treating antibiotic-resistant Clostridium difficile-induced colitis [123] , and is now being used as treatment in selected patients [124, 125] .", [["FMT", "CHEMICAL", 0, 3], ["Clostridium difficile", "DISEASE", 68, 89], ["colitis", "DISEASE", 98, 105], ["FMT", "SIMPLE_CHEMICAL", 0, 3], ["Clostridium difficile", "ORGANISM", 68, 89], ["colitis", "PATHOLOGICAL_FORMATION", 98, 105], ["patients", "ORGANISM", 161, 169], ["Clostridium difficile", "SPECIES", 68, 89], ["patients", "SPECIES", 161, 169], ["Clostridium difficile", "SPECIES", 68, 89], ["antibiotic", "TREATMENT", 47, 57], ["resistant Clostridium difficile", "PROBLEM", 58, 89], ["induced colitis", "PROBLEM", 90, 105], ["Clostridium difficile", "OBSERVATION", 68, 89], ["colitis", "OBSERVATION", 98, 105]]], ["The new microbiome engrafts quickly and lasts for at least a month, indicating a potential difficulty in inducing long-term beneficial changes in the microbiome via only targeting the microbial side.", [["The new microbiome engrafts", "TREATMENT", 0, 27], ["new", "OBSERVATION_MODIFIER", 4, 7], ["long-term beneficial", "OBSERVATION_MODIFIER", 114, 134]]], ["While there are encouraging data, questions remain whether FMT may also affect lung health, and whether lung microbiota transplantation is feasible.", [["lung", "ANATOMY", 79, 83], ["lung", "ANATOMY", 104, 108], ["FMT", "SIMPLE_CHEMICAL", 59, 62], ["lung", "ORGAN", 79, 83], ["lung microbiota", "MULTI-TISSUE_STRUCTURE", 104, 119], ["lung microbiota transplantation", "TREATMENT", 104, 135], ["lung", "ANATOMY", 79, 83], ["lung", "ANATOMY", 104, 108], ["microbiota transplantation", "OBSERVATION", 109, 135]]], ["Furthermore, recently, severe complications of FMT have been reported due to transfer of drug-resistant bacteria [126] .", [["FMT", "CHEMICAL", 47, 50], ["severe complications of FMT", "PROBLEM", 23, 50], ["drug-resistant bacteria", "PROBLEM", 89, 112], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["complications", "OBSERVATION", 30, 43]]], ["Thus, it is essential to determine whether such approaches, that so far only transiently change the microbiome, can be used for the required long-term treatments of chronic (lung) diseases that coincide with a variety of structural changes, aberrant mucociliary clearance, and many more [40] .Implications for the development of novel therapiesAlong with living bacteria, specific microbial molecules such as lipopolysaccharide (LPS) and peptidoglycan can induce or modulate inflammatory responses [127] [128] [129] .", [["lung", "ANATOMY", 174, 178], ["mucociliary", "ANATOMY", 250, 261], ["chronic (lung) diseases", "DISEASE", 165, 188], ["lipopolysaccharide", "CHEMICAL", 409, 427], ["LPS", "CHEMICAL", 429, 432], ["peptidoglycan", "CHEMICAL", 438, 451], ["lung", "ORGAN", 174, 178], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 250, 261], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 409, 427], ["LPS", "SIMPLE_CHEMICAL", 429, 432], ["peptidoglycan", "SIMPLE_CHEMICAL", 438, 451], ["long-term treatments", "TREATMENT", 141, 161], ["chronic (lung) diseases", "PROBLEM", 165, 188], ["structural changes", "PROBLEM", 221, 239], ["aberrant mucociliary clearance", "PROBLEM", 241, 271], ["novel therapies", "TREATMENT", 329, 344], ["living bacteria", "PROBLEM", 355, 370], ["specific microbial molecules", "PROBLEM", 372, 400], ["lipopolysaccharide (LPS)", "TEST", 409, 433], ["peptidoglycan", "TEST", 438, 451], ["modulate inflammatory responses", "PROBLEM", 466, 497], ["long-term treatments", "OBSERVATION_MODIFIER", 141, 161], ["chronic", "OBSERVATION_MODIFIER", 165, 172], ["lung", "ANATOMY", 174, 178], ["mucociliary clearance", "OBSERVATION", 250, 271], ["inflammatory", "OBSERVATION_MODIFIER", 475, 487]]], ["In addition, culture supernatants of probiotic bacteria display anti-inflammatory effects, which have been ascribed to the presence of secreted immune-modulatory metabolites [130] .", [["supernatants", "ANATOMY", 21, 33], ["culture supernatants", "TEST", 13, 33], ["probiotic bacteria", "PROBLEM", 37, 55], ["anti-inflammatory effects", "PROBLEM", 64, 89], ["anti-inflammatory effects", "OBSERVATION", 64, 89]]], ["For example, culture supernatants of certain probiotic Bifidobacterium species decreased the secretion of type 2 cytokines from immune cell lines and the expression of costimulatory molecules on primary dendritic cells [131] .", [["supernatants", "ANATOMY", 21, 33], ["immune cell lines", "ANATOMY", 128, 145], ["primary dendritic cells", "ANATOMY", 195, 218], ["immune cell lines", "CELL", 128, 145], ["dendritic cells", "CELL", 203, 218], ["type 2 cytokines", "PROTEIN", 106, 122], ["immune cell lines", "CELL_LINE", 128, 145], ["costimulatory molecules", "PROTEIN", 168, 191], ["primary dendritic cells", "CELL_TYPE", 195, 218], ["culture supernatants", "TEST", 13, 33], ["Bifidobacterium species", "PROBLEM", 55, 78], ["type 2 cytokines", "PROBLEM", 106, 122], ["immune cell lines", "TREATMENT", 128, 145], ["primary dendritic cells", "PROBLEM", 195, 218], ["immune cell lines", "OBSERVATION", 128, 145], ["costimulatory molecules", "OBSERVATION", 168, 191], ["dendritic cells", "OBSERVATION", 203, 218]]], ["A likely mechanism is quorum sensing.", [["likely", "UNCERTAINTY", 2, 8], ["quorum sensing", "OBSERVATION", 22, 36]]], ["Quorum sensing is a means of communication among bacteria of the same species to coordinate effector functions such as biofilm formation, sporulation or toxin secretion.", [["biofilm", "ANATOMY", 119, 126], ["communication among bacteria", "PROBLEM", 29, 57], ["biofilm formation", "PROBLEM", 119, 136], ["toxin secretion", "PROBLEM", 153, 168]]], ["The best-described quorum sensing molecules are acyl homoserine lactones (AHLs) [132] .", [["acyl homoserine lactones", "CHEMICAL", 48, 72], ["AHLs", "CHEMICAL", 74, 78], ["acyl homoserine lactones", "CHEMICAL", 48, 72], ["AHLs", "CHEMICAL", 74, 78], ["acyl homoserine lactones", "SIMPLE_CHEMICAL", 48, 72], ["AHLs", "SIMPLE_CHEMICAL", 74, 78], ["acyl homoserine lactones", "TREATMENT", 48, 72]]], ["Several AHLs are targeted by the host to interfere with growth of pathogens [133] , and are in turn exploited by bacteria to regulate host gene expression for their benefit.", [["pathogens", "PROBLEM", 66, 75], ["bacteria", "PROBLEM", 113, 121], ["AHLs", "OBSERVATION", 8, 12]]], ["Some AHLs can bind to distinct bitter taste receptors expressed on the airway epithelium [134] and innate and adaptive immune cells [135, 136] , thereby modulating barrier and immune functions.", [["airway epithelium", "ANATOMY", 71, 88], ["immune cells", "ANATOMY", 119, 131], ["barrier", "ANATOMY", 164, 171], ["airway epithelium", "TISSUE", 71, 88], ["adaptive immune cells", "CELL", 110, 131], ["barrier", "TISSUE", 164, 171], ["bitter taste receptors", "PROTEIN", 31, 53], ["innate and adaptive immune cells", "CELL_TYPE", 99, 131], ["immune cells", "TEST", 119, 131], ["airway", "ANATOMY", 71, 77]]], ["The most-studied AHL, 3-O-C12-HSL, can activate phagocytes to increase phagocytosis, expression of adhesion receptors and chemotaxis [137, 138] , but is itself cleaved and inactivated by airway epithelial cells [133] .Implications for the development of novel therapiesAnother example of bacterial-derived modulators of the host's immune responses are outer membrane vesicles (OMVs) [139] .", [["phagocytes", "ANATOMY", 48, 58], ["airway epithelial cells", "ANATOMY", 187, 210], ["outer membrane vesicles", "ANATOMY", 352, 375], ["OMVs", "ANATOMY", 377, 381], ["3-O-C12", "CHEMICAL", 22, 29], ["3-O-C12-HSL", "CHEMICAL", 22, 33], ["AHL", "SIMPLE_CHEMICAL", 17, 20], ["3-O-C12-HSL", "SIMPLE_CHEMICAL", 22, 33], ["phagocytes", "CELL", 48, 58], ["airway epithelial cells", "CELL", 187, 210], ["outer membrane vesicles", "CELLULAR_COMPONENT", 352, 375], ["OMVs", "CELLULAR_COMPONENT", 377, 381], ["HSL", "PROTEIN", 30, 33], ["phagocytes", "CELL_TYPE", 48, 58], ["adhesion receptors", "PROTEIN", 99, 117], ["airway epithelial cells", "CELL_TYPE", 187, 210], ["The most-studied AHL", "TEST", 0, 20], ["adhesion receptors", "TEST", 99, 117], ["chemotaxis", "TEST", 122, 132], ["airway epithelial cells", "TEST", 187, 210], ["novel therapies", "TREATMENT", 254, 269], ["increase phagocytosis", "OBSERVATION", 62, 83], ["airway", "ANATOMY", 187, 193], ["epithelial cells", "OBSERVATION", 194, 210]]], ["OMVs are spherical bilayered membrane vesicles released from the surface of both Gram-negative and Gram-positive bacteria, and contain much of the biological material from the parent bacterium, but in a nonreplicative form [140, 141] .", [["OMVs", "ANATOMY", 0, 4], ["membrane vesicles", "ANATOMY", 29, 46], ["surface", "ANATOMY", 65, 72], ["OMVs", "ORGANISM_SUBSTANCE", 0, 4], ["membrane vesicles", "CELLULAR_COMPONENT", 29, 46], ["surface", "CELLULAR_COMPONENT", 65, 72], ["Gram-", "GENE_OR_GENE_PRODUCT", 81, 86], ["Gram-", "GENE_OR_GENE_PRODUCT", 99, 104], ["spherical bilayered membrane vesicles", "PROBLEM", 9, 46], ["Gram-positive bacteria", "PROBLEM", 99, 121], ["the parent bacterium", "PROBLEM", 172, 192], ["spherical", "OBSERVATION_MODIFIER", 9, 18], ["bilayered", "OBSERVATION_MODIFIER", 19, 28], ["membrane vesicles", "OBSERVATION", 29, 46], ["surface", "OBSERVATION_MODIFIER", 65, 72], ["both", "ANATOMY_MODIFIER", 76, 80], ["Gram-", "ANATOMY", 81, 86], ["negative", "OBSERVATION", 86, 94], ["Gram-positive bacteria", "OBSERVATION", 99, 121]]], ["Evidence suggests that the release of OMVs provides bacteria with competitive advantages when exposed to acute and chronic host-associated stressors [142] .", [["OMVs", "GENE_OR_GENE_PRODUCT", 38, 42], ["OMVs", "PROBLEM", 38, 42], ["bacteria", "PROBLEM", 52, 60], ["acute and chronic host-associated stressors", "PROBLEM", 105, 148], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["chronic", "OBSERVATION_MODIFIER", 115, 122]]], ["They may protect bacteria against innate and adaptive immune responses [143] [144] [145] , antimicrobial peptides and antibiotics [146, 147] .", [["bacteria", "PROBLEM", 17, 25], ["antimicrobial peptides", "TREATMENT", 91, 113], ["antibiotics", "TREATMENT", 118, 129]]], ["Moreover, OMVs contain factors (e.g. siderophores) aiding in the acquisition of nutrients in an environment devoid of crucial elements such as iron [147] .", [["OMVs", "ANATOMY", 10, 14], ["iron", "CHEMICAL", 143, 147], ["iron", "CHEMICAL", 143, 147], ["OMVs", "ORGANISM_SUBSTANCE", 10, 14], ["iron", "SIMPLE_CHEMICAL", 143, 147]]], ["Besides supporting the survival of the parent bacteria, OMVs may also play role in the progression of pulmonary diseases.", [["OMVs", "ANATOMY", 56, 60], ["pulmonary", "ANATOMY", 102, 111], ["pulmonary diseases", "DISEASE", 102, 120], ["OMVs", "ORGANISM_SUBSTANCE", 56, 60], ["pulmonary", "ORGAN", 102, 111], ["the parent bacteria", "PROBLEM", 35, 54], ["OMVs", "TREATMENT", 56, 60], ["pulmonary diseases", "PROBLEM", 102, 120], ["may also play", "UNCERTAINTY", 61, 74], ["progression", "OBSERVATION_MODIFIER", 87, 98], ["pulmonary", "ANATOMY", 102, 111], ["diseases", "OBSERVATION", 112, 120]]], ["Bacteria frequently associated with COPD exacerbations are known to release OMVs [148] .", [["COPD", "DISEASE", 36, 40], ["Bacteria", "PROBLEM", 0, 8], ["COPD exacerbations", "PROBLEM", 36, 54], ["COPD", "OBSERVATION", 36, 40]]], ["Furthermore, macrophages stimulated with OMVs derived from prominent airway pathogens such as P. aeruginosa, H. influenzae or M. catarrhalis release higher amounts of tumour necrosis factor-\u03b1 and IL-6 [148] .", [["macrophages", "ANATOMY", 13, 24], ["OMVs", "ANATOMY", 41, 45], ["airway", "ANATOMY", 69, 75], ["necrosis", "DISEASE", 174, 182], ["macrophages", "CELL", 13, 24], ["OMVs", "GENE_OR_GENE_PRODUCT", 41, 45], ["airway", "MULTI-TISSUE_STRUCTURE", 69, 75], ["P. aeruginosa", "ORGANISM", 94, 107], ["H. influenzae", "ORGANISM", 109, 122], ["M. catarrhalis", "ORGANISM", 126, 140], ["tumour necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 167, 191], ["IL-6", "GENE_OR_GENE_PRODUCT", 196, 200], ["macrophages", "CELL_TYPE", 13, 24], ["tumour necrosis factor-\u03b1", "PROTEIN", 167, 191], ["IL", "PROTEIN", 196, 198], ["P. aeruginosa", "SPECIES", 94, 107], ["H. influenzae", "SPECIES", 109, 122], ["M. catarrhalis", "SPECIES", 126, 140], ["P. aeruginosa", "SPECIES", 94, 107], ["H. influenzae", "SPECIES", 109, 122], ["M. catarrhalis", "SPECIES", 126, 140], ["OMVs", "TREATMENT", 41, 45], ["prominent airway pathogens", "PROBLEM", 59, 85], ["P. aeruginosa", "PROBLEM", 94, 107], ["H. influenzae", "PROBLEM", 109, 122], ["M. catarrhalis", "PROBLEM", 126, 140], ["tumour necrosis factor", "TEST", 167, 189], ["IL", "TEST", 196, 198], ["prominent", "OBSERVATION_MODIFIER", 59, 68], ["airway", "ANATOMY", 69, 75], ["tumour necrosis", "OBSERVATION", 167, 182]]], ["Legionella-derived OMVs significantly enhanced bacterial replication in macrophages [149] , and bacteria-free P. aeruginosa OMVs have been shown to potently induce pulmonary inflammation in mice [150] , strengthening the idea that OMVs exert disease-promoting activities.", [["OMVs", "ANATOMY", 19, 23], ["macrophages", "ANATOMY", 72, 83], ["OMVs", "ANATOMY", 124, 128], ["pulmonary", "ANATOMY", 164, 173], ["OMVs", "ANATOMY", 231, 235], ["pulmonary inflammation", "DISEASE", 164, 186], ["OMVs", "ORGANISM_SUBSTANCE", 19, 23], ["macrophages", "CELL", 72, 83], ["P. aeruginosa OMVs", "ORGANISM", 110, 128], ["pulmonary", "ORGAN", 164, 173], ["mice", "ORGANISM", 190, 194], ["OMVs", "ORGANISM_SUBSTANCE", 231, 235], ["macrophages", "CELL_TYPE", 72, 83], ["P. aeruginosa", "SPECIES", 110, 123], ["mice", "SPECIES", 190, 194], ["P. aeruginosa", "SPECIES", 110, 123], ["mice", "SPECIES", 190, 194], ["Legionella", "TEST", 0, 10], ["OMVs", "PROBLEM", 19, 23], ["bacterial replication in macrophages", "PROBLEM", 47, 83], ["bacteria", "PROBLEM", 96, 104], ["P. aeruginosa OMVs", "PROBLEM", 110, 128], ["pulmonary inflammation", "PROBLEM", 164, 186], ["bacterial replication", "OBSERVATION", 47, 68], ["pulmonary", "ANATOMY", 164, 173], ["inflammation", "OBSERVATION", 174, 186], ["disease", "OBSERVATION", 242, 249]]], ["In addition, OMVs have been shown to induce tolerance and hyporesponsiveness, thereby facilitating bacterial adherence to and internalisation by macrophages, which may contribute to clearance of the infection [149, 151] .", [["OMVs", "ANATOMY", 13, 17], ["macrophages", "ANATOMY", 145, 156], ["infection", "DISEASE", 199, 208], ["OMVs", "ORGANISM_SUBSTANCE", 13, 17], ["macrophages", "CELL", 145, 156], ["macrophages", "CELL_TYPE", 145, 156], ["OMVs", "TREATMENT", 13, 17], ["hyporesponsiveness", "PROBLEM", 58, 76], ["the infection", "PROBLEM", 195, 208], ["bacterial adherence", "OBSERVATION", 99, 118], ["macrophages", "OBSERVATION", 145, 156], ["infection", "OBSERVATION", 199, 208]]], ["Thus, despite our increasing knowledge on OMVs and their potential role in interkingdom communication, there is a need for further research to better understand their pathogenic properties and possible therapeutic or prophylactic implications (e.g. novel vaccines).Implications for the development of novel therapiesAn interesting alternative to FMT or probiotic bacteria might be to use immune-modulatory microbial metabolites or \"beneficial\" OMVs.", [["OMVs", "ANATOMY", 42, 46], ["OMVs", "ANATOMY", 444, 448], ["FMT", "CHEMICAL", 346, 349], ["OMVs", "ORGANISM_SUBSTANCE", 42, 46], ["FMT", "SIMPLE_CHEMICAL", 346, 349], ["OMVs", "ORGANISM_SUBSTANCE", 444, 448], ["prophylactic implications (e.g. novel vaccines", "TREATMENT", 217, 263], ["novel therapies", "TREATMENT", 301, 316], ["probiotic bacteria", "PROBLEM", 353, 371]]], ["Such chemically defined bacterial substances could be produced at large scale under controlled conditions, applied in defined (effective) doses both systemically or locally, and may have fewer adverse side-effects, i.e. in immunocompromised patients, compared to live bacteria [152] .", [["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["Such chemically defined bacterial substances", "PROBLEM", 0, 44], ["fewer adverse side-effects", "PROBLEM", 187, 213], ["bacterial substances", "OBSERVATION", 24, 44]]], ["Several studies have already used defined bacterial metabolites to treat AAD in mice.", [["AAD", "DISEASE", 73, 76], ["mice", "ORGANISM", 80, 84], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["Several studies", "TEST", 0, 15], ["bacterial metabolites", "PROBLEM", 42, 63], ["AAD", "PROBLEM", 73, 76]]], ["LPS from Escherichia coli O111 [153] , bacterial polysaccharide A [154] , oligodeoxynucleotides with bacterial CpG motifs [155] , flagellin B [156] , short-chain fatty acids [47] , D-tryptophan [157] and the neutrophil-activating protein from Helicobacter pylori [158] all suppressed airway eosinophilia and type 2 T-helper cell-mediated immune responses in murine models of AAD.", [["airway", "ANATOMY", 284, 290], ["cell", "ANATOMY", 324, 328], ["LPS", "CHEMICAL", 0, 3], ["fatty acids", "CHEMICAL", 162, 173], ["D-tryptophan", "CHEMICAL", 181, 193], ["eosinophilia", "DISEASE", 291, 303], ["AAD", "DISEASE", 375, 378], ["CpG", "CHEMICAL", 111, 114], ["fatty acids", "CHEMICAL", 162, 173], ["D-tryptophan", "CHEMICAL", 181, 193], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["Escherichia coli", "ORGANISM", 9, 25], ["O111", "ORGANISM", 26, 30], ["bacterial polysaccharide A", "SIMPLE_CHEMICAL", 39, 65], ["flagellin B", "GENE_OR_GENE_PRODUCT", 130, 141], ["short-chain fatty acids", "SIMPLE_CHEMICAL", 150, 173], ["D-tryptophan [157]", "SIMPLE_CHEMICAL", 181, 199], ["neutrophil", "CELL", 208, 218], ["Helicobacter pylori", "ORGANISM", 243, 262], ["airway", "MULTI-TISSUE_STRUCTURE", 284, 290], ["T-helper cell", "CELL", 315, 328], ["murine", "ORGANISM", 358, 364], ["bacterial CpG motifs", "DNA", 101, 121], ["neutrophil-activating protein", "PROTEIN", 208, 237], ["Escherichia coli", "SPECIES", 9, 25], ["Helicobacter pylori", "SPECIES", 243, 262], ["murine", "SPECIES", 358, 364], ["Escherichia coli", "SPECIES", 9, 25], ["Helicobacter pylori", "SPECIES", 243, 262], ["LPS", "TEST", 0, 3], ["Escherichia coli O111", "TEST", 9, 30], ["bacterial polysaccharide A", "TEST", 39, 65], ["oligodeoxynucleotides with bacterial CpG motifs", "TREATMENT", 74, 121], ["flagellin B", "TEST", 130, 141], ["short-chain fatty acids", "TEST", 150, 173], ["D-tryptophan", "TEST", 181, 193], ["the neutrophil", "TEST", 204, 218], ["activating protein", "TEST", 219, 237], ["Helicobacter pylori", "TEST", 243, 262], ["all suppressed airway eosinophilia", "PROBLEM", 269, 303], ["type", "TEST", 308, 312], ["AAD", "PROBLEM", 375, 378], ["airway", "ANATOMY", 284, 290], ["eosinophilia", "OBSERVATION", 291, 303], ["AAD", "OBSERVATION", 375, 378]]], ["Likewise, several molecules from the parasite helminths have now been identified, among which excretory-secretory (ES)-62 and cystatin (AvCystatin) from Acanthocheilonema vitae, TGF-\u03b2 mimic (TGM) and Heligmosomoides polygyrus alarmin release inhibitor (HpARI) from H. polygyrus and IL-4-inducing principle from schistosome eggs (IPSE) are the most promising, with effects in allergic asthma models [159] [160] [161] [162] [163] .Implications for the development of novel therapiesNevertheless, there are significant limitations concerning the use of bacterial or parasite metabolites for therapeutic or preventative approaches.", [["eggs", "ANATOMY", 323, 327], ["allergic asthma", "DISEASE", 375, 390], ["parasite helminths", "ORGANISM", 37, 55], ["excretory-secretory (ES)-62", "GENE_OR_GENE_PRODUCT", 94, 121], ["cystatin", "GENE_OR_GENE_PRODUCT", 126, 134], ["AvCystatin", "GENE_OR_GENE_PRODUCT", 136, 146], ["Acanthocheilonema vitae", "ORGANISM", 153, 176], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 178, 183], ["Heligmosomoides polygyrus", "ORGANISM", 200, 225], ["alarmin", "GENE_OR_GENE_PRODUCT", 226, 233], ["HpARI", "GENE_OR_GENE_PRODUCT", 253, 258], ["H. polygyrus", "ORGANISM", 265, 277], ["IL-4", "GENE_OR_GENE_PRODUCT", 282, 286], ["schistosome", "ORGANISM", 311, 322], ["cystatin", "PROTEIN", 126, 134], ["AvCystatin", "PROTEIN", 136, 146], ["TGF-\u03b2", "PROTEIN", 178, 183], ["Acanthocheilonema vitae", "SPECIES", 153, 176], ["Heligmosomoides polygyrus", "SPECIES", 200, 225], ["H. polygyrus", "SPECIES", 265, 277], ["Acanthocheilonema vitae", "SPECIES", 153, 176], ["Heligmosomoides polygyrus", "SPECIES", 200, 225], ["H. polygyrus", "SPECIES", 265, 277], ["the parasite helminths", "PROBLEM", 33, 55], ["cystatin", "TEST", 126, 134], ["AvCystatin", "TEST", 136, 146], ["Acanthocheilonema", "TEST", 153, 170], ["vitae", "TEST", 171, 176], ["TGF", "TEST", 178, 181], ["Heligmosomoides polygyrus alarmin release inhibitor", "TREATMENT", 200, 251], ["H. polygyrus and IL", "TREATMENT", 265, 284], ["schistosome eggs", "PROBLEM", 311, 327], ["allergic asthma models", "PROBLEM", 375, 397], ["novel therapies", "TREATMENT", 465, 480], ["bacterial or parasite metabolites", "PROBLEM", 550, 583], ["preventative approaches", "TREATMENT", 603, 626], ["several", "OBSERVATION_MODIFIER", 10, 17], ["molecules", "OBSERVATION", 18, 27], ["parasite", "OBSERVATION_MODIFIER", 37, 45], ["helminths", "OBSERVATION", 46, 55]]], ["These molecules have a very narrow window of beneficial and therapeutic doses, which might be difficult to control in local tissues.", [["tissues", "ANATOMY", 124, 131], ["tissues", "TISSUE", 124, 131], ["therapeutic doses", "TREATMENT", 60, 77], ["very", "OBSERVATION_MODIFIER", 23, 27], ["narrow window", "OBSERVATION_MODIFIER", 28, 41], ["local tissues", "ANATOMY", 118, 131]]], ["Furthermore, the detailed mechanisms of action remain largely unknown, hampering translation to human studies.", [["human", "ORGANISM", 96, 101], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["human studies", "TEST", 96, 109]]], ["And finally, single metabolites, just as single bacterial strains, might not be sufficiently effective to treat or prevent complex chronic diseases with highly aberrant gut and lung microenvironments.", [["gut", "ANATOMY", 169, 172], ["lung", "ANATOMY", 177, 181], ["gut", "ORGANISM_SUBDIVISION", 169, 172], ["lung", "ORGAN", 177, 181], ["single bacterial strains", "PROBLEM", 41, 65], ["complex chronic diseases", "PROBLEM", 123, 147], ["highly aberrant gut and lung microenvironments", "PROBLEM", 153, 199], ["chronic", "OBSERVATION_MODIFIER", 131, 138], ["diseases", "OBSERVATION", 139, 147], ["lung", "ANATOMY", 177, 181]]], ["Thus, further studies are urgently needed to determine the mode of action, but also the efficacy of single or combined metabolites to develop novel metabolite-based treatment options.Implications for the development of novel therapiesCombining host and microbiome targeted therapeutic approaches While microbiome-based therapies are intriguing, it is important to restore the ecological niche in the lung.", [["lung", "ANATOMY", 400, 404], ["lung", "ORGAN", 400, 404], ["further studies", "TEST", 6, 21], ["novel metabolite", "TREATMENT", 142, 158], ["based treatment options", "TREATMENT", 159, 182], ["novel therapies", "TREATMENT", 219, 234], ["microbiome targeted therapeutic approaches", "TREATMENT", 253, 295], ["therapies", "TREATMENT", 319, 328], ["ecological niche", "OBSERVATION", 376, 392], ["lung", "ANATOMY", 400, 404]]], ["A diseased lung forms a completely different habitat for microbes favouring a different microbial flora.", [["lung", "ANATOMY", 11, 15], ["lung", "ORGAN", 11, 15], ["A diseased lung forms", "PROBLEM", 0, 21], ["a different microbial flora", "PROBLEM", 76, 103], ["diseased", "OBSERVATION", 2, 10], ["lung", "ANATOMY", 11, 15], ["microbial flora", "OBSERVATION", 88, 103]]], ["In cystic fibrosis and bronchiectasis Haemophilus and Pseudomonas spp. increasingly dominate the lung microbiota, while specific antibiotic treatment further promotes their outgrowth [89, 90] .", [["cystic", "ANATOMY", 3, 9], ["lung", "ANATOMY", 97, 101], ["cystic fibrosis", "DISEASE", 3, 18], ["bronchiectasis Haemophilus and Pseudomonas spp", "DISEASE", 23, 69], ["Pseudomonas spp", "ORGANISM", 54, 69], ["lung", "ORGAN", 97, 101], ["Pseudomonas spp", "SPECIES", 54, 69], ["cystic fibrosis", "PROBLEM", 3, 18], ["bronchiectasis Haemophilus", "PROBLEM", 23, 49], ["Pseudomonas spp", "PROBLEM", 54, 69], ["increasingly dominate the lung microbiota", "PROBLEM", 71, 112], ["specific antibiotic treatment", "TREATMENT", 120, 149], ["cystic", "OBSERVATION_MODIFIER", 3, 9], ["fibrosis", "OBSERVATION", 10, 18], ["bronchiectasis", "OBSERVATION", 23, 37], ["Pseudomonas", "OBSERVATION_MODIFIER", 54, 65], ["spp", "OBSERVATION_MODIFIER", 66, 69], ["lung", "ANATOMY", 97, 101], ["microbiota", "OBSERVATION", 102, 112]]], ["This could be a consequence of reduced competition from commensals being destroyed by the antibiotics, or the persistent aberrant ecological niche in cystic fibrosis lungs.", [["cystic fibrosis lungs", "ANATOMY", 150, 171], ["fibrosis", "DISEASE", 157, 165], ["lungs", "ORGAN", 166, 171], ["reduced competition", "PROBLEM", 31, 50], ["the antibiotics", "TREATMENT", 86, 101], ["cystic fibrosis lungs", "PROBLEM", 150, 171], ["reduced", "OBSERVATION_MODIFIER", 31, 38], ["persistent", "OBSERVATION_MODIFIER", 110, 120], ["aberrant", "OBSERVATION_MODIFIER", 121, 129], ["ecological", "OBSERVATION_MODIFIER", 130, 140], ["niche", "OBSERVATION_MODIFIER", 141, 146], ["cystic", "OBSERVATION_MODIFIER", 150, 156], ["fibrosis", "OBSERVATION", 157, 165], ["lungs", "ANATOMY", 166, 171]]], ["Supporting the latter, a recent study showed that the use of ivacaftor to increase CFTR function in patients with the G511D mutation, thereby partially restoring mucociliary clearance, rapidly decreased P. aeruginosa burden in sputum of patients [164] .", [["mucociliary", "ANATOMY", 162, 173], ["sputum", "ANATOMY", 227, 233], ["ivacaftor", "CHEMICAL", 61, 70], ["decreased P. aeruginosa burden", "DISEASE", 193, 223], ["ivacaftor", "CHEMICAL", 61, 70], ["ivacaftor", "SIMPLE_CHEMICAL", 61, 70], ["CFTR", "GENE_OR_GENE_PRODUCT", 83, 87], ["patients", "ORGANISM", 100, 108], ["G511D", "GENE_OR_GENE_PRODUCT", 118, 123], ["mucociliary", "ORGAN", 162, 173], ["P. aeruginosa", "ORGANISM", 203, 216], ["sputum", "ORGANISM_SUBSTANCE", 227, 233], ["patients", "ORGANISM", 237, 245], ["CFTR", "PROTEIN", 83, 87], ["patients", "SPECIES", 100, 108], ["P. aeruginosa", "SPECIES", 203, 216], ["patients", "SPECIES", 237, 245], ["P. aeruginosa", "SPECIES", 203, 216], ["a recent study", "TEST", 23, 37], ["ivacaftor", "TREATMENT", 61, 70], ["CFTR function", "PROBLEM", 83, 96], ["the G511D mutation", "PROBLEM", 114, 132], ["partially restoring mucociliary clearance", "PROBLEM", 142, 183], ["rapidly decreased P. aeruginosa burden in sputum", "PROBLEM", 185, 233], ["aeruginosa", "OBSERVATION_MODIFIER", 206, 216]]], ["However, P. aeruginosa was not eradicated, and outgrowth of P. aeruginosa was observed after 1 year of treatment, which might be due to incomplete restoration of the niche [164] .Implications for the development of novel therapiesThus, it seems inevitable that in order to restore the shifted host-microbe balance in chronic lung diseases, it is necessary to restore epithelial barrier and repair function.", [["lung", "ANATOMY", 325, 329], ["epithelial barrier", "ANATOMY", 367, 385], ["chronic lung diseases", "DISEASE", 317, 338], ["P. aeruginosa", "ORGANISM", 9, 22], ["P. aeruginosa", "ORGANISM", 60, 73], ["lung", "ORGAN", 325, 329], ["epithelial barrier", "TISSUE", 367, 385], ["P. aeruginosa", "SPECIES", 9, 22], ["P. aeruginosa", "SPECIES", 60, 73], ["P. aeruginosa", "SPECIES", 9, 22], ["P. aeruginosa", "SPECIES", 60, 73], ["P. aeruginosa", "PROBLEM", 9, 22], ["P. aeruginosa", "PROBLEM", 60, 73], ["treatment", "TREATMENT", 103, 112], ["novel therapies", "TREATMENT", 215, 230], ["chronic lung diseases", "PROBLEM", 317, 338], ["epithelial barrier", "TREATMENT", 367, 385], ["repair function", "TREATMENT", 390, 405], ["chronic", "OBSERVATION_MODIFIER", 317, 324], ["lung", "ANATOMY", 325, 329], ["diseases", "OBSERVATION", 330, 338], ["repair function", "OBSERVATION", 390, 405]]], ["Failure to achieve this may result in recurrence of microbial dysbiosis.", [["microbial dysbiosis", "DISEASE", 52, 71], ["Failure", "PROBLEM", 0, 7], ["microbial dysbiosis", "PROBLEM", 52, 71], ["microbial dysbiosis", "OBSERVATION", 52, 71]]], ["Restoration of epithelial cell function could be achieved by inducing expression of antimicrobial peptides through vitamin D treatment (which also has anti-inflammatory effects) or by restoring the barrier and antiviral immunity by farm-dust treatment [27].Conclusions and knowledge gapsThere is substantial evidence for the functional involvement of the microbiome in chronic respiratory diseases, making it an interesting target for future therapies (figure 2).", [["epithelial cell", "ANATOMY", 15, 30], ["respiratory", "ANATOMY", 377, 388], ["vitamin D", "CHEMICAL", 115, 124], ["respiratory diseases", "DISEASE", 377, 397], ["vitamin D", "CHEMICAL", 115, 124], ["epithelial cell", "CELL", 15, 30], ["vitamin D", "SIMPLE_CHEMICAL", 115, 124], ["epithelial cell function", "PROBLEM", 15, 39], ["antimicrobial peptides", "TREATMENT", 84, 106], ["vitamin D treatment", "TREATMENT", 115, 134], ["anti-inflammatory effects", "TREATMENT", 151, 176], ["the barrier", "TREATMENT", 194, 205], ["antiviral immunity", "TREATMENT", 210, 228], ["knowledge gaps", "TEST", 273, 287], ["chronic respiratory diseases", "PROBLEM", 369, 397], ["future therapies", "TREATMENT", 435, 451], ["epithelial cell function", "OBSERVATION", 15, 39], ["substantial evidence for", "UNCERTAINTY", 296, 320], ["microbiome", "OBSERVATION_MODIFIER", 355, 365], ["chronic", "OBSERVATION_MODIFIER", 369, 376], ["respiratory diseases", "OBSERVATION", 377, 397]]], ["Targeting the microbiome via FMTDiagnosisBacterial/parasitic metabolites Outer membrane vesicles Whole microbiomes for patient subphenotypingDisease mechanismsWhole microbiome profiles Bacterial/parasitic metabolites Outer membrane vesiclesPreventionBacterial/parasitic metabolites Specific (probiotic) strains Exploiting host-microbiome cross-talk in chronic respiratory disease Therapy Microbiome transplanation Bacterial/parasitic metabolites FIGURE 2 Opportunities for exploiting the host-microbiome cross-talk in chronic respiratory disease.", [["Outer membrane vesicles", "ANATOMY", 73, 96], ["Outer membrane vesicles", "ANATOMY", 217, 240], ["respiratory", "ANATOMY", 526, 537], ["chronic respiratory disease", "DISEASE", 352, 379], ["chronic respiratory disease", "DISEASE", 518, 545], ["FMTDiagnosisBacterial", "SIMPLE_CHEMICAL", 29, 50], ["Outer membrane vesicles", "CELLULAR_COMPONENT", 73, 96], ["patient", "ORGANISM", 119, 126], ["membrane vesicles", "CELLULAR_COMPONENT", 223, 240], ["patient", "SPECIES", 119, 126], ["the microbiome", "TEST", 10, 24], ["parasitic metabolites Outer membrane vesicles", "PROBLEM", 51, 96], ["patient subphenotyping", "TEST", 119, 141], ["Disease mechanisms", "PROBLEM", 141, 159], ["Whole microbiome profiles", "TEST", 159, 184], ["Bacterial/parasitic metabolites Outer membrane vesicles", "PROBLEM", 185, 240], ["PreventionBacterial/parasitic metabolites", "PROBLEM", 240, 281], ["Specific (probiotic) strains", "TREATMENT", 282, 310], ["chronic respiratory disease Therapy", "TREATMENT", 352, 387], ["Bacterial/parasitic metabolites", "PROBLEM", 414, 445], ["chronic respiratory disease", "PROBLEM", 518, 545], ["parasitic metabolites", "OBSERVATION", 51, 72], ["Outer", "ANATOMY_MODIFIER", 73, 78], ["membrane vesicles", "ANATOMY", 79, 96], ["parasitic metabolites", "OBSERVATION", 195, 216], ["Outer", "ANATOMY_MODIFIER", 217, 222], ["membrane vesicles", "OBSERVATION", 223, 240], ["parasitic metabolites", "OBSERVATION", 260, 281], ["chronic", "OBSERVATION_MODIFIER", 352, 359], ["respiratory disease", "OBSERVATION", 360, 379], ["chronic", "OBSERVATION_MODIFIER", 518, 525], ["respiratory disease", "OBSERVATION", 526, 545]]], ["The complexity of the host-microbe cross-talk in the lung microenvironment should be taken into account when studying chronic lung diseases.", [["lung", "ANATOMY", 53, 57], ["lung", "ANATOMY", 126, 130], ["chronic lung diseases", "DISEASE", 118, 139], ["lung", "ORGAN", 53, 57], ["lung", "ORGAN", 126, 130], ["chronic lung diseases", "PROBLEM", 118, 139], ["complexity", "OBSERVATION_MODIFIER", 4, 14], ["lung", "ANATOMY", 53, 57], ["chronic", "OBSERVATION_MODIFIER", 118, 125], ["lung", "ANATOMY", 126, 130], ["diseases", "OBSERVATION", 131, 139]]], ["Understanding the detailed mechanisms of this cross-talk could potentially lead to the development of novel therapies, preventative strategies or superior diagnostic tools to differentiate subphenotypes of patients.Preventionhttps://doi.org/10.1183/13993003.02320-2019 seems encouraging; however, there remains an urgent need to better understand the complex hostmicrobiome cross-talk.", [["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["novel therapies", "TREATMENT", 102, 117], ["preventative strategies", "TREATMENT", 119, 142], ["superior diagnostic tools", "TEST", 146, 171]]], ["There is still little information regarding the cause-and-effect relationship between the airway microbiota and disease onset/progression, except for some initial hints.", [["airway", "ANATOMY", 90, 96], ["airway microbiota", "MULTI-TISSUE_STRUCTURE", 90, 107], ["the airway microbiota", "PROBLEM", 86, 107], ["disease onset/progression", "PROBLEM", 112, 137], ["airway", "ANATOMY", 90, 96]]], ["Host genetics, transcriptomics and metabolomics will help resolve these issues, and provide new paradigms of how this contributes to disease severity and exacerbations.", [["metabolomics", "TREATMENT", 35, 47], ["disease severity", "PROBLEM", 133, 149], ["exacerbations", "PROBLEM", 154, 167]]], ["While existing treatments affect the microbiome, possibly influencing their effectiveness, the safety, optimal time point and dose of effective interventions based on whole microbiomes, metabolites or combinations thereof need to be elucidated in (longitudinal) multicentre trials.", [["effective interventions", "TREATMENT", 134, 157], ["whole microbiomes", "TREATMENT", 167, 184]]], ["Furthermore, the microbiome could be a good indicator of patient subphenotypes and therapy responses, which should be further investigated in clinical samples, advanced disease-relevant culture models, and representative in vivo in animal models (figure 2).", [["samples", "ANATOMY", 151, 158], ["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["therapy responses", "TREATMENT", 83, 100], ["advanced disease", "PROBLEM", 160, 176], ["relevant culture models", "TEST", 177, 200]]]], "PMC7114516": [["IntroductionSevere acute respiratory syndrome (SARS), a disease that first occurred in November 2002 in Guangdong Province of China (Xu et al., 2004a, Xu et al., 2004b), has spread to 28 regions around the world in 2003 causing 774 deaths in 8096 infected individuals (WHO, 2004).", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["deaths", "DISEASE", 232, 238], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["a disease", "PROBLEM", 54, 63], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["A novel coronavirus, SARS-CoV, was identified as the etiological agent of the disease (Drosten et al., 2003, Ksiazek et al., 2003, Peiris et al., 2003) and phylogenetic analysis indicated that the virus was different from previously known coronaviruses (Marra et al., 2003, Rota et al., 2003).", [["coronavirus", "ORGANISM", 8, 19], ["SARS-CoV", "ORGANISM", 21, 29], ["coronaviruses", "ORGANISM", 239, 252], ["coronavirus", "SPECIES", 8, 19], ["SARS-CoV", "SPECIES", 21, 29], ["A novel coronavirus", "PROBLEM", 0, 19], ["SARS-CoV", "PROBLEM", 21, 29], ["the disease", "PROBLEM", 74, 85], ["phylogenetic analysis", "TEST", 156, 177], ["the virus", "PROBLEM", 193, 202], ["coronavirus", "OBSERVATION", 8, 19], ["disease", "OBSERVATION", 78, 85], ["virus", "OBSERVATION", 197, 202]]], ["Although the identification of the etiological agent and molecular studies on the SARS-CoV proceeded rather rapidly, the puzzle on the origin of the disease was still not fully resolved.", [["SARS", "DISEASE", 82, 86], ["SARS-CoV", "ORGANISM", 82, 90], ["SARS-CoV", "SPECIES", 82, 90], ["molecular studies", "TEST", 57, 74], ["the disease", "PROBLEM", 145, 156], ["disease", "OBSERVATION", 149, 156], ["resolved", "OBSERVATION", 177, 185]]], ["From the very beginning, data suggested that SARS was originated from animals.", [["SARS", "DISEASE", 45, 49], ["SARS", "PROBLEM", 45, 49], ["SARS", "OBSERVATION", 45, 49]]], ["For examples: (1) Animal food handlers who handle, kill, or butcher \u201cexotic\u201d animals for food were over represented among early-onset SARS cases (Xu et al., 2004a, Xu et al., 2004b, Zhong et al., 2003).", [["SARS", "DISEASE", 134, 138]]], ["(2) Serological studies of traders from several selected animal markets in Guangzhou, Guangdong Province in 2003 indicated that the animal traders had significantly higher prevalence of IgG antibodies against the SARS-CoV than vegetable traders or control groups (Xu et al., 2004a, Xu et al., 2004b, CDC, 2003).", [["SARS", "DISEASE", 213, 217], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 186, 200], ["SARS-CoV", "ORGANISM", 213, 221], ["vegetable", "ORGANISM", 227, 236], ["IgG antibodies", "PROTEIN", 186, 200], ["SARS-CoV", "SPECIES", 213, 221], ["Serological studies", "TEST", 4, 23], ["IgG antibodies", "TEST", 186, 200], ["the SARS", "PROBLEM", 209, 217]]], ["These data pointed to the fact that animals being sold in markets as a likely source of the virus.", [["the virus", "PROBLEM", 88, 97], ["virus", "OBSERVATION", 92, 97]]], ["Therefore, after the outbreak of SARS, many scientists concentrated their efforts on investigating the animal origin of SARS-CoV.IntroductionA breakthrough came in May of 2003 when viruses related to SARS were identified in animals.", [["SARS", "DISEASE", 33, 37], ["SARS", "DISEASE", 120, 124], ["SARS", "DISEASE", 200, 204], ["SARS-CoV", "ORGANISM", 120, 128], ["SARS-CoV", "SPECIES", 120, 128], ["SARS", "PROBLEM", 33, 37], ["IntroductionA breakthrough", "PROBLEM", 129, 155], ["viruses", "PROBLEM", 181, 188], ["SARS", "PROBLEM", 200, 204]]], ["A team led by Yi Guan (Hong Kong University) and colleagues from the Center for Disease Control (CDC) Shenzhen, studied 25 individuals from 8 different species including 6 masked palm civets (Paguma larvata), 1 raccoon dog (Nyctereutes procyonoides), 2 Chinese ferret-badgers (Melogale moschata), 3 hog-badgers (Arctonyx collaris), 3 beavers (Castor fiber), 4 domestic cats (Felis catus), 3 Chinese hares (Lepus sinensis) and 2 Chinese muntjac (Muntiacus reevesi) gathered in Dongmen Market, Shenzhen, Guangdong Province (Guan et al., 2003).", [["Paguma larvata", "ORGANISM", 192, 206], ["raccoon", "ORGANISM", 211, 218], ["dog", "ORGANISM_SUBDIVISION", 219, 222], ["Nyctereutes procyonoides", "ORGANISM", 224, 248], ["ferret", "ORGANISM", 261, 267], ["badgers", "ORGANISM", 268, 275], ["Melogale moschata", "ORGANISM", 277, 294], ["hog", "ORGANISM", 299, 302], ["badgers", "ORGANISM", 303, 310], ["Arctonyx collaris", "ORGANISM", 312, 329], ["cats", "ORGANISM", 369, 373], ["Felis catus", "ORGANISM", 375, 386], ["Lepus sinensis", "ORGANISM", 406, 420], ["Muntiacus reevesi", "ORGANISM", 445, 462], ["Paguma larvata", "SPECIES", 192, 206], ["raccoon dog", "SPECIES", 211, 222], ["Nyctereutes procyonoides", "SPECIES", 224, 248], ["ferret-badgers", "SPECIES", 261, 275], ["Melogale moschata", "SPECIES", 277, 294], ["hog", "SPECIES", 299, 302], ["badgers", "SPECIES", 303, 310], ["Arctonyx collaris", "SPECIES", 312, 329], ["beavers", "SPECIES", 334, 341], ["cats", "SPECIES", 369, 373], ["Felis catus", "SPECIES", 375, 386], ["Lepus sinensis", "SPECIES", 406, 420], ["muntjac", "SPECIES", 436, 443], ["Muntiacus reevesi", "SPECIES", 445, 462], ["palm civets", "SPECIES", 179, 190], ["Paguma larvata", "SPECIES", 192, 206], ["raccoon dog", "SPECIES", 211, 222], ["Nyctereutes procyonoides", "SPECIES", 224, 248], ["Chinese ferret-badgers", "SPECIES", 253, 275], ["Melogale moschata", "SPECIES", 277, 294], ["hog-badgers", "SPECIES", 299, 310], ["Arctonyx collaris", "SPECIES", 312, 329], ["Felis catus", "SPECIES", 375, 386], ["Chinese hares", "SPECIES", 391, 404], ["Lepus sinensis", "SPECIES", 406, 420], ["Chinese muntjac", "SPECIES", 428, 443], ["Muntiacus reevesi", "SPECIES", 445, 462], ["Paguma larvata)", "TREATMENT", 192, 207], ["1 raccoon dog (Nyctereutes procyonoides)", "TREATMENT", 209, 249], ["hog-badgers (Arctonyx collaris)", "TREATMENT", 299, 330], ["3 beavers (Castor fiber", "TREATMENT", 332, 355]]], ["Nasal and faecal swabs from the animals were tested for SARS-CoV nucleic acid by using reverse transcription-polymerase chain reaction (RT-PCR) on the N gene of the human SARS-CoV, and all the swaps were inoculated into FRhK-4 cells for virus isolation.", [["Nasal", "ANATOMY", 0, 5], ["faecal swabs", "ANATOMY", 10, 22], ["FRhK-4 cells", "ANATOMY", 220, 232], ["nucleic acid", "CHEMICAL", 65, 77], ["Nasal", "MULTI-TISSUE_STRUCTURE", 0, 5], ["faecal swabs", "ORGANISM_SUBSTANCE", 10, 22], ["animals", "ORGANISM", 32, 39], ["human", "ORGANISM", 165, 170], ["SARS-CoV", "ORGANISM", 171, 179], ["FRhK-4 cells", "CELL", 220, 232], ["N gene", "DNA", 151, 157], ["FRhK-4 cells", "CELL_LINE", 220, 232], ["human", "SPECIES", 165, 170], ["SARS-CoV", "SPECIES", 56, 64], ["human SARS-CoV", "SPECIES", 165, 179], ["Nasal and faecal swabs", "TEST", 0, 22], ["SARS", "PROBLEM", 56, 60], ["CoV nucleic acid", "TEST", 61, 77], ["reverse transcription", "TEST", 87, 108], ["polymerase chain reaction", "PROBLEM", 109, 134], ["RT-PCR", "TEST", 136, 142], ["the human SARS", "TEST", 161, 175], ["CoV", "PROBLEM", 176, 179], ["all the swaps", "TEST", 185, 198], ["virus isolation", "TREATMENT", 237, 252], ["faecal", "ANATOMY", 10, 16]]], ["All of the six masked palm civets and one raccoon dog were positive for SARS-CoV by either RT-PCR and/or virus isolation.", [["civets", "ANATOMY", 27, 33], ["SARS", "DISEASE", 72, 76], ["raccoon", "ORGANISM", 42, 49], ["dog", "ORGANISM", 50, 53], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 72, 80], ["dog", "SPECIES", 50, 53], ["raccoon dog", "SPECIES", 42, 53], ["SARS-CoV", "SPECIES", 72, 80], ["one raccoon dog", "TEST", 38, 53], ["SARS", "PROBLEM", 72, 76], ["CoV", "PROBLEM", 77, 80], ["PCR", "TEST", 94, 97], ["virus isolation", "TREATMENT", 105, 120]]], ["Sera from five animals including three masked palm civets, a raccoon dog and a Chinese ferret badger, had neutralizing antibody against a SARS-CoV isolated from a masked palm civet (SZ16).", [["SARS", "DISEASE", 138, 142], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["dog", "ORGANISM", 69, 72], ["ferret", "ORGANISM", 87, 93], ["SARS-CoV", "ORGANISM", 138, 146], ["palm", "ORGANISM_SUBDIVISION", 170, 174], ["neutralizing antibody", "PROTEIN", 106, 127], ["raccoon dog", "SPECIES", 61, 72], ["ferret", "SPECIES", 87, 93], ["raccoon dog", "SPECIES", 61, 72], ["Chinese ferret badger", "SPECIES", 79, 100], ["SARS-CoV", "SPECIES", 138, 146], ["Sera", "TEST", 0, 4], ["neutralizing antibody", "TREATMENT", 106, 127], ["a SARS", "PROBLEM", 136, 142], ["CoV", "PROBLEM", 143, 146]]], ["The neutralizing antibody titer was \u2265640, 40, 40 for the three masked palm civets, \u2265640 for the raccoon dog and 160 for the Chinese ferret badger (Guan et al., 2003).", [["dog", "ORGANISM", 104, 107], ["ferret", "ORGANISM", 132, 138], ["dog", "SPECIES", 104, 107], ["ferret", "SPECIES", 132, 138], ["raccoon dog", "SPECIES", 96, 107], ["Chinese ferret badger", "SPECIES", 124, 145], ["The neutralizing antibody titer", "TEST", 0, 31], ["the raccoon dog", "TEST", 92, 107]]], ["It is interesting to note that one of the masked palm civet, which was tested positive for SARS-CoV nucleic acid both in nasal and faecal swabs was negative for neutralizing antibodies against its own SZ16 virus.", [["nasal", "ANATOMY", 121, 126], ["faecal swabs", "ANATOMY", 131, 143], ["nucleic acid", "CHEMICAL", 100, 112], ["palm", "ORGANISM_SUBDIVISION", 49, 53], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 91, 99], ["nasal", "ORGANISM_SUBDIVISION", 121, 126], ["faecal swabs", "ORGANISM_SUBSTANCE", 131, 143], ["SZ16 virus", "ORGANISM", 201, 211], ["neutralizing antibodies", "PROTEIN", 161, 184], ["SARS-CoV", "SPECIES", 91, 99], ["SZ16 virus", "SPECIES", 201, 211], ["the masked palm civet", "TEST", 38, 59], ["SARS", "PROBLEM", 91, 95], ["CoV nucleic acid", "TEST", 96, 112], ["nasal and faecal swabs", "TEST", 121, 143], ["neutralizing antibodies", "PROBLEM", 161, 184], ["its own SZ16 virus", "PROBLEM", 193, 211], ["nasal", "ANATOMY", 121, 126], ["faecal", "ANATOMY", 131, 137]]], ["It implied that this animal was either newly infected or it had developed mechanisms to avoid generating neutralizing antibodies.", [["neutralizing antibodies", "PROTEIN", 105, 128], ["generating neutralizing antibodies", "PROBLEM", 94, 128], ["newly", "OBSERVATION_MODIFIER", 39, 44], ["infected", "OBSERVATION", 45, 53], ["neutralizing antibodies", "OBSERVATION", 105, 128]]], ["This study raised the initial alert that masked palm civets and other wildlife animals may play a role in the transmission of SARS-CoV and led to a temporary ban on the hunting, sale, transportation and export of all wild animals in Guangdong Province.IntroductionLater in 2003, the role of masked palm civets and other animals was questioned and a debate ensued on whether these animals are actually the origin of the SARS-CoV.", [["SARS", "DISEASE", 126, 130], ["SARS", "DISEASE", 419, 423], ["SARS-CoV", "ORGANISM", 126, 134], ["palm", "ORGANISM_SUBDIVISION", 298, 302], ["animals", "ORGANISM", 380, 387], ["SARS-CoV", "ORGANISM", 419, 427], ["SARS-CoV", "SPECIES", 126, 134], ["SARS-CoV", "SPECIES", 419, 427], ["This study", "TEST", 0, 10]]], ["A rather convincing evidence implicating masked palm civets came in approximately half a year later in the winter of 2003\u20132004.", [["palm", "ORGANISM_SUBDIVISION", 48, 52], ["masked palm civets", "PROBLEM", 41, 59], ["palm", "OBSERVATION_MODIFIER", 48, 52]]], ["Between 16 December 2003 and 8 January 2004, a total of four patients were identified as SARS cases with mild flu-like syndromes and no secondary transmission (Liang et al., 2004).", [["SARS", "DISEASE", 89, 93], ["flu-like syndromes", "DISEASE", 110, 128], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["SARS cases", "PROBLEM", 89, 99], ["mild flu-like syndromes", "PROBLEM", 105, 128], ["mild", "OBSERVATION_MODIFIER", 105, 109], ["flu", "OBSERVATION", 110, 113], ["no", "UNCERTAINTY", 133, 135]]], ["Epidemiological information collected by the Guangdong CDC and Guangzhou CDC indicated that three of the patients had direct or indirect contact to masked palm civets.", [["patients", "ORGANISM", 105, 113], ["palm", "ORGANISM_SUBDIVISION", 155, 159], ["patients", "SPECIES", 105, 113]]], ["The second patient was a waitress in a local restaurant (TDLR), where live masked palm civets were kept for exotic dishes, and she often passed by or stood in close proximity of the animal cages (Wang et al., 2005b).", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18]]], ["The fourth patient dined in the same restaurant and his dining table was within 5 m of civet cages (Wang et al., 2005b).", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18], ["fourth", "OBSERVATION_MODIFIER", 4, 10]]], ["The third patient dined in a neighboring restaurant (SJR), which shared the kitchen with TDLR (Song et al., 2005).", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17]]], ["The masked palm civets kept in TDLR restaurant were reported to have been originally purchased from the Xinyuan Live Animal Market (Wang et al., 2005b).", [["palm", "ORGANISM_SUBDIVISION", 11, 15], ["The masked palm civets", "TREATMENT", 0, 22], ["palm", "OBSERVATION_MODIFIER", 11, 15]]], ["Three research teams published their results on the SARS-CoV-like viruses in masked palm civets from the TDLR restaurant and from the Xinyuan Live Animal Market as well as the four patients (Kan et al., 2005, Song et al., 2005, Wang et al., 2005b).", [["SARS-CoV-like viruses", "DISEASE", 52, 73], ["SARS-CoV", "ORGANISM", 52, 60], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["SARS-CoV", "SPECIES", 52, 60], ["the SARS", "TEST", 48, 56], ["viruses", "PROBLEM", 66, 73]]], ["Almost identical sequences of the SARS-CoV spike genes were identified in samples from some of the patients and from masked palm civets in either the restaurant or the Xinyuan Live Animal Market (Kan et al., 2005, Song et al., 2005, Wang et al., 2005b).", [["samples", "ANATOMY", 74, 81], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["samples", "CANCER", 74, 81], ["patients", "ORGANISM", 99, 107], ["SARS-CoV spike genes", "DNA", 34, 54], ["patients", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 34, 42], ["the SARS", "PROBLEM", 30, 38], ["CoV spike genes", "PROBLEM", 39, 54]]], ["Based on virological and epidemiological findings, Guangdong provincial officials took an aggressive action on 5 January 2004 to destroy any animals that might harbor the SARS-CoV in farms and in animal food markets.", [["SARS", "DISEASE", 171, 175], ["SARS-CoV", "ORGANISM", 171, 179], ["SARS-CoV", "SPECIES", 171, 179], ["the SARS", "PROBLEM", 167, 175], ["SARS", "OBSERVATION", 171, 175]]], ["Quarantine on all civets reared for human consumption in farms all over China was imposed.", [["Quarantine", "CHEMICAL", 0, 10], ["Quarantine", "CHEMICAL", 0, 10], ["human", "ORGANISM", 36, 41], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["Quarantine", "TREATMENT", 0, 10], ["all civets", "TREATMENT", 14, 24]]], ["Since then, no additional community-acquired SARS cases have been reported.IntroductionAlthough masked palm civets were identified as direct origin of at least some of the SARS cases, the following data indicated that it might not necessarily be the natural animal reservoir of the SARS-CoV: (1) The so far sequenced SARS-CoVs from masked palm civets harbored a nucleic acid identity higher than 99.6%, implying that SARS-CoV-like viruses might have recently entered into the masked palm civet population.", [["SARS", "DISEASE", 45, 49], ["SARS", "DISEASE", 172, 176], ["SARS", "DISEASE", 282, 286], ["SARS", "DISEASE", 317, 321], ["nucleic acid", "CHEMICAL", 362, 374], ["SARS", "DISEASE", 417, 421], ["palm", "ORGANISM_SUBDIVISION", 103, 107], ["SARS-CoV", "ORGANISM", 282, 290], ["palm", "ORGANISM_SUBDIVISION", 339, 343], ["SARS-CoV-like viruses", "ORGANISM", 417, 438], ["SARS-CoVs", "DNA", 317, 326], ["SARS-CoV", "SPECIES", 282, 290], ["SARS-CoV", "SPECIES", 417, 425], ["acquired SARS cases", "PROBLEM", 36, 55], ["masked palm civets", "PROBLEM", 96, 114], ["SARS", "PROBLEM", 317, 321], ["CoVs", "PROBLEM", 322, 326], ["masked palm civets", "TEST", 332, 350], ["a nucleic acid identity", "TEST", 360, 383], ["SARS", "PROBLEM", 417, 421], ["CoV-like viruses", "PROBLEM", 422, 438], ["no", "UNCERTAINTY", 12, 14]]], ["(2) Although masked palm civets in markets had a high prevalence for SARS-CoV during the epidemic (Guan et al., 2003, Kan et al., 2005, Tu et al., 2004), investigations on farmed masked palm civets were often negative for the SARS-CoV (Kan et al., 2005, Tu et al., 2004) with only a few exceptions (Hu et al., 2005, Tu et al., 2004).", [["SARS-CoV", "DISEASE", 69, 77], ["SARS", "DISEASE", 226, 230], ["palm", "ORGANISM_SUBDIVISION", 20, 24], ["SARS-CoV", "ORGANISM", 69, 77], ["palm", "ORGANISM_SUBDIVISION", 186, 190], ["SARS-CoV", "SPECIES", 69, 77], ["SARS-CoV", "SPECIES", 226, 234], ["SARS", "PROBLEM", 69, 73], ["the SARS", "PROBLEM", 222, 230]]], ["(3) An investigation of 21 wild masked palm civets trapped in Hong Kong indicated that those animals were free of SARS-CoV-like viruses suggesting the virus is not widely circulating in wild masked palm civets (Poon et al., 2005).IntroductionFor a number of reasons, attention turned to bats as a likely reservoir of the SARS-CoV.", [["SARS", "DISEASE", 114, 118], ["SARS", "DISEASE", 321, 325], ["palm", "ORGANISM_SUBDIVISION", 39, 43], ["SARS-CoV-like viruses", "ORGANISM", 114, 135], ["palm", "ORGANISM_SUBDIVISION", 198, 202], ["SARS-CoV", "ORGANISM", 321, 329], ["SARS-CoV", "SPECIES", 114, 122], ["SARS-CoV", "SPECIES", 321, 329], ["An investigation", "TEST", 4, 20], ["SARS", "PROBLEM", 114, 118], ["CoV", "PROBLEM", 119, 122], ["like viruses", "PROBLEM", 123, 135], ["the virus", "PROBLEM", 147, 156], ["virus", "OBSERVATION", 151, 156]]], ["Bats have long been known as an important reservoir for many zoonotic viruses including rabies virus, Hendra virus, Nipha virus, Ebola virus and St. Louis encephalitis viruses (Halpin et al., 2000, Leroy et al., 2005, Mackenzie et al., 2001, Mackenzie and Field, 2004).", [["zoonotic viruses", "DISEASE", 61, 77], ["rabies virus", "DISEASE", 88, 100], ["Hendra virus", "DISEASE", 102, 114], ["Ebola virus", "DISEASE", 129, 140], ["encephalitis", "DISEASE", 155, 167], ["Bats", "CELL", 0, 4], ["rabies virus", "ORGANISM", 88, 100], ["Hendra virus", "ORGANISM", 102, 114], ["Nipha virus", "ORGANISM", 116, 127], ["Ebola virus", "ORGANISM", 129, 140], ["St. Louis encephalitis viruses", "ORGANISM", 145, 175], ["rabies virus", "SPECIES", 88, 100], ["Hendra virus", "SPECIES", 102, 114], ["Nipha virus", "SPECIES", 116, 127], ["Ebola virus", "SPECIES", 129, 140], ["St. Louis encephalitis", "SPECIES", 145, 167], ["rabies virus", "SPECIES", 88, 100], ["Hendra virus", "SPECIES", 102, 114], ["Nipha virus", "SPECIES", 116, 127], ["Ebola virus", "SPECIES", 129, 140], ["St. Louis encephalitis viruses", "SPECIES", 145, 175], ["an important reservoir", "TREATMENT", 29, 51], ["many zoonotic viruses", "PROBLEM", 56, 77], ["rabies virus", "PROBLEM", 88, 100], ["Hendra virus", "PROBLEM", 102, 114], ["Nipha virus", "PROBLEM", 116, 127], ["Ebola virus", "PROBLEM", 129, 140]]], ["An early study by Poon et al. (2005) on 81 bats belonging to 12 different species identified a novel bat coronavirus (Bat-CoV) from three different bat species of the same genus, Miniopterus magnater, Miniopterus pusillus, and Miniopterus schreibersi.", [["bat coronavirus", "ORGANISM", 101, 116], ["Bat-CoV", "ORGANISM", 118, 125], ["Miniopterus magnater", "ORGANISM", 179, 199], ["Miniopterus pusillus", "ORGANISM", 201, 221], ["Miniopterus schreibersi", "ORGANISM", 227, 250], ["bat coronavirus", "SPECIES", 101, 116], ["Miniopterus magnater", "SPECIES", 179, 199], ["Miniopterus pusillus", "SPECIES", 201, 221], ["Miniopterus schreibersi", "SPECIES", 227, 250], ["bat coronavirus", "SPECIES", 101, 116], ["Bat-CoV", "SPECIES", 118, 125], ["Miniopterus magnater", "SPECIES", 179, 199], ["Miniopterus pusillus", "SPECIES", 201, 221], ["Miniopterus schreibersi", "SPECIES", 227, 250], ["An early study", "TEST", 0, 14], ["a novel bat coronavirus", "PROBLEM", 93, 116], ["Miniopterus pusillus", "PROBLEM", 201, 221], ["same genus", "ANATOMY", 167, 177], ["Miniopterus pusillus", "OBSERVATION", 201, 221], ["Miniopterus schreibersi", "OBSERVATION", 227, 250]]], ["However, the Bat-CoV belonged to group 1 coronavirus and was not closely related to SARS-CoV since its RNA fragments shared only 41\u201362% nucleotide sequence identities to SARS-CoV (Poon et al., 2005).", [["SARS", "DISEASE", 84, 88], ["nucleotide", "CHEMICAL", 136, 146], ["SARS", "DISEASE", 170, 174], ["Bat-CoV", "ORGANISM", 13, 20], ["group 1 coronavirus", "ORGANISM", 33, 52], ["SARS-CoV", "ORGANISM", 84, 92], ["CoV", "PROTEIN", 17, 20], ["SARS-CoV", "DNA", 84, 92], ["group 1 coronavirus", "SPECIES", 33, 52], ["Bat-CoV", "SPECIES", 13, 20], ["group 1 coronavirus", "SPECIES", 33, 52], ["SARS-CoV", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 170, 178], ["group 1 coronavirus", "PROBLEM", 33, 52], ["SARS", "PROBLEM", 84, 88], ["its RNA fragments", "PROBLEM", 99, 116], ["nucleotide sequence", "TEST", 136, 155]]], ["This initial failure to identify a SARS-CoV-like virus in bats was soon compensated by the successful detection, by two other independent groups, of several SARS-CoV-like viruses in different species of horseshoe bats (Lau et al., 2005, Li et al., 2005b).IntroductionThis review summarizes the research aimed at investigating the origin in masked palm civets, bats, as well as other animals.", [["SARS", "DISEASE", 35, 39], ["SARS", "DISEASE", 157, 161], ["SARS-CoV-like virus", "ORGANISM", 35, 54], ["bats", "ORGANISM", 58, 62], ["SARS-CoV-like viruses", "ORGANISM", 157, 178], ["horseshoe", "ORGANISM", 203, 212], ["palm", "ORGANISM_SUBDIVISION", 347, 351], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 157, 165], ["This initial failure", "PROBLEM", 0, 20], ["a SARS", "PROBLEM", 33, 39], ["CoV-like virus in bats", "PROBLEM", 40, 62], ["several SARS", "PROBLEM", 149, 161], ["viruses", "PROBLEM", 171, 178], ["failure", "OBSERVATION", 13, 20], ["virus", "OBSERVATION", 49, 54], ["horseshoe bats", "OBSERVATION", 203, 217]]], ["For readers interested in more detailed information on interaction of SARS-CoV spike protein with receptors of different species in relation to animal origin of SARS-CoV, we highly recommend the recent review paper by Li et al. (2006).Masked palm civets ::: Masked palm civets and SARS-CoVMasked palm civets (P. larvata) belong to Carnivora, Viverridae.", [["SARS", "DISEASE", 70, 74], ["SARS", "DISEASE", 161, 165], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 70, 78], ["SARS-CoV", "ORGANISM", 161, 169], ["P. larvata", "ORGANISM", 309, 319], ["Viverridae", "ORGANISM", 342, 352], ["SARS-CoV spike protein", "PROTEIN", 70, 92], ["P. larvata", "SPECIES", 309, 319], ["SARS-CoV", "SPECIES", 70, 78], ["SARS-CoV", "SPECIES", 161, 169], ["SARS-CoVMasked palm civets", "SPECIES", 281, 307], ["P. larvata", "SPECIES", 309, 319], ["SARS", "PROBLEM", 70, 74], ["CoV spike protein", "PROBLEM", 75, 92], ["different species", "PROBLEM", 111, 128], ["SARS", "PROBLEM", 161, 165], ["SARS", "PROBLEM", 281, 285]]], ["There are nine subspecises of P. larvata in China, including P. l. larvata, P. l. taivana, P. l. reevesi, P. l. hainana, P. l. intrudens, P. l. chichingensis, P. l. neglecta, P. l. nigriceps, and P. l. lanigera (Gao et al., 1987).", [["P. larvata", "ORGANISM", 30, 40], ["P.", "ORGANISM", 61, 63], ["l. larvata", "ORGANISM", 64, 74], ["P. l. taivana", "ORGANISM", 76, 89], ["P. l. reevesi", "ORGANISM", 91, 104], ["P. l. hainana", "ORGANISM", 106, 119], ["P. l. intrudens", "ORGANISM", 121, 136], ["P. l. chichingensis", "ORGANISM", 138, 157], ["P. l. neglecta", "ORGANISM", 159, 173], ["P. l. nigriceps", "ORGANISM", 175, 190], ["P. l. lanigera", "ORGANISM", 196, 210], ["P. larvata", "SPECIES", 30, 40], ["P.", "SPECIES", 61, 63], ["l. larvata", "SPECIES", 64, 74], ["P.", "SPECIES", 76, 78], ["l. taivana", "SPECIES", 79, 89], ["P.", "SPECIES", 91, 93], ["l. reevesi", "SPECIES", 94, 104], ["P.", "SPECIES", 106, 108], ["l. hainana", "SPECIES", 109, 119], ["P.", "SPECIES", 121, 123], ["l. intrudens", "SPECIES", 124, 136], ["P.", "SPECIES", 138, 140], ["l. chichingensis", "SPECIES", 141, 157], ["P.", "SPECIES", 159, 161], ["l. neglecta", "SPECIES", 162, 173], ["P.", "SPECIES", 175, 177], ["l. nigriceps", "SPECIES", 178, 190], ["P.", "SPECIES", 196, 198], ["l. lanigera", "SPECIES", 199, 210], ["P. larvata", "SPECIES", 30, 40], ["P. l. larvata", "SPECIES", 61, 74], ["P. l. taivana", "SPECIES", 76, 89], ["P. l. reevesi", "SPECIES", 91, 104], ["P. l. hainana", "SPECIES", 106, 119], ["P. l. intrudens", "SPECIES", 121, 136], ["P. l. chichingensis", "SPECIES", 138, 157], ["P. l. neglecta", "SPECIES", 159, 173], ["P. l. nigriceps", "SPECIES", 175, 190], ["P. l. lanigera", "SPECIES", 196, 210]]], ["The animals are mainly arboreal, nocturnal and largely solitary.", [["animals", "ORGANISM", 4, 11], ["mainly", "OBSERVATION_MODIFIER", 16, 22], ["arboreal", "OBSERVATION_MODIFIER", 23, 31], ["solitary", "OBSERVATION_MODIFIER", 55, 63]]], ["They eat mostly fruits but also supplement their diet with rodents, birds, insects and roots.Masked palm civets ::: Masked palm civets and SARS-CoVFarming of masked palm civets in China started in late 1950s mainly for fur (Liu, 1959), but breeding became popular in the late 1980s with increasing demands for them as an exotic food.", [["fruits", "ANATOMY", 16, 22], ["roots", "ANATOMY", 87, 92], ["SARS", "DISEASE", 139, 143], ["fruits", "ORGANISM_SUBDIVISION", 16, 22], ["birds", "ORGANISM_SUBDIVISION", 68, 73], ["roots", "ORGAN", 87, 92], ["palm", "ORGANISM_SUBDIVISION", 165, 169], ["SARS", "PROBLEM", 139, 143], ["masked palm civets", "TREATMENT", 158, 176], ["roots", "ANATOMY", 87, 92]]], ["The farms started either from capture and breeding of local wild animals or from breeding stocks brought in from other farms.", [["The farms", "TREATMENT", 0, 9], ["breeding stocks", "TREATMENT", 81, 96]]], ["The feed for the farmed animals varied depending on the particular farm but usually contained grains such as maize, beans, rice and animal feed such as powdered products from fish or bones and often supplemented with fresh meat and/or parts from other animals (Zhou, 1994, Shao and Li, 1997).", [["grains", "ANATOMY", 94, 100], ["bones", "ANATOMY", 183, 188], ["meat", "ANATOMY", 223, 227], ["grains", "ORGANISM_SUBDIVISION", 94, 100], ["beans", "ORGANISM_SUBDIVISION", 116, 121], ["rice", "ORGANISM_SUBDIVISION", 123, 127], ["fish", "ORGANISM_SUBDIVISION", 175, 179], ["bones", "ORGAN", 183, 188], ["meat", "ORGANISM_SUBDIVISION", 223, 227], ["maize", "SPECIES", 109, 114], ["beans", "SPECIES", 116, 121], ["rice", "SPECIES", 123, 127], ["maize", "SPECIES", 109, 114], ["beans", "SPECIES", 116, 121], ["rice", "SPECIES", 123, 127], ["The feed", "TREATMENT", 0, 8], ["bones", "ANATOMY", 183, 188]]], ["By studying body temperature and weight, food intake, shedding and living habits of 87 wild masked palm civets in farms, Zhang et al. (1991a) found that masked palm civets in Shanxi Province hibernated slightly from December to February for about 75\u201385 days.", [["body", "ANATOMY", 12, 16], ["body", "ORGANISM_SUBDIVISION", 12, 16], ["palm", "ORGANISM_SUBDIVISION", 160, 164], ["weight", "TEST", 33, 39]]], ["A similar study showed that the masked palm civets in Hunan Province (south of Yangzhi River) also hibernated slightly from December to February as their body temperature dropped 3\u20134 \u00b0C and other physiological indexes decreased significantly compared with those during normal period (Kang et al., 1997).Masked palm civets ::: Masked palm civets and SARS-CoVMasked palm civets are naturally timid.", [["body", "ANATOMY", 154, 158], ["SARS", "DISEASE", 349, 353], ["body", "ORGANISM_SUBDIVISION", 154, 158], ["A similar study", "TEST", 0, 15], ["their body temperature", "TEST", 148, 170], ["other physiological indexes", "PROBLEM", 190, 217], ["SARS", "PROBLEM", 349, 353], ["CoVMasked palm civets", "TREATMENT", 354, 375]]], ["Farm breeding seemed to have been successful and only limited number diseases have been reported.", [["Farm breeding", "PROBLEM", 0, 13], ["limited number diseases", "PROBLEM", 54, 77]]], ["Viral enteritis caused by a parvovirus was one of the common diseases in masked palm civets.", [["Viral enteritis", "DISEASE", 0, 15], ["parvovirus", "DISEASE", 28, 38], ["parvovirus", "ORGANISM", 28, 38], ["palm", "ORGANISM_SUBDIVISION", 80, 84], ["Viral enteritis", "PROBLEM", 0, 15], ["a parvovirus", "PROBLEM", 26, 38], ["the common diseases", "PROBLEM", 50, 69], ["enteritis", "OBSERVATION", 6, 15], ["parvovirus", "OBSERVATION", 28, 38], ["common", "OBSERVATION_MODIFIER", 54, 60], ["diseases", "OBSERVATION", 61, 69], ["palm civets", "OBSERVATION", 80, 91]]], ["An inactivated vaccine against this virus was developed to immunize the animals (Duan et al., 2001).", [["An inactivated vaccine", "TREATMENT", 0, 22], ["this virus", "PROBLEM", 31, 41]]], ["An investigation of four apparently healthy masked palm civets in Taiwan has shown that they had antibodies against feline parvovirus (FPV) but not to feline herpesvirus type 1 or to feline calicivirus (Ikeda et al., 1999).", [["feline parvovirus", "DISEASE", 116, 133], ["feline herpesvirus type 1", "DISEASE", 151, 176], ["feline calicivirus", "DISEASE", 183, 201], ["palm", "ORGANISM_SUBDIVISION", 51, 55], ["feline parvovirus", "ORGANISM", 116, 133], ["FPV", "ORGANISM", 135, 138], ["feline herpesvirus type 1", "ORGANISM", 151, 176], ["feline calicivirus", "ORGANISM", 183, 201], ["antibodies", "PROTEIN", 97, 107], ["feline parvovirus", "SPECIES", 116, 133], ["feline herpesvirus", "SPECIES", 151, 169], ["feline calicivirus", "SPECIES", 183, 201], ["feline parvovirus", "SPECIES", 116, 133], ["FPV", "SPECIES", 135, 138], ["feline herpesvirus type 1", "SPECIES", 151, 176], ["feline calicivirus", "SPECIES", 183, 201], ["An investigation", "TEST", 0, 16], ["antibodies", "PROBLEM", 97, 107], ["feline parvovirus", "PROBLEM", 116, 133]]], ["Moreover, the titer of neutralizing antibodies against FPV ranged from 160 to >5120 (Ikeda et al., 1999).", [["neutralizing antibodies", "PROTEIN", 23, 46], ["FPV", "SPECIES", 55, 58], ["neutralizing antibodies", "TEST", 23, 46], ["FPV", "TEST", 55, 58]]], ["Bacterial and parasitic diseases have also been reported for masked palm civets (Yang et al., 2000, Zhao, 2003).SARS-CoV-like viruses in masked palm civets ::: Masked palm civets and SARS-CoVWhen SARS-CoV-like viruses were first identified in masked palm civets from a Shenzhen market (Guan et al., 2003), several investigators concentrated their efforts on exploring the prevalence of these viruses in this animal (Table 1).SARS-CoV-like viruses in masked palm civets ::: Masked palm civets and SARS-CoV", [["Bacterial and parasitic diseases", "DISEASE", 0, 32], ["SARS-CoV-like viruses", "DISEASE", 112, 133], ["SARS", "DISEASE", 183, 187], ["SARS-CoV-like viruses", "DISEASE", 425, 446], ["SARS", "DISEASE", 496, 500], ["SARS-CoV-like viruses", "ORGANISM", 112, 133], ["palm", "ORGANISM_SUBDIVISION", 144, 148], ["palm", "ORGANISM_SUBDIVISION", 167, 171], ["SARS-CoVWhen SARS-CoV-like viruses", "ORGANISM", 183, 217], ["SARS-CoV-like viruses", "ORGANISM", 425, 446], ["palm", "ORGANISM_SUBDIVISION", 457, 461], ["SARS-CoV", "SPECIES", 112, 120], ["SARS-CoVWhen SARS-CoV", "SPECIES", 183, 204], ["SARS-CoV", "SPECIES", 425, 433], ["SARS-CoV", "SPECIES", 496, 504], ["Bacterial and parasitic diseases", "PROBLEM", 0, 32], ["SARS", "PROBLEM", 112, 116], ["SARS", "PROBLEM", 183, 187], ["CoVWhen SARS", "PROBLEM", 188, 200], ["viruses", "PROBLEM", 210, 217], ["these viruses", "PROBLEM", 386, 399], ["SARS", "PROBLEM", 425, 429], ["SARS", "PROBLEM", 496, 500], ["parasitic diseases", "OBSERVATION", 14, 32], ["viruses", "OBSERVATION", 126, 133], ["viruses", "OBSERVATION", 392, 399], ["viruses", "OBSERVATION", 439, 446], ["CoV", "ANATOMY", 501, 504]]]], "4387c3aab647609c9350f7e38790548be005966a": [["Coagulopathy is a common feature of the coronavirus-2019 (COVID-19) and entails a worse prognosis.", [["Coagulopathy", "DISEASE", 0, 12], ["Coagulopathy", "PROBLEM", 0, 12], ["the coronavirus", "TEST", 36, 51], ["COVID", "TEST", 58, 63], ["a worse prognosis", "PROBLEM", 80, 97]]], ["Studies have reported conflicting results regarding the effect of anticoagulation treatment on mortality in patients with COVID-19.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["anticoagulation treatment", "TREATMENT", 66, 91], ["mortality", "TREATMENT", 95, 104], ["COVID", "TEST", 122, 127]]], ["In this meta-analysis study, we aim to examine the effect of anticoagulation use on mortality in patients with COVID-19.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["this meta-analysis study", "TEST", 3, 27], ["anticoagulation", "TREATMENT", 61, 76], ["COVID", "TEST", 111, 116]]], ["Inclusion criteria were: 1) Cohort studies, case series studies, or case reports.", [["Cohort studies", "TEST", 28, 42], ["case series studies", "TEST", 44, 63]]], ["2) The study population included patients with confirmed COVID-19 infection 3) Use of anticoagulation, whether in therapeutic or prophylactic doses, was reported in the study.", [["infection", "DISEASE", 66, 75], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["The study population", "TEST", 3, 23], ["COVID-19 infection", "PROBLEM", 57, 75], ["anticoagulation", "TREATMENT", 86, 101], ["prophylactic doses", "TREATMENT", 129, 147], ["the study", "TEST", 165, 174], ["infection", "OBSERVATION", 66, 75]]], ["4) Mortality among patients who received anticoagulation was reported in the study or could be calculated and compared to those who did not receive anticoagulation.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["anticoagulation", "TREATMENT", 41, 56], ["the study", "TEST", 73, 82], ["anticoagulation", "TREATMENT", 148, 163]]], ["Mortality rates were pooled using a random effect model.", [["Mortality rates", "TEST", 0, 15], ["a random effect model", "TREATMENT", 34, 55]]], ["Risk ratio (RR) and its 95% confidence interval (CI)", [["Risk ratio", "TEST", 0, 10], ["RR", "TEST", 12, 14]]]], "PMC7331623": [["Declared as a pandemic, this disease has deeply impacted many aspects of life in affected communities.", [["this disease", "PROBLEM", 24, 36]]], ["Relative lack of knowledge about the disease particularities has led to significant efforts devoted to alleviating its effects (Lipsitch, Swerdlow & Finelli, 2020).IntroductionAlternatives to mitigate the disease spread include social distancing (Anderson et al., 2020).", [["the disease particularities", "PROBLEM", 33, 60], ["IntroductionAlternatives", "TREATMENT", 164, 188], ["the disease spread", "PROBLEM", 201, 219]]], ["However, isolation policies manifest drawbacks as economic impact, with significant effects on macroeconomic indicators and unemployment rates (Nicola et al., 2020).", [["isolation policies", "TREATMENT", 9, 27]]], ["To address this, governments worldwide have proposed guidelines to manage the essential workforce, considered pivotal for maintaining strategic services and provide an appropriate response to the pandemics expansion (Black et al., 2020).IntroductionWidespread reports of threats to critical national infrastructure have been presented, with significant impact associated with medical attention (Kandel et al., 2020).", [["strategic services", "TREATMENT", 134, 152]]], ["Significant pressure is being faced by emergency response workers, with some countries on the brink of collapse of their national health systems (Tanne et al., 2020).", [["pressure", "OBSERVATION_MODIFIER", 12, 20], ["collapse", "OBSERVATION", 103, 111]]], ["The main concern associated with COVID-19 is the lack of extensive testing capacity.", [["COVID-19", "CHEMICAL", 33, 41], ["COVID", "TEST", 33, 38], ["extensive testing capacity", "TEST", 57, 83], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Shortage of diagnostic material and other medical supplies pose as a major restraining factor in pandemics control (Ranney, Griffeth & Jha, 2020).IntroductionThe most common COVID-19 symptoms are similar to other viral infectious diseases, making the prompt clinical diagnostic impractical (Adhikari et al., 2020).", [["viral infectious diseases", "DISEASE", 213, 238], ["diagnostic material", "TREATMENT", 12, 31], ["symptoms", "PROBLEM", 183, 191], ["other viral infectious diseases", "PROBLEM", 207, 238], ["viral", "OBSERVATION_MODIFIER", 213, 218], ["infectious", "OBSERVATION", 219, 229]]], ["Official guidelines emphasize the use of quantitative real-time PCR (qRT-PCR) assays for detection of viral RNA in diagnosis as the primary reference standard (Tahamtan & Ardebili, 2020).", [["viral RNA", "RNA", 102, 111], ["quantitative real-time PCR", "TEST", 41, 67], ["qRT", "TEST", 69, 72], ["viral RNA", "PROBLEM", 102, 111], ["viral RNA", "OBSERVATION", 102, 111]]], ["In many countries, test results are hardly available within at least a week, forcing physicians and health care providers to take strategic decisions regarding patient care without quality information.IntroductionPrevious reports have described alterations in laboratory findings in COVID-19 patients.", [["patient", "ORGANISM", 160, 167], ["patients", "ORGANISM", 292, 300], ["patient", "SPECIES", 160, 167], ["patients", "SPECIES", 292, 300], ["laboratory findings", "TEST", 260, 279]]], ["Hematological effects include leukopenia, lymphocytopenia and thrombocytopenia, while biochemical results show variation on alanine and aspartate aminotransferases, creatine kinase and D-dimer levels, among other parameters (Guan et al., 2020; Huang et al., 2020).", [["leukopenia", "DISEASE", 30, 40], ["lymphocytopenia", "DISEASE", 42, 57], ["thrombocytopenia", "DISEASE", 62, 78], ["alanine", "CHEMICAL", 124, 131], ["aspartate", "CHEMICAL", 136, 145], ["creatine", "CHEMICAL", 165, 173], ["alanine", "CHEMICAL", 124, 131], ["aspartate", "CHEMICAL", 136, 145], ["creatine", "CHEMICAL", 165, 173], ["alanine", "AMINO_ACID", 124, 131], ["aspartate", "AMINO_ACID", 136, 145], ["aminotransferases", "AMINO_ACID", 146, 163], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 165, 180], ["D-dimer", "SIMPLE_CHEMICAL", 185, 192], ["alanine and aspartate aminotransferases", "PROTEIN", 124, 163], ["creatine kinase", "PROTEIN", 165, 180], ["Hematological effects", "PROBLEM", 0, 21], ["leukopenia", "PROBLEM", 30, 40], ["lymphocytopenia", "PROBLEM", 42, 57], ["thrombocytopenia", "PROBLEM", 62, 78], ["alanine", "TEST", 124, 131], ["aspartate aminotransferases", "TEST", 136, 163], ["creatine kinase", "TEST", 165, 180], ["D-dimer levels", "TEST", 185, 199], ["leukopenia", "OBSERVATION", 30, 40], ["lymphocytopenia", "OBSERVATION", 42, 57], ["thrombocytopenia", "OBSERVATION", 62, 78]]], ["Some efforts have been applied to evaluate clinical and epidemiological aspects of this disease using computational methods, such as diagnosis, prognosis, symptoms severity, mortality, and response to different treatments.", [["this disease", "PROBLEM", 83, 95], ["computational methods", "TREATMENT", 102, 123], ["symptoms severity", "PROBLEM", 155, 172], ["mortality", "PROBLEM", 174, 183], ["different treatments", "TREATMENT", 201, 221]]], ["A useful review of some of these methods is presented by Wynants et al. (2020).IntroductionThe main objective of this article is to provide insights to healthcare decision-makers facing scarcity situations, as a shortage of test capacity or limitations in the essential workforce.", [["test capacity", "TEST", 224, 237], ["main", "OBSERVATION_MODIFIER", 95, 99]]], ["A useful method of doing so is using hemogram test results.", [["hemogram test", "TEST", 37, 50]]], ["This clinical exam is widely available, inexpensive, and fast, applying automation to maximize throughput.", [["This clinical exam", "TEST", 0, 18]]], ["To do so, we have analyzed hemogram data from Brazilian symptomatic patients with available test results for COVID-19.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["hemogram data", "TEST", 27, 40], ["available test", "TEST", 82, 96], ["COVID", "TEST", 109, 114]]], ["We propose a framework using a Na\u00efve-Bayes model for machine learning, where test conditions can be adjusted to respond to actual lack of resources problems.", [["machine learning", "TREATMENT", 53, 69]]], ["Finally, four distinct scarcity scenarios examples are presented, including handling of the essential workforce and shortage of testing and treatment resources.Data collection ::: Materials and MethodsA total of 5,644 patients admitted to the emergency department of Hospital Israelita Albert Einstein (HIAE, S\u00e3o Paulo, Brazil) presenting COVID-19-like symptoms were tested via qRT-PCR.", [["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 218, 226], ["testing", "TEST", 128, 135], ["treatment resources", "TREATMENT", 140, 159], ["COVID", "TEST", 339, 344], ["symptoms", "PROBLEM", 353, 361], ["qRT", "TEST", 378, 381], ["distinct", "OBSERVATION_MODIFIER", 14, 22], ["scarcity", "OBSERVATION", 23, 31]]], ["A total number of 599 patients (10.61%) presented positive results for COVID-19.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["COVID", "TEST", 71, 76]]], ["The full dataset contains patients anonymized ID, age, qRT-PCR results, data on clinical evolution, and a total of 105 clinical tests.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["clinical tests", "TEST", 119, 133]]], ["Not all data was available for all patients, therefore the amount of missing information is significant, with most available parameters informed for a small fraction of subjects.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43]]], ["All variables were normalized (i.e., mean = 0 and variance = 1) to maintain anonymity and remove scale effects.", [["mean", "TEST", 37, 41], ["variance", "TEST", 50, 58]]], ["No missing data imputation was performed during model generation to avoid bias.", [["missing data imputation", "PROBLEM", 3, 26]]], ["Considering the significant amount of missing data, only 510 patients presented values for all 15 parameters evaluated in hemogram results (comprising the following cell counts or hematological measures: hematocrit, hemoglobin, platelets, mean platelet volume, red blood cells, lymphocytes, leukocytes, basophils, eosinophils, monocytes, neutrophils, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and red blood cell distribution width (RDW).", [["cell", "ANATOMY", 165, 169], ["platelets", "ANATOMY", 228, 237], ["platelet", "ANATOMY", 244, 252], ["red blood cells", "ANATOMY", 261, 276], ["lymphocytes", "ANATOMY", 278, 289], ["leukocytes", "ANATOMY", 291, 301], ["basophils", "ANATOMY", 303, 312], ["eosinophils", "ANATOMY", 314, 325], ["monocytes", "ANATOMY", 327, 336], ["neutrophils", "ANATOMY", 338, 349], ["corpuscular", "ANATOMY", 356, 367], ["corpuscular", "ANATOMY", 387, 398], ["corpuscular", "ANATOMY", 422, 433], ["red blood cell", "ANATOMY", 471, 485], ["patients", "ORGANISM", 61, 69], ["cell", "CELL", 165, 169], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 216, 226], ["platelets", "CELL", 228, 237], ["platelet", "CELL", 244, 252], ["red blood cells", "CELL", 261, 276], ["lymphocytes", "CELL", 278, 289], ["leukocytes", "CELL", 291, 301], ["basophils", "CELL", 303, 312], ["eosinophils", "CELL", 314, 325], ["monocytes", "CELL", 327, 336], ["neutrophils", "CELL", 338, 349], ["corpuscular", "TISSUE", 356, 367], ["corpuscular hemoglobin", "GENE_OR_GENE_PRODUCT", 387, 409], ["corpuscular hemoglobin", "GENE_OR_GENE_PRODUCT", 422, 444], ["red blood cell", "CELL", 471, 485], ["hemoglobin", "PROTEIN", 216, 226], ["platelets", "CELL_TYPE", 228, 237], ["red blood cells", "CELL_TYPE", 261, 276], ["lymphocytes", "CELL_TYPE", 278, 289], ["leukocytes", "CELL_TYPE", 291, 301], ["basophils", "CELL_TYPE", 303, 312], ["eosinophils", "CELL_TYPE", 314, 325], ["monocytes", "CELL_TYPE", 327, 336], ["neutrophils", "CELL_TYPE", 338, 349], ["hemoglobin", "PROTEIN", 399, 409], ["MCH", "PROTEIN", 411, 414], ["hemoglobin", "PROTEIN", 434, 444], ["patients", "SPECIES", 61, 69], ["hemogram results", "TEST", 122, 138], ["the following cell counts", "TEST", 151, 176], ["hematological measures", "TEST", 180, 202], ["hematocrit", "TEST", 204, 214], ["hemoglobin", "TEST", 216, 226], ["platelets", "TEST", 228, 237], ["mean platelet volume", "TEST", 239, 259], ["red blood cells", "TEST", 261, 276], ["lymphocytes", "TEST", 278, 289], ["leukocytes", "TEST", 291, 301], ["basophils", "TEST", 303, 312], ["eosinophils", "TEST", 314, 325], ["monocytes", "TEST", 327, 336], ["neutrophils", "TEST", 338, 349], ["mean corpuscular volume", "TEST", 351, 374], ["MCV", "TEST", 376, 379], ["mean corpuscular hemoglobin", "TEST", 382, 409], ["MCH", "TEST", 411, 414], ["mean corpuscular hemoglobin concentration", "TEST", 417, 458], ["MCHC", "TEST", 460, 464], ["red blood cell distribution width", "TEST", 471, 504], ["RDW", "TEST", 506, 509], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["amount", "OBSERVATION_MODIFIER", 28, 34], ["leukocytes", "ANATOMY", 291, 301], ["basophils", "ANATOMY", 303, 312], ["red blood cell", "OBSERVATION", 471, 485], ["distribution", "OBSERVATION_MODIFIER", 486, 498], ["width", "OBSERVATION_MODIFIER", 499, 504]]], ["Data for the above parameters were used in model construction, along with qRT-PCR COVID-19 test results.", [["the above parameters", "TEST", 9, 29], ["qRT", "TEST", 74, 77], ["PCR COVID", "TEST", 78, 87]]], ["No baseline characteristics detailing can be presented for the evaluated cohort, once additional patients description is not accessible.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105]]], ["The full dataset is available in https://www.kaggle.com/einsteindata4u/covid19 and can also be found in Supplemental Materials.Data pre-processing ::: Machine learning analysis: Na\u00efve Bayes classifier ::: Materials and MethodsSamples presenting a missing value in any of the 15 evaluated features were removed, in order to avoid bias introduction in model.", [["a missing value", "TEST", 245, 260], ["bias introduction in model", "TREATMENT", 329, 355]]], ["A total of 510 patients (73 positives for COVID-19 and 437 negatives) presented complete data and were considered for the model construction.Classification algorithm ::: Machine learning analysis: Na\u00efve Bayes classifier ::: Materials and MethodsIn this work, we use a Gaussian Na\u00efve Bayes (NB) classifier, which is a probabilistic machine learning model used for classification tasks.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["COVID", "TEST", 42, 47], ["the model construction", "TREATMENT", 118, 140], ["Methods", "TREATMENT", 238, 245], ["a Gaussian Na\u00efve Bayes", "TREATMENT", 266, 288]]], ["The main reasons for choosing this classifier are due to its low computational cost, its ability to handle missing data and because it presented better classification performance when compared to other evaluated ML techniques, for this particular dataset (data not shown).", [["its low computational cost", "PROBLEM", 57, 83], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The Na\u00efve Bayes (NB) method combines the previous probability of an event (also called prior probability, or simply prior) with additional evidence (as, e.g., a set of clinical data from a patient) to calculate a combined, conditional probability that includes the prior probability given the extra information.", [["patient", "ORGANISM", 189, 196], ["patient", "SPECIES", 189, 196], ["a combined, conditional probability", "PROBLEM", 211, 246]]], ["The result is the posterior probability of an outcome, or simply posterior.", [["posterior", "OBSERVATION_MODIFIER", 18, 27], ["outcome", "OBSERVATION", 46, 53], ["posterior", "ANATOMY_MODIFIER", 65, 74]]], ["This classifier is called \u201cna\u00efve\u201d because it considers that each exam result (variables) is independent of each other.", [["each exam", "TEST", 60, 69]]], ["Besides this drawback, it can outperform more robust alternatives in classification tasks, and once it reflects the uncertainty involved in the diagnosis, Bayesian approaches are more suitable than deterministic techniques (Gorry & Barnett, 1968; Hastie, Tibshirani & Friedman, 2009).Missing data tolerance ::: Model development and validation ::: Materials and MethodsIn order to evaluate the adequacy and generalization power of the proposed model, as well as its tolerance to handle samples containing missing data (i.e., at least one variable with no informed values), an additional set of 92 samples (10 positives for COVID-19 and 82 negatives) was obtained from the patient database.", [["samples", "ANATOMY", 597, 604], ["samples", "CANCER", 597, 604], ["patient", "ORGANISM", 672, 679], ["patient", "SPECIES", 672, 679], ["Methods", "TREATMENT", 362, 369], ["missing data", "TEST", 505, 517], ["COVID", "TEST", 623, 628], ["the patient database", "TEST", 668, 688]]], ["Those samples were not initially employed in model delineation, considering they present a single missing value among all 15 employed hemogram parameters.", [["samples", "ANATOMY", 6, 13], ["hemogram parameters", "TEST", 134, 153]]], ["This \u201cincomplete dataset\u201d, comprising 92 samples with a single missing value information per sample, was then submitted to the previously generated model, in order to evaluate classification performance and missing values handling ability for the model.Descriptive analysis ::: ResultsFor data description, probability density function (PDF) of all 15 hemogram parameters were estimated through the original sample by kernel density estimator.", [["samples", "ANATOMY", 41, 48], ["samples", "CANCER", 41, 48], ["data description", "TEST", 289, 305], ["all 15 hemogram parameters", "TEST", 345, 371]]], ["Some hemogram parameters present notable differences between the distributions of positive and negative results, mainly regarding its modal value (distribution peak value) and variance (distribution width).", [["Some hemogram parameters", "TEST", 0, 24], ["notable", "OBSERVATION_MODIFIER", 33, 40], ["positive", "OBSERVATION", 82, 90], ["distribution", "OBSERVATION_MODIFIER", 186, 198], ["width", "OBSERVATION_MODIFIER", 199, 204]]], ["Regarding basophiles, eosinophils, leukocytes and platelets counts, qRT-PCR positive group distribution shows lower modal value and lower variance.", [["basophiles", "ANATOMY", 10, 20], ["eosinophils", "ANATOMY", 22, 33], ["leukocytes", "ANATOMY", 35, 45], ["platelets", "ANATOMY", 50, 59], ["basophiles", "CELL", 10, 20], ["eosinophils", "CELL", 22, 33], ["leukocytes", "CELL", 35, 45], ["platelets", "CELL", 50, 59], ["basophiles", "CELL_TYPE", 10, 20], ["eosinophils", "CELL_TYPE", 22, 33], ["leukocytes", "CELL_TYPE", 35, 45], ["platelets", "CELL_TYPE", 50, 59], ["basophiles", "TEST", 10, 20], ["eosinophils", "TEST", 22, 33], ["leukocytes", "TEST", 35, 45], ["platelets counts", "TEST", 50, 66], ["qRT", "TEST", 68, 71], ["PCR", "TEST", 72, 75], ["lower modal value", "PROBLEM", 110, 127], ["lower variance", "PROBLEM", 132, 146], ["eosinophils", "OBSERVATION", 22, 33], ["leukocytes", "ANATOMY", 35, 45], ["lower modal", "OBSERVATION_MODIFIER", 110, 121], ["lower variance", "OBSERVATION", 132, 146]]], ["On the other hand, monocyte count displays opposite behavior, once lower modal value and variance are observed for the qRT-PCR positive group.", [["monocyte", "ANATOMY", 19, 27], ["monocyte", "CELL", 19, 27], ["monocyte count", "TEST", 19, 33], ["the qRT-PCR", "TEST", 115, 126]]], ["The remaining nine hemogram parameters did not show a notable difference between negative and positive groups.", [["The remaining nine hemogram parameters", "TEST", 0, 38], ["notable", "OBSERVATION_MODIFIER", 54, 61], ["difference", "OBSERVATION", 62, 72]]], ["All variables contribute to the classification model, and despite the fact classification can be perfomed without the complete set of parameters (i.e., including missing data), a most sucessfull prediction is achieved when complete hemogram information is used as input.", [["complete hemogram information", "TEST", 223, 252]]], ["PDF analysis results are presented in Fig. 1.Na\u00efve Bayes model results ::: ResultsA NB classifier based on training set hemogram data was developed.", [["PDF analysis", "TEST", 0, 12], ["training set hemogram data", "TEST", 107, 133]]], ["Under the model, the complete range of prior probabilities (from 0.0001 to 0.9999 by 0.0001 increments) was scrutinized, and posterior probability of each class was computed for different prior conditions.", [["different prior conditions", "PROBLEM", 178, 204]]], ["A posterior probability value of 0.5 was defined as the classification threshold in one of the positive or negative predicted groups.", [["A posterior probability value", "TEST", 0, 29], ["posterior", "OBSERVATION_MODIFIER", 2, 11]]], ["Resulting model showed a good predictive power of the qRT-PCR test result based on hemogram data.", [["the qRT", "TEST", 50, 57], ["PCR test", "TEST", 58, 66], ["hemogram data", "TEST", 83, 96]]], ["Figure 2 shows the accuracy, sensitivity, F1 score, and specificity curves derived from the model for different prior probabilities of each class (positive or negative for COVID-19).", [["the accuracy", "TEST", 15, 27], ["F1 score", "TEST", 42, 50], ["specificity curves", "TEST", 56, 74], ["COVID", "TEST", 172, 177]]], ["Reported prior probabilities refer to positive COVID-19 condition.Na\u00efve Bayes model results ::: ResultsWhen setting the prior probability to the maximum defined value (0.9999), the NB classifier correctly diagnosed all PCR positive cases.", [["NB", "CANCER", 181, 183], ["all PCR", "TEST", 215, 222]]], ["On the other hand, such configuration improperly predicted 77.3% of negative PCR results as positive.", [["negative PCR", "TEST", 68, 80]]], ["Regarding the lower possible prior probability setting, it does not classify a single observation as positive.", [["a single observation", "TEST", 77, 97]]], ["Such characteristics can also be noticed in the general accuracy, since smaller values for the prior used in the classifier tend to diagnose all observations as belonging to the dominant class (negative) and consequently raising the total of correctly classified samples.", [["samples", "ANATOMY", 263, 270], ["samples", "CANCER", 263, 270]]], ["Under this condition, all metrics are approximately 76.6%.Na\u00efve Bayes model results ::: ResultsRegarding the model sensitivity, the rate of positive samples correctly classified is over 85% within 0.999 to 0.5276 range, with small decrease of it when the prior probability of positive result is diminished within this range.", [["the model sensitivity", "TEST", 105, 126], ["the rate", "TEST", 128, 136], ["small", "OBSERVATION_MODIFIER", 225, 230], ["decrease", "OBSERVATION_MODIFIER", 231, 239], ["diminished", "OBSERVATION", 295, 305]]], ["When prior is set to values under 0.1, the number of positive predicted samples decreases rapidly, yielding lower sensitivity.", [["samples", "ANATOMY", 72, 79], ["samples", "CANCER", 72, 79], ["positive predicted samples", "PROBLEM", 53, 79], ["lower sensitivity", "OBSERVATION_MODIFIER", 108, 125]]], ["As for specificity, it presents linear growth as tested priors decrease.", [["linear growth", "PROBLEM", 32, 45], ["linear", "OBSERVATION_MODIFIER", 32, 38], ["growth", "OBSERVATION_MODIFIER", 39, 45]]], ["Ultimately, the accuracy results profile are similar to specificity, due to the negative patients dominance.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97]]], ["Figure 3A displays the ROC (receiver operating characteristics) curve for the methods.", [["the ROC", "TEST", 19, 26], ["the methods", "TREATMENT", 74, 85]]], ["Figures 3B\u20133D presents prediction results for the baseline model, using a dummy classifier for the most frequent class (negative qRT-PCR, Fig. 3B), and for stratified (Fig. 3C) and uniform (Fig. 3D) evaluations.Na\u00efve Bayes model results ::: ResultsAs mentioned above, prior probability choice has a critical relevance in proposed model use.", [["a dummy classifier", "TREATMENT", 72, 90], ["qRT", "TEST", 129, 132], ["PCR", "TEST", 133, 136], ["uniform (Fig. 3D) evaluations", "TEST", 181, 210]]], ["It is clear that, when extreme values of positive probability are applied (close to 0 or 1), specific classes (positive or negative qRT-PCR test results predictions) are favored, increasing its ability of correct detection.", [["positive probability", "PROBLEM", 41, 61], ["qRT", "TEST", 132, 135], ["PCR test", "TEST", 136, 144], ["clear", "OBSERVATION", 6, 11]]], ["As an example, when a value of 0.9999 is set for prior probability of positive result is set, an increase in misclassification in negative class results is observed.", [["a value", "TEST", 20, 27], ["increase", "OBSERVATION_MODIFIER", 97, 105]]], ["At the same time, it is possible to properly identify samples where hemogram evidence strongly indicates a negative result, according to the model.", [["samples", "ANATOMY", 54, 61], ["hemogram evidence", "TEST", 68, 85]]], ["This is based on the fact that evidence used in the model construction (in present case, hemogram data) must strongly support the reduction of posterior probability of disease to values under 0.5, therefore leading to a negative result.", [["hemogram data", "TEST", 89, 102], ["disease", "PROBLEM", 168, 175], ["reduction", "OBSERVATION_MODIFIER", 130, 139], ["posterior", "OBSERVATION_MODIFIER", 143, 152], ["disease", "OBSERVATION", 168, 175]]], ["This logic can be applied to fine tune the prior probability used in the model, in order to improve correct classification of positive or negative groups prediction.", [["positive or negative groups prediction", "PROBLEM", 126, 164], ["positive", "OBSERVATION", 126, 134]]], ["Samples including a single missing value (n = 92, including 10 qRT-PCR positives) were used to test the missing data tolerance presented by the proposed model.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a single missing value", "TEST", 18, 40], ["qRT", "TEST", 63, 66]]], ["Figure 4 presents results obtained from the model application to this incomplete (lacking information for one variable per sample) dataset.Application framework ::: DiscussionThe proposed NB model can be applied in two distinct situations.", [["NB", "CANCER", 188, 190], ["the model application", "TREATMENT", 40, 61], ["The proposed NB model", "TREATMENT", 175, 196]]], ["When clinical data is available for a particular patient, it is highly recommended that medical staff determine the prior probability on a case-by-case basis.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56]]], ["When no clinical or medical data is available, or when decisions regarding resource management involving multiple symptomatic patients are necessary, the model can be used in multiple individuals simultaneously, aiming to identify those with higher probabilities of presenting positive qRT-PCR results.Individual assessment ::: DiscussionIndividual risk management and personal evaluation is essential for COVID-19 response (Gasmi et al., 2020).", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["resource management", "TREATMENT", 75, 94], ["multiple symptomatic patients", "PROBLEM", 105, 134], ["personal evaluation", "TEST", 369, 388], ["COVID", "TEST", 406, 411]]], ["Individuals presenting COVID-19 symptoms are medically evaluated where no COVID-19 test is available for appropriate diagnosis confirmation.", [["symptoms", "PROBLEM", 32, 40], ["COVID", "TEST", 74, 79]]], ["Medical practitioners can determine a probability of disease based on anamnesis, symptoms, clinical exams, laboratory findings and other available data.", [["disease", "PROBLEM", 53, 60], ["anamnesis", "TEST", 70, 79], ["symptoms", "PROBLEM", 81, 89], ["clinical exams", "TEST", 91, 105], ["laboratory findings", "TEST", 107, 126], ["other available data", "TEST", 131, 151]]], ["This probability of infection, as determined by the physician or medical team, can be considered as the prior probability.", [["infection", "DISEASE", 20, 29], ["infection", "PROBLEM", 20, 29], ["infection", "OBSERVATION", 20, 29]]], ["Using hemogram data as input, and informing the prior probability of COVID-19 based on medical findings, the model will consider hemogram data to inform a posterior probability, which can be higher or lower than the original, and based on the hemogram alterations caused by the virus infection.", [["infection", "DISEASE", 284, 293], ["COVID-19", "DNA", 69, 77], ["hemogram data", "TEST", 6, 19], ["COVID", "TEST", 69, 74], ["hemogram data", "TEST", 129, 142], ["a posterior probability", "PROBLEM", 153, 176], ["the hemogram alterations", "TEST", 239, 263], ["the virus infection", "PROBLEM", 274, 293], ["higher", "OBSERVATION_MODIFIER", 191, 197], ["virus infection", "OBSERVATION", 278, 293]]], ["It is important that hemogram data would not be included in original medical assessment and prior determination, in order to avoid bias and reduce model overfit.Multiple patients evaluation ::: DiscussionIt can be used in situations where decisions are necessary for resource management including multiple individuals.", [["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["hemogram data", "TEST", 21, 34], ["original medical assessment", "TEST", 60, 87], ["prior determination", "TEST", 92, 111], ["Multiple patients evaluation", "TEST", 161, 189], ["resource management", "TREATMENT", 267, 286]]], ["This method increases the correct selection of candidates belonging to the target group, when compared to random selection.", [["This method", "TREATMENT", 0, 11]]], ["When additional clinical data is available, or become available later, patients selected during bulk evaluation should be reassessed individually as proposed in the general framework, in order to reduce misclassifications.Applications to scarcity scenarios ::: DiscussionExamples of proposed model use are presented for some specific scarcity scenarios in Table 2.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["bulk evaluation", "TEST", 96, 111], ["misclassifications", "PROBLEM", 203, 221]]], ["Prior selection should be carefully decided, based on current context or situation proposed, and must consider the classification group where higher accuracy is intended.Applications to scarcity scenarios ::: DiscussionHigh accuracy in qRT-PCR result prediction is achieved based on hemogram information only.", [["qRT", "DNA", 236, 239], ["hemogram information", "TEST", 283, 303]]], ["Further analysis performed on the original data (not shown) suggest that additional clinical results can improve prediction efficiency.", [["Further analysis", "TEST", 0, 16], ["the original data", "TEST", 30, 47]]], ["This conclusion is in accordance with previous findings suggesting biochemical and immunological abnormalities, in addition to hematologic alterations, can be caused by COVID-19 disease (Henry et al., 2020).", [["hematologic", "ANATOMY", 127, 138], ["hematologic alterations", "DISEASE", 127, 150], ["previous findings", "TEST", 38, 55], ["biochemical and immunological abnormalities", "PROBLEM", 67, 110], ["hematologic alterations", "PROBLEM", 127, 150], ["COVID-19 disease", "PROBLEM", 169, 185]]], ["The use of large and comprehensive datasets, containing as much information as possible regarding clinical and laboratory findings, symptoms, disease evolution, and other relevant aspects, is crucial in devising useful and adequate models.", [["symptoms", "PROBLEM", 132, 140], ["disease evolution", "PROBLEM", 142, 159], ["large", "OBSERVATION_MODIFIER", 11, 16]]], ["The development of nationwide or regional databases based on local data is essential, in order to capture epidemiological idiosyncrasies associated with such populations (Terpos et al., 2020).", [["idiosyncrasies", "DISEASE", 122, 136], ["regional databases", "TEST", 33, 51], ["local data", "TEST", 61, 71]]], ["Also, natural differences in hemogram results from distinct demographic groups (as seen in reference values according to age, sex, or other physiological factors) can aggregate noise to the model, which can be reduced when large database are employed in model construction, and results can be devised for each ethnographic strata.Applications to scarcity scenarios ::: DiscussionDespite having high overall accuracy, performance metrics obtained with proposed model show unequal ability to predict positive or negative results.", [["hemogram", "TEST", 29, 37], ["distinct", "OBSERVATION_MODIFIER", 51, 59]]], ["This situation is caused by a significant imbalance in number of samples belonging to each of this qRT-PCR result groups in original data.", [["samples", "ANATOMY", 65, 72], ["a significant imbalance", "PROBLEM", 28, 51], ["this qRT", "TEST", 94, 102], ["original data", "TEST", 124, 137], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["imbalance", "OBSERVATION", 42, 51]]], ["The option of maintaining original data in model construction was adopted, since it better represents actual COVID-19 prevalence among symptomatic patients, and therefore seems to represent a more realistic situation.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155]]], ["Additional simulations applying a balanced model (data not shown) using positive group oversampling (to compensate its insufficiency in original data) have devised alternative models with superior predictive power.", [["a balanced model", "TREATMENT", 32, 48], ["positive group oversampling", "TREATMENT", 72, 99], ["its insufficiency", "PROBLEM", 115, 132]]], ["Alternative balanced model results are presented in Supplemental Material (Fig. S1).", [["S1", "GENE_OR_GENE_PRODUCT", 80, 82], ["S1", "PROTEIN", 80, 82]]], ["Therefore, additional positive samples will be added to the data and used in future model versions.Applications to scarcity scenarios ::: DiscussionAs a perspective, collection of hemogram results from asymptomatic patients (in addition to symptomatic individuals) can be used to evaluate the utility of this approach on the detection of asymptomatic infections, in order to provide alternatives in diagnostics, especially in a context of testing deficiency.", [["samples", "ANATOMY", 31, 38], ["infections", "DISEASE", 351, 361], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223], ["additional positive samples", "PROBLEM", 11, 38], ["collection of hemogram", "TEST", 166, 188], ["symptomatic individuals", "PROBLEM", 240, 263], ["asymptomatic infections", "PROBLEM", 338, 361], ["diagnostics", "TEST", 399, 410], ["testing deficiency", "PROBLEM", 439, 457], ["asymptomatic", "OBSERVATION_MODIFIER", 338, 350], ["infections", "OBSERVATION", 351, 361]]], ["A web-based application was developed by the authors, in which hemogram data can be introduced for a single individual, along with prior probability of infection, based on data used to generate the present model.", [["infection", "DISEASE", 152, 161], ["A web-based application", "TREATMENT", 0, 23], ["hemogram data", "TEST", 63, 76], ["infection", "PROBLEM", 152, 161], ["infection", "OBSERVATION", 152, 161]]], ["Future implementation will allow the upload of multiple patients simultaneously, and construction or testing of user data-derived models.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["This service will allow easy access and practical application of the proposed model.ConclusionMachine learning models based on hemogram data can be employed in COVID-19 pandemics management, in order to assist strategical medical decisions in different scarcity scenarios.", [["easy access", "TREATMENT", 24, 35], ["practical application of the proposed model", "TREATMENT", 40, 83], ["hemogram data", "TEST", 127, 140], ["COVID-19 pandemics management", "TREATMENT", 160, 189]]], ["Even though the method proposed in this work is not suitable to be used as a diagnostic technique, it can be employed to provide additional, useful information regarding data-driven resource allocation, in shortage conditions.", [["a diagnostic technique", "TEST", 75, 97]]]]}